<SEC-DOCUMENT>0001280776-24-000009.txt : 20240508
<SEC-HEADER>0001280776-24-000009.hdr.sgml : 20240508
<ACCEPTANCE-DATETIME>20240508072020
ACCESSION NUMBER:		0001280776-24-000009
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240508
DATE AS OF CHANGE:		20240508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		24924240

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a,d:03de21a4a78a4bacaed2eb604caec2ce-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:vtl="http://vitaltherapies.com/20240331" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-28">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-240">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-254">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-255">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-305">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-306">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-127" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-452">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:unit id="financialinstitution"><xbrli:measure>vtl:financialInstitution</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="numberofvote"><xbrli:measure>vtl:numberOfVote</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtl:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:EquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-28</xbrli:startDate><xbrli:endDate>2023-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2024</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"/><td style="width:46.038%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.406%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">332</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"/><td style="width:35.856%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On May 2, 2024, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">90,079,016</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_13">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_13">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_13">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_16">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_19">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_28">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_61">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_73">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_76">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_82">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_85">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_94">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_97">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_100">35</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:73.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.809%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">97,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">46,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">5,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">102,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">52,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-37">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-39">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-40">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-41">104,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-42">54,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">6,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">5,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">12,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">18,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-47">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-48">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">20,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">24,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-51">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-52">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="f-53">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="f-54">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">20,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-56">25,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-58"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-59"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-60">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-62">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-63"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-64"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-66">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March 31, 2024 and December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-69"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-70">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-71">500,000,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-72">130,000,000</ix:nonFraction> shares authorized as of March 31, 2024 and December 31, 2023, respectively, and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-73"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-74">90,079,016</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-76">45,177,730</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-77">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-78">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-79">519,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-80">436,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-81">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-82">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-83">440,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-84">410,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-85">83,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-86">28,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-87">104,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-88">54,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-89">18,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-90">22,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-91">5,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-92">4,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-93">23,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-94">27,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">23,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-96">27,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-97">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-98">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of the tranche rights</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-99">4,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">2,094</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-102">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-103">5,703</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-104">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">29,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">25,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-107"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-108">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-109"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-110">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-111"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-112">97,299,955</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-114">43,664,783</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:78.333%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.589%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">29,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">25,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-117">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-118">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-119">29,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-120">24,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_22"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"/><td style="width:43.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.832%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.832%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.398%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.366%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.819%"/><td style="width:0.1%"/></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-121">45,177,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-122">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">436,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-125">410,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-126">28,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-127">29,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-128">29,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-129">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-130">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-131">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-132">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and pre-funded warrants - January 2024 Financing, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-133">4,037</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-134">44,751,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-135">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-136">52,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-137">52,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of tranche rights liability to equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-138">28,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-139">28,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - At The Market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-140">6</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-141">150,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-142">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-143">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-144">90,079,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-145">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-146">519,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-147">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-148">440,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">83,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"/><td style="width:42.950%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.832%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.407%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.102%"/><td style="width:0.1%"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-150">39,307,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-151">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">317,280</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-156">25,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">25,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-158">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-159">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-160">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-161">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued from exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-162">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-163">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-164">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">44,403,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-166">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">429,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">342,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">91,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_28"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"/><td style="width:79.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.221%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-171">29,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-172">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-173">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-174">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency  loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-175">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-176">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-177">2,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-178">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of tranche rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:ChangeInFairValueOfTrancheRights" format="ixt:num-dot-decimal" scale="3" id="f-179">4,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:ChangeInFairValueOfTrancheRights" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fees expensed as part of January 2024 Financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ManagementFeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ManagementFeeExpense" format="ixt:fixed-zero" scale="3" id="f-182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-183">389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-184">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-185">1,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-186">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-187">6,145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-188">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-189">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-190">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-191">23,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-192">19,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromInvestments" format="ixt:num-dot-decimal" scale="3" id="f-194">5,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-195">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-196">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:40.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-197">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-198">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through  At The Market Sales Agreement, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-199">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-202">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from January 2024 Financing, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-203">74,273</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:40.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-205">74,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-206">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-207">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-208">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-209">50,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-210">13,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-211">46,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-212">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-213">97,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-214">92,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of tranche rights liability to equity upon increase in authorized shares</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" format="ixt:num-dot-decimal" scale="3" id="f-215">28,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-218">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-219" continuedAt="f-219-1" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="f-219-1" continuedAt="f-219-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company had approximately <ix:nonFraction unitRef="employee" contextRef="c-39" decimals="-1" name="dei:EntityNumberOfEmployees" id="f-220">80</ix:nonFraction> employees as of May 1, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome and irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:NumberOfDevelopmentPrograms" format="ixt-sec:numwordsen" id="f-221">three</ix:nonFraction> development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-222">440.5</ix:nonFraction> million as of March 31, 2024 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-223">410.9</ix:nonFraction> million as of December 31, 2023.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2024, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-224">430.9</ix:nonFraction> million from private and public offerings of preferred stock, common stock, pre-funded warrants and tranche rights. As of March 31, 2024, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-225">97.3</ix:nonFraction> million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-226" continuedAt="f-226-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-226-1"><ix:continuation id="f-219-2">instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 22, 2024. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation></ix:continuation> </span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-227" continuedAt="f-227-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-227-1" continuedAt="f-227-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-228" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-229" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" id="f-230" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-231">73.2</ix:nonFraction>&#160;million, Germany of approximately $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-232">22.5</ix:nonFraction>&#160;million and Australia of approximately $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-233">1.6</ix:nonFraction>&#160;million as of March 31, 2024. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="c-3" decimals="INF" name="vtl:NumberOfFinancialInstitutionsUsedForCashDeposits" format="ixt-sec:numwordsen" scale="0" id="f-234">two</ix:nonFraction> large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-235">5.2</ix:nonFraction>% during the period ended March 31, 2024. Cash and cash equivalents in Germany are earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-45" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-236">3.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-46" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-237">3.75</ix:nonFraction>% during the period ended March 31, 2024.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-227-2" continuedAt="f-227-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-238" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-239" continuedAt="f-239-1" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-239-1">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-240">three</span> to <ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-241">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-242">26,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-243">32,000</ix:nonFraction> for the three months ended March 31, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-244" continuedAt="f-244-1" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-244-1">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-245"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-246">no</ix:nonFraction></ix:nonFraction> impairment losses during the three months ended March 31, 2024 and 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-247" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-248" continuedAt="f-248-1" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-227-3" continuedAt="f-227-4"><ix:continuation id="f-248-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="f-249" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of <ix:nonFraction unitRef="number" contextRef="c-49" decimals="3" name="vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" scale="-2" id="f-250">43.5</ix:nonFraction>% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to <ix:nonFraction unitRef="eur" contextRef="c-42" decimals="-6" name="vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" format="ixt-sec:numwordsen" scale="0" id="f-251">one million</ix:nonFraction> Euros per year.  We recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="0" id="f-252">36,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-253">1.8</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-254"><span style="-sec-ix-hidden:f-255">other income</span></span> related to research activities performed during the three months ended March 31, 2024 and 2023, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-256" escape="true"><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-257" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-258" continuedAt="f-258-1" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="c-47" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-259">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="c-48" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-260">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-227-4" continuedAt="f-227-5"><ix:continuation id="f-258-1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" id="f-261">three</ix:nonFraction> existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-262" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-263" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2024 and 2023, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2019 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-264" continuedAt="f-264-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants and Tranche Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, financial instruments are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If financial instruments do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the financial instruments should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified financial instruments are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the financial instruments after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If financial </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-227-5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-264-1">instruments do not require liability classification under ASC 815-40, in order to conclude financial instruments should be classified as equity, the Company assesses whether the financial instruments are indexed to its common stock and whether the financial instruments are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified financial instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</ix:continuation>  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-265" continuedAt="f-265-1" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-265-1">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. The weighted average shares outstanding calculation for basic and diluted earnings per share for the three months ended March 31, 2024 includes <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-266">11,193,564</ix:nonFraction> pre-funded warrants.</ix:continuation>  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-267" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:73.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-268">10,318,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-269">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-270" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i03de21a4a78a4bacaed2eb604caec2ce_40"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-271" continuedAt="f-271-1" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="f-271-1" continuedAt="f-271-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="f-272" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.059%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-273">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-274">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="f-275">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="f-276">703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" scale="3" id="f-277">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" scale="3" id="f-278">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ResearchAndDevelopmentGrant" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ResearchAndDevelopmentGrant" format="ixt:num-dot-decimal" scale="3" id="f-280">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-281">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-282">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-283">5,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-284">5,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-285" continuedAt="f-285-1" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.474%"/><td style="width:0.1%"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-286">6,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-287">4,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-288">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-289">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-290">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-291">213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-292">6,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-293">5,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-271-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:continuation id="f-285-1"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-294">11,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-295">16,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-296">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-297">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="f-298">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedCompensationCurrent" format="ixt:num-dot-decimal" scale="3" id="f-299">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-300">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-301">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-302">12,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-303">18,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-304" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.389%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-305"><span style="-sec-ix-hidden:f-306">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-307">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-308">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-309">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-310">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-311">960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-312">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-313" continuedAt="f-313-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-313-1" continuedAt="f-313-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 for the research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional <ix:nonNumeric contextRef="c-53" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-314">27</ix:nonNumeric> months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="c-54" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-315">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="c-55" name="vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-316">six month</ix:nonNumeric> rent holiday at the beginning of the lease as well as a <ix:nonNumeric contextRef="c-55" name="vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-317">three month</ix:nonNumeric> rent holiday upon the <ix:nonNumeric contextRef="c-53" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-318">27</ix:nonNumeric> month extension starting May 2023. There were net additions of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-319">544,000</ix:nonFraction> related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="c-53" decimals="3" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-320">6</ix:nonFraction>% for the original leases and <ix:nonFraction unitRef="number" contextRef="c-57" decimals="3" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-321">8</ix:nonFraction>% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-322">257,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-323">195,000</ix:nonFraction> for the three months ended March 31, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-313-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-324" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2024</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:83.833%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.752%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="f-325">551,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="f-326">433,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="f-327">78,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="f-328">82,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="f-329">79,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" format="ixt:fixed-zero" scale="0" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="f-331">1,223,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="f-332">93,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="f-333">1,130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="f-334">3.0</ix:nonFraction>&#160;million, all of which is expected to be paid in 2024 and 2025.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-335" continuedAt="f-335-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="f-335-1" continuedAt="f-335-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-336" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:50.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.830%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-337">72,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-338">72,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-341">72,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-342">72,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.239%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-345">34,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-346">34,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-349">34,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-350">34,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-41" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-353">5.2</ix:nonFraction>% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2024. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded tranche rights of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="vtl:TrancheRightFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-354">23.6</ix:nonFraction>&#160;million at January 8, 2024 as a result of the January 2024 Financing (see note 6).  The fair value measurement of the tranche rights associated with the January 2024 Financing was classified as Level 3 under the fair value hierarchy.  The fair value of the the tranche rights was determined using a Black Scholes Option Pricing Model. The inputs to this model included a risk-free rate range of <ix:nonFraction unitRef="number" contextRef="c-75" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-355">3.93</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-76" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-356">4.36</ix:nonFraction>%, a stock price volatility range of <ix:nonFraction unitRef="number" contextRef="c-75" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-357">105</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="c-76" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-358">115</ix:nonFraction>%, an expected dividend rate of <ix:nonFraction unitRef="number" contextRef="c-77" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-359">&#8212;</ix:nonFraction>% and remaining term of <ix:nonNumeric contextRef="c-75" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-360">1.81</ix:nonNumeric>-<ix:nonNumeric contextRef="c-76" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-361">4.81</ix:nonNumeric> years.  This liability was revalued on March 4, 2024, upon approval to increase its authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-362">130</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-363">500</ix:nonFraction>&#160;million, which resulted in the reclassification of the tranche rights from a liability to equity.  This revaluation resulted in an increase in the tranche rights liability of $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" format="ixt:num-dot-decimal" scale="6" id="f-364">4.8</ix:nonFraction>&#160;million using a Black Scholes Option Pricing Model. The inputs to this model as of the date of the reclassification included a risk-free rate range of <ix:nonFraction unitRef="number" contextRef="c-79" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-365">4.16</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-80" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-366">4.63</ix:nonFraction>%, a stock price volatility range of <ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-367">90</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-368">105</ix:nonFraction>%, an expected dividend rate of <ix:nonFraction unitRef="number" contextRef="c-81" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-369">&#8212;</ix:nonFraction>% and remaining term of <ix:nonNumeric contextRef="c-79" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-370">1.66</ix:nonNumeric>-<ix:nonNumeric contextRef="c-80" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-371">4.66</ix:nonNumeric> years. The inputs used in the determination of fair value of the liability are level 3 inputs.  <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-372" continuedAt="f-372-1" escape="true">A rollforward of the fair value of the tranche rights is as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="f-372-1"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.818%"><tr><td style="width:1.0%"/><td style="width:66.928%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of January 8, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="0" id="f-374">23,600</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value through March 4, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="0" id="f-375">4,796</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to equity</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" sign="-" name="vtl:ReclassificationToEquity" format="ixt:num-dot-decimal" scale="0" id="f-376">28,396</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="0" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-335-2">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</ix:continuation>  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-378" continuedAt="f-378-1" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="f-378-1" continuedAt="f-378-2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, we filed a shelf registration statement on Form S-3 (the "2023 Shelf Registration Statement").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2023 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of May 8, 2024, the 2023 Shelf Registration statement has not been declared effective by the SEC, however, the Company can (i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expired 2020 Shelf Registration Statement until the 2023 Shelf Registration Statement has been declared effective (or May 22, 2024, if sooner); and (ii) after the 2023 Shelf Registration Statement has been declared effective, offer and sell additional securities registered on the new Form S-3, as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">unsold securities from the expired 2020 Shelf Registration Statement that are permitted by SEC rules to be included in the 2023 Shelf Registration Statement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, the Company filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement"). The 2020 Shelf Registration Statement permitted the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. The 2020 Shelf Registration Statement expired in November 2023 but, as explained above, unsold securities from this expired registration statement can continue to be sold under the 2023 Shelf Registration Statement. As of March 31, 2024, there is $75.0 million of unsold securities from this 2020 Shelf Registration Statement.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-379">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners LLC) as agent ("December 2020 ATM"). The Company has used and intends to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-83" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" format="ixt-sec:numwordsen" id="f-380">ten</ix:nonFraction> days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-381">7.3</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a Prospectus Supplement to the 2020 Shelf Registration Statement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-382">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with Leerink Partners LLC (formerly SVB Leerink LLC) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-85" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" format="ixt-sec:numwordsen" scale="0" id="f-383">ten</ix:nonFraction> days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2024, $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-384">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="f-385">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, we raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-386">0.2</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-387">150,000</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-388">1.31</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-389">0.2</ix:nonFraction>&#160;million after deducting sales agent commissions of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="0" id="f-390">6,000</ix:nonFraction>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three months ended March 31, 2023.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="f-378-2" continuedAt="f-378-3"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement of up to $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-391">240</ix:nonFraction>&#160;million ("The January 2024 Financing")</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2024, Immunic entered into a Securities Purchase Agreement with select accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a three-tranche private placement shares of the Company&#8217;s common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-392">0.0001</ix:nonFraction> par value per share or in lieu thereof, pre-funded warrants to purchase shares of Common Stock. The Pre-Funded Warrants are exercisable immediately for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-393">0.0001</ix:nonFraction> per share and until exercised in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first tranche, which closed on January 8, 2024, resulted in the purchase by the Investors of an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-394">80</ix:nonFraction>&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-395">1.43</ix:nonFraction> per share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The second tranche is a conditional mandatory purchase by the Investors of an additional $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-396">80</ix:nonFraction>&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-93" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-397">1.716</ix:nonFraction> per share, equal to <ix:nonFraction unitRef="number" contextRef="c-93" decimals="2" name="vtl:SaleOfStockConsiderationReceivedPercentage" scale="-2" id="f-398">120</ix:nonFraction>% of the price paid in the first tranche and is subject to the satisfaction of three conditions:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the <ix:nonNumeric contextRef="c-92" name="vtl:ThresholdTradingDaysForWeightedAveragePriceCalculation" format="ixt-sec:durwordsen" id="f-399">10-day</ix:nonNumeric> volume-weighted average price of the Common Stock is at least $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="2" name="vtl:WeightedAveragePriceOfLast10Days" scale="0" id="f-400">8.00</ix:nonFraction> per share during the 6 months following the data release; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">aggregate trading volume during the same <ix:nonNumeric contextRef="c-92" name="vtl:ThresholdTradingDaysForAggregateTradingVolumeCalculation" format="ixt-sec:durwordsen" id="f-401">10-day</ix:nonNumeric> period is at least $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-6" name="vtl:SaleOfStockAggregateTradingVolumeOfLast10Days" format="ixt:num-dot-decimal" scale="6" id="f-402">100</ix:nonFraction>&#160;million.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The third tranche must occur no later than <ix:nonNumeric contextRef="c-94" name="vtl:SaleOfStockEquityOfferingsPeriod" format="ixt-sec:durwordsen" id="f-403">three years</ix:nonNumeric> after the second tranche and is conditioned on the same volume-weighted average share price and minimum trading volumes as the second tranche. The third tranche provides for the issuance of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-404">80</ix:nonFraction>&#160;million of shares of common stock (or pre-funded warrants) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a &#8220;cashless&#8221; or net settlement basis, which would reduce the cash proceeds to be raised by the Company in the Private Placement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the conditions in the second or third tranches can be waived by holders of a majority of the outstanding securities (including the lead investor).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement resulted in gross proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-405">80</ix:nonFraction>&#160;million in the first tranche, and an additional $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-406">80</ix:nonFraction>&#160;million if and when the second tranche occurs. If the second tranche is completed and conditions for the third tranche are satisfied or waived, the Company could receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-407">80</ix:nonFraction>&#160;million in the third tranche. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the closing date of the transaction of January 8, 2024, the Company did not have enough authorized shares to be able to issue the potential shares for tranche 2 and tranche 3 (collectively referred to hereafter as "the tranche rights").  Therefore, the Company recorded the value associated to the tranche rights as a liability of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" format="ixt:num-dot-decimal" scale="6" id="f-408">23.6</ix:nonFraction>&#160;million and allocated the remainder of the $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="vtl:TrancheRightsAsALiabilityRemainderAmount" format="ixt:num-dot-decimal" scale="6" id="f-409">80</ix:nonFraction>&#160;million received (or $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="vtl:TrancheRightsAsALiabilityReceivedAmount" format="ixt:num-dot-decimal" scale="6" id="f-410">56.4</ix:nonFraction>&#160;million) with the common stock and pre-funded warrants to equity.  On March 4, 2024, the stockholders voted to increase the Company's authorized common shares from <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-411">130</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-412">500</ix:nonFraction>&#160;million shares.  As a result of the ability to issue shares in satisfaction of the tranche rights, the instrument was reclassified to stockholders' equity.  The Company allocated the transaction cost across the instruments on a relative fair value basis at the grant date. As a result $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-413">4.0</ix:nonFraction>&#160;million was netted against the equity proceeds and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-414">1.7</ix:nonFraction>&#160;million  was recorded in other expense in the Consolidated Statements of Operation for the three months ended March 31, 2024.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company registered for resale by the investors in the January 2024 Financing up to <ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="vtl:CommonStockNumberOfSharesRegisteredForResale" format="ixt:num-dot-decimal" scale="0" id="f-415">55,944,850</ix:nonFraction> shares of common stock issued (or issuable upon exercise of pre-funded warrants) in the first tranche. The Company will not receive any proceeds from the sale of these shares of common stock. These shares are registered on a registration statement on Form S-3 (registration No. 333-277040), which was declared effective by the SEC on April 30, 2024. </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the stockholders of the Company voted to increase the authorized shares of the Company from <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-416">130,000,000</ix:nonFraction> shares of common stock to <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-417">500,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-418">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to <ix:nonFraction unitRef="numberofvote" contextRef="c-3" decimals="INF" name="vtl:NumberOfVotesPerEachShareOfCommonStock" format="ixt-sec:numwordsen" scale="0" id="f-419">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-378-3"><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2024, <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="f-420"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="f-421">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-422">11,193,564</ix:nonFraction> pre-funded warrants in connection with the January 2024 Financing, which all remain outstanding as of March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-423">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-424">0.0001</ix:nonFraction> par value preferred stock, rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-425">No</ix:nonFraction> preferred shares were issued or outstanding as of March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="c-1" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="f-426" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2024 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-427">1,000,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-428">11,193,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-429">10,318,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares reserved for tranche 2 rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-430">46,620,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Maximum shares reserved for tranche 3 rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-431">46,620,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-432">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-433">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-434">9,131,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-435">124,973,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_52"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-436" continuedAt="f-436-1" escape="true">Stock-Based Compensation Plans </ix:nonNumeric></span></div><ix:continuation id="f-436-1" continuedAt="f-436-2"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="c-114" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-437">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-438">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares initially reserved for delivery under the plan was <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-439">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This maximum number was increased by <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-440">1</ix:nonFraction>&#160;million shares through approval by stockholders of the Company at the Company's Special Meeting of stockholders held on March 4, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-441">199,989</ix:nonFraction> shares life-to-date under the ESPP.   The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="f-442">0</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-443">46,000</ix:nonFraction> of expense related to the plan during the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan, as amended on June 28, 2023 (the &#8220;2019 Plan&#8221;), which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-444">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-436-2" continuedAt="f-436-3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included an evergreen provision that allowed for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="c-121" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="f-445">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-446">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-447">4,408,871</ix:nonFraction> shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-448">4,440,000</ix:nonFraction> shares as well as to eliminate the evergreen provision.  On March 4, 2024, the stockholders voted at the Company's Special Meeting to increase the allowable shares under the 2019 plan by <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-449">9,100,000</ix:nonFraction>.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="c-125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="f-450">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="c-126" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-451">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-452">three</span> or <ix:nonNumeric contextRef="c-128" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-453">four years</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Repricing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the Company's stockholders voted to approve the repricing of outstanding stock options having an exercise price above $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-454">3.00</ix:nonFraction> per share to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-79" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-455">1.72</ix:nonFraction> per share.  All other terms of the grant remained the same. There were <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="vtl:ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-456">3,317,596</ix:nonFraction> stock options that were repriced to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-81" decimals="2" name="vtl:ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" scale="0" id="f-457">1.72</ix:nonFraction> per share.  The repricing will result in an addition $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="f-458">1.2</ix:nonFraction>&#160;million of stock compensation being recognized by the Company over the remaining term of the repriced grants and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-459">0.9</ix:nonFraction>&#160;million of this amount recognized in the quarter ended March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-460" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2024 and 2023, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-461">6,196,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-462">7.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-463">4,175,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-464">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repricing Modification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" format="ixt:fixed-zero" scale="0" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="vtl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" scale="0" id="f-468">9.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-469">53,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-470">5.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-471">10,318,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-472">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-473">8.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-474">462,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-475">10,318,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-476">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-477">8.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-478">462,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-479">3,224,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-480">2.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-481">7.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-482">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:52.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.421%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-483">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-484">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-485">1,815,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-486">1.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-489">11,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-490">13.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-491">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-492">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-493">8.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-494">161,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-495">5,595,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-496">8.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-497">8.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-498">161,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-499">1,888,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-500">12.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-501">7.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-502">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-436-3" continuedAt="f-436-4"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-503">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan (excluding the repriced stock options) during the three months ended March 31, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-504">0.97</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-505">1.15</ix:nonFraction>, respectively. The weighted average grant date fair value of the repriced stock options was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" scale="0" id="f-506">1.22</ix:nonFraction>.  <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-507" continuedAt="f-507-1" escape="true">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span><ix:continuation id="f-507-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-508">4.05</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-509">3.97</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-510">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-511">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-512">100.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-513">102.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-135" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-514">6.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-136" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-515">6.02</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-516" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:72.529%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-517">1,163,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-518">903,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-519">1,587,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-520">1,076,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-521">2,750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="f-522">1,979,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-523">13.5</ix:nonFraction>&#160;million in total unrecognized compensation expense relating to the 2019 Plan, including $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="f-524">0.3</ix:nonFraction>&#160;million related to repriced stock options, to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-135" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-525">3.17</ix:nonNumeric> years.  There was $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-526">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-527">0.3</ix:nonFraction>&#160;million of stock-based compensation expense during the three months ended March 31, 2024 related to the repricing included in general and administrative and research and development expense respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-436-4"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#8220;Vital&#8221;) following an exchange transaction (the &#8220;Transaction&#8221;) with Immunic AG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-528">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-529">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-530"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-531">No</ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three months ended March 31, 2024 and 2023, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-532" continuedAt="f-532-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-532-1"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="vtl:SalaryAndWageOfficerMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-533">30,250</ix:nonFraction> per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#8217;s monthly base salary to $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="0" name="vtl:SalaryAndWageOfficerMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-534">32,368</ix:nonFraction> from $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="0" name="vtl:SalaryAndWageOfficerMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-535">30,250</ix:nonFraction> (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item&#160;1 &#8220;Financial Statements&#8221; in this Quarterly Report and audited Consolidated Financial Statements for the years ended December 31, 2023 and 2022 of Immunic, Inc. filed with the Securities and Exchange Commission ("SEC"), on our Annual Report on Form 10-K on February 22, 2024. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors,&#8221; and the differences may be material. These risk factors include, but are not limited to statements relating to our two development programs and the targeted diseases; the potential for vidofludimus calcium and IMU-856 to safely and effectively target diseases; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We  had approximately 80 employees as of May 1, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease (&#8220;IBD&#8221;), short bowel syndrome and irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="text-align:justify;text-indent:22.5pt"><img src="vtl-20240331_g1.jpg" alt="pipeline_01_2023_2000px.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;), designed to corroborate vidofludimus calcium&#8217;s neuroprotective potential, are ongoing. On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus calcium&#8217;s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential. Top-line data from the CALLIPER trial, for which the recruitment of in total 467 patients was completed in August 2023, is expected to be available in April 2025. Moreover, we currently expect to report an interim futility analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials in the second quarter of 2026. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Preclinical data showed that vidofludimus calcium activates the neuroprotective transcription factor nuclear receptor related 1 (&#8220;Nurr1&#8221;), which is associated with direct neuroprotective properties and may enhance the potential benefit for patients. Additionally, vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and antiviral effects of vidofludimus calcium. We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting MS patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging (&#8220;MRI&#8221;) lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&#8220;NfL&#8221;), an important biomarker of neuronal damage. Vidofludimus calcium has shown in clinical trials reported to date a consistent pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,800 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (&#8220;SIRT6&#8221;), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, IBD, short bowel syndrome, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. Based on preclinical investigations demonstrating no suppression of immune cells, IMU-856 may have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications and may allow the potential for combination with available treatments in gastroenterological diseases.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data from a Phase 1b clinical trial in celiac disease patients during periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We are currently preparing clinical Phase 2 testing of IMU-856 in patients with ongoing active celiac disease (&#8220;OACD&#8221;) despite gluten-free diet, while also considering further potential clinical applications in other gastrointestinal disorders.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic has selected IMU-381 as a development candidate to specifically address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">Additional research and development activities remain ongoing through preclinical research examining the potential to treat a broad set of neuroinflammatory, autoimmune and viral diseases with new molecules leveraging our chemical and pharmacological research platform as well as generated intellectual property in these areas.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this should result in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to perform research and development activities in the Australasia region. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including delays in clinical trials, the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Strategy </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in RMS and PMS, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Continuing preclinical research to complement the existing clinical activities, explore additional indications for future development and generating additional molecules for potential future development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products approved for commercial sale and has not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception in 2016.  We have an accumulated deficit of approximately $440.5 million as of March 31, 2024 and $410.9 million as of December 31, 2023.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the development of our product candidates and add personnel necessary to advance our pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect that our operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2024, we have raised net cash of approximately $430.9 million from private and public offerings of preferred stock, common stock, pre-funded warrants and tranche rights. As of March 31, 2024, we had cash and cash equivalents of approximately $97.3 million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">Key Status Updates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Private Placement of up to $240 Million ("The January 2024 Financing")</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2024, Immunic entered into a Securities Purchase Agreement with select accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a three-tranche private placement shares of the Company&#8217;s common stock, $0.0001 par value per share or in lieu thereof, pre-funded warrants to purchase shares of Common Stock. The Pre-Funded Warrants are exercisable immediately for $0.0001 per share and until exercised in full.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first tranche, which closed on January 8, 2024, resulted in the purchase by the Investors of an aggregate of $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.43 per share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The second tranche is a conditional mandatory purchase by the Investors of an additional $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.716 per share, equal to 120% of the price paid in the first tranche and is subject to the satisfaction of three conditions:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the 10-day volume-weighted average price of the Common Stock is at least $8.00 per share during the 6 months following the data release; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">aggregate trading volume during the same 10-day period is at least $100&#160;million.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The third tranche must occur no later than three years after the second tranche and is conditioned on the same volume-weighted average share price and minimum trading volumes as the second tranche. The third tranche provides for the issuance of $80&#160;million of shares of common stock (or pre-funded warrants) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a &#8220;cashless&#8221; or net settlement basis, which would reduce the cash proceeds to be raised by the Company in the Private Placement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the conditions in the second or third tranches can be waived by holders of a majority of the outstanding securities (including the lead investor).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement resulted in gross proceeds to the Company of approximately $80&#160;million in the first tranche, and an additional $80&#160;million if and when the second tranche occurs. If the second tranche is completed and conditions for the third tranche are satisfied or waived, the Company could receive up to an additional $80&#160;million in the third tranche. However, the amount of cash received in the third tranche would depend on the extent to which the Investors elect to fund the third tranche through a &#8220;cashless&#8221; or net settlement basis. Therefore, total gross proceeds from the offering to the Company could actually be between $80&#160;million and $240&#160;million. Gross proceeds to the Company will be reduced by fees paid to the placement agents, capital markets advisors and payments of transaction expenses. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-856 and IMU-381, and for other general corporate purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the closing date of the transaction of January 8, 2024, the Company did not have enough authorized shares to be able to issue the potential shares for tranche 2 and tranche 3 (collectively referred to hereafter as "the tranche rights").  Therefore, the Company recorded the value associated to the tranche rights as a liability of $23.6 million and allocated the remainder of the $80 million received (or $56.4 million) with the common stock and pre-funded warrants to equity.  On March 4, 2024, the stockholders voted to increase the Company's authorized common shares from 130&#160;million to 500&#160;million shares.  As a result of the ability to issue shares in satisfaction of the tranche rights, the instrument was reclassified to stockholders' equity.  The Company allocated the transaction cost across the instruments on a relative fair value basis. As a result $4.0 million was netted against the equity proceeds and $1.7&#160;million  was recorded in other expense in the Consolidated Statements of Operation for the three months ended March 31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financing was led by BVF Partners L.P., and included participation from new and existing investors, including Avidity Partners, Janus Henderson Investors, Soleus Capital, RTW Investments and Adage Capital Partners LP. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leerink Partners acted as the lead placement agent and Ladenburg Thalmann acted as a placement agent in connection with the offering. Piper Sandler, B. Riley Securities and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as capital markets advisors to the Company.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company registered for resale by the investors in the January 2024 Financing up to 55,944,850 shares of common stock issued (or issuable upon exercise of pre-funded warrants) in the first tranche. The Company will not receive any proceeds from the sale of these shares of common stock. These shares are registered on a registration statement on Form S-3 (registration No. 333-277040), which was declared effective by the SEC on April 30, 2024. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 20, 2024, we announced Notice of Allowance from the United States Patent and Trademark Office (&#8220;USPTO&#8221;) for patent application 16/981,122, entitled, &#8220;Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,&#8221; covering the composition-of-matter of a specific polymorph of vidofludimus calcium and a related </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">method of production of the material. The claims are expected to provide protection into 2039, unless extended further. The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology&#174; Neuroimmunology &amp; Neuroinflammation</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 30, 2024, we announced that data from our phase 2 EMPhASIS trial of vidofludimus calcium in patients with relapsing-remitting MS has been published online on April 25, 2024 in Neurology&#174; Neuroimmunology &amp; Neuroinflammation, an official journal of the American Academy of Neurology. The paper, lead authored by coordinating investigator, Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, is entitled, &#8220;Safety and Dose-Response of Vidofludimus Calcium in Relapsing Multiple Sclerosis: Extended Results of a Placebo-Controlled Phase 2 Trial.&#8221;</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $316.8 million in research and development expenses through March 31, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, IMU-856 and IMU-381. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $726,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $726,000 of income in total which was classified in Other Income in the accompanying consolidated statement of operations. No income was recorded for the periods ending March 31, 2023 and 2024. The funding of this grant is now completed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2023 and 2024 as global interest rates have been increasing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in the Fair Value of the Tranche Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change in fair value of the tranche rights is a non-cash charge related to the change in fair value of the tranche 2 and tranche 3 rights associated with the January 2024 Financing from January 8, 2024 until March 4, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists of (i) deal costs from the January 2024 Financing related to tranche rights that were established at the time of the  deal closing (ii) a research and development tax incentive related to clinical trials performed in Australia, (iii) a German Government research and development grant and (iv) foreign currency transaction gains and losses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2024 and 2023 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended March 31, 2024 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.621%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,881&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,251&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,370)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,881)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,251)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of the tranche rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,273)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(278)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,703)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,682)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,584)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,272)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,312)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses decreased by $4.2 million during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023. The decrease reflects (i) a decrease of $2.4 million from deprioritizing the izumerogant program in psoriasis and castration-resistant prostate cancer, (ii) a $1.4 million decrease in external development costs related to the vidofludimus calcium programs and (iii) a $1.1 million decrease in external development costs related to IMU-856 due to the completion of the phase 1 trial in celiac disease. The decreases were offset by a $0.7 million increase in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">personnel costs, $0.3 million of which is related to non-cash stock compensation and the remainder of which is due to an increase in headcount.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $0.9 million during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023. The increase was primarily due to (i) a $0.8 million increase in personnel expense in general and administrative, $0.5 million of which is related to non-cash stock compensation expense and the remainder of which is related to an increase in headcount and (ii) $0.1 million in legal and consultancy expenses.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Interest income increased by $0.4 million during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023 due to higher interest rates.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The change in fair value of the tranche rights of $4.8 million is a non-cash charge related to the change in value of the tranche rights associated with the January 2024 Financing from January 8, 2024 until March 4, 2024.  These tranches were initially classified as a liability but were reclassified to equity on March 4, 2024 when stockholders approved the increase in our authorized shares from 130 million to 500 million shares of common stock and therefore the tranche 2 and tranche 3 rights needed to be revalued to fair value upon the reclass to equity.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income decreased by $3.3 million during the three months ended March 31, 2024, as compared to the three months ended March 31, 2023. The decrease was primarily attributable to (i) a $1.7 million expense related to the portion of deal costs from the January 2024 Financing related to the tranche rights that were established at the time of the  deal closing, (ii) the German Federal Ministry of Finance grant of $1.1 million being recognized  in the fourth quarter of 2023 which was one quarter earlier than in the prior year that was recognized in the first quarter of 2023 and (iii) a $0.5 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products approved for commercial sale and has not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since inception in 2016.  We have an accumulated deficit of approximately $440.5 million as of March 31, 2024 and $410.9 million as of December 31, 2023.  Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2024, we have raised net cash of approximately $430.9 million from private and public offerings of preferred stock, common stock, prefunded warrants and tranche rights. As of March 31, 2024, we had cash and cash equivalents of approximately $97.3 million. With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, we filed a shelf registration statement on Form S-3 (the "2023 Shelf Registration Statement").  The 2023 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of May 8, 2024, the 2023 Shelf Registration statement has not been declared effective by the SEC, however, the Company can (i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expired 2020 Shelf Registration Statement until the 2023 Shelf Registration Statement has been declared effective (or May 22, 2024, if sooner); and (ii) after the 2023 Shelf Registration Statement has been declared effective, offer and sell additional securities to be registered on the new Form S-3, as well as unsold securities from the expired 2020 Shelf Registration Statement that are permitted by SEC rules to be included in the new 2023 Shelf Registration Statement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permitted the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. The 2020 Shelf Registration Statement expired in November 2023 but, as explained above, unsold securities from this expired registration statement can continue to be sold under the 2023 Shelf Registration Statement. As of March 31, 2024, there is $75.0 million of unsold securities from this 2020 Shelf Registration Statement.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement to the 2020 Shelf Registration Statement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners LLC) as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, $7.3 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, we filed a Prospectus Supplement to the 2020 Shelf Registration Statement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with Leerink Partners LLC (formerly SVB Leerink LLC) as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2024, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We agreed to pay Leerink Partners LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, we raised gross proceeds of $0.2 million pursuant to the December 2020 ATM through the sale of 150,000 shares of common stock at a weighted average price of $1.31 per share. The net proceeds from the December 2020 ATM were $0.2 million after deducting sales agent commissions of $6,000. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any ATM activity during the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement of up to $240 Million</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2024, Immunic entered into a Securities Purchase Agreement with select accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a three-tranche private placement shares of the Company&#8217;s common stock, $0.0001 par value per share or in lieu thereof, pre-funded warrants to purchase shares of Common Stock. The pre-funded warrants are exercisable immediately for $0.0001 per share and until exercised in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first tranche, which closed on January 8, 2024, resulted in the purchase by the Investors of an aggregate of $80 million of Common Stock (or pre-funded warrants) from the Company at a price of $1.43 per share;  The second tranche is a conditional mandatory purchase by the Investors of an additional $80 million of Common Stock (or pre-funded warrants) from the Company at a price of $1.716 per share, equal to 120% of the price paid in the first tranche and is subject to the satisfaction of three conditions:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the 10-day volume-weighted average price of the Common Stock is at least $8.00 per share during the 6 months following the data release; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">aggregate trading volume during the same 10-day period is at least $100 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third tranche must occur no later than three years after the second tranche and is conditioned on the same volume-weighted average share price and minimum trading volumes as the second tranche. The third tranche provides for the issuance of $80 million of shares of common stock (or pre-funded warrants) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a &#8220;cashless&#8221; or net settlement basis, which would reduce the cash proceeds to be raised by the Company in the Private Placement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the conditions in the second or third tranches can be waived by holders of a majority of the outstanding securities (including the lead Investor).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement resulted in gross proceeds to the Company of approximately $80 million in the first tranche, and an additional $80 million if and when the second tranche occurs. If the second tranche is completed and conditions for the third tranche are satisfied or waived, the Company could receive up to an additional $80 million in the third tranche. However, the amount of cash received in the third tranche would depend on the extent to which the Investors elect to fund the third tranche through a &#8220;cashless&#8221; or net settlement basis. Therefore, total gross proceeds from the offering to the Company could actually be between $80 million and $240 million. Gross proceeds to the Company will be reduced by fees paid to the placement agents, capital markets advisors and payments of transaction expenses. The Company intends to use the net proceeds from the Private Placement to fund the ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-856 and IMU-381, and for other general corporate purposes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. We expect our expenses to continue to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, duration, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. We do not expect to achieve revenue from product sales prior to the use of all the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us.  Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates over the past few years. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, or other business combination, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have to curtail our product development programs and liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, we had approximately  $97.3 million in cash and cash equivalents.</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the three months ended March 31, 2024 and 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,969)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,513)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2024, operating activities used $24.0 million of cash. The use of cash primarily resulted from (i) our net loss of $29.6 million adjusted for non-cash charges of $7.9 million related to a $4.8 million change in the fair value of the tranche rights, $2.8 million for stock-based compensation and $0.3 million related to unrealized foreign currency loss and depreciation and amortization as well as fees expensed as part of the January 2024 Financing (ii) a $4.0 million net decrease in our operating assets and liabilities. Changes in our operating assets and liabilities during the three months ended March 31, 2024 consisted primarily of  a net decrease of $4.4 million in accounts payable and other accrued expenses partially offset by $0.4 million decrease in our other current assets and prepaid expenses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2023, operating activities used $19.5 million of cash. The use of cash primarily resulted from (i) our net loss of $25.3 million adjusted for non-cash charges of $2.0 million related to stock-based compensation, $0.5 million related to unrealized foreign currency loss and depreciation and amortization and (ii) a $3.3 million net decrease in our operating assets and liabilities. Changes in our operating assets and liabilities during the three months ended March 31, 2023 consisted primarily of  a decrease of $3.2 million in accounts payable and other accrued expenses as well as a $0.1 million decrease in our other current assets and prepaid expenses. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024, net investing activities used $31,000 due to the purchase of property and equipment.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, net investing activities provided $5.3 million of cash, primarily due to the sale of $5.4 million of time deposits partially offset by the purchase of $104,000 of property and equipment. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $74.4 million during the three months ended March 31, 2024 primarily consisting of net cash proceeds from the January 2024 Financing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $51,000 during the three months ended March 31, 2023 consisting of net cash proceeds from the issuance of common stock related to the exercise of pre-funded warrants.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2024, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 - Collaboration Arrangements of the Notes to the Financial Statements regarding the Company&#8217;s obligations under the option agreement with Daiichi Sankyo, which includes the potential payment of future development, regulatory and sales milestone payments, as well as royalties related to IMU-856</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2024:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:84.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, we have non-cancelable contractual obligations under certain agreements related to our development programs vidofludimus calcium and IMU-856 totaling approximately $3.0&#160;million, all of which is expected to be paid in 2024 and 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2024, we had a change in our warrants and tranche rights accounting policy which is described along with our other significant accounting policies in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) Note 2 to our audited consolidated financial statements for the years ended December 31, 2023 and 2022 filed in our Annual Report on Form 10-K on February 22, 2024.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents and investments of $97.3 million as of March 31, 2024, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $22.5&#160;million of these funds are held in German bank accounts that were earning between 3.5%-3.75% interest as of March 31, 2024.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on our financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our consolidated balance sheets. As of March 31, 2024, our German and Australian subsidiaries had net current assets (defined as current assets less current liabilities), subject to foreign currency translation risk, of $10.3 million. A decrease of approximately $1.0 million in net current assets would result as of March 31 2024, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the three months ended March 31, 2024, would have impacted our net loss by approximately $1.9 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934, as amended ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_79"></div><div><span><br/></span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Risk factors in the Company's 2023 Form 10K filed on February 22, 2024.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_100"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan, as amended</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 21, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380521001075/e620824_s8-immunic.htm">Amended and Restated 2021 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 28, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001425/e619010_ex10-1.htm">Addendum No. 5, dated October 17, 2023, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 17, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-3.htm">Employment Agreement, dated December 18, 2023, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 18, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-1.htm">ifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 18, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-2.htm">Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 18, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523001637/e619130_ex10-4.htm">Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 18, 2023</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380524000022/e619173_ex10-1.htm">Securities Purchase Agreement, dated January 4, 2024, by and among the Company and the Investors.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 4, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-4.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000128077623000004/imux-ex105dienstvertragand.htm">Service Agreement, dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000128077623000004/imux-ex106dienstvertragdan.htm">Service Agreement, dated September 29, 2016, between Immunic AG and Daniel Vitt.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 23, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex10-5.htm">Employment Agreement between Dr. Daniel Vitt and Immunic AG.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000797/e618637_ex99-3.htm">Employment Agreement, dated September 4, 2019, between Immunic, Inc. and Dr. Andreas Muehler.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 5, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380520000499/e619564_ex10-2.htm">Employment Agreement dated April 17, 2020, between Immunic, Inc. and Duane Nash.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 20, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-3.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521000860/e620704_ex10-4.htm">Employment Agreement, dated June 10, 2021 between Immunic, Inc. and Glenn Whaley</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 10, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001280776/000119380521001455/e621010_ex10-1.htm">Employment Agreement, dated October 14, 2021, between Immunic, Inc. and Patrick Walsh</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 14, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i03de21a4a78a4bacaed2eb604caec2ce_103">Power of Attorney (included on the signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33124xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33124xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-3x31x24xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-33124xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:53.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i03de21a4a78a4bacaed2eb604caec2ce_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;8, 2024&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>imux-33124xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i50ef9e4a287e4c6c9ba3a40af1d0725b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>imux-33124xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia7b2866d19b34f7db98f4e30b8bb7a3f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>imux-3x31x24xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id8e872d9988440688265e4493bccff17_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>imux-33124xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia7fb5e7d499040b3b362d7be4a0b057d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 8, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vtl-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000009 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>0000011 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>0000013 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>0000014 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>0000016 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>9954473 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954474 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>9954475 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>9954476 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>9954477 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>9954480 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>9954481 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>9954482 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>9954483 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>9954484 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>9954486 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>9954486 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954487 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFairValueofTrancheRightsDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails">
        <link:definition>9954488 - Disclosure - Fair Value - Schedule of Fair Value of Tranche Rights (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalInformationDetail" roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail">
        <link:definition>9954489 - Disclosure - Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityOfferingDetails" roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails">
        <link:definition>9954491 - Disclosure - Common Stock - Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>9954492 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPrefundedWarrantsDetails" roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails">
        <link:definition>9954493 - Disclosure - Common Stock - Pre-funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>9954494 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockScheduleofSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails">
        <link:definition>9954495 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>9954496 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails">
        <link:definition>9954497 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail">
        <link:definition>9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>9954499 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954500 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" abstract="false" name="ThresholdTradingDaysForWeightedAveragePriceCalculation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" abstract="false" name="GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TrancheRightFairValueDisclosure" abstract="false" name="TrancheRightFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_PlaneggGermanyMember" abstract="true" name="PlaneggGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_January2024PIPETransactionMember" abstract="true" name="January2024PIPETransactionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AtTheMarketSalesAgreementMember" abstract="true" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" abstract="false" name="ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" abstract="false" name="ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_WeightedAveragePriceOfLast10Days" abstract="false" name="WeightedAveragePriceOfLast10Days" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_CommonStockAndPreFundedWarrantsMember" abstract="true" name="CommonStockAndPreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentGrant" abstract="false" name="ResearchAndDevelopmentGrant" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_SalaryAndWageOfficerMonthlyBaseSalary" abstract="false" name="SalaryAndWageOfficerMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" abstract="false" name="GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SaleOfStockConsiderationReceivedPercentage" abstract="false" name="SaleOfStockConsiderationReceivedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" abstract="false" name="FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_AccreditedInvestorsMember" abstract="true" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" abstract="false" name="FairValueChangeInFairValueOfTrancheRightsTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_TrancheRightsAsALiabilityReceivedAmount" abstract="false" name="TrancheRightsAsALiabilityReceivedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" abstract="false" name="SaleOfStockAggregateTradingVolumeOfLast10Days" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NumberOfVotesPerEachShareOfCommonStock" abstract="false" name="NumberOfVotesPerEachShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_SaleOfStockEquityOfferingsPeriod" abstract="false" name="SaleOfStockEquityOfferingsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" abstract="false" name="ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtl_TrancheRightsAsALiabilityRemainderAmount" abstract="false" name="TrancheRightsAsALiabilityRemainderAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_ReclassificationToEquity" abstract="false" name="ReclassificationToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_ChangeInFairValueOfTrancheRights" abstract="false" name="ChangeInFairValueOfTrancheRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" abstract="false" name="ThresholdTradingDaysForAggregateTradingVolumeCalculation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_CommonStockNumberOfSharesRegisteredForResale" abstract="false" name="CommonStockNumberOfSharesRegisteredForResale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vtl-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a0cf1a3b-8fce-4fff-9a1c-2c7ec2eb0ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83ff7f47-d601-4214-9e9f-e49ed8ff41ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_a0cf1a3b-8fce-4fff-9a1c-2c7ec2eb0ca2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_83ff7f47-d601-4214-9e9f-e49ed8ff41ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2c9fbf1-ce4c-464f-84c0-b31aca528ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ab38333c-3e06-4000-a7de-579766b4e9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2c9fbf1-ce4c-464f-84c0-b31aca528ea9" xlink:to="loc_us-gaap_StockholdersEquity_ab38333c-3e06-4000-a7de-579766b4e9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0802db45-c8b8-432a-9021-bcef7f09403a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2c9fbf1-ce4c-464f-84c0-b31aca528ea9" xlink:to="loc_us-gaap_Liabilities_0802db45-c8b8-432a-9021-bcef7f09403a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_931a36d6-74a8-43ff-8661-ebcc2c01e405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2c9fbf1-ce4c-464f-84c0-b31aca528ea9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_931a36d6-74a8-43ff-8661-ebcc2c01e405" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5e1a1a8f-917b-4677-a5bd-135c8e44d802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:to="loc_us-gaap_PreferredStockValue_5e1a1a8f-917b-4677-a5bd-135c8e44d802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_73bb1abe-a40d-4241-a9bf-abc4610e7f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:to="loc_us-gaap_CommonStockValue_73bb1abe-a40d-4241-a9bf-abc4610e7f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_60753370-7db0-4f72-a2d9-46534731b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:to="loc_us-gaap_AdditionalPaidInCapital_60753370-7db0-4f72-a2d9-46534731b1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfaa8029-a51a-45a2-b88d-7d58d746d3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dfaa8029-a51a-45a2-b88d-7d58d746d3ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6d05d99e-67dd-4005-9ec0-5aa0e7ccd594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_09910d27-9f38-4dec-a0a1-51851b36ec27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6d05d99e-67dd-4005-9ec0-5aa0e7ccd594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e8818a65-7e0e-473d-aebf-adbb83872529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f1d588cc-869e-49ba-88fb-74257cf2fd54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8818a65-7e0e-473d-aebf-adbb83872529" xlink:to="loc_us-gaap_LiabilitiesCurrent_f1d588cc-869e-49ba-88fb-74257cf2fd54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_966d3754-b176-426e-be05-8f86609a58b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e8818a65-7e0e-473d-aebf-adbb83872529" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_966d3754-b176-426e-be05-8f86609a58b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2c4e75bf-0d4d-4236-ae6f-96d5bc5ce51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37154e5-470e-4a93-a378-2967b05b5e18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c4e75bf-0d4d-4236-ae6f-96d5bc5ce51d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a37154e5-470e-4a93-a378-2967b05b5e18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_823d80ce-57a1-47b7-99a2-661333d3b835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_2c4e75bf-0d4d-4236-ae6f-96d5bc5ce51d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_823d80ce-57a1-47b7-99a2-661333d3b835" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e9b57c42-7af6-4f9f-9dbd-ab987f1a8835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_891ceefe-13a0-4805-9c9b-f35aab17dba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e9b57c42-7af6-4f9f-9dbd-ab987f1a8835" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_891ceefe-13a0-4805-9c9b-f35aab17dba6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2a986ec0-2099-4d46-93a9-bc9b8b46f8da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e9b57c42-7af6-4f9f-9dbd-ab987f1a8835" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2a986ec0-2099-4d46-93a9-bc9b8b46f8da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b3c8664-242b-4cb3-b625-8815dcbc28a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e9b57c42-7af6-4f9f-9dbd-ab987f1a8835" xlink:to="loc_us-gaap_AssetsCurrent_7b3c8664-242b-4cb3-b625-8815dcbc28a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b159db4e-e788-4908-83db-37401b65b3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1c30ce5d-b310-4f38-a0e7-553b7e7cc9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b159db4e-e788-4908-83db-37401b65b3b9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1c30ce5d-b310-4f38-a0e7-553b7e7cc9c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f22d304-b97d-45da-86a4-48b3cbd5b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b159db4e-e788-4908-83db-37401b65b3b9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f22d304-b97d-45da-86a4-48b3cbd5b5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e1096410-6fb1-4083-b62a-3db043cf05f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b159db4e-e788-4908-83db-37401b65b3b9" xlink:to="loc_us-gaap_AccountsPayableCurrent_e1096410-6fb1-4083-b62a-3db043cf05f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1e59084-ac1d-4d08-968f-666e70457996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b68e0093-a643-4dc8-8021-b99caa353815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a1e59084-ac1d-4d08-968f-666e70457996" xlink:to="loc_us-gaap_OperatingIncomeLoss_b68e0093-a643-4dc8-8021-b99caa353815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8c353563-9e22-427f-8f6f-3d73bb485932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a1e59084-ac1d-4d08-968f-666e70457996" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8c353563-9e22-427f-8f6f-3d73bb485932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a9424ab5-8632-4ae4-a9c6-5358c9d7cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0c43c50f-ed92-419f-9ba2-99883e598045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a9424ab5-8632-4ae4-a9c6-5358c9d7cac5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0c43c50f-ed92-419f-9ba2-99883e598045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_fe420e40-9242-40c8-8220-d992edd7070a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_a9424ab5-8632-4ae4-a9c6-5358c9d7cac5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_fe420e40-9242-40c8-8220-d992edd7070a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a8b16796-7395-40c3-8073-27a3f4b465c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_e965d378-1bcf-4f46-a121-d2939077073a" xlink:href="vtl-20240331.xsd#vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a8b16796-7395-40c3-8073-27a3f4b465c5" xlink:to="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_e965d378-1bcf-4f46-a121-d2939077073a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8851048c-603a-4f25-8fb7-4663a1b20fca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a8b16796-7395-40c3-8073-27a3f4b465c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8851048c-603a-4f25-8fb7-4663a1b20fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fcecddae-e3df-4a19-b9c1-09b7d1e9d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a8b16796-7395-40c3-8073-27a3f4b465c5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fcecddae-e3df-4a19-b9c1-09b7d1e9d36c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_98387fe6-8e8d-43fa-ae34-0d662857c161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3076a871-df1e-4713-be1a-768fdd616d07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_98387fe6-8e8d-43fa-ae34-0d662857c161" xlink:to="loc_us-gaap_OperatingExpenses_3076a871-df1e-4713-be1a-768fdd616d07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e772653-dba8-4d86-8704-dfc8e9d7b7be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f2a1b5ba-3fc0-4bb4-98a1-58364b1d3d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e772653-dba8-4d86-8704-dfc8e9d7b7be" xlink:to="loc_us-gaap_NetIncomeLoss_f2a1b5ba-3fc0-4bb4-98a1-58364b1d3d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_23a06db3-91d2-4939-be37-93558bcfb689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1e772653-dba8-4d86-8704-dfc8e9d7b7be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_23a06db3-91d2-4939-be37-93558bcfb689" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed1e9016-bf8b-4fa1-9b8e-033730e86b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_adf9ef75-45a4-41a9-abe1-b08a1a4200c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed1e9016-bf8b-4fa1-9b8e-033730e86b8f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_adf9ef75-45a4-41a9-abe1-b08a1a4200c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_c849fa80-64c3-4bf9-b89b-9e455ad4c031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed1e9016-bf8b-4fa1-9b8e-033730e86b8f" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_c849fa80-64c3-4bf9-b89b-9e455ad4c031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_020e699a-0e7c-46d5-9267-a9488effb60d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_020e699a-0e7c-46d5-9267-a9488effb60d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aac00caa-1e35-4bd1-adac-d1b110e51586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_NetIncomeLoss_aac00caa-1e35-4bd1-adac-d1b110e51586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_72796269-1251-4837-947f-8898260ea8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_72796269-1251-4837-947f-8898260ea8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ab06b296-0748-4fb6-8381-e5833f3fdbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ab06b296-0748-4fb6-8381-e5833f3fdbc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2097c0fe-b8f2-4498-9e84-3b138dd21b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2097c0fe-b8f2-4498-9e84-3b138dd21b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4edf78ec-76b3-41ee-b793-8eb701a2d211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4edf78ec-76b3-41ee-b793-8eb701a2d211" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86b0cb8c-7f9a-4bfb-a967-72e97945ac56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_86b0cb8c-7f9a-4bfb-a967-72e97945ac56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_45cfe6ee-d9e6-4497-8fc1-a7fc83f4b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_ShareBasedCompensation_45cfe6ee-d9e6-4497-8fc1-a7fc83f4b2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangeInFairValueOfTrancheRights_af566704-b48e-4b4b-af2d-e6903101b27f" xlink:href="vtl-20240331.xsd#vtl_ChangeInFairValueOfTrancheRights"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_vtl_ChangeInFairValueOfTrancheRights_af566704-b48e-4b4b-af2d-e6903101b27f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_79e9eb13-bbf9-4d8a-af2e-be156e4c2787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_56c790b8-9e25-40a4-8f8f-971b5546e7ba" xlink:to="loc_us-gaap_ManagementFeeExpense_79e9eb13-bbf9-4d8a-af2e-be156e4c2787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5e21f45-9e0e-45cf-9066-ba38db52149e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3fa40d63-7655-406d-8403-629b9e00b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5e21f45-9e0e-45cf-9066-ba38db52149e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3fa40d63-7655-406d-8403-629b9e00b8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4936c3d6-86db-42fd-8355-aeeb79e1e500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5e21f45-9e0e-45cf-9066-ba38db52149e" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4936c3d6-86db-42fd-8355-aeeb79e1e500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_892c6b8a-f3d3-4186-a01f-17c0a5ebb759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c5e21f45-9e0e-45cf-9066-ba38db52149e" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_892c6b8a-f3d3-4186-a01f-17c0a5ebb759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02a83de5-044e-42f2-b509-505ee7fd82d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2030021b-fcf8-465f-aea2-539d71c3f636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02a83de5-044e-42f2-b509-505ee7fd82d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2030021b-fcf8-465f-aea2-539d71c3f636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0b39af5-4eb7-4d7d-98ca-07f6ab1d32b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02a83de5-044e-42f2-b509-505ee7fd82d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0b39af5-4eb7-4d7d-98ca-07f6ab1d32b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4c3469f-22d6-4ceb-b780-0b2e2422d1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02a83de5-044e-42f2-b509-505ee7fd82d9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a4c3469f-22d6-4ceb-b780-0b2e2422d1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2614bb44-5925-49b8-bbce-3be6cc7065b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02a83de5-044e-42f2-b509-505ee7fd82d9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2614bb44-5925-49b8-bbce-3be6cc7065b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_d7f6d8f8-66c3-43a4-b331-a8c8d7c76941" xlink:href="vtl-20240331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_d7f6d8f8-66c3-43a4-b331-a8c8d7c76941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_e1fe7beb-03b5-41a7-8a9c-58cd066b744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:to="loc_us-gaap_OtherAssetsCurrent_e1fe7beb-03b5-41a7-8a9c-58cd066b744d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_f176e9c9-f758-42ea-859f-dd50ee7e458d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_f176e9c9-f758-42ea-859f-dd50ee7e458d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_879971d1-911d-4aaa-8f90-105dd2ad1b77" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_879971d1-911d-4aaa-8f90-105dd2ad1b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentGrant_956024b1-a10b-407a-b6b8-60ce67dabcdd" xlink:href="vtl-20240331.xsd#vtl_ResearchAndDevelopmentGrant"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc51389f-7de0-4200-9d14-cff488803427" xlink:to="loc_vtl_ResearchAndDevelopmentGrant_956024b1-a10b-407a-b6b8-60ce67dabcdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b9f486d0-4cf4-451e-8d83-6bc214dcc800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_85c6b85e-3b99-40bd-88b4-31c8f6b836e4" xlink:href="vtl-20240331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_b9f486d0-4cf4-451e-8d83-6bc214dcc800" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_85c6b85e-3b99-40bd-88b4-31c8f6b836e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_70ccf640-9f3b-437f-8542-38fdb9753de8" xlink:href="vtl-20240331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_b9f486d0-4cf4-451e-8d83-6bc214dcc800" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_70ccf640-9f3b-437f-8542-38fdb9753de8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_03123fc7-0a64-477c-8d08-a0c32082144b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_b9f486d0-4cf4-451e-8d83-6bc214dcc800" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_03123fc7-0a64-477c-8d08-a0c32082144b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b78b359f-394e-455a-828f-a4340362286b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_33e21620-3e52-4481-829e-3cb7a4ca1fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b78b359f-394e-455a-828f-a4340362286b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_33e21620-3e52-4481-829e-3cb7a4ca1fa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_c788a775-3364-4a7b-83bb-cb5614cce5a6" xlink:href="vtl-20240331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b78b359f-394e-455a-828f-a4340362286b" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_c788a775-3364-4a7b-83bb-cb5614cce5a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_c96b1d1f-f2c3-4c5c-b535-127e0414abf2" xlink:href="vtl-20240331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b78b359f-394e-455a-828f-a4340362286b" xlink:to="loc_vtl_AccruedCompensationCurrent_c96b1d1f-f2c3-4c5c-b535-127e0414abf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_5d5006b8-b900-43b2-9c4b-f280eb3688a6" xlink:href="vtl-20240331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b78b359f-394e-455a-828f-a4340362286b" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_5d5006b8-b900-43b2-9c4b-f280eb3688a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1cd5e1d5-45d6-40fd-aeaa-251e20262bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fb1999f5-1ab3-4a6f-8032-fb23cef146bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1cd5e1d5-45d6-40fd-aeaa-251e20262bda" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fb1999f5-1ab3-4a6f-8032-fb23cef146bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_2696365a-edc0-48d1-8d41-d4b4d433e17e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_1cd5e1d5-45d6-40fd-aeaa-251e20262bda" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_2696365a-edc0-48d1-8d41-d4b4d433e17e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70d9ab75-2fc6-4916-b750-60af5d14b0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8c80167e-a723-4f4a-88c4-2b39e8fc60fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70d9ab75-2fc6-4916-b750-60af5d14b0f6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8c80167e-a723-4f4a-88c4-2b39e8fc60fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b9a68307-69f6-486e-a41f-f263dbbc0838" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_70d9ab75-2fc6-4916-b750-60af5d14b0f6" xlink:to="loc_us-gaap_OperatingLeaseLiability_b9a68307-69f6-486e-a41f-f263dbbc0838" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_73e451b2-10f2-498c-9da0-8ec316697968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_73e451b2-10f2-498c-9da0-8ec316697968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3dfd177-3887-4ebc-a1bd-3d1e693746f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a3dfd177-3887-4ebc-a1bd-3d1e693746f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_02187bba-766c-4316-88c2-1ca2dbeee9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_02187bba-766c-4316-88c2-1ca2dbeee9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1342f455-81ff-42e8-9e79-0ed777688edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1342f455-81ff-42e8-9e79-0ed777688edf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_25467638-43ce-4c97-bef3-d3378be4dec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_25467638-43ce-4c97-bef3-d3378be4dec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_72440b64-df33-44c7-870a-2ad2690e291b" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5704cba2-718f-4690-b809-d7727e1fecd3" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_72440b64-df33-44c7-870a-2ad2690e291b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vtl-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:to="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:to="loc_us-gaap_EquityComponentDomain_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:to="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b55e6d8b-f878-4532-ba9f-24009460c043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_CommonStockMember_b55e6d8b-f878-4532-ba9f-24009460c043" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aef1ef58-cf33-40aa-967b-821a095be851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aef1ef58-cf33-40aa-967b-821a095be851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_041bd9f9-0a8d-43b3-b373-93a42bd7a3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_041bd9f9-0a8d-43b3-b373-93a42bd7a3fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_81da9832-8669-46d3-825b-25bbb143f369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_RetainedEarningsMember_81da9832-8669-46d3-825b-25bbb143f369" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bd42a9f-6851-430a-b55f-2a00417769fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9bd42a9f-6851-430a-b55f-2a00417769fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_January2024PIPETransactionMember_077ab413-554c-4226-a6a7-1a92e638cc67" xlink:href="vtl-20240331.xsd#vtl_January2024PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:to="loc_vtl_January2024PIPETransactionMember_077ab413-554c-4226-a6a7-1a92e638cc67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_e0e2e112-e3b6-4ee9-8a06-e86425442938" xlink:href="vtl-20240331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_e0e2e112-e3b6-4ee9-8a06-e86425442938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ef93608f-8782-4d5c-aee0-c7c3e4436b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ef93608f-8782-4d5c-aee0-c7c3e4436b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eaf3f5b0-9390-4893-a3bc-37ad7e067789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockholdersEquity_eaf3f5b0-9390-4893-a3bc-37ad7e067789" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06f466d3-cbc4-4ca8-a656-f10617e1f879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_NetIncomeLoss_06f466d3-cbc4-4ca8-a656-f10617e1f879" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed1eba57-b1d6-4784-82ca-8231ea38ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed1eba57-b1d6-4784-82ca-8231ea38ffef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d60dc17d-39f2-4fbd-aa2a-851d3b063ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d60dc17d-39f2-4fbd-aa2a-851d3b063ccc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8171ffb3-3ca4-41df-bcd3-6f96318999a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8171ffb3-3ca4-41df-bcd3-6f96318999a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3acf0c59-2dfa-44fa-aded-fd8afae542ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3acf0c59-2dfa-44fa-aded-fd8afae542ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_64e2dea7-ef7e-420f-9ceb-c03f82b00731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_64e2dea7-ef7e-420f-9ceb-c03f82b00731" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afb91b26-cfc9-428d-b302-022377e29d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afb91b26-cfc9-428d-b302-022377e29d67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5c6b26c-1b4e-41ec-bd84-08727891cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5c6b26c-1b4e-41ec-bd84-08727891cd0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5b1644a5-d9ec-4b50-ba0f-c565a65d20f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5b1644a5-d9ec-4b50-ba0f-c565a65d20f5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d850fe24-95b7-4d24-a3d5-6b58c2724a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45869f5e-b73c-4136-94b5-95dd8383b48c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:to="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a92a1d62-932e-46e9-ac6a-fb8ccb247e40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a92a1d62-932e-46e9-ac6a-fb8ccb247e40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_January2024PIPETransactionMember_eaf8dbec-d1ad-4e87-b8db-be99994a0d52" xlink:href="vtl-20240331.xsd#vtl_January2024PIPETransactionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:to="loc_vtl_January2024PIPETransactionMember_eaf8dbec-d1ad-4e87-b8db-be99994a0d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_e5aa510c-8fb2-4ae6-85aa-0ca0d6a16a5a" xlink:href="vtl-20240331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_e5aa510c-8fb2-4ae6-85aa-0ca0d6a16a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9cfbb32-7418-4137-b6e3-9693f5848efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9cfbb32-7418-4137-b6e3-9693f5848efe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c605e32f-c838-41db-bfdd-1ef54b5aecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:to="loc_us-gaap_SubsequentEventMember_c605e32f-c838-41db-bfdd-1ef54b5aecb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_dfd94a01-4ede-4f85-a182-da5c6d27e6e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_dei_EntityNumberOfEmployees_dfd94a01-4ede-4f85-a182-da5c6d27e6e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_7016a580-c7f4-40cf-a087-30567a4c5781" xlink:href="vtl-20240331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_7016a580-c7f4-40cf-a087-30567a4c5781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_378116c3-6f37-4120-b9c6-e5bf967ae942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_378116c3-6f37-4120-b9c6-e5bf967ae942" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e89aeaf6-5703-4e63-be42-a9f80d8fa79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e89aeaf6-5703-4e63-be42-a9f80d8fa79c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a2fce2a-6101-4c3d-b362-36bba0b09e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a2fce2a-6101-4c3d-b362-36bba0b09e3d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1201df6b-6edc-4382-800d-2f6c4bb4d3d9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:to="loc_srt_RangeMember_1201df6b-6edc-4382-800d-2f6c4bb4d3d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:to="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83ae3cb2-d68b-4da8-a3ee-899adf9f0658" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:to="loc_srt_MaximumMember_83ae3cb2-d68b-4da8-a3ee-899adf9f0658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4840dec-df54-40c7-ae65-e970be4a6901" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:to="loc_srt_MinimumMember_f4840dec-df54-40c7-ae65-e970be4a6901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a08f5b77-2d20-408e-b3bb-3f79fa38103d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:to="loc_srt_SegmentGeographicalDomain_a08f5b77-2d20-408e-b3bb-3f79fa38103d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:to="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3fd2741-55ce-4500-a994-aea6a8b7d9b0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_US_b3fd2741-55ce-4500-a994-aea6a8b7d9b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_0bc28974-74ca-4bb2-909d-2e32c9b07356" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_DE_0bc28974-74ca-4bb2-909d-2e32c9b07356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_a930efbf-4fef-4477-85cd-606fd782e033" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_AU_a930efbf-4fef-4477-85cd-606fd782e033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86542d83-d648-4f70-9d8d-596369740eee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_86542d83-d648-4f70-9d8d-596369740eee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_d41586a3-cae6-44fa-8d8d-5261b1176a1c" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:to="loc_vtl_PreFundedWarrantsMember_d41586a3-cae6-44fa-8d8d-5261b1176a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c420555f-ce39-461b-8129-8db0f6acc13b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c420555f-ce39-461b-8129-8db0f6acc13b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8a17ee3d-98fd-4805-be90-7f5dbf36803e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8a17ee3d-98fd-4805-be90-7f5dbf36803e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ca3ac08-df28-4333-abc5-1941b64dd373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ca3ac08-df28-4333-abc5-1941b64dd373" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_33826d9c-4cad-419b-8ce1-28bdda82db64" xlink:href="vtl-20240331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_33826d9c-4cad-419b-8ce1-28bdda82db64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_880c7657-b482-412b-8b41-bc21c7250216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_InvestmentInterestRate_880c7657-b482-412b-8b41-bc21c7250216" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7bb7064-a2be-48d1-b42c-b8016897a613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7bb7064-a2be-48d1-b42c-b8016897a613" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6b98ee49-d3ba-4f03-aa35-bc29794da7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_Depreciation_6b98ee49-d3ba-4f03-aa35-bc29794da7e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_e8833566-a6cb-400d-8fce-a9b015213dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_e8833566-a6cb-400d-8fce-a9b015213dc1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_7e10a756-a61e-4d7a-a3a1-98254acac9c2" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_7e10a756-a61e-4d7a-a3a1-98254acac9c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_93d58165-1d3f-42a1-a3a0-7c0626fb91e8" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_93d58165-1d3f-42a1-a3a0-7c0626fb91e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_786218de-209b-4ecb-8a9e-0e888f835f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_786218de-209b-4ecb-8a9e-0e888f835f7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_01b36203-b9f6-4892-b76f-90e01391350e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_01b36203-b9f6-4892-b76f-90e01391350e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7c91fb83-86a9-4af0-a557-fd76a71eff57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7c91fb83-86a9-4af0-a557-fd76a71eff57" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_025d0fcb-63de-49e2-85df-99fc893f5713" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_025d0fcb-63de-49e2-85df-99fc893f5713" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c09f69-a0dc-4dac-9255-9a94576e056e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c09f69-a0dc-4dac-9255-9a94576e056e" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_7bb145f2-112c-45ad-a4d4-56200c22ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:to="loc_us-gaap_StockOptionMember_7bb145f2-112c-45ad-a4d4-56200c22ae93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7afdde7f-4a4a-44c6-b38c-a8766a9fe762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7afdde7f-4a4a-44c6-b38c-a8766a9fe762" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:to="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_62825118-412d-413a-84c3-426333f38d3c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:to="loc_srt_SegmentGeographicalDomain_62825118-412d-413a-84c3-426333f38d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:to="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_32daeec3-279d-4e8c-b42e-6ce7d2eab8b3" xlink:href="vtl-20240331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_GrafelfingGermanyMember_32daeec3-279d-4e8c-b42e-6ce7d2eab8b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_83fc904f-9907-46ae-a307-7ea39b9c4aa6" xlink:href="vtl-20240331.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_NewYorkCityMember_83fc904f-9907-46ae-a307-7ea39b9c4aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_9a5559b8-461b-4996-902c-615c2ed06fb5" xlink:href="vtl-20240331.xsd#vtl_PlaneggGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_PlaneggGermanyMember_9a5559b8-461b-4996-902c-615c2ed06fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8c42efbd-e9e2-425a-9a28-c4b69905b6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8c42efbd-e9e2-425a-9a28-c4b69905b6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f49101b4-85b3-4590-b173-c864866c8606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f49101b4-85b3-4590-b173-c864866c8606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_63450781-6aaa-4a17-b21e-f8e82614b637" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_63450781-6aaa-4a17-b21e-f8e82614b637" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_a6c54c3b-b908-4f69-b3e4-f7d01724d79f" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_a6c54c3b-b908-4f69-b3e4-f7d01724d79f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_00def543-287f-4302-845a-b14181d824f6" xlink:href="vtl-20240331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_00def543-287f-4302-845a-b14181d824f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_eb837df5-b6c6-4760-bd0b-8b1255fcebc0" xlink:href="vtl-20240331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_eb837df5-b6c6-4760-bd0b-8b1255fcebc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_cd9b6e22-08ec-42cd-909c-536e402d2b64" xlink:href="vtl-20240331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_cd9b6e22-08ec-42cd-909c-536e402d2b64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_86211a9e-0db5-4861-8bb4-925cca5f5879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_ContractualObligation_86211a9e-0db5-4861-8bb4-925cca5f5879" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3233152e-9ce8-4b86-9d89-076c052b8537_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3233152e-9ce8-4b86-9d89-076c052b8537_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7d287b4-a4a1-4ab3-872b-87400435cb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7d287b4-a4a1-4ab3-872b-87400435cb23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a3b516af-3ffd-4b8b-b3bd-115489aea4aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a3b516af-3ffd-4b8b-b3bd-115489aea4aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d31c6d7-e48a-41e8-98c1-3b10586deb11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d31c6d7-e48a-41e8-98c1-3b10586deb11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a09e486f-1c01-4265-81c5-72f67aafe700_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a09e486f-1c01-4265-81c5-72f67aafe700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_83f6f81a-1b44-4e0f-98cd-0634743e0697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_83f6f81a-1b44-4e0f-98cd-0634743e0697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6fd8a976-0de3-4e2c-9462-fc70e9817c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6fd8a976-0de3-4e2c-9462-fc70e9817c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48029e5e-98f5-4d77-bb2e-0a530a65e2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48029e5e-98f5-4d77-bb2e-0a530a65e2e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a45bfd31-869b-43ac-84c1-23de87403903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a45bfd31-869b-43ac-84c1-23de87403903" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:to="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4973bfe0-758a-44de-8951-cca05524e151_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:to="loc_srt_SegmentGeographicalDomain_4973bfe0-758a-44de-8951-cca05524e151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:to="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_335567a5-b1ea-4bc5-9c9b-109020e3460e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:to="loc_country_US_335567a5-b1ea-4bc5-9c9b-109020e3460e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:to="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b175137-8856-42de-9ba0-047779b761d6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:to="loc_srt_RangeMember_4b175137-8856-42de-9ba0-047779b761d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:to="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8981f49-eacb-4031-b609-4aa11b0ca964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:to="loc_srt_MinimumMember_b8981f49-eacb-4031-b609-4aa11b0ca964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52319123-17a4-49a2-aaf1-27e0c0471cab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:to="loc_srt_MaximumMember_52319123-17a4-49a2-aaf1-27e0c0471cab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_942f9756-4ea9-443b-9650-da2d1db6a622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_InvestmentInterestRate_942f9756-4ea9-443b-9650-da2d1db6a622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightFairValueDisclosure_65f1a633-eacd-4bd8-837c-b00d41716fdc" xlink:href="vtl-20240331.xsd#vtl_TrancheRightFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_vtl_TrancheRightFairValueDisclosure_65f1a633-eacd-4bd8-837c-b00d41716fdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e370b30-ef55-433a-8f85-ff04edf859d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e370b30-ef55-433a-8f85-ff04edf859d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95a22d12-6741-4195-861d-6d9834fdd646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95a22d12-6741-4195-861d-6d9834fdd646" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_17aa1ada-1145-45aa-955a-87edfa61fafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_17aa1ada-1145-45aa-955a-87edfa61fafe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2d47eef-9cfc-4de4-acc9-e22094c94772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2d47eef-9cfc-4de4-acc9-e22094c94772" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20d9e911-74f7-4141-bf6b-abdbc62ee9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20d9e911-74f7-4141-bf6b-abdbc62ee9c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_50813e18-c8ec-4d3f-aea1-2d68214177a8" xlink:href="vtl-20240331.xsd#vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_50813e18-c8ec-4d3f-aea1-2d68214177a8" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5178cb72-9579-4088-b4fe-9243ee943a3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5178cb72-9579-4088-b4fe-9243ee943a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_78d6d9d2-5804-41de-ad27-25c0b2b989a5" xlink:href="vtl-20240331.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:to="loc_vtl_December2020ATMMember_78d6d9d2-5804-41de-ad27-25c0b2b989a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_983c8470-204e-4474-bded-eadff9f1b31b" xlink:href="vtl-20240331.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:to="loc_vtl_May2022ATMMember_983c8470-204e-4474-bded-eadff9f1b31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_222a90f1-a77c-44da-b8b7-b252b3b75518" xlink:href="vtl-20240331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_222a90f1-a77c-44da-b8b7-b252b3b75518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_0eab057c-4e45-449f-82ff-d5f615bbea83" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_0eab057c-4e45-449f-82ff-d5f615bbea83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_fb32f23b-1b70-4027-b1ac-057c7b54c6c7" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_fb32f23b-1b70-4027-b1ac-057c7b54c6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b5856d04-7c36-4853-8688-712c77562066" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b5856d04-7c36-4853-8688-712c77562066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0bb35d8-e7ad-46f8-a5e1-0ccc4e1ff70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0bb35d8-e7ad-46f8-a5e1-0ccc4e1ff70e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c923cb22-1244-4bb7-80bb-3fb6a3ecbb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c923cb22-1244-4bb7-80bb-3fb6a3ecbb58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_9f81abda-89ef-4d1b-a7aa-2bfb987027ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_9f81abda-89ef-4d1b-a7aa-2bfb987027ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1165873-84bb-4f4c-bcf1-f3e653f7e792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1165873-84bb-4f4c-bcf1-f3e653f7e792" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_c3d57b15-76f8-47f8-bab7-969a1fd55177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_PaymentsForCommissions_c3d57b15-76f8-47f8-bab7-969a1fd55177" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5569dffd-a27f-495a-bb70-8b2b6931286f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5569dffd-a27f-495a-bb70-8b2b6931286f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4bc6a839-e9fb-427d-ad8d-3ded22ea222c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_us-gaap_CommonStockMember_4bc6a839-e9fb-427d-ad8d-3ded22ea222c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_79a3389b-fde3-49b6-a9ad-638aa544dccb" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_vtl_PreFundedWarrantsMember_79a3389b-fde3-49b6-a9ad-638aa544dccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4125faa7-d355-4484-afbb-622a21418811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_us-gaap_PrivatePlacementMember_4125faa7-d355-4484-afbb-622a21418811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockAndPreFundedWarrantsMember_38deb504-77b2-45cb-bf52-84e37346f703" xlink:href="vtl-20240331.xsd#vtl_CommonStockAndPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_vtl_CommonStockAndPreFundedWarrantsMember_38deb504-77b2-45cb-bf52-84e37346f703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_04947d22-57f7-45bb-a5c6-e982be099168_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_04947d22-57f7-45bb-a5c6-e982be099168_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccreditedInvestorsMember_c451518b-b85b-46ed-bc43-698a22c1a290" xlink:href="vtl-20240331.xsd#vtl_AccreditedInvestorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:to="loc_vtl_AccreditedInvestorsMember_c451518b-b85b-46ed-bc43-698a22c1a290" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d3d2bcd3-b897-49c9-954e-6f3f6001f1db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:to="loc_us-gaap_ClassOfStockDomain_d3d2bcd3-b897-49c9-954e-6f3f6001f1db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:to="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6d6a6417-8a94-4be0-a99d-7ee95de64e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_us-gaap_CommonStockMember_6d6a6417-8a94-4be0-a99d-7ee95de64e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_4a6962dd-461c-4b84-8348-8bfe4aec3f2a" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_vtl_PreFundedWarrantsMember_4a6962dd-461c-4b84-8348-8bfe4aec3f2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockAndPreFundedWarrantsMember_76f25b37-c662-45be-aa60-5eb3f6640b31" xlink:href="vtl-20240331.xsd#vtl_CommonStockAndPreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_vtl_CommonStockAndPreFundedWarrantsMember_76f25b37-c662-45be-aa60-5eb3f6640b31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_87ab1f92-c41c-459b-9b74-5dccc639d7dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:to="loc_us-gaap_VestingDomain_87ab1f92-c41c-459b-9b74-5dccc639d7dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:to="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9851181-7b3e-40a9-b3fd-27a97f00cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9851181-7b3e-40a9-b3fd-27a97f00cee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d68fc0-449d-4c65-9f17-9221f75d437c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d68fc0-449d-4c65-9f17-9221f75d437c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5bad863d-c5bb-4b50-b524-8957b64dbe48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5bad863d-c5bb-4b50-b524-8957b64dbe48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_069cbcb4-8067-446c-860a-5856535d8895_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:to="loc_srt_RangeMember_069cbcb4-8067-446c-860a-5856535d8895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:to="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4c3232d-a214-48d9-9610-75298d640310" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:to="loc_srt_MinimumMember_c4c3232d-a214-48d9-9610-75298d640310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_017b5f90-b980-49f5-8842-53c713e737ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:to="loc_srt_MaximumMember_017b5f90-b980-49f5-8842-53c713e737ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51cd5555-70ba-4d7d-874f-99f3295887df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51cd5555-70ba-4d7d-874f-99f3295887df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_546b8b81-6f57-4d09-bb60-88d72604b2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_546b8b81-6f57-4d09-bb60-88d72604b2f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e31b22dc-a362-40d6-a7f5-371e6513b137_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e31b22dc-a362-40d6-a7f5-371e6513b137_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMember_7c0d5db5-8ab1-41c0-8979-71785dd1d9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:to="loc_us-gaap_EquityMember_7c0d5db5-8ab1-41c0-8979-71785dd1d9bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7cc0bb98-2c51-455f-9367-34f1f37fa589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7cc0bb98-2c51-455f-9367-34f1f37fa589" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8602904d-07ee-4a98-897b-9929fe415b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8602904d-07ee-4a98-897b-9929fe415b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ce9aa533-ace9-4b10-bdbe-ab62fcd2cc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ce9aa533-ace9-4b10-bdbe-ab62fcd2cc7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockConsiderationReceivedPercentage_db601ec5-4679-48f2-a121-e71866451ce0" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockConsiderationReceivedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockConsiderationReceivedPercentage_db601ec5-4679-48f2-a121-e71866451ce0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_72f7d71f-db5a-4899-83d6-fc392870e81c" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_72f7d71f-db5a-4899-83d6-fc392870e81c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_WeightedAveragePriceOfLast10Days_9913cc36-4e9a-4db9-be5c-38455a223e40" xlink:href="vtl-20240331.xsd#vtl_WeightedAveragePriceOfLast10Days"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_WeightedAveragePriceOfLast10Days_9913cc36-4e9a-4db9-be5c-38455a223e40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_5e557f30-8705-4f90-b78d-4719364ab46e" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_5e557f30-8705-4f90-b78d-4719364ab46e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_310eadbc-c4a9-47eb-b613-79a2be83d8b9" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockAggregateTradingVolumeOfLast10Days"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_310eadbc-c4a9-47eb-b613-79a2be83d8b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockEquityOfferingsPeriod_c4854e79-79f2-418e-a98d-6d1687c4680b" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockEquityOfferingsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockEquityOfferingsPeriod_c4854e79-79f2-418e-a98d-6d1687c4680b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_e13cdc56-4c45-4fbe-a80e-ae969746681e" xlink:href="vtl-20240331.xsd#vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_e13cdc56-4c45-4fbe-a80e-ae969746681e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityRemainderAmount_09e6a42a-bcb9-440c-bb4d-cda399aa8afd" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityRemainderAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_TrancheRightsAsALiabilityRemainderAmount_09e6a42a-bcb9-440c-bb4d-cda399aa8afd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityReceivedAmount_09ffeb9e-7b29-458d-b2de-6de3a4258de0" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityReceivedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_TrancheRightsAsALiabilityReceivedAmount_09ffeb9e-7b29-458d-b2de-6de3a4258de0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8b0baaeb-9245-4444-b0bf-32e5f858086e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8b0baaeb-9245-4444-b0bf-32e5f858086e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b6b9d8f9-e36b-4b09-a6b3-02e45642b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b6b9d8f9-e36b-4b09-a6b3-02e45642b5b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_770d47a8-4057-4507-a150-b57bdd137592" xlink:href="vtl-20240331.xsd#vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_770d47a8-4057-4507-a150-b57bdd137592" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockNumberOfSharesRegisteredForResale_446783b6-bc11-49a4-bb38-faeca4fa27db" xlink:href="vtl-20240331.xsd#vtl_CommonStockNumberOfSharesRegisteredForResale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_CommonStockNumberOfSharesRegisteredForResale_446783b6-bc11-49a4-bb38-faeca4fa27db" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockCommonStockDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:to="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_84127839-606d-4c81-8700-22c7639d1a48_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:to="loc_srt_RangeMember_84127839-606d-4c81-8700-22c7639d1a48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:to="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d048a09-638f-446d-94a2-f75b3474683f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:to="loc_srt_MinimumMember_2d048a09-638f-446d-94a2-f75b3474683f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d58e681-e7a2-49a5-8c10-4e427cbd3fea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:to="loc_srt_MaximumMember_4d58e681-e7a2-49a5-8c10-4e427cbd3fea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7fd7ba7c-fa03-4489-9d20-62d329301c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7fd7ba7c-fa03-4489-9d20-62d329301c34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b6dcee2-925a-4e1c-9a7a-497bf1105d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b6dcee2-925a-4e1c-9a7a-497bf1105d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_5724b0b9-0c79-4125-b7a8-556b0b845bc2" xlink:href="vtl-20240331.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_5724b0b9-0c79-4125-b7a8-556b0b845bc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d4590d85-31f1-4edf-9a78-e55d740e5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d4590d85-31f1-4edf-9a78-e55d740e5d61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_330c9928-bfe5-4094-b89a-732c19fdb1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_330c9928-bfe5-4094-b89a-732c19fdb1da" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockPrefundedWarrantsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10ba88ed-192c-4044-ac92-82248104ff9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_10ba88ed-192c-4044-ac92-82248104ff9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_ec3328a7-41c4-40e9-b89c-8685c3b0109d" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:to="loc_vtl_PreFundedWarrantsMember_ec3328a7-41c4-40e9-b89c-8685c3b0109d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21932858-5d9b-4e43-9b7c-80b4956d290c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21932858-5d9b-4e43-9b7c-80b4956d290c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockScheduleofSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_873680dd-40d4-43b3-9df9-2191d1b247ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_873680dd-40d4-43b3-9df9-2191d1b247ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6a340fbf-1378-4287-8deb-aef415b77c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6a340fbf-1378-4287-8deb-aef415b77c46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_bd0ffd32-ad40-4b56-9d44-7e68bf66c3ef" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_vtl_PreFundedWarrantsMember_bd0ffd32-ad40-4b56-9d44-7e68bf66c3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_fd324e64-9754-4815-87a7-666503bb1c3d" xlink:href="vtl-20240331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_fd324e64-9754-4815-87a7-666503bb1c3d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:to="loc_us-gaap_PlanNameDomain_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:to="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_a523d4a6-a9cd-4858-aab3-10818b8802f4" xlink:href="vtl-20240331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_a523d4a6-a9cd-4858-aab3-10818b8802f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_a93ecf9b-21f2-4538-a381-6ce1dd304083" xlink:href="vtl-20240331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_a93ecf9b-21f2-4538-a381-6ce1dd304083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_e3b77941-9a0e-436b-92bb-516318378415" xlink:href="vtl-20240331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_e3b77941-9a0e-436b-92bb-516318378415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a2ed66d7-f1e9-4518-b1f5-f9783e2e97ec" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a2ed66d7-f1e9-4518-b1f5-f9783e2e97ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:to="loc_us-gaap_VestingDomain_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:to="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e391b842-f4fc-48b6-b2c8-058d00876b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e391b842-f4fc-48b6-b2c8-058d00876b44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_44789164-4d57-4979-85ce-0be0f592a307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_44789164-4d57-4979-85ce-0be0f592a307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a27e339-5831-4ee3-b31d-2d63acfcfe37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a27e339-5831-4ee3-b31d-2d63acfcfe37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:to="loc_us-gaap_PlanNameDomain_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:to="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_7fcdad9e-a083-42a9-b053-22d56343a4dd" xlink:href="vtl-20240331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_7fcdad9e-a083-42a9-b053-22d56343a4dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_875965d0-ec86-4adb-a809-52396d0a940e" xlink:href="vtl-20240331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_875965d0-ec86-4adb-a809-52396d0a940e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_c924f102-e9ce-426f-9dcb-b19427063902" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_c924f102-e9ce-426f-9dcb-b19427063902" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_e969ca37-982b-470f-8268-b11a93a5b959" xlink:href="vtl-20240331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_e969ca37-982b-470f-8268-b11a93a5b959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_91e2f625-d80a-4c44-8cda-0be4149d0f5b" xlink:href="vtl-20240331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_91e2f625-d80a-4c44-8cda-0be4149d0f5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed0c05ce-0ce3-422b-b14b-9b10d7731b21_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:to="loc_srt_RangeMember_ed0c05ce-0ce3-422b-b14b-9b10d7731b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:to="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44906644-523e-4076-b772-965600058332" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:to="loc_srt_MaximumMember_44906644-523e-4076-b772-965600058332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_adcb18cd-5931-4f88-b33d-0a10b91dd7f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:to="loc_srt_MinimumMember_adcb18cd-5931-4f88-b33d-0a10b91dd7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9845a53e-ea4c-41df-bf05-ce885e645e0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9845a53e-ea4c-41df-bf05-ce885e645e0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_ea43ce45-bcff-4441-b842-f01a2a58efa1" xlink:href="vtl-20240331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_ea43ce45-bcff-4441-b842-f01a2a58efa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_881b0da8-cdde-49f9-be8b-fcc301f77d42" xlink:href="vtl-20240331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_881b0da8-cdde-49f9-be8b-fcc301f77d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c80ba62-7609-4340-b20e-dc5c9bca12f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c80ba62-7609-4340-b20e-dc5c9bca12f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_683850bb-9ac5-4f6c-833a-a79db4876138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_683850bb-9ac5-4f6c-833a-a79db4876138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29130001-991f-4684-8e74-733f1c06070c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29130001-991f-4684-8e74-733f1c06070c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_55bc6c15-ec8b-415f-9107-0938d0f404cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_55bc6c15-ec8b-415f-9107-0938d0f404cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_77dd77eb-200c-41b9-8315-19ff8ccf404c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_77dd77eb-200c-41b9-8315-19ff8ccf404c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af1b4336-f24c-4d37-a776-3cc15bb0217d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af1b4336-f24c-4d37-a776-3cc15bb0217d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_071d050f-540b-4c70-bf94-03c45c958d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_071d050f-540b-4c70-bf94-03c45c958d00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e1956e7-e933-4257-999b-7c5b767592d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e1956e7-e933-4257-999b-7c5b767592d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d634279-9b8c-4172-9dd7-2557a4f621d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d634279-9b8c-4172-9dd7-2557a4f621d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_0455824f-c7f9-4c5e-b770-625d43c63b36" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_0455824f-c7f9-4c5e-b770-625d43c63b36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_3a68f8c0-78f3-42a1-8812-05444ca0cada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_3a68f8c0-78f3-42a1-8812-05444ca0cada" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f5c344-badd-4e0b-b899-38b25348c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f5c344-badd-4e0b-b899-38b25348c14b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_85f8c1fb-52b0-4977-8e83-5f73ed1050d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_85f8c1fb-52b0-4977-8e83-5f73ed1050d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b27f909-521c-46a9-988f-ced3574ed036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b27f909-521c-46a9-988f-ced3574ed036" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_efa80e1b-59e2-4463-8469-100e121470db" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_efa80e1b-59e2-4463-8469-100e121470db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_55ec2787-d1e3-4a81-be65-bb4924d8376c" xlink:href="vtl-20240331.xsd#vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_55ec2787-d1e3-4a81-be65-bb4924d8376c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_69ea1450-adf8-4f6c-a2cf-ee8c380bf05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_69ea1450-adf8-4f6c-a2cf-ee8c380bf05b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17311fcc-6e2d-4310-9dbd-3f225d3c081f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17311fcc-6e2d-4310-9dbd-3f225d3c081f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d06a54b2-2e22-46b4-bb56-3e5a608eb16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d06a54b2-2e22-46b4-bb56-3e5a608eb16f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b480dd7a-eb4e-4505-8c61-139db4f96ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b480dd7a-eb4e-4505-8c61-139db4f96ac8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_9baab67f-2d48-46d7-b825-6147b9d65a6d" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_9baab67f-2d48-46d7-b825-6147b9d65a6d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_796ea565-c333-46e1-a44d-48495685b3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_796ea565-c333-46e1-a44d-48495685b3c6" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95a7a40-e6b8-430d-9b96-6bb0293addb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95a7a40-e6b8-430d-9b96-6bb0293addb0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00911a68-2098-4123-99ed-dc54c49e06d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00911a68-2098-4123-99ed-dc54c49e06d5" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:to="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bf84448-2d2c-48b3-95f2-42f5a9d3124a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bf84448-2d2c-48b3-95f2-42f5a9d3124a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48733a93-2b44-42bf-ac51-f1986b47b318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48733a93-2b44-42bf-ac51-f1986b47b318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:to="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6a3312b8-2706-4372-b412-137a828460e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:to="loc_us-gaap_PlanNameDomain_6a3312b8-2706-4372-b412-137a828460e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:to="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dcc0d394-d604-484e-a49c-6d29e1728991" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dcc0d394-d604-484e-a49c-6d29e1728991" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e33fbe5-cf35-4f48-be3f-0fba55c90ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e33fbe5-cf35-4f48-be3f-0fba55c90ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_94296b9d-193f-468d-aafa-ff9aed0f6d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_94296b9d-193f-468d-aafa-ff9aed0f6d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66b9c233-1f6a-4838-8e51-0c8496b7c655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66b9c233-1f6a-4838-8e51-0c8496b7c655" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_66f07f9e-dc91-46b9-b128-610d72c715d1" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_66f07f9e-dc91-46b9-b128-610d72c715d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c46617ff-5117-43c2-8e22-3905fdff78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c46617ff-5117-43c2-8e22-3905fdff78b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be82543c-831e-4ab9-9050-9e8e5b68c42f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f3dee242-c1b6-4a14-ba72-73604e05c0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f3dee242-c1b6-4a14-ba72-73604e05c0e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f500a4b-23fc-41ef-b0c8-f930613c3101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f500a4b-23fc-41ef-b0c8-f930613c3101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_72459f66-4d4a-4926-ae89-b1e7edded145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_72459f66-4d4a-4926-ae89-b1e7edded145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3315c3d7-01f9-4677-835a-ea8caa1a3662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3315c3d7-01f9-4677-835a-ea8caa1a3662" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76574fcf-c676-49c7-9431-3cc004c30f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76574fcf-c676-49c7-9431-3cc004c30f2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_d1e203ea-eb16-43c2-99b2-a01785682d55" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_d1e203ea-eb16-43c2-99b2-a01785682d55" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a22cba3a-7ecd-4a57-b5c2-270895be3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a22cba3a-7ecd-4a57-b5c2-270895be3f7a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18a5aa0e-7c1e-4307-9777-d343d54597a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5bb57ebb-79b4-49b4-8bf1-e56edb714720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5bb57ebb-79b4-49b4-8bf1-e56edb714720" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f973b47-fe53-4f52-8a88-30562c2f8667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f973b47-fe53-4f52-8a88-30562c2f8667" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0c2ca53a-4eb6-4a73-bfca-3086fec51b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0c2ca53a-4eb6-4a73-bfca-3086fec51b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_743f29c2-5485-47e7-b7e5-18bcb27d0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_743f29c2-5485-47e7-b7e5-18bcb27d0cf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b34858c-8f4e-4b60-8b4c-c375fe32faff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b34858c-8f4e-4b60-8b4c-c375fe32faff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b5c67270-9e1a-4c9f-8f98-3c427018f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b5c67270-9e1a-4c9f-8f98-3c427018f9df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b39d945-79ee-4050-b265-6fa95ad0a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b39d945-79ee-4050-b265-6fa95ad0a6b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a2711d2-3f4a-450d-91de-e5283585dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a2711d2-3f4a-450d-91de-e5283585dccb" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:to="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:to="loc_us-gaap_PlanNameDomain_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:to="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_97dc4f8f-7d66-4856-ae2b-a2d48be0e32d" xlink:href="vtl-20240331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_97dc4f8f-7d66-4856-ae2b-a2d48be0e32d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dc4751fb-9f30-4d33-a8a7-ba0ceb070848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dc4751fb-9f30-4d33-a8a7-ba0ceb070848" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d5ab3c49-a5a6-44db-8fa8-51b84b45dff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d5ab3c49-a5a6-44db-8fa8-51b84b45dff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87717daf-752b-4d23-b35c-97e6d11c212b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87717daf-752b-4d23-b35c-97e6d11c212b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_524c3df8-dedb-458c-8a0e-0ceeed560741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_524c3df8-dedb-458c-8a0e-0ceeed560741" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:to="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_36c4d1aa-ffca-403a-9779-31f3b38da1bf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_36c4d1aa-ffca-403a-9779-31f3b38da1bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_8f12aed1-2b1c-459c-aa8f-19a7517598bb" xlink:href="vtl-20240331.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:to="loc_vtl_EmployeeMember_8f12aed1-2b1c-459c-aa8f-19a7517598bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_925678e3-b9c9-4be3-9183-e757c867bde2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_925678e3-b9c9-4be3-9183-e757c867bde2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9ab2c06d-8e61-4859-adfa-3528572934ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9ab2c06d-8e61-4859-adfa-3528572934ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db602d75-7a7e-4182-91a6-d25291dbbfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db602d75-7a7e-4182-91a6-d25291dbbfd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2ec8be5a-b02a-417b-a4f9-ebd3be13e326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:to="loc_us-gaap_ShareBasedCompensation_2ec8be5a-b02a-417b-a4f9-ebd3be13e326" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbe38600-f917-46af-b5b3-94444f19581f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fbe38600-f917-46af-b5b3-94444f19581f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_7bf1371c-f5fc-4a01-aecd-0bd019f0364c" xlink:href="vtl-20240331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_7bf1371c-f5fc-4a01-aecd-0bd019f0364c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_63ecef88-d284-49bd-b9c0-48b68fd666df_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_63ecef88-d284-49bd-b9c0-48b68fd666df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_d1221d18-8819-4eb7-83fc-da3866fadcad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_d1221d18-8819-4eb7-83fc-da3866fadcad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_4e91b15b-2f12-4059-8af2-960ef23d3446_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_4e91b15b-2f12-4059-8af2-960ef23d3446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_43f62e31-f263-4c87-98ad-99a41e407e97" xlink:href="vtl-20240331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_43f62e31-f263-4c87-98ad-99a41e407e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:to="loc_us-gaap_RelatedPartyDomain_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:to="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_57113c5d-8574-4445-ae33-070cd190fc91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_57113c5d-8574-4445-ae33-070cd190fc91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7807a1e8-959c-4220-a3fa-5accb3581f46_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7807a1e8-959c-4220-a3fa-5accb3581f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_44b3c6d6-ff2e-408d-b536-2d584068e743" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:to="loc_srt_ScenarioForecastMember_44b3c6d6-ff2e-408d-b536-2d584068e743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary_eb937da0-efa6-445c-a517-8180d76139e4" xlink:href="vtl-20240331.xsd#vtl_SalaryAndWageOfficerMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:to="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary_eb937da0-efa6-445c-a517-8180d76139e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vtl-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c92e9475-f98a-40a5-b916-1f5b387ed3cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value as of January 8, 2024</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_53f157de-a908-4947-af53-ad0f5fc72c04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in other share (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c6688633-83f2-41c5-bb98-452a68bbcb6c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a54e9178-cbb6-49a6-bc87-98e51b6724d5_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_302b8980-74d6-4ccd-8abf-ff3e9cd19580_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ed199b20-2ded-4e90-9865-a60672a547dd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMember_8704526e-a884-4cd3-ad9e-a5c8b32db67b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_EquityMember_label_en-US" xlink:label="lab_us-gaap_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMember" xlink:to="lab_us-gaap_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaabb1e7-c508-46a4-8177-a54c24b938a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_751ad4c2-29f7-47b7-b968-79a509dba397_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b23b58d-8528-4c82-a882-41fe0ade2e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3ef8f776-7000-4acd-af11-8cddfda7b409_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_626af414-144d-4901-b30d-0eaf78c04c55_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d982258f-091b-4ca8-a493-890dae6f60e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_e532ad62-444d-4472-9154-564796ff3e84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c38e4fb0-795c-4cd8-b779-d4c906f9a131_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c4f41d08-05e8-4d30-b319-fcb2bf433ae8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_4879c342-feff-4f63-8ff6-a844e8debbbd_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1fab4755-6c0c-4977-b1c4-123f38b5e6ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b734881f-5de3-44fe-a027-c8e5c8113ebc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_cfac0ee9-03fa-4603-847a-cfab96b78d76_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8eec15bb-330f-4824-b792-78c11295b1ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_94f85727-67dc-4536-a1db-4e0158ad905b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d79afe4c-65cd-440b-a0fb-16e14a30ee1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock through At The Market Sales Agreement, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_21ae5063-360f-4b89-aec5-a0e1bcf79f57_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2e6195d5-74c0-49f6-8939-a816c073b978_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_56433c77-4867-46f6-b44e-61be76b7dac8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_75ea4250-de0d-45db-9c43-4436c1986520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_97942387-f1fe-4b8a-8e0b-55dda5f9d9de_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d0195ead-14d9-442e-8816-1fb49ce2c0d2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccreditedInvestorsMember_21c9fdac-4b47-451d-88f1-6fe546f5400a_terseLabel_en-US" xlink:label="lab_vtl_AccreditedInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredited Investors</link:label>
    <link:label id="lab_vtl_AccreditedInvestorsMember_label_en-US" xlink:label="lab_vtl_AccreditedInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredited Investors [Member]</link:label>
    <link:label id="lab_vtl_AccreditedInvestorsMember_documentation_en-US" xlink:label="lab_vtl_AccreditedInvestorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredited Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccreditedInvestorsMember" xlink:href="vtl-20240331.xsd#vtl_AccreditedInvestorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccreditedInvestorsMember" xlink:to="lab_vtl_AccreditedInvestorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_037ee1ba-d64e-4eb9-a1dd-b7cf0e52cd78_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b51bd64b-72df-45f5-89c0-c93d83b5a3c2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_38900dc5-a72c-412c-8793-8097aa516692_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b9a6975a-aef7-4a74-9bb2-d5710a8ae63a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c7187b22-fbd7-4630-ac4a-539a8f4a8bef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b59b56b3-2e35-4c1c-b73c-8e0de5cd7146_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3c2e8647-7ed3-4483-aabf-fd87ce335cf1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_f0241bb9-a4fb-45e9-8bbf-01f0fb8f5190_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d9c3c4e1-aec0-4324-97a7-99240f07cb16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c65ea5ff-86e3-4100-a26b-2a5487b5ff98_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3b64b4a5-4193-4d39-a630-26b38bd5ec64_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_f27713e7-2493-492b-938f-a7cf037942e3_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20240331.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_dc476115-a480-449e-99c0-7b82f89c32f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7fd18827-090f-4a51-840f-c1828e2b61e7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_caad4d38-524e-44e0-813d-986819763e17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_0c84166f-cf80-4c7b-b97d-b1891ccacadf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4cc88c3a-ca96-4f9c-aefd-13c67eafe6ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_40cfa67c-8874-464f-93a1-d7307e17ae19_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_055ae95e-ddf2-43b1-b0b3-95979a72fa00_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_267295d0-aaff-4cb1-9823-d26da2c5631a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5434eadb-c116-490d-9767-60fd901f1278_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_7ec2a820-5ef1-4bd5-ada1-cc051d0c781e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9f54485c-b459-4491-ad0d-2be87d8066a1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_22f9d606-2536-44fb-8a90-441563e6d633_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation, exercise price (in dollars per share)</link:label>
    <link:label id="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_label_en-US" xlink:label="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Option, Exercise Price</link:label>
    <link:label id="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_documentation_en-US" xlink:label="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Option, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:href="vtl-20240331.xsd#vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:to="lab_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_725de52c-c49d-4b84-acd3-3e4ba5dc270c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sale of investments - other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromInvestments" xlink:to="lab_us-gaap_PaymentsForProceedsFromInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_9ba68218-5982-4474-ac0a-12a425d261e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_696bab30-9db7-46aa-bb4f-c007479fba0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aedd879e-17bc-47cb-ab00-b42d8a9576d4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5f1cb8f6-f25e-4367-b07a-55a936c00037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TrancheRightFairValueDisclosure_c6dad45a-b7c9-4f09-b0db-85fea21fb193_terseLabel_en-US" xlink:label="lab_vtl_TrancheRightFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche right, fair value</link:label>
    <link:label id="lab_vtl_TrancheRightFairValueDisclosure_label_en-US" xlink:label="lab_vtl_TrancheRightFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Right, Fair Value Disclosure</link:label>
    <link:label id="lab_vtl_TrancheRightFairValueDisclosure_documentation_en-US" xlink:label="lab_vtl_TrancheRightFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Right, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightFairValueDisclosure" xlink:href="vtl-20240331.xsd#vtl_TrancheRightFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TrancheRightFairValueDisclosure" xlink:to="lab_vtl_TrancheRightFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PlaneggGermanyMember_96533370-e734-44e4-86c1-3edb4def70fd_terseLabel_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Planegg, Germany</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_label_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Planegg, Germany [Member]</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_documentation_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Planegg, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember" xlink:href="vtl-20240331.xsd#vtl_PlaneggGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PlaneggGermanyMember" xlink:to="lab_vtl_PlaneggGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1a6adb14-2f94-4590-8b9d-dbf0ec5174a8_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_d188b8a2-00fc-47c0-b5db-114ec213d43c_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20240331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f286b5e7-6713-4450-886f-48d164de04a1_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c4046ff8-df67-4ed6-8979-c41cb5f24fc4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7a803883-be0f-4cee-bf97-a7766d01533f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_014e3144-f929-4671-93c0-6e9f48100b97_terseLabel_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days for aggregate trading volume calculation</link:label>
    <link:label id="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_label_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Trading Days for Aggregate Trading Volume Calculation</link:label>
    <link:label id="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_documentation_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Trading Days for Aggregate Trading Volume Calculation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:to="lab_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e60f4646-0246-41a1-87d7-0f3b2d262121_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_15754e4b-81f8-41ba-a609-1926bdb589cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_16b4f0da-242e-431d-ba1b-4272d97d1765_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9e3b0077-1752-424d-82ed-3c3816a19c53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_06aa7cc0-31e2-4ff1-b1ec-431eae49db09_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_706234e4-4187-4b0a-8d00-990cce3e0c21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a6c7a292-765e-4827-946f-e62a168c68b8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_12c31cc7-9c23-498b-be13-9fa8f866830d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_99e27705-835d-4aaa-865d-31161ff3a2bb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_WeightedAveragePriceOfLast10Days_74621a96-d4d6-4532-8775-9b382c992508_terseLabel_en-US" xlink:label="lab_vtl_WeightedAveragePriceOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average price (in USD per share)</link:label>
    <link:label id="lab_vtl_WeightedAveragePriceOfLast10Days_label_en-US" xlink:label="lab_vtl_WeightedAveragePriceOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Price of Last 10 Days</link:label>
    <link:label id="lab_vtl_WeightedAveragePriceOfLast10Days_documentation_en-US" xlink:label="lab_vtl_WeightedAveragePriceOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Price of Last 10 Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_WeightedAveragePriceOfLast10Days" xlink:href="vtl-20240331.xsd#vtl_WeightedAveragePriceOfLast10Days"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_WeightedAveragePriceOfLast10Days" xlink:to="lab_vtl_WeightedAveragePriceOfLast10Days" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_81a43311-c84c-4888-8a79-dc84c072940b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_4f349391-97b1-4519-843b-de531a4dff44_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_452ed408-9628-41c5-aafc-0e695c07148e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7769e66f-2b17-41fe-af51-4ba47bcc9a16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_3a14116a-7129-4637-b357-fbd6874aa07c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cf619362-5820-4daf-9b9b-1821e423b659_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b51ec926-892f-4c22-9d99-322cadb6cb59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_07224823-a4b9-45c2-96c6-6546653e8972_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_ff98e74c-0211-480b-a96b-7962c057d75e_terseLabel_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents and Investments- other</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Other Investments [Policy Text Block]</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:href="vtl-20240331.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:to="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_c7df7942-4611-45dc-aac1-cc51a0a1bc45_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20240331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8369005a-fd09-41a9-ba05-7a65bfce2e60_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_347afe52-a190-4575-ac2e-c3f214bfdf30_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20240331.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_74b59079-530c-42ad-a441-972d68212a2f_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized, percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_721d9a6c-e0af-415b-acf2-245999b08ef2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_8ac9ea61-d047-4743-8c8b-b179f98dde63_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees expensed as part of January 2024 Financing</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f3202115-015c-4ce2-b548-004de25e033e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_47bf1c47-c44f-4e40-8030-022feb2ed60b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_7654318f-8f2d-48f1-9798-1de79599116e_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20240331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c0801c50-d8bf-41c2-a865-d34fd266cf26_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from January 2024 Financing, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_25e981c3-5d0b-44fe-b105-d1c9b941b3d1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_6375068e-77fa-4eac-a321-9de484a0bb28_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20240331.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0c119cf5-03f7-4f9c-97c6-08e336fceb6f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_72f98470-462e-4390-968e-75301844d75a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_cca148ca-7759-4a26-8900-227a8bb3db67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b5978672-0e0e-490f-9705-ea978e6f65dd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_b5304e26-5096-429e-ba32-d2a6c7a674f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value through March 4, 2024</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_793690fe-4008-4843-ae0a-bdbb0bd0a9a6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cff1f860-fb27-4f20-82b3-225ef0ec50c6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_12bdc707-5bea-49d2-8493-b2d721612710_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5e4faeb2-6b18-41ef-b66d-20e2cd1c58a8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4f420689-857d-48c2-8768-41c02c3673b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cadf0341-dc78-450b-81c7-c58bc4c14dfd_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_01144bae-e00c-4b46-bf7b-3f31622504a6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e8aa4c37-102c-477e-9a94-540986664b95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_30a4d17d-d86c-44fe-86ac-13816e5db011_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e65b46d3-9619-4b94-95eb-799f11133b6c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_42ea91b0-7740-4326-847b-e8c5e60f8e82_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_138a5dc1-88ca-42e1-983a-7b6b8d8f3db9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_acafcdda-f1e8-4b94-b93b-14c29433c1aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_1a7fd2cc-cef3-4b71-9c26-874eaf19ba08_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2c78a348-3651-438f-a657-758be23b4c9b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cd2234e0-fc43-449e-9d84-5cd3fb04ae9b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_badd8f2f-50f0-41bf-958f-4793a87c3319_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a3f324fd-86cb-458f-bf04-43582bf87b4c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_51057efa-8b9e-4416-a4e4-2348b0174adf_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_21530eaf-e09d-44a9-8afa-5caa5a3f26fb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d365b17b-8902-4be6-b045-15d1696aa347_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_f1e6f115-df10-4786-b1f9-cdf0d185296e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d75d8e5-ad32-4d85-a4ae-8a573afb671d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_80578bc6-eb5c-4f1a-8b79-a057c12e26dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_be0e6c0b-cdb8-4c05-9448-738ccce5f505_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_13155f3a-d1f7-4ca7-9a9a-b9b125ddbfb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_6151e066-9c36-4956-ae76-06669b8dfa02_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_e47bc065-3e81-402b-a045-b3d96db800ac_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_a11fe2bd-c168-473b-892b-3c97f67c54d4_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_d0e08655-7431-403f-beeb-9622462f9a02_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_38ded047-2051-4707-8ce2-158b558ec8b2_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cf4aa735-b5da-4a15-9ea5-59773c5dbb3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_773b1984-9a94-4f24-ab81-9c04d5a5557a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6d6e7b1f-7235-4904-9c40-656dee1f4175_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c2d9f248-85a6-49c2-aa94-63eada668445_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7a36e4c5-e1dd-41c5-9670-7d729a58036b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_74d92964-e545-44fb-9818-753d9f517819_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ae73a2c2-2aab-4d88-abce-430712039b98_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_05901ff3-9321-4bf6-ad5d-7105d7b90bef_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20240331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_30c3ec3e-24b8-4a75-b2c3-32339ac1a088_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_082bf2b2-ef7b-4404-b15d-0da98d16524a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period over which compensation cost will be recognized, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_61542513-7cfe-406e-b377-a3ea49d611ea_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6d1d9c19-464a-4c88-a9a8-834fe774ddf6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3721bfc1-a774-4e72-a69f-d3f4e2d62e82_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bbebc103-34c8-4086-800d-87a6cb8ec970_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8608d207-531d-4a80-8fb2-d0f9176a3f3f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_f6f4b62e-580d-4e22-a587-fe8718bf1241_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_12112a4c-6ae5-4ba7-9fab-956e0fb024db_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9938a998-927c-4b43-9e29-0146fc3486a3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_df430b72-7062-4350-9b6e-b4a1efd68801_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_784bfcce-df16-4b85-963c-659cba7ea264_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3a23f7ab-c915-4b36-9dd2-587cf8cc6697_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ReclassificationToEquity_7a2034bf-cb5f-4d96-a70b-49b16f3961a2_terseLabel_en-US" xlink:label="lab_vtl_ReclassificationToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification to equity</link:label>
    <link:label id="lab_vtl_ReclassificationToEquity_label_en-US" xlink:label="lab_vtl_ReclassificationToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification to Equity</link:label>
    <link:label id="lab_vtl_ReclassificationToEquity_documentation_en-US" xlink:label="lab_vtl_ReclassificationToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification to Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ReclassificationToEquity" xlink:href="vtl-20240331.xsd#vtl_ReclassificationToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ReclassificationToEquity" xlink:to="lab_vtl_ReclassificationToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_e4789640-127c-4c70-ba4a-14d07627906f_terseLabel_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_label_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Qualified Research and Development Expenditures, Maximum Amount</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_documentation_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance, Qualified Research and Development Expenditures, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:to="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_eb33dfd3-81cb-4e3f-ada2-475363edc702_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary_5f75af24-c963-420c-bc92-30ef804f9e5a_terseLabel_en-US" xlink:label="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:href="vtl-20240331.xsd#vtl_SalaryAndWageOfficerMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:to="lab_vtl_SalaryAndWageOfficerMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_b659135f-83da-4be0-98cb-5b0a30d92cc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_17975dbf-c2e8-4f50-9772-9b3c766fd979_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ebd54865-e093-44fc-880e-ca55a4924a35_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0593f2e6-6dfe-440f-9418-960cca152afb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_74c81210-0895-4dab-8f41-3064b39acc48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_cafbcf6e-bb0b-4403-945b-1b89f89eb50f_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_611d0afd-9d02-4a31-a3d5-224dd9a182ec_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_7167540b-2c6e-41ed-a755-72627d151b61_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20240331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_0b90330b-0eb6-470d-9cb8-906f6aa8ff36_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_93c2465e-1296-40b5-8496-fc2d50530cc5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Tranche Rights</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_60f321a0-5fdd-4a06-9312-121ea416b51a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_62f754a5-79f2-48a3-b442-59b9dfb719bd_terseLabel_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days for weighted average price calculation</link:label>
    <link:label id="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_label_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Trading Days for Weighted Average Price Calculation</link:label>
    <link:label id="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_documentation_en-US" xlink:label="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold Trading Days for Weighted Average Price Calculation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:to="lab_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_df726dfc-8c67-4f59-87cf-f4f7d753c11f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_dc887197-4d86-462c-8b9a-45a20989dcb7_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_b96b3c55-e575-4b4e-a3b2-983f70878621_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Employee stock purchase plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20240331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d6e4e0a-08f6-477e-bf30-074f8ef26685_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_78f8899d-038e-4da6-9f15-0d908a32d08c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_bfa465e3-2fa6-4797-b740-56dd3ef5a2f3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0183f20d-a0ea-449b-a3db-9306921e18e0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_ab121ebb-d4a4-4324-85e0-14d27d6db4c9_negatedTerseLabel_en-US" xlink:label="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the tranche rights</link:label>
    <link:label id="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_eeab68c2-118f-43e7-81b0-83deed1fabc3_terseLabel_en-US" xlink:label="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of the tranche rights</link:label>
    <link:label id="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_label_en-US" xlink:label="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs</link:label>
    <link:label id="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_documentation_en-US" xlink:label="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:href="vtl-20240331.xsd#vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:to="lab_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_244c87eb-2c69-407a-8283-aa14659481ad_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20240331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_94040261-7d72-4311-acbe-78074fcd409c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a64029c9-9c16-4e5a-868b-f7e91b963547_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5df2b60c-a2ca-4576-86e2-72681d73ee94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2cf02fab-fe05-4817-864a-5e548e2b5c8d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PreFundedWarrantsMember_dd22f0c1-0a99-4c5a-8a3e-9948daef1c24_terseLabel_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-funded stock warrants</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PreFundedWarrantsMember" xlink:to="lab_vtl_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentGrant_52d0e837-27e0-4b09-8e47-b796a5bd3a77_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research grant</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentGrant_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Grant</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentGrant_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentGrant" xlink:href="vtl-20240331.xsd#vtl_ResearchAndDevelopmentGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentGrant" xlink:to="lab_vtl_ResearchAndDevelopmentGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87885492-e3b3-4047-915a-6a389ca222a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_762b0a1d-63e1-4fe9-9a88-32f4727a9903_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_741aaf41-c8ab-4664-8f1e-3d6f8749ab3f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b1789b08-aa54-4b9b-806d-fab809405fc9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityRemainderAmount_bb17c4b0-880c-4b88-b447-0519718d6a83_terseLabel_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche rights as a liability, remainder amount</link:label>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityRemainderAmount_label_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Rights as a Liability, Remainder Amount</link:label>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityRemainderAmount_documentation_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Rights as a Liability, Remainder Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityRemainderAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:to="lab_vtl_TrancheRightsAsALiabilityRemainderAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6c81b71d-35e9-4052-93a9-6169ff68aa83_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9014b535-e02c-4410-a0ba-614518c63f52_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_51ecc968-3108-4317-b65d-9f1c9b6c29e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0db80701-f513-4486-b9c0-48709d1b6603_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2ac2674f-233e-4ea8-bf4d-a085efdbc130_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_6fcbf720-4094-4e3a-a730-8d9299eaac73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c86f2782-8842-4a8e-a6f7-b2e159a3cad0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_218eee9f-2f43-49e6-80e1-080afa473e20_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4f59d1ac-127d-49a3-8f1a-c61615a50e2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8457a4bf-0cc1-4c9e-bf37-d6b90737a7e1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_c54e3daa-f2c2-4636-94bd-b0c38ad3eded_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2b5775b3-c898-4b44-8616-b77545d2d1ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_72d7653f-9ee0-4d42-8a96-182aa3808d18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f0d6db1b-a1e6-46f5-b3df-f2baa226e539_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_caa17188-d9a4-492c-8f2c-ef82227eb817_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20240331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9d80b7ce-3e3e-4432-ba8a-3e8d9fee1154_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_094c45b0-5b48-435c-9303-47f353f54777_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_730547c7-7776-4fcd-a043-7ebf1bb08293_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_7d9fe6d7-1f1b-4eb1-b5ce-da87af3797f9_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d6699695-c5d0-463e-a11a-ca993c2fc340_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d7abf776-fa31-4832-b417-8a25e01a0b25_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a2985e54-8d00-491c-a37f-67d0f045f505_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4aa4102d-e913-4bd8-a2c7-52ed661f9c2c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_c3c0c366-4ca4-46dd-84e7-747797dc790f_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3f5a0de9-557c-4000-9a24-1519dfd58b7f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d9c31f3-c45c-448e-a074-e760c1741074_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20517f86-b214-4837-92e4-a1e383dd33ea_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8e2d8c89-9474-4fa6-8efc-a7ef6b62ee2b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_3757c156-57c3-43b3-a0f6-c4da137efef2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_c86dc817-e1b0-49fc-9f41-228715cf6963_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_06e9577e-744e-4c2e-9857-4a6a6f3c5ecf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_81b99345-906f-4ec5-a6e3-55f30b0c42ab_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20240331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_69c6f8e4-37c4-4c88-bb7f-a13cb8f4e94e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_5ae82b23-55a7-4097-bbf3-d142add16ca2_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_86edb503-485a-40c7-a1d1-f8671da95d6d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_00b4ade0-2bd6-45bd-a388-2c26c6e503ea_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2d3aa716-0936-4001-9da7-6f7ecb72d0b5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 500,000,000 and 130,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively, and 90,079,016 and 45,177,730 shares issued and outstanding as of March 31, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b6c262c7-853f-461f-9856-8914ff6444ac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_00820a21-57ed-4d38-ad7a-d5878bea78e7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8615c694-61fc-4de2-8951-9dfa31bf1e4e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_14a3fc1c-e707-4bef-b4d9-3c83acdd0900_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repricing Modification (in shares)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Modification in Period</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Modification in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4faeeeee-fd5a-45c0-bd70-9f3297e93f86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4d20d091-0b9e-44df-9bb7-0c3b58aab89a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9afa41f4-ce58-41b9-8a15-fb71ea1ad1d1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_24cf4788-104a-485b-a187-f42de04726b2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_3d2929e0-12a5-417d-85fd-3188cd09cf5a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_37ffb9ac-5639-4a6f-89b8-ecb32105cea5_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_63372234-74aa-4bca-b6b0-513f66259f68_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">March 31, 2024</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_c75efe6c-405c-4b31-8964-058c7034b1dd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_eb1298e2-0b3b-4338-924e-78ceea47067e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued from exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_76ec4582-04d0-4906-beab-b8b5e594171c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_51bba42a-c879-42f7-85d6-6cc596a11cb9_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20240331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_97c4dd6e-e9be-4c34-9461-d47227c6e98f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares_85696488-4f6f-4b3c-88d6-1fd27276e9ba_terseLabel_en-US" xlink:label="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of tranche rights liability to equity upon increase in authorized shares</link:label>
    <link:label id="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares_label_en-US" xlink:label="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Tranche Rights Liability to Equity Upon Increase in Authorized Shares</link:label>
    <link:label id="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares_documentation_en-US" xlink:label="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Tranche Rights Liability to Equity Upon Increase in Authorized Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:href="vtl-20240331.xsd#vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:to="lab_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_327c5395-3f8d-4299-9df0-7ed37298f376_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6be60a7d-20b1-4b19-8822-2ca1e81ec4c1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_7974a123-cf21-4a2f-a763-2d849c7c7074_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_ef3313cd-9b17-4769-aec0-02cafb6292db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_cfa8248c-bf78-4237-b52d-6abdd088ee0f_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20240331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bbc65418-906a-4471-84d3-05a80fa40004_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3567c1ed-3e00-4704-8f16-f3e7e2ce6e81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_df0e750a-fa98-44d7-bec7-4e95305dc521_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20240331.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_83113102-1922-4ca0-9ea1-fd9a453cec5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_79184323-38ab-4e0d-825c-f51e10b5daac_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in operating lease, right-of-use asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20240331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b035e911-e1d0-45ed-a22c-85b9e21aa7c9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_63535dd5-ecb9-4c67-bab6-0e61c5a4324a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_544a82d2-ae85-4caf-8b11-9d1a31c934cb_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_862fabaa-d1cf-4185-9fe3-99b0d40953f0_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0d96e2d-794f-4d4d-931a-f2546b5b47bd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_de1e03a7-b665-43df-abeb-686814f15459_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_448b60d9-abe3-4242-84cc-d16826f7490e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_d526d243-08e0-4425-b844-796854926bee_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20240331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_0f715935-15e4-4cfe-9163-caec00d55d9f_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_a4af4fbf-47d7-4871-9851-c7d797c83e75_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_38312832-4425-495e-bb31-e18790d4d7ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued from exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3006e65f-550b-4261-be41-b3377e87ec17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_465cc4fd-1f3e-4bea-aaeb-4c68c9ac845f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_22925273-77c9-4559-a34d-46027cdc0d07_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of existing operating leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4cf98897-0d5b-4efb-bb58-b2968371973d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_377c422d-49c0-40a9-a3c1-bed21d9e9ed0_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20240331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6f3523df-4837-4cf4-9c02-dcd98f6bd688_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_afd0f16b-9e21-454b-ac41-2976407ade67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_12555cc5-b10b-4255-ae98-58a8d2cf0b3b_terseLabel_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_label_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Sales Agreement [Member]</link:label>
    <link:label id="lab_vtl_AtTheMarketSalesAgreementMember_documentation_en-US" xlink:label="lab_vtl_AtTheMarketSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember" xlink:href="vtl-20240331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AtTheMarketSalesAgreementMember" xlink:to="lab_vtl_AtTheMarketSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c5492ecd-50a2-4dcf-b8ba-3257471cbb1b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_464b5747-12d0-4bb1-be38-ce099315ed32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_952c576f-8e94-4ea1-ba2f-b4dffb19f402_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_63969f06-4a7d-4b6f-a9db-cc484379bbde_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a2c01590-7830-416a-bbee-8953395ebdaa_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7ec4c594-d0a4-4422-b7cc-df678898a79a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_25442334-8ac9-4eba-ac64-a0e6f915a5b2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_2ab061a4-e935-471b-80d5-4aae648df099_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate trading volume of last 10 days</link:label>
    <link:label id="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_label_en-US" xlink:label="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Trading Volume of Last 10 Days</link:label>
    <link:label id="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_documentation_en-US" xlink:label="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Aggregate Trading Volume of Last 10 Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockAggregateTradingVolumeOfLast10Days"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:to="lab_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bba5ecc3-ba9a-4ea5-958c-64ba908c2148_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d93923f1-afa5-49af-864d-738410d27d18_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5070e0da-33fa-441c-8b8c-2c26364e09d2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_69edef5e-5721-4d1f-95fb-02ee7c86adf3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_695e7241-9b2d-4666-ae1c-3465c7f2571a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Tranche Rights</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2ad94f96-d378-4706-b611-3609220b5801_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_a0493f08-5b22-4642-8925-ffe67f2f7540_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_89e56cd9-018b-4dfa-ad6e-16580ef4c797_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c1f8e148-6d0a-476c-b7d0-154a586d5846_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_27fff3cf-b269-4cfa-b9a6-168b3e30ee38_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0dec86b4-67c9-42d8-8730-bb94cf05df38_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2ba62705-cca6-4ff3-bcdd-6e435b639243_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_0cf161cb-435e-46d4-886b-75b3f8a9cfc5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_36a99b5e-d254-470e-bb05-2301e3a38917_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ad94e46c-d6c8-443a-8a8e-b36816fc9348_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a7dcfedb-1022-42c5-b285-a9ac80c677e8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f7f79e8d-3617-400d-88fe-7e8ef47816d8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_34ba9702-8311-47a0-b145-83021cd4fac9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0902292f-2d4a-4000-9af8-cfcff574e8af_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_23be6120-3da9-44f4-bbce-c29acb74262e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_c747637f-551c-42fa-a895-ec8dffe2951b_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20240331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_87fbc092-0aad-4a39-aebb-d18db3133e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_66503540-6a66-4f7c-ae1a-85d016f010ea_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_ccf50781-253d-411c-92b4-95983ebb1dec_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20240331.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_5f9299b7-adf2-482e-afa9-19a4fb3bbaa6_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20240331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f29cebb0-c5e0-4771-9179-0e266d6f350a_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b587cd65-faf5-453a-a730-22ee22551bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9f411193-f904-4f10-a4fd-d564cfbd9848_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_317389b8-90c1-40b8-86d6-31e1c6f676e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_751164c1-8683-40ad-bce2-d51d2712b126_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_8f5889b2-3ad6-4169-9753-b8aba615f9f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_88d75a7a-c3a9-4356-938c-3cc70d694291_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_e643f6fa-a766-4a06-83e1-db02ad30abd3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_94ebe361-159e-4491-8b0a-9195db59267a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_393f5776-ae64-47d9-b1c8-86dbdafd47bf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_2416e8a6-2862-434f-bc41-22faba9fa91f_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, extended rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7d23f3b6-6c66-4fab-8fef-1bb6f5155e4b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c2b5175e-4c5f-421f-9815-080bad5c3117_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b2201ebe-9961-420a-8cc4-6576114996da_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_6dfab2cc-a5b7-4fab-bd0d-f0d220eccf59_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_72f5b810-675f-48ac-9e78-5fba4e558094_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_07c2ced5-9448-49e3-8961-57ca62d7c49c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_b77a2096-5b69-48ab-b650-c81883172d58_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf registration, termination, prior written notice, number of days</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice, Number of Days</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice, Number of Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_January2024PIPETransactionMember_5c7f7465-de24-4a41-8e84-f1d23da49487_terseLabel_en-US" xlink:label="lab_vtl_January2024PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">January 2024 PIPE Transaction</link:label>
    <link:label id="lab_vtl_January2024PIPETransactionMember_label_en-US" xlink:label="lab_vtl_January2024PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">January 2024 PIPE Transaction [Member]</link:label>
    <link:label id="lab_vtl_January2024PIPETransactionMember_documentation_en-US" xlink:label="lab_vtl_January2024PIPETransactionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">January 2024 PIPE Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_January2024PIPETransactionMember" xlink:href="vtl-20240331.xsd#vtl_January2024PIPETransactionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_January2024PIPETransactionMember" xlink:to="lab_vtl_January2024PIPETransactionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0b00e651-369b-405e-9efe-9cddeee37f29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_4d4afba6-1ac5-4a9d-957c-3505b9eea54f_terseLabel_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_label_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_documentation_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:href="vtl-20240331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:to="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_649f457c-d9a6-4e4c-aabd-a60fb88e8c6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_67439a04-d75d-46d7-ae2d-036bd986269a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_5efde27e-af7a-4347-a188-2a6527d903ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b7a6854-71a9-4cef-a687-a996ad1e07de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_81a8c99d-de2f-4df6-bf89-9d18c8204b2f_terseLabel_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government R&amp;D assistance rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_label_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Qualified Research and Development Expenditures, Percent</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_documentation_en-US" xlink:label="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance, Qualified Research and Development Expenditures, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:to="lab_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_8545f5e5-841e-4f61-94ea-c491aa84ff77_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repricing Modifications (usd per share)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Repricing Modifications Price</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Repricing Modifications Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:to="lab_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityReceivedAmount_a25dde1b-507b-49cc-bdd4-c5edebcf29d0_terseLabel_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche rights as a liability, received amount</link:label>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityReceivedAmount_label_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tranche Rights as a Liability, Received Amount</link:label>
    <link:label id="lab_vtl_TrancheRightsAsALiabilityReceivedAmount_documentation_en-US" xlink:label="lab_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tranche Rights as a Liability, Received Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityReceivedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:to="lab_vtl_TrancheRightsAsALiabilityReceivedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_58b20b91-f52c-49dd-b71d-5f3623876f90_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weight average fair value repriced stock options (in USD per share)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value for Repriced Stock Options</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value for Repriced Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_70b17f9f-1c59-4b4d-a0a9-2de7df958d01_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_89f7d3df-c28d-446d-a1a1-1187f82ed508_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_04374aac-3637-4ea7-91bd-f997fd5ccd2b_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating and variable lease cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20240331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_3aa8d631-6195-46aa-a182-bb8115ff55d1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_2b3b97b0-4e06-450b-8934-932fa81d59ca_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_4d886513-ab1a-4e96-8692-39425ffca9c7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of tranche rights liability to equity</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e5d9dcda-9df7-4801-a7cd-bbcc1a45f73e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_55034aac-92ed-4b6a-916b-f5d5f32953e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_23f5a0b9-e79b-4ba3-aab6-aa4c0fd322e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 3</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_4b3bdc7a-46ec-4982-84fa-987cac9e6fcf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a48b13ee-bba9-49f5-aecd-488d2c3e0593_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_d681ced8-43fb-4fe2-bd20-56dc79594a92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_04fa7d88-fa14-4376-ab24-c13cd567cea9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a4efb8d-e8a0-43e6-85e7-7eefc6ddc59c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_7454a08c-1955-4082-9c89-469050134d31_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_ec8cc3ca-67c9-4468-bc8d-569f402bfb0b_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20240331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a76d52d8-6c7f-4dab-9a3b-d49137321265_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_cfbb001b-259f-4634-95dc-839512279c44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value, Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CommonStockNumberOfSharesRegisteredForResale_eb1a5ce9-3118-4855-83ce-37e0ae520717_terseLabel_en-US" xlink:label="lab_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares registered for resale</link:label>
    <link:label id="lab_vtl_CommonStockNumberOfSharesRegisteredForResale_label_en-US" xlink:label="lab_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Shares Registered For Resale</link:label>
    <link:label id="lab_vtl_CommonStockNumberOfSharesRegisteredForResale_documentation_en-US" xlink:label="lab_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Number Of Shares Registered For Resale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:href="vtl-20240331.xsd#vtl_CommonStockNumberOfSharesRegisteredForResale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:to="lab_vtl_CommonStockNumberOfSharesRegisteredForResale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d2cbc153-7936-4e3e-abc1-225df6bc2f04_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b1c425b5-4e35-4383-b048-204c9c5d8f3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche 2</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CommonStockAndPreFundedWarrantsMember_987c432e-a0fe-4732-81e2-696ce65cecfd_terseLabel_en-US" xlink:label="lab_vtl_CommonStockAndPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock and Pre-funded Warrants</link:label>
    <link:label id="lab_vtl_CommonStockAndPreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_CommonStockAndPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock and Pre-funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_CommonStockAndPreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_CommonStockAndPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock and Pre-funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockAndPreFundedWarrantsMember" xlink:href="vtl-20240331.xsd#vtl_CommonStockAndPreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CommonStockAndPreFundedWarrantsMember" xlink:to="lab_vtl_CommonStockAndPreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_eed46f67-2731-4143-a36b-39f19013e325_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_9dbd860f-df4e-4341-9b5f-3dfec13588d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_65abe989-987a-41e1-86cb-4f06c8850e5b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_a226423e-d565-45b3-87c4-8bbbed676119_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms" xlink:href="vtl-20240331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentPrograms" xlink:to="lab_vtl_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d7bbf385-a683-40b2-9e79-fbeedf75ccac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_67d33c67-081b-4f49-8c10-bf1dbf1cda61_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_9d644f13-72ee-4153-bb31-3fbe1fab6dfe_terseLabel_en-US" xlink:label="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of future tranche right liability upon settlement</link:label>
    <link:label id="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_label_en-US" xlink:label="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement</link:label>
    <link:label id="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_documentation_en-US" xlink:label="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:href="vtl-20240331.xsd#vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:to="lab_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_72630200-c6ed-4360-8e3e-b94ef1318225_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d4ce7118-aed8-4582-a27e-7723da190b01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4618cafb-4978-462c-b3e9-4898df3be133_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f250e572-9c35-4cf4-95b1-acab44b489a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_c42a24e3-d5a8-4cba-834c-db4a7011563b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockConsiderationReceivedPercentage_a2dbf59b-b1c0-4db5-925a-b11ed75e3963_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received, percentage</link:label>
    <link:label id="lab_vtl_SaleOfStockConsiderationReceivedPercentage_label_en-US" xlink:label="lab_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received, Percentage</link:label>
    <link:label id="lab_vtl_SaleOfStockConsiderationReceivedPercentage_documentation_en-US" xlink:label="lab_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockConsiderationReceivedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:to="lab_vtl_SaleOfStockConsiderationReceivedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cd29b322-5c4b-4d07-aa50-3cf2e258e228_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_ac1c027f-cd57-403c-8c05-b710c73c0ae2_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_6fac5c31-0232-4657-abe6-45835aec12d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_b957820d-0d2b-4132-919d-4765e284ec48_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20240331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e6540eb-0e8a-4364-92c8-acbe9040b3b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_4318f08c-bc91-43b9-a5e7-ffe29e41f043_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_500751c7-9504-4804-bca4-a8faec7eb2c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_7e37a330-dd57-4684-9c66-91cf8e72056c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f6f0c085-5c7b-438c-a8a2-a2f9a5d76157_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_fd012d92-4dc4-45cc-8722-3fb0b2af4749_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_91034dda-2c75-46ca-8dcb-fd0ac81537de_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d207c3f3-7bf9-4c20-ae2d-93ae97a7403e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f43b7eb6-1848-448a-9f16-63afff52f5f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d44c71d7-f4eb-475d-a3a3-68f1ea89aabb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_11b59db2-89a7-4dc2-8f76-ac15f15e43d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e4e42489-f3e0-4ed3-b943-aed2b68a3fe8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_61c87e85-e91a-44f5-86be-85be43b88bb3_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_d6045cc1-8526-4300-a0e4-891c69a779ef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_78797738-bcf3-435b-92d2-80ef5f7066ef_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_7fa36c9d-082e-467c-b877-2833d66fd6ee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_40b32f00-781d-4bb1-a85f-f6e83064a2b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d77bc807-68e7-447b-a988-613255e3556d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation expense related to stock options</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_1acc7df1-69eb-4924-a79b-e946b73f8b35_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_81ff7088-d4a7-433a-9dde-156cb82f3e89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockEquityOfferingsPeriod_f8ca3768-6ab2-4357-bc82-16987c76945c_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockEquityOfferingsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third tranche close period after second tranche (in years)</link:label>
    <link:label id="lab_vtl_SaleOfStockEquityOfferingsPeriod_label_en-US" xlink:label="lab_vtl_SaleOfStockEquityOfferingsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Equity Offerings, Period</link:label>
    <link:label id="lab_vtl_SaleOfStockEquityOfferingsPeriod_documentation_en-US" xlink:label="lab_vtl_SaleOfStockEquityOfferingsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Equity Offerings, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockEquityOfferingsPeriod" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockEquityOfferingsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockEquityOfferingsPeriod" xlink:to="lab_vtl_SaleOfStockEquityOfferingsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_9b1be821-6cc0-4ed7-9dfc-21ae262701db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a063ce71-59f6-47cf-88d8-27b5f5358003_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ddc0e9bb-d665-40fe-a150-43ff7b937235_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_17580304-6f2b-4ad1-9915-cef7221a6807_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ChangeInFairValueOfTrancheRights_23db52ab-9e06-425c-930d-5c43a13b1da4_terseLabel_en-US" xlink:label="lab_vtl_ChangeInFairValueOfTrancheRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of tranche rights</link:label>
    <link:label id="lab_vtl_ChangeInFairValueOfTrancheRights_label_en-US" xlink:label="lab_vtl_ChangeInFairValueOfTrancheRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Tranche Rights</link:label>
    <link:label id="lab_vtl_ChangeInFairValueOfTrancheRights_documentation_en-US" xlink:label="lab_vtl_ChangeInFairValueOfTrancheRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Tranche Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangeInFairValueOfTrancheRights" xlink:href="vtl-20240331.xsd#vtl_ChangeInFairValueOfTrancheRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ChangeInFairValueOfTrancheRights" xlink:to="lab_vtl_ChangeInFairValueOfTrancheRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_43720402-5ae2-45ef-a967-b38ea0eaafb0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e767469e-bab6-41a1-b6bc-e52fe925eb75_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_106f44b8-f0b3-4f87-bdc7-8388073d86c9_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_e2c8fe63-6a1d-4d7e-b63d-9110ee6cad05_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal option period (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6d92d861-8b40-4456-89db-3bca006e0ea1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_f8ac633f-7059-4789-8507-d8ccc1a48592_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_0daee859-5d06-46b8-a903-5d3ccd238e08_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6ff0c738-5cb3-4395-9be7-5d34196ca444_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_acae0ada-7616-4fb2-8d05-012afa561544_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f1e6a60d-cc46-4d0b-ad26-53b467872948_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_e4ff2eab-93e4-4757-be19-dc0fa0dc4100_terseLabel_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per each share of common stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_label_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_documentation_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:href="vtl-20240331.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:to="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_9c86a775-9a4e-4fcb-bdab-df6c3502b785_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2608fca9-31a3-447d-84f8-079f2ee7a533_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ee6699fc-5b1b-47a0-987b-e7a9d626271f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00a40175-573e-449d-9461-973deff7201b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued from exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_95e9ca75-db75-450c-8901-13f99f02555d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_541b64e0-f720-4ae7-8473-24dc5dd852a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_d158458b-7064-4a06-8164-7d2e7f15db3f_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_998e58c5-b10b-4704-b2f0-6819a46712ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_7b6ee320-8903-423a-86f9-fcddd03cd72c_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options repriced (in shares)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation By Share-Based Payment Award, Options, Repriced, Number Of Shares</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation By Share-Based Payment Award, Options, Repriced, Number Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:to="lab_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_bb19a25a-a607-41e5-a82c-01d4e6fb3ef4_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20240331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1adbd7d7-064d-4ee5-b428-e20f54ce6f1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vtl-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8c1301f6-8ccd-487d-9d84-8db22292e305,g:62d958ce-4a4f-4631-8609-2fecb122580a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20240331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8014781e-eaa9-4f95-a8ef-9cc94d09c761" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentType_8014781e-eaa9-4f95-a8ef-9cc94d09c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_280e9d6e-20e1-4126-a4f3-5166674595c8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentQuarterlyReport_280e9d6e-20e1-4126-a4f3-5166674595c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d1625f55-6535-4c82-9296-5ccbd849999a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentPeriodEndDate_d1625f55-6535-4c82-9296-5ccbd849999a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5be8129d-d318-47cb-8e45-59df0acf5f95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentTransitionReport_5be8129d-d318-47cb-8e45-59df0acf5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0cc2efd7-30b7-4c67-bf5c-c61a869ddfd5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityFileNumber_0cc2efd7-30b7-4c67-bf5c-c61a869ddfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b4cc0d70-cff9-4864-a320-2a209278452f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityRegistrantName_b4cc0d70-cff9-4864-a320-2a209278452f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cb3fe826-4bd8-452b-b92e-b8ea9a77892d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cb3fe826-4bd8-452b-b92e-b8ea9a77892d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e13ec533-780b-47b5-a4d5-03699a230dbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityTaxIdentificationNumber_e13ec533-780b-47b5-a4d5-03699a230dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4d906056-4e73-48de-a849-d479d895cd76" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityAddressAddressLine1_4d906056-4e73-48de-a849-d479d895cd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_44a5a5c3-2ce4-4bb1-b825-a0952f68b7a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityAddressAddressLine2_44a5a5c3-2ce4-4bb1-b825-a0952f68b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1e119e8b-7aa0-4806-b2a6-cc7691fa3e51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityAddressCityOrTown_1e119e8b-7aa0-4806-b2a6-cc7691fa3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_219a26e9-c5c0-40bc-863f-cc8f9639e79a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityAddressStateOrProvince_219a26e9-c5c0-40bc-863f-cc8f9639e79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_92e64043-ee71-4443-bbea-49532f98f032" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityAddressPostalZipCode_92e64043-ee71-4443-bbea-49532f98f032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_497ff2bc-c9e2-4031-b535-a5868455f793" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_CityAreaCode_497ff2bc-c9e2-4031-b535-a5868455f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ec11a857-0ad7-45d7-9377-d3a6a4e0fae8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_LocalPhoneNumber_ec11a857-0ad7-45d7-9377-d3a6a4e0fae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0fe9736d-4d15-441d-8829-bbb8acad0f1b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_Security12bTitle_0fe9736d-4d15-441d-8829-bbb8acad0f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f902b0f9-8f9c-4f55-beab-a230af63bd2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_TradingSymbol_f902b0f9-8f9c-4f55-beab-a230af63bd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e36ce6a3-b7b8-4508-a1d8-3474866a19df" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_SecurityExchangeName_e36ce6a3-b7b8-4508-a1d8-3474866a19df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ff244805-1233-483e-b808-e69a916b38de" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityCurrentReportingStatus_ff244805-1233-483e-b808-e69a916b38de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_28d108df-fdb1-4a80-90e9-0c8ee4758571" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityInteractiveDataCurrent_28d108df-fdb1-4a80-90e9-0c8ee4758571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d29726b9-a8ab-4e99-8110-bfa664fbb6d3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityFilerCategory_d29726b9-a8ab-4e99-8110-bfa664fbb6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_962332d3-ca4f-438b-ab88-c764f6caa51f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntitySmallBusiness_962332d3-ca4f-438b-ab88-c764f6caa51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_028e1a62-29de-4229-9b90-117fdf08e504" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityEmergingGrowthCompany_028e1a62-29de-4229-9b90-117fdf08e504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_365db6bd-ced9-4ce8-b0d9-b05f6f169a15" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityShellCompany_365db6bd-ced9-4ce8-b0d9-b05f6f169a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c5ec921e-dee6-4bb2-9e9f-606a9a87a76e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c5ec921e-dee6-4bb2-9e9f-606a9a87a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ef6ca6cc-00c4-46b5-a421-1d4128b0291c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentFiscalYearFocus_ef6ca6cc-00c4-46b5-a421-1d4128b0291c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8977240d-4a7f-4cae-a374-e1e1163ad840" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8977240d-4a7f-4cae-a374-e1e1163ad840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3f56f46c-6a3a-4d06-9307-4c891e07fb39" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_AmendmentFlag_3f56f46c-6a3a-4d06-9307-4c891e07fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_35fc5f44-a5d0-4903-a2ef-4edb167ea9aa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_CurrentFiscalYearEndDate_35fc5f44-a5d0-4903-a2ef-4edb167ea9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_72bc8f4b-2758-47b3-b393-661b08c6fe37" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7db84692-31c2-41d6-825d-d67e88f95265" xlink:to="loc_dei_EntityCentralIndexKey_72bc8f4b-2758-47b3-b393-661b08c6fe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b2fb573c-83e8-48e5-95d7-5182a9c93298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2fb573c-83e8-48e5-95d7-5182a9c93298" xlink:to="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3944c87a-7827-4f3e-845f-5c8941ebe257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3944c87a-7827-4f3e-845f-5c8941ebe257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc8b0c84-c918-427c-ad5e-92b035b2183d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3944c87a-7827-4f3e-845f-5c8941ebe257" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc8b0c84-c918-427c-ad5e-92b035b2183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bb9cef5-7b52-4403-b420-5b75bcb8a17a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3944c87a-7827-4f3e-845f-5c8941ebe257" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4bb9cef5-7b52-4403-b420-5b75bcb8a17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0c86adba-2940-431b-8982-25c18455b7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3944c87a-7827-4f3e-845f-5c8941ebe257" xlink:to="loc_us-gaap_AssetsCurrent_0c86adba-2940-431b-8982-25c18455b7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a447544a-ae78-4d27-b893-e4cbd7bc5e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a447544a-ae78-4d27-b893-e4cbd7bc5e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6cbeb2b-523b-4e0e-9e61-529cb0d627c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f6cbeb2b-523b-4e0e-9e61-529cb0d627c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0cb4c596-90a2-49ac-9b35-4e970f1f2cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_f560798e-3e7d-4df1-baf2-ee55ad76caa1" xlink:to="loc_us-gaap_Assets_0cb4c596-90a2-49ac-9b35-4e970f1f2cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b2fb573c-83e8-48e5-95d7-5182a9c93298" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7be8dfe9-0f89-47b0-965c-325166fa9ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:to="loc_us-gaap_AccountsPayableCurrent_7be8dfe9-0f89-47b0-965c-325166fa9ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0ad21342-fe0f-4f60-8015-d041197b1f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0ad21342-fe0f-4f60-8015-d041197b1f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_59be461d-6538-4e13-b6e9-82a5bc23edd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_59be461d-6538-4e13-b6e9-82a5bc23edd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_43cc6161-e16a-4df1-b019-129251438a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_40dc767f-8350-4ec1-a6ee-9bc865f37b48" xlink:to="loc_us-gaap_LiabilitiesCurrent_43cc6161-e16a-4df1-b019-129251438a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_96f674f8-4f32-454b-8fe1-b5e8438ba2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_96f674f8-4f32-454b-8fe1-b5e8438ba2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71924722-dafd-48f8-a3aa-2dbcedffaebb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_96f674f8-4f32-454b-8fe1-b5e8438ba2d3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_71924722-dafd-48f8-a3aa-2dbcedffaebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f5481e6c-4b85-4d61-b5a2-9697faf42675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_96f674f8-4f32-454b-8fe1-b5e8438ba2d3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_f5481e6c-4b85-4d61-b5a2-9697faf42675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_092ecf92-0469-4280-9270-a9ebd71d87a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_Liabilities_092ecf92-0469-4280-9270-a9ebd71d87a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_33f5062e-c937-41bc-b3ed-bd71ea5a2868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_33f5062e-c937-41bc-b3ed-bd71ea5a2868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d4fb9aaa-2234-4d57-9ed2-b32d11f84cea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_PreferredStockValue_d4fb9aaa-2234-4d57-9ed2-b32d11f84cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_129bd4dd-bd08-4dd3-9a7d-aad6e3f362ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_CommonStockValue_129bd4dd-bd08-4dd3-9a7d-aad6e3f362ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cc203922-0a13-47aa-9b58-732592e6340c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cc203922-0a13-47aa-9b58-732592e6340c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ad8e8e0-5f13-463c-a999-e0c8c7f42207" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4ad8e8e0-5f13-463c-a999-e0c8c7f42207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3612df2b-ac1a-4453-9384-40bb5fd64e41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3612df2b-ac1a-4453-9384-40bb5fd64e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ddfce5a8-7776-4781-9b35-a35f90d7d063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_32ffed08-ee1f-4517-ab9e-a651231b83c2" xlink:to="loc_us-gaap_StockholdersEquity_ddfce5a8-7776-4781-9b35-a35f90d7d063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2ac6b12-0325-4620-8b50-6f5bc41616ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_05cb676a-28b1-4355-80fc-0706e50e3cbb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2ac6b12-0325-4620-8b50-6f5bc41616ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2634f4e6-84ef-4a74-ab98-d77af8a111f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2634f4e6-84ef-4a74-ab98-d77af8a111f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_742d5491-be23-41e2-8a21-372fd6b91e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_742d5491-be23-41e2-8a21-372fd6b91e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cdd8be3d-8ee9-4a90-9f26-939b229cf9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cdd8be3d-8ee9-4a90-9f26-939b229cf9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_336d03bb-b985-433a-8002-fd467e97ff3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_336d03bb-b985-433a-8002-fd467e97ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_78963c22-d996-4a14-b135-2b700867450e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_78963c22-d996-4a14-b135-2b700867450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f0dff7b7-2b0e-4cab-ba40-d9f70013acad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f0dff7b7-2b0e-4cab-ba40-d9f70013acad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3fed2125-80b1-444d-8c57-80cbb7253f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_CommonStockSharesIssued_3fed2125-80b1-444d-8c57-80cbb7253f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b604865a-2787-422a-b231-032b647b5598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_60b4adfa-49f8-4a9d-9ef4-701686bdd168" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b604865a-2787-422a-b231-032b647b5598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6c4789ee-6a2f-425b-8521-2478db28ca02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6c4789ee-6a2f-425b-8521-2478db28ca02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8f932bfd-87b9-434a-a389-dc6da2f42244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6c4789ee-6a2f-425b-8521-2478db28ca02" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8f932bfd-87b9-434a-a389-dc6da2f42244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58ac42e8-c40b-4784-892a-478e9dd00585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6c4789ee-6a2f-425b-8521-2478db28ca02" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58ac42e8-c40b-4784-892a-478e9dd00585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3fcb18b8-9e74-48c5-9551-7f0504bb089d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6c4789ee-6a2f-425b-8521-2478db28ca02" xlink:to="loc_us-gaap_OperatingExpenses_3fcb18b8-9e74-48c5-9551-7f0504bb089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_40c9458c-381b-4ddf-a426-9ea2c432d9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_OperatingIncomeLoss_40c9458c-381b-4ddf-a426-9ea2c432d9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4ee3c119-77bb-46a7-83d9-9aedaac0ca55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4ee3c119-77bb-46a7-83d9-9aedaac0ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_d300a3bc-128d-4589-acc4-c3a846000ba6" xlink:href="vtl-20240331.xsd#vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:to="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_d300a3bc-128d-4589-acc4-c3a846000ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4e945a4e-4c72-44db-8983-03a3bfb6bae7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4e945a4e-4c72-44db-8983-03a3bfb6bae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_444f8502-6582-4b0a-bc4d-ddcb062bc9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7a5832fc-a015-471c-b05b-d8f299e2f7fd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_444f8502-6582-4b0a-bc4d-ddcb062bc9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d000297b-06d1-4a38-90a1-3114a76b67b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_NetIncomeLoss_d000297b-06d1-4a38-90a1-3114a76b67b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1b958383-6f6c-4dda-92ab-9ca2b4a137f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_EarningsPerShareBasic_1b958383-6f6c-4dda-92ab-9ca2b4a137f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b49046c3-be4c-4773-80d9-21944b7c4896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b49046c3-be4c-4773-80d9-21944b7c4896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_79dfd439-f461-437c-bdef-a5e5477f4f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_79dfd439-f461-437c-bdef-a5e5477f4f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8221880-149f-4048-b089-f30299cf4003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_06b940b2-4728-4c01-87e8-8ff2531d3803" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8221880-149f-4048-b089-f30299cf4003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_efb1a1f2-a9de-4fb0-8620-7aa4b2ef0c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f0a54ef-a8eb-45f6-8031-058f36628943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_efb1a1f2-a9de-4fb0-8620-7aa4b2ef0c1e" xlink:to="loc_us-gaap_NetIncomeLoss_5f0a54ef-a8eb-45f6-8031-058f36628943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ab749595-5bb6-46d6-8ef1-49693d6fd92b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_efb1a1f2-a9de-4fb0-8620-7aa4b2ef0c1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ab749595-5bb6-46d6-8ef1-49693d6fd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_557f4c0e-acb1-405c-9574-67a37f8eb1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ab749595-5bb6-46d6-8ef1-49693d6fd92b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_557f4c0e-acb1-405c-9574-67a37f8eb1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_74fbdd8e-b961-43c1-a272-a9acc5c4bf08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_efb1a1f2-a9de-4fb0-8620-7aa4b2ef0c1e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_74fbdd8e-b961-43c1-a272-a9acc5c4bf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_bbbc7542-01ad-4860-b7a9-efe57111fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_bbbc7542-01ad-4860-b7a9-efe57111fffb" xlink:to="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9c4ffaa5-f8b4-450b-8ddd-6fba0deb4b0d" xlink:to="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b55e6d8b-f878-4532-ba9f-24009460c043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_CommonStockMember_b55e6d8b-f878-4532-ba9f-24009460c043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_aef1ef58-cf33-40aa-967b-821a095be851" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_aef1ef58-cf33-40aa-967b-821a095be851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_041bd9f9-0a8d-43b3-b373-93a42bd7a3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_041bd9f9-0a8d-43b3-b373-93a42bd7a3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_81da9832-8669-46d3-825b-25bbb143f369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1af22123-89c0-4492-bfae-31c867c36565" xlink:to="loc_us-gaap_RetainedEarningsMember_81da9832-8669-46d3-825b-25bbb143f369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9bd42a9f-6851-430a-b55f-2a00417769fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_January2024PIPETransactionMember_077ab413-554c-4226-a6a7-1a92e638cc67" xlink:href="vtl-20240331.xsd#vtl_January2024PIPETransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:to="loc_vtl_January2024PIPETransactionMember_077ab413-554c-4226-a6a7-1a92e638cc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_e0e2e112-e3b6-4ee9-8a06-e86425442938" xlink:href="vtl-20240331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_625d2537-dba2-4a81-bd9c-576d9c03a513" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_e0e2e112-e3b6-4ee9-8a06-e86425442938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_81713e83-49ba-4277-9d20-d56b12929210" xlink:to="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_84a557aa-d465-4677-a572-6a149871c7d6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ef93608f-8782-4d5c-aee0-c7c3e4436b54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ef93608f-8782-4d5c-aee0-c7c3e4436b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eaf3f5b0-9390-4893-a3bc-37ad7e067789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockholdersEquity_eaf3f5b0-9390-4893-a3bc-37ad7e067789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_06f466d3-cbc4-4ca8-a656-f10617e1f879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_NetIncomeLoss_06f466d3-cbc4-4ca8-a656-f10617e1f879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed1eba57-b1d6-4784-82ca-8231ea38ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed1eba57-b1d6-4784-82ca-8231ea38ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d60dc17d-39f2-4fbd-aa2a-851d3b063ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d60dc17d-39f2-4fbd-aa2a-851d3b063ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8171ffb3-3ca4-41df-bcd3-6f96318999a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8171ffb3-3ca4-41df-bcd3-6f96318999a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3acf0c59-2dfa-44fa-aded-fd8afae542ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3acf0c59-2dfa-44fa-aded-fd8afae542ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_64e2dea7-ef7e-420f-9ceb-c03f82b00731" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_64e2dea7-ef7e-420f-9ceb-c03f82b00731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afb91b26-cfc9-428d-b302-022377e29d67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_afb91b26-cfc9-428d-b302-022377e29d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5c6b26c-1b4e-41ec-bd84-08727891cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a5c6b26c-1b4e-41ec-bd84-08727891cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5b1644a5-d9ec-4b50-ba0f-c565a65d20f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5b1644a5-d9ec-4b50-ba0f-c565a65d20f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d850fe24-95b7-4d24-a3d5-6b58c2724a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d850fe24-95b7-4d24-a3d5-6b58c2724a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45869f5e-b73c-4136-94b5-95dd8383b48c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1bdc3624-651e-45a5-a0a4-ebc0d0280e0a" xlink:to="loc_us-gaap_StockholdersEquity_45869f5e-b73c-4136-94b5-95dd8383b48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_aed04f5e-e3b9-4083-9cec-0dc6ca8717c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_aed04f5e-e3b9-4083-9cec-0dc6ca8717c3" xlink:to="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a92a1d62-932e-46e9-ac6a-fb8ccb247e40" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_January2024PIPETransactionMember_eaf8dbec-d1ad-4e87-b8db-be99994a0d52" xlink:href="vtl-20240331.xsd#vtl_January2024PIPETransactionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:to="loc_vtl_January2024PIPETransactionMember_eaf8dbec-d1ad-4e87-b8db-be99994a0d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AtTheMarketSalesAgreementMember_e5aa510c-8fb2-4ae6-85aa-0ca0d6a16a5a" xlink:href="vtl-20240331.xsd#vtl_AtTheMarketSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8e2ec966-772f-4d09-882c-c00419d98dcd" xlink:to="loc_vtl_AtTheMarketSalesAgreementMember_e5aa510c-8fb2-4ae6-85aa-0ca0d6a16a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ce4b07cd-4c3a-4a42-ab2f-b7541a078a12" xlink:to="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9cfbb32-7418-4137-b6e3-9693f5848efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8812e7ed-f288-413d-ae90-f0d3b028c422" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9cfbb32-7418-4137-b6e3-9693f5848efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20240331.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c7b7f821-42b7-48d4-bb8a-e5984fb92520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c7b7f821-42b7-48d4-bb8a-e5984fb92520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b5e0aba-a9d0-4aea-8dc8-05bb8f6ad1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c7b7f821-42b7-48d4-bb8a-e5984fb92520" xlink:to="loc_us-gaap_NetIncomeLoss_6b5e0aba-a9d0-4aea-8dc8-05bb8f6ad1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c7b7f821-42b7-48d4-bb8a-e5984fb92520" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_29a7ffe5-d6b5-44fd-9d02-b0be05d8c9df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_29a7ffe5-d6b5-44fd-9d02-b0be05d8c9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f19d9aed-d987-48ae-a0de-7f91fb089678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_f19d9aed-d987-48ae-a0de-7f91fb089678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d57c4efa-cd5c-4e42-b59e-eccfe93018b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_us-gaap_ShareBasedCompensation_d57c4efa-cd5c-4e42-b59e-eccfe93018b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ChangeInFairValueOfTrancheRights_e7a1c085-9c94-433c-9e89-dd558f9eb0cf" xlink:href="vtl-20240331.xsd#vtl_ChangeInFairValueOfTrancheRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_vtl_ChangeInFairValueOfTrancheRights_e7a1c085-9c94-433c-9e89-dd558f9eb0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_1abba39f-c621-4e4b-97b3-9964f0b37ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_us-gaap_ManagementFeeExpense_1abba39f-c621-4e4b-97b3-9964f0b37ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5fc5a605-1696-4e74-bb1a-57f1ba7ac779" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c7bee74d-619c-417f-98c7-b95e1ef9ebbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c7bee74d-619c-417f-98c7-b95e1ef9ebbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_25f57fbf-6c88-4a33-aea2-7a806836153f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_25f57fbf-6c88-4a33-aea2-7a806836153f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc511f59-daef-44f8-9c33-10050e82df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cc511f59-daef-44f8-9c33-10050e82df6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_dae86c4d-aff4-4479-a056-2f186ced40cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9635116b-e811-44f0-9a35-31f42e1cfbc0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_dae86c4d-aff4-4479-a056-2f186ced40cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9917b94e-277c-42f1-b40b-ed4453234790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_c7b7f821-42b7-48d4-bb8a-e5984fb92520" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9917b94e-277c-42f1-b40b-ed4453234790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1aeedeab-80f9-4824-85c8-33991540d97a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1aeedeab-80f9-4824-85c8-33991540d97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_03668a8a-64ee-4114-945c-5db1ca1b5c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1aeedeab-80f9-4824-85c8-33991540d97a" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_03668a8a-64ee-4114-945c-5db1ca1b5c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87fc4d7a-b76d-4995-adcc-1061a6fe99c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1aeedeab-80f9-4824-85c8-33991540d97a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_87fc4d7a-b76d-4995-adcc-1061a6fe99c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_645471cb-28f6-4809-ae90-eb5ae8280d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_1aeedeab-80f9-4824-85c8-33991540d97a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_645471cb-28f6-4809-ae90-eb5ae8280d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d5f9371d-ea45-401a-a712-aae32f133b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d5f9371d-ea45-401a-a712-aae32f133b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ddd0cc12-36bc-431c-a404-75069475a98f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ddd0cc12-36bc-431c-a404-75069475a98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b52fd459-19b6-4741-987a-87763a75b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b52fd459-19b6-4741-987a-87763a75b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47a75ab4-34bb-4a9d-b82c-5669c3962e88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_5bf9afcc-7948-4f7d-bb4f-18f945fdff62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47a75ab4-34bb-4a9d-b82c-5669c3962e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8adb7a3b-a047-4e24-b497-f64c22bec6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8adb7a3b-a047-4e24-b497-f64c22bec6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_561d457b-685a-41f3-83b8-4cd9bc1f960b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_561d457b-685a-41f3-83b8-4cd9bc1f960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51431cb2-57e3-4f9f-940a-69bcad06e981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51431cb2-57e3-4f9f-940a-69bcad06e981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0894c22d-cf43-49da-9982-7066bc849d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0894c22d-cf43-49da-9982-7066bc849d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_37730db3-c804-46fb-aa19-0aa1f204f4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_82a1524f-c357-4f08-ba97-e5ad39cbbb5a" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_37730db3-c804-46fb-aa19-0aa1f204f4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares_6f10459e-7bf1-4f58-85fe-27a8ca5235b2" xlink:href="vtl-20240331.xsd#vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_37730db3-c804-46fb-aa19-0aa1f204f4b0" xlink:to="loc_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares_6f10459e-7bf1-4f58-85fe-27a8ca5235b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_29368c9a-9b36-49cf-a743-68039fe982c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_37730db3-c804-46fb-aa19-0aa1f204f4b0" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_29368c9a-9b36-49cf-a743-68039fe982c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20240331.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8a79dce2-b670-4644-b230-6fc6a7dd2f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_91ce0a68-594d-4fa2-a9e8-13fd151c2ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8a79dce2-b670-4644-b230-6fc6a7dd2f70" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_91ce0a68-594d-4fa2-a9e8-13fd151c2ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d198748-03cb-4e47-b223-d603f9f44350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_92b457e3-ee72-4d0a-847c-95c18ad67615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d198748-03cb-4e47-b223-d603f9f44350" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_92b457e3-ee72-4d0a-847c-95c18ad67615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ed80aa-f667-4594-92dd-ff8f4f8a50de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8a6759be-3dc9-42a6-bfdd-3c024ca4187b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9ed80aa-f667-4594-92dd-ff8f4f8a50de" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_8a6759be-3dc9-42a6-bfdd-3c024ca4187b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f22e088-5bee-41c7-8580-06a3d6eec8db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5079f9d8-ac45-4081-98e8-28b7d5e69507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6f22e088-5bee-41c7-8580-06a3d6eec8db" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5079f9d8-ac45-4081-98e8-28b7d5e69507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e68484d-b493-4412-ad9b-def5006a7bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_08c154a1-f557-48eb-b369-68dc195ebee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e68484d-b493-4412-ad9b-def5006a7bab" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_08c154a1-f557-48eb-b369-68dc195ebee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ec00835d-9fc9-49a8-a2db-a87f5947db1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17efa19f-7ca9-42c5-b470-6d6a91b94fec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ec00835d-9fc9-49a8-a2db-a87f5947db1a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_17efa19f-7ca9-42c5-b470-6d6a91b94fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_437d2bef-b3e2-4824-9b2e-a151ac83ad05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a1afbba3-64a3-44d1-8f00-f6357839d696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_437d2bef-b3e2-4824-9b2e-a151ac83ad05" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a1afbba3-64a3-44d1-8f00-f6357839d696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20240331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9e89f42c-4ffe-4090-9b57-bc77eb9bc173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0d6e2fb4-9592-422a-be9f-ead4c73f2998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9e89f42c-4ffe-4090-9b57-bc77eb9bc173" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0d6e2fb4-9592-422a-be9f-ead4c73f2998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9cc6dd46-fa12-44d8-8690-bd834d2b23ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9cc6dd46-fa12-44d8-8690-bd834d2b23ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_6cbd039d-8513-415c-bea4-0913e6ce6a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_UseOfEstimates_6cbd039d-8513-415c-bea4-0913e6ce6a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_60e889f0-eaf2-4837-8e9f-236aba2ed412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_60e889f0-eaf2-4837-8e9f-236aba2ed412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_8b1e6289-d5cd-4569-b5df-0a2c3fc208ea" xlink:href="vtl-20240331.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_8b1e6289-d5cd-4569-b5df-0a2c3fc208ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_846491f1-ba5d-456f-a994-b78b2c159c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_846491f1-ba5d-456f-a994-b78b2c159c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_592255f8-2d09-468d-b790-39dcaa040f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_592255f8-2d09-468d-b790-39dcaa040f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a4e056c-4f28-4911-a187-047558e50cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1a4e056c-4f28-4911-a187-047558e50cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_dff41723-dbed-4f74-a8b1-d4586c2c3510" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_dff41723-dbed-4f74-a8b1-d4586c2c3510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_11c041ad-9960-4764-ba3c-6be54b603584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_11c041ad-9960-4764-ba3c-6be54b603584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_a1221120-2a23-4f90-941e-5a8682748718" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_a1221120-2a23-4f90-941e-5a8682748718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_3acf07fa-4e77-4a73-b4fd-b9facc0268ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_3acf07fa-4e77-4a73-b4fd-b9facc0268ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5a5f5ff1-67e0-45b0-8de1-e5c50bc9c1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5a5f5ff1-67e0-45b0-8de1-e5c50bc9c1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_687f8371-e217-467d-8e02-d639d82f2af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_687f8371-e217-467d-8e02-d639d82f2af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49088136-84a9-49a4-9479-d461915f9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49088136-84a9-49a4-9479-d461915f9ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6e258887-4e60-4b4e-aa62-8c4683d515e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6e258887-4e60-4b4e-aa62-8c4683d515e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_7c8b65e2-1638-43e0-96eb-9c1eb1e382f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_7c8b65e2-1638-43e0-96eb-9c1eb1e382f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d2e69d0-3999-4fcf-9a3d-df621e3aa3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_3d2e69d0-3999-4fcf-9a3d-df621e3aa3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7cf252a-999e-4fab-b9ee-dd979b874d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0d5afa96-da68-499d-a3a3-9c6857a8085a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b7cf252a-999e-4fab-b9ee-dd979b874d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9cd99de4-6034-4c6e-98be-7c7f959b2a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c08fc678-d816-49e2-b78d-d4db02a8f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9cd99de4-6034-4c6e-98be-7c7f959b2a69" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c08fc678-d816-49e2-b78d-d4db02a8f7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43927a91-9069-4554-bfae-164d43129839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_141753b3-507c-4367-81a3-b7827ec971fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43927a91-9069-4554-bfae-164d43129839" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_141753b3-507c-4367-81a3-b7827ec971fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_71a2a21f-ca33-4faf-bf89-75986bae9fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43927a91-9069-4554-bfae-164d43129839" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_71a2a21f-ca33-4faf-bf89-75986bae9fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_fef1a24c-5187-4ab3-ae76-6cc6c538e6db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_43927a91-9069-4554-bfae-164d43129839" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_fef1a24c-5187-4ab3-ae76-6cc6c538e6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c252ecf-f4e9-4723-9c65-ef4ac4f5f830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3ce195ad-136f-49bb-a476-5cbf3297bf21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5c252ecf-f4e9-4723-9c65-ef4ac4f5f830" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_3ce195ad-136f-49bb-a476-5cbf3297bf21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05549d68-5c45-4c12-8a2c-d0522c3d6f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c7c684ea-c890-4b99-a854-85e146ece4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05549d68-5c45-4c12-8a2c-d0522c3d6f6b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c7c684ea-c890-4b99-a854-85e146ece4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7a176957-65ec-4f2c-82e6-cc485e800cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05549d68-5c45-4c12-8a2c-d0522c3d6f6b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7a176957-65ec-4f2c-82e6-cc485e800cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_942cb752-68ea-4e86-b88a-048bb6cf5de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_e2577f2d-3550-4965-a100-741a425b9331" xlink:href="vtl-20240331.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_942cb752-68ea-4e86-b88a-048bb6cf5de4" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_e2577f2d-3550-4965-a100-741a425b9331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d379ba5-965a-4f39-9191-b9bf34341f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c8fc5e5d-c445-40e8-8969-1a87ebda4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d379ba5-965a-4f39-9191-b9bf34341f28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_c8fc5e5d-c445-40e8-8969-1a87ebda4a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9592867b-7d66-490a-9724-c3517ff6fced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d379ba5-965a-4f39-9191-b9bf34341f28" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_9592867b-7d66-490a-9724-c3517ff6fced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_201f69ed-07b6-40ba-a185-9793b90c2625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2d379ba5-965a-4f39-9191-b9bf34341f28" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_201f69ed-07b6-40ba-a185-9793b90c2625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7c591f95-3a70-48ec-8af2-64a19908fa29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7c591f95-3a70-48ec-8af2-64a19908fa29" xlink:to="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_da3a158a-4ef8-4fe9-9c4c-4bea8c40d65c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c605e32f-c838-41db-bfdd-1ef54b5aecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_61773de2-8bdf-431e-93e1-806bc7daae15" xlink:to="loc_us-gaap_SubsequentEventMember_c605e32f-c838-41db-bfdd-1ef54b5aecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_156cb41e-ecc6-4073-9d31-21deb14e9674" xlink:to="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_dfd94a01-4ede-4f85-a182-da5c6d27e6e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_dei_EntityNumberOfEmployees_dfd94a01-4ede-4f85-a182-da5c6d27e6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_7016a580-c7f4-40cf-a087-30567a4c5781" xlink:href="vtl-20240331.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_7016a580-c7f4-40cf-a087-30567a4c5781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_378116c3-6f37-4120-b9c6-e5bf967ae942" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_378116c3-6f37-4120-b9c6-e5bf967ae942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e89aeaf6-5703-4e63-be42-a9f80d8fa79c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e89aeaf6-5703-4e63-be42-a9f80d8fa79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a2fce2a-6101-4c3d-b362-36bba0b09e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8594faff-1c42-4042-a870-e479c8016745" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a2fce2a-6101-4c3d-b362-36bba0b09e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c0c92043-5ac6-443e-aaa0-97d043e16423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c0c92043-5ac6-443e-aaa0-97d043e16423" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1201df6b-6edc-4382-800d-2f6c4bb4d3d9" xlink:to="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_83ae3cb2-d68b-4da8-a3ee-899adf9f0658" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:to="loc_srt_MaximumMember_83ae3cb2-d68b-4da8-a3ee-899adf9f0658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f4840dec-df54-40c7-ae65-e970be4a6901" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7795b8da-2852-443b-b1b4-7f891d36cfb6" xlink:to="loc_srt_MinimumMember_f4840dec-df54-40c7-ae65-e970be4a6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a08f5b77-2d20-408e-b3bb-3f79fa38103d" xlink:to="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3fd2741-55ce-4500-a994-aea6a8b7d9b0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_US_b3fd2741-55ce-4500-a994-aea6a8b7d9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_0bc28974-74ca-4bb2-909d-2e32c9b07356" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_DE_0bc28974-74ca-4bb2-909d-2e32c9b07356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_a930efbf-4fef-4477-85cd-606fd782e033" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7a292142-840b-4608-9e14-207bbd068488" xlink:to="loc_country_AU_a930efbf-4fef-4477-85cd-606fd782e033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_86542d83-d648-4f70-9d8d-596369740eee" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_d41586a3-cae6-44fa-8d8d-5261b1176a1c" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_237a8d53-09eb-4104-b1e7-1d3438befca2" xlink:to="loc_vtl_PreFundedWarrantsMember_d41586a3-cae6-44fa-8d8d-5261b1176a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_c420555f-ce39-461b-8129-8db0f6acc13b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8a17ee3d-98fd-4805-be90-7f5dbf36803e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edac8e2a-493f-4f02-8b0f-af2326208905" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8a17ee3d-98fd-4805-be90-7f5dbf36803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_cd390816-ff59-4a4a-8c44-27e621854881" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ca3ac08-df28-4333-abc5-1941b64dd373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ca3ac08-df28-4333-abc5-1941b64dd373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_33826d9c-4cad-419b-8ce1-28bdda82db64" xlink:href="vtl-20240331.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits_33826d9c-4cad-419b-8ce1-28bdda82db64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_880c7657-b482-412b-8b41-bc21c7250216" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_InvestmentInterestRate_880c7657-b482-412b-8b41-bc21c7250216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7bb7064-a2be-48d1-b42c-b8016897a613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c7bb7064-a2be-48d1-b42c-b8016897a613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6b98ee49-d3ba-4f03-aa35-bc29794da7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_Depreciation_6b98ee49-d3ba-4f03-aa35-bc29794da7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_e8833566-a6cb-400d-8fce-a9b015213dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_e8833566-a6cb-400d-8fce-a9b015213dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_7e10a756-a61e-4d7a-a3a1-98254acac9c2" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent_7e10a756-a61e-4d7a-a3a1-98254acac9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_93d58165-1d3f-42a1-a3a0-7c0626fb91e8" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_93d58165-1d3f-42a1-a3a0-7c0626fb91e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_786218de-209b-4ecb-8a9e-0e888f835f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_786218de-209b-4ecb-8a9e-0e888f835f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_01b36203-b9f6-4892-b76f-90e01391350e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_01b36203-b9f6-4892-b76f-90e01391350e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7c91fb83-86a9-4af0-a557-fd76a71eff57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7c91fb83-86a9-4af0-a557-fd76a71eff57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_025d0fcb-63de-49e2-85df-99fc893f5713" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_025d0fcb-63de-49e2-85df-99fc893f5713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c09f69-a0dc-4dac-9255-9a94576e056e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_d7eb7541-e865-4807-897b-c9e2c88cfd7f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_31c09f69-a0dc-4dac-9255-9a94576e056e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1cdcc083-66fd-4fa8-9112-1f5bb3cfae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cdcc083-66fd-4fa8-9112-1f5bb3cfae9b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_96bbb0db-db05-4024-9d3f-ce0a1b4ee6d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_7bb145f2-112c-45ad-a4d4-56200c22ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b4181d6e-5528-4b6c-941a-2920cc8dd601" xlink:to="loc_us-gaap_StockOptionMember_7bb145f2-112c-45ad-a4d4-56200c22ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_51e0c829-bd91-4859-895d-b3ed9c40ec25" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7afdde7f-4a4a-44c6-b38c-a8766a9fe762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_cfd0eadc-30f6-40c2-977d-e7d47a3b4854" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7afdde7f-4a4a-44c6-b38c-a8766a9fe762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_eabc3ebe-bebc-4c2e-af8f-4500e5d03ac4" xlink:href="vtl-20240331.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_eabc3ebe-bebc-4c2e-af8f-4500e5d03ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_888e6df7-747c-4101-9a78-62e4b132445e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_888e6df7-747c-4101-9a78-62e4b132445e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_73129267-8f13-4ebe-a318-a5a2014cd762" xlink:href="vtl-20240331.xsd#vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount_73129267-8f13-4ebe-a318-a5a2014cd762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentGrant_0b637523-23bc-4c07-be97-d8c7adad6f3f" xlink:href="vtl-20240331.xsd#vtl_ResearchAndDevelopmentGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_vtl_ResearchAndDevelopmentGrant_0b637523-23bc-4c07-be97-d8c7adad6f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_fe48ca36-577e-4ca6-b9b4-708b89240ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_us-gaap_OtherAssetsCurrent_fe48ca36-577e-4ca6-b9b4-708b89240ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f62172d-e5fb-4d33-baa2-8efbf33cbec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5857de4e-5bcd-4ba1-b33b-8d722452a909" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8f62172d-e5fb-4d33-baa2-8efbf33cbec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05ee570e-ea0c-43b8-97e1-fdc9956a24e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_4ad4b9e5-3cad-4388-a7fa-9f105879df8a" xlink:href="vtl-20240331.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05ee570e-ea0c-43b8-97e1-fdc9956a24e7" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_4ad4b9e5-3cad-4388-a7fa-9f105879df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_292c3959-dbb7-4217-bba2-e24c3d6f2a6f" xlink:href="vtl-20240331.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05ee570e-ea0c-43b8-97e1-fdc9956a24e7" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_292c3959-dbb7-4217-bba2-e24c3d6f2a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_73bdc30a-98fe-48c9-b7bd-710d7332992f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05ee570e-ea0c-43b8-97e1-fdc9956a24e7" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_73bdc30a-98fe-48c9-b7bd-710d7332992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_936ac732-f6d0-42f1-9181-2cebb08b168d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_05ee570e-ea0c-43b8-97e1-fdc9956a24e7" xlink:to="loc_us-gaap_AccountsPayableCurrent_936ac732-f6d0-42f1-9181-2cebb08b168d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_1e0fac9b-2e45-434e-aa35-7cc307b94b11" xlink:href="vtl-20240331.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_1e0fac9b-2e45-434e-aa35-7cc307b94b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_9bcf4596-89a1-49e7-82bc-37db4fd192b7" xlink:href="vtl-20240331.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_9bcf4596-89a1-49e7-82bc-37db4fd192b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_13dffc2d-ad99-4360-92b9-342b08f04904" xlink:href="vtl-20240331.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:to="loc_vtl_AccruedCompensationCurrent_13dffc2d-ad99-4360-92b9-342b08f04904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75a1ab28-eee4-44c0-af37-a818fb88d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_75a1ab28-eee4-44c0-af37-a818fb88d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b0f75f3d-88d6-4976-a9dc-123e66950fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ffab352-7a1b-4de9-97c6-9f2545c9f9eb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b0f75f3d-88d6-4976-a9dc-123e66950fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c2df13b-0dfc-42bd-8901-07059e928c18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ef691a3-d04a-4c3c-8701-5c5d86e4eb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c2df13b-0dfc-42bd-8901-07059e928c18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4ef691a3-d04a-4c3c-8701-5c5d86e4eb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_702654de-f7ba-4d3b-bc93-5df48dc91077" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c2df13b-0dfc-42bd-8901-07059e928c18" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_702654de-f7ba-4d3b-bc93-5df48dc91077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d581c2fe-7f18-4afc-ad7b-351d9327ec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c2df13b-0dfc-42bd-8901-07059e928c18" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d581c2fe-7f18-4afc-ad7b-351d9327ec9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8226fdb8-a876-4903-9f09-01014be0e170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c2df13b-0dfc-42bd-8901-07059e928c18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8226fdb8-a876-4903-9f09-01014be0e170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_69261b59-9b1b-4d15-8d6e-0f32ac326716" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_69261b59-9b1b-4d15-8d6e-0f32ac326716" xlink:to="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:to="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_62825118-412d-413a-84c3-426333f38d3c" xlink:to="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_32daeec3-279d-4e8c-b42e-6ce7d2eab8b3" xlink:href="vtl-20240331.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_GrafelfingGermanyMember_32daeec3-279d-4e8c-b42e-6ce7d2eab8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_83fc904f-9907-46ae-a307-7ea39b9c4aa6" xlink:href="vtl-20240331.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_NewYorkCityMember_83fc904f-9907-46ae-a307-7ea39b9c4aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_9a5559b8-461b-4996-902c-615c2ed06fb5" xlink:href="vtl-20240331.xsd#vtl_PlaneggGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b5a0a609-441d-4538-88c6-007b82b08af8" xlink:to="loc_vtl_PlaneggGermanyMember_9a5559b8-461b-4996-902c-615c2ed06fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_0fd316b8-8b64-4166-8c58-8e9f6acb1ea3" xlink:to="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8c42efbd-e9e2-425a-9a28-c4b69905b6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8c42efbd-e9e2-425a-9a28-c4b69905b6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f49101b4-85b3-4590-b173-c864866c8606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f49101b4-85b3-4590-b173-c864866c8606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_63450781-6aaa-4a17-b21e-f8e82614b637" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_63450781-6aaa-4a17-b21e-f8e82614b637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_a6c54c3b-b908-4f69-b3e4-f7d01724d79f" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_a6c54c3b-b908-4f69-b3e4-f7d01724d79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_00def543-287f-4302-845a-b14181d824f6" xlink:href="vtl-20240331.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_00def543-287f-4302-845a-b14181d824f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_eb837df5-b6c6-4760-bd0b-8b1255fcebc0" xlink:href="vtl-20240331.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_eb837df5-b6c6-4760-bd0b-8b1255fcebc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_cd9b6e22-08ec-42cd-909c-536e402d2b64" xlink:href="vtl-20240331.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_cd9b6e22-08ec-42cd-909c-536e402d2b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_86211a9e-0db5-4861-8bb4-925cca5f5879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_3f74534e-e52f-4d79-8da3-7bd2a3c6e072" xlink:to="loc_us-gaap_ContractualObligation_86211a9e-0db5-4861-8bb4-925cca5f5879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e3a982b-ea96-47af-ab0a-0c46c19fbca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e3a982b-ea96-47af-ab0a-0c46c19fbca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_180e416a-0fbb-41b5-b21a-1afc2d2083ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_180e416a-0fbb-41b5-b21a-1afc2d2083ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a332660d-88b9-46dd-8a84-73014bea4893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a332660d-88b9-46dd-8a84-73014bea4893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22ad4201-96a7-43c3-a0ca-47426e4471bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22ad4201-96a7-43c3-a0ca-47426e4471bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_887b28fd-0ad7-4632-a5ad-2562fa5a7571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_887b28fd-0ad7-4632-a5ad-2562fa5a7571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_7cfacd93-6b7e-4115-8f17-f7cd492f83cb" xlink:href="vtl-20240331.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_7cfacd93-6b7e-4115-8f17-f7cd492f83cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_40d28818-fe9a-4cb7-82a2-2ef9532edf68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_40d28818-fe9a-4cb7-82a2-2ef9532edf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c2cf60a2-237b-4d80-9bab-584d3c8fc77b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c2cf60a2-237b-4d80-9bab-584d3c8fc77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bb9f8f2a-493a-45e2-92e4-a731c452af8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_65852efe-1bbb-4b49-a8fa-9954f226a247" xlink:to="loc_us-gaap_OperatingLeaseLiability_bb9f8f2a-493a-45e2-92e4-a731c452af8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b56d8f6e-802b-4504-9898-727b132e502e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b56d8f6e-802b-4504-9898-727b132e502e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3233152e-9ce8-4b86-9d89-076c052b8537" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d7d287b4-a4a1-4ab3-872b-87400435cb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_187f1ccf-5d87-414b-9acc-4d913b4f77dd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d7d287b4-a4a1-4ab3-872b-87400435cb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_a3b516af-3ffd-4b8b-b3bd-115489aea4aa" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0d31c6d7-e48a-41e8-98c1-3b10586deb11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_65fd10a8-ae56-4fc3-909f-67c87528bc3c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0d31c6d7-e48a-41e8-98c1-3b10586deb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a09e486f-1c01-4265-81c5-72f67aafe700" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_83f6f81a-1b44-4e0f-98cd-0634743e0697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_83f6f81a-1b44-4e0f-98cd-0634743e0697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6fd8a976-0de3-4e2c-9462-fc70e9817c92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6fd8a976-0de3-4e2c-9462-fc70e9817c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_48029e5e-98f5-4d77-bb2e-0a530a65e2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dbc404c6-d978-494b-88ea-124318f45cda" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_48029e5e-98f5-4d77-bb2e-0a530a65e2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9927cdcb-0432-4fdf-932c-da4c8213cb6f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_718ae9ec-1c2b-4c85-a651-d9de809f4aa4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a45bfd31-869b-43ac-84c1-23de87403903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_90916448-5efb-4d5b-aa10-81e573361f23" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_a45bfd31-869b-43ac-84c1-23de87403903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueScheduleofFairValueofTrancheRightsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5fe8d3ca-a86e-42af-8307-5625c7f5c041" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5fe8d3ca-a86e-42af-8307-5625c7f5c041" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3a8bc30-f908-4b4a-9011-007f30cb55fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b3a8bc30-f908-4b4a-9011-007f30cb55fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2b099fc1-67c6-4af3-b6e6-8e9e5288ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2b099fc1-67c6-4af3-b6e6-8e9e5288ac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a15c4b75-7c9b-4eaf-b4ed-e28d242a93d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_a15c4b75-7c9b-4eaf-b4ed-e28d242a93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ReclassificationToEquity_96a20305-49a4-4e1c-a644-f4f47da6a2ad" xlink:href="vtl-20240331.xsd#vtl_ReclassificationToEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:to="loc_vtl_ReclassificationToEquity_96a20305-49a4-4e1c-a644-f4f47da6a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c8531bdf-76b1-495f-9afb-3218f8e935f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b79462fb-4347-4a33-92b9-28671fee9466" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c8531bdf-76b1-495f-9afb-3218f8e935f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#FairValueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe34459f-eb1a-4dc8-89df-09eaa98516b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe34459f-eb1a-4dc8-89df-09eaa98516b4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:to="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4973bfe0-758a-44de-8951-cca05524e151" xlink:to="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_335567a5-b1ea-4bc5-9c9b-109020e3460e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_48669da1-cc75-43af-88ad-e94d0a9e072e" xlink:to="loc_country_US_335567a5-b1ea-4bc5-9c9b-109020e3460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:to="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4b175137-8856-42de-9ba0-047779b761d6" xlink:to="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8981f49-eacb-4031-b609-4aa11b0ca964" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:to="loc_srt_MinimumMember_b8981f49-eacb-4031-b609-4aa11b0ca964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_52319123-17a4-49a2-aaf1-27e0c0471cab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6abba383-bb88-4d75-a1b1-4a2de921d7ba" xlink:to="loc_srt_MaximumMember_52319123-17a4-49a2-aaf1-27e0c0471cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5312e863-a5f1-4471-a0ad-f04226e9b846" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_942f9756-4ea9-443b-9650-da2d1db6a622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_InvestmentInterestRate_942f9756-4ea9-443b-9650-da2d1db6a622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightFairValueDisclosure_65f1a633-eacd-4bd8-837c-b00d41716fdc" xlink:href="vtl-20240331.xsd#vtl_TrancheRightFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_vtl_TrancheRightFairValueDisclosure_65f1a633-eacd-4bd8-837c-b00d41716fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e370b30-ef55-433a-8f85-ff04edf859d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e370b30-ef55-433a-8f85-ff04edf859d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95a22d12-6741-4195-861d-6d9834fdd646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_95a22d12-6741-4195-861d-6d9834fdd646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_17aa1ada-1145-45aa-955a-87edfa61fafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_17aa1ada-1145-45aa-955a-87edfa61fafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2d47eef-9cfc-4de4-acc9-e22094c94772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2d47eef-9cfc-4de4-acc9-e22094c94772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20d9e911-74f7-4141-bf6b-abdbc62ee9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20d9e911-74f7-4141-bf6b-abdbc62ee9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_50813e18-c8ec-4d3f-aea1-2d68214177a8" xlink:href="vtl-20240331.xsd#vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_523f6575-7c54-44eb-a3bd-d5fd71b206d1" xlink:to="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_50813e18-c8ec-4d3f-aea1-2d68214177a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0232237a-9dcc-42f5-89f9-b905193327cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0232237a-9dcc-42f5-89f9-b905193327cd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5178cb72-9579-4088-b4fe-9243ee943a3a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_78d6d9d2-5804-41de-ad27-25c0b2b989a5" xlink:href="vtl-20240331.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:to="loc_vtl_December2020ATMMember_78d6d9d2-5804-41de-ad27-25c0b2b989a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_983c8470-204e-4474-bded-eadff9f1b31b" xlink:href="vtl-20240331.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9e9cd4e2-cc6c-4bc9-b549-3b51c7ddba0e" xlink:to="loc_vtl_May2022ATMMember_983c8470-204e-4474-bded-eadff9f1b31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4c7a5bee-dd1c-4435-af58-6582ef3d71cb" xlink:to="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_222a90f1-a77c-44da-b8b7-b252b3b75518" xlink:href="vtl-20240331.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_222a90f1-a77c-44da-b8b7-b252b3b75518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_0eab057c-4e45-449f-82ff-d5f615bbea83" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays_0eab057c-4e45-449f-82ff-d5f615bbea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_fb32f23b-1b70-4027-b1ac-057c7b54c6c7" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_fb32f23b-1b70-4027-b1ac-057c7b54c6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b5856d04-7c36-4853-8688-712c77562066" xlink:href="vtl-20240331.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_b5856d04-7c36-4853-8688-712c77562066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0bb35d8-e7ad-46f8-a5e1-0ccc4e1ff70e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b0bb35d8-e7ad-46f8-a5e1-0ccc4e1ff70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c923cb22-1244-4bb7-80bb-3fb6a3ecbb58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c923cb22-1244-4bb7-80bb-3fb6a3ecbb58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_9f81abda-89ef-4d1b-a7aa-2bfb987027ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_9f81abda-89ef-4d1b-a7aa-2bfb987027ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1165873-84bb-4f4c-bcf1-f3e653f7e792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d1165873-84bb-4f4c-bcf1-f3e653f7e792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_c3d57b15-76f8-47f8-bab7-969a1fd55177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7e86da73-a41a-41dd-86c4-c9439fec3579" xlink:to="loc_us-gaap_PaymentsForCommissions_c3d57b15-76f8-47f8-bab7-969a1fd55177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5c71829a-a3a0-4b62-936d-2ef8b654f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5c71829a-a3a0-4b62-936d-2ef8b654f09b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_5569dffd-a27f-495a-bb70-8b2b6931286f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4bc6a839-e9fb-427d-ad8d-3ded22ea222c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_us-gaap_CommonStockMember_4bc6a839-e9fb-427d-ad8d-3ded22ea222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_79a3389b-fde3-49b6-a9ad-638aa544dccb" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_vtl_PreFundedWarrantsMember_79a3389b-fde3-49b6-a9ad-638aa544dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4125faa7-d355-4484-afbb-622a21418811" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_us-gaap_PrivatePlacementMember_4125faa7-d355-4484-afbb-622a21418811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockAndPreFundedWarrantsMember_38deb504-77b2-45cb-bf52-84e37346f703" xlink:href="vtl-20240331.xsd#vtl_CommonStockAndPreFundedWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_47b2c444-c84e-49ba-bdcc-96633edc0bf7" xlink:to="loc_vtl_CommonStockAndPreFundedWarrantsMember_38deb504-77b2-45cb-bf52-84e37346f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_04947d22-57f7-45bb-a5c6-e982be099168" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccreditedInvestorsMember_c451518b-b85b-46ed-bc43-698a22c1a290" xlink:href="vtl-20240331.xsd#vtl_AccreditedInvestorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8598f72d-75d1-41af-9cfc-5ea5a51034a2" xlink:to="loc_vtl_AccreditedInvestorsMember_c451518b-b85b-46ed-bc43-698a22c1a290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d3d2bcd3-b897-49c9-954e-6f3f6001f1db" xlink:to="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6d6a6417-8a94-4be0-a99d-7ee95de64e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_us-gaap_CommonStockMember_6d6a6417-8a94-4be0-a99d-7ee95de64e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_4a6962dd-461c-4b84-8348-8bfe4aec3f2a" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_vtl_PreFundedWarrantsMember_4a6962dd-461c-4b84-8348-8bfe4aec3f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockAndPreFundedWarrantsMember_76f25b37-c662-45be-aa60-5eb3f6640b31" xlink:href="vtl-20240331.xsd#vtl_CommonStockAndPreFundedWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5f270935-957e-46fe-8740-7ed68175cc5d" xlink:to="loc_vtl_CommonStockAndPreFundedWarrantsMember_76f25b37-c662-45be-aa60-5eb3f6640b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_87ab1f92-c41c-459b-9b74-5dccc639d7dc" xlink:to="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9851181-7b3e-40a9-b3fd-27a97f00cee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_e9851181-7b3e-40a9-b3fd-27a97f00cee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d68fc0-449d-4c65-9f17-9221f75d437c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a4d68fc0-449d-4c65-9f17-9221f75d437c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5bad863d-c5bb-4b50-b524-8957b64dbe48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_07d7e199-92c1-4765-9cd7-ce0c7da4f32c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_5bad863d-c5bb-4b50-b524-8957b64dbe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_069cbcb4-8067-446c-860a-5856535d8895" xlink:to="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4c3232d-a214-48d9-9610-75298d640310" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:to="loc_srt_MinimumMember_c4c3232d-a214-48d9-9610-75298d640310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_017b5f90-b980-49f5-8842-53c713e737ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46847edd-98be-4d9a-a7a3-43fb879026b3" xlink:to="loc_srt_MaximumMember_017b5f90-b980-49f5-8842-53c713e737ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51cd5555-70ba-4d7d-874f-99f3295887df" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_546b8b81-6f57-4d09-bb60-88d72604b2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ae94a52c-f646-4cf7-b11b-1bc1abc27d81" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_546b8b81-6f57-4d09-bb60-88d72604b2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e31b22dc-a362-40d6-a7f5-371e6513b137" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMember_7c0d5db5-8ab1-41c0-8979-71785dd1d9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2bd9754a-cdee-49dd-afb4-c76b634abaa8" xlink:to="loc_us-gaap_EquityMember_7c0d5db5-8ab1-41c0-8979-71785dd1d9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d1b2d267-6f47-4a4a-9f07-9cbf9ccbd632" xlink:to="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7cc0bb98-2c51-455f-9367-34f1f37fa589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7cc0bb98-2c51-455f-9367-34f1f37fa589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8602904d-07ee-4a98-897b-9929fe415b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8602904d-07ee-4a98-897b-9929fe415b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ce9aa533-ace9-4b10-bdbe-ab62fcd2cc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ce9aa533-ace9-4b10-bdbe-ab62fcd2cc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockConsiderationReceivedPercentage_db601ec5-4679-48f2-a121-e71866451ce0" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockConsiderationReceivedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockConsiderationReceivedPercentage_db601ec5-4679-48f2-a121-e71866451ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_72f7d71f-db5a-4899-83d6-fc392870e81c" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation_72f7d71f-db5a-4899-83d6-fc392870e81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_WeightedAveragePriceOfLast10Days_9913cc36-4e9a-4db9-be5c-38455a223e40" xlink:href="vtl-20240331.xsd#vtl_WeightedAveragePriceOfLast10Days"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_WeightedAveragePriceOfLast10Days_9913cc36-4e9a-4db9-be5c-38455a223e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_5e557f30-8705-4f90-b78d-4719364ab46e" xlink:href="vtl-20240331.xsd#vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation_5e557f30-8705-4f90-b78d-4719364ab46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_310eadbc-c4a9-47eb-b613-79a2be83d8b9" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockAggregateTradingVolumeOfLast10Days"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days_310eadbc-c4a9-47eb-b613-79a2be83d8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockEquityOfferingsPeriod_c4854e79-79f2-418e-a98d-6d1687c4680b" xlink:href="vtl-20240331.xsd#vtl_SaleOfStockEquityOfferingsPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_SaleOfStockEquityOfferingsPeriod_c4854e79-79f2-418e-a98d-6d1687c4680b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_e13cdc56-4c45-4fbe-a80e-ae969746681e" xlink:href="vtl-20240331.xsd#vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement_e13cdc56-4c45-4fbe-a80e-ae969746681e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityRemainderAmount_09e6a42a-bcb9-440c-bb4d-cda399aa8afd" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityRemainderAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_TrancheRightsAsALiabilityRemainderAmount_09e6a42a-bcb9-440c-bb4d-cda399aa8afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TrancheRightsAsALiabilityReceivedAmount_09ffeb9e-7b29-458d-b2de-6de3a4258de0" xlink:href="vtl-20240331.xsd#vtl_TrancheRightsAsALiabilityReceivedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_TrancheRightsAsALiabilityReceivedAmount_09ffeb9e-7b29-458d-b2de-6de3a4258de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8b0baaeb-9245-4444-b0bf-32e5f858086e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8b0baaeb-9245-4444-b0bf-32e5f858086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b6b9d8f9-e36b-4b09-a6b3-02e45642b5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b6b9d8f9-e36b-4b09-a6b3-02e45642b5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_770d47a8-4057-4507-a150-b57bdd137592" xlink:href="vtl-20240331.xsd#vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts_770d47a8-4057-4507-a150-b57bdd137592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CommonStockNumberOfSharesRegisteredForResale_446783b6-bc11-49a4-bb38-faeca4fa27db" xlink:href="vtl-20240331.xsd#vtl_CommonStockNumberOfSharesRegisteredForResale"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d3b8974-9025-4211-8b3a-47ef439439ae" xlink:to="loc_vtl_CommonStockNumberOfSharesRegisteredForResale_446783b6-bc11-49a4-bb38-faeca4fa27db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a27fb5a0-56fa-4318-897a-c491aa5a459a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a27fb5a0-56fa-4318-897a-c491aa5a459a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:to="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_84127839-606d-4c81-8700-22c7639d1a48" xlink:to="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d048a09-638f-446d-94a2-f75b3474683f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:to="loc_srt_MinimumMember_2d048a09-638f-446d-94a2-f75b3474683f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4d58e681-e7a2-49a5-8c10-4e427cbd3fea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f7cba40-6fda-46f4-a867-66b013efd2d2" xlink:to="loc_srt_MaximumMember_4d58e681-e7a2-49a5-8c10-4e427cbd3fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4a4af713-59da-49f3-8078-3c27ee93355f" xlink:to="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7fd7ba7c-fa03-4489-9d20-62d329301c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7fd7ba7c-fa03-4489-9d20-62d329301c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b6dcee2-925a-4e1c-9a7a-497bf1105d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b6dcee2-925a-4e1c-9a7a-497bf1105d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_5724b0b9-0c79-4125-b7a8-556b0b845bc2" xlink:href="vtl-20240331.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_5724b0b9-0c79-4125-b7a8-556b0b845bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_d4590d85-31f1-4edf-9a78-e55d740e5d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_d4590d85-31f1-4edf-9a78-e55d740e5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_330c9928-bfe5-4094-b89a-732c19fdb1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d35e34c1-93a1-4706-8762-435c3141a229" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_330c9928-bfe5-4094-b89a-732c19fdb1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockPrefundedWarrantsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ad4f6644-5008-4e79-b3ee-25fd04a4889a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ad4f6644-5008-4e79-b3ee-25fd04a4889a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10ba88ed-192c-4044-ac92-82248104ff9b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_ec3328a7-41c4-40e9-b89c-8685c3b0109d" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f752cabb-6bc6-46aa-a1b9-3f0b54b483f7" xlink:to="loc_vtl_PreFundedWarrantsMember_ec3328a7-41c4-40e9-b89c-8685c3b0109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4ecd4f5f-d070-4208-9637-9efe6accd096" xlink:to="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21932858-5d9b-4e43-9b7c-80b4956d290c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_37b94b8e-abd8-430a-926a-8c9d6b5eabbd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21932858-5d9b-4e43-9b7c-80b4956d290c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4efa4bf7-0b0c-4ec5-9570-170b62c05023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ada665d9-d9c5-47be-a8a3-f6691f200b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4efa4bf7-0b0c-4ec5-9570-170b62c05023" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ada665d9-d9c5-47be-a8a3-f6691f200b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13e35c2e-f16e-4f6e-80ed-a908c60aa77e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4efa4bf7-0b0c-4ec5-9570-170b62c05023" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_13e35c2e-f16e-4f6e-80ed-a908c60aa77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_af89dbcc-9c6c-48f9-a359-4ff44b885b34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4efa4bf7-0b0c-4ec5-9570-170b62c05023" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_af89dbcc-9c6c-48f9-a359-4ff44b885b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#CommonStockScheduleofSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f73e0e51-5cee-4f29-914f-8b1251f1ca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f73e0e51-5cee-4f29-914f-8b1251f1ca0c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_873680dd-40d4-43b3-9df9-2191d1b247ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6a340fbf-1378-4287-8deb-aef415b77c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6a340fbf-1378-4287-8deb-aef415b77c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_bd0ffd32-ad40-4b56-9d44-7e68bf66c3ef" xlink:href="vtl-20240331.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_vtl_PreFundedWarrantsMember_bd0ffd32-ad40-4b56-9d44-7e68bf66c3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_fd324e64-9754-4815-87a7-666503bb1c3d" xlink:href="vtl-20240331.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41505626-5477-41a9-ba62-2c5690e298bb" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_fd324e64-9754-4815-87a7-666503bb1c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_3f3c3b6a-a8e3-42ac-ae2b-c93d28f10860" xlink:to="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_a523d4a6-a9cd-4858-aab3-10818b8802f4" xlink:href="vtl-20240331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_a523d4a6-a9cd-4858-aab3-10818b8802f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_a93ecf9b-21f2-4538-a381-6ce1dd304083" xlink:href="vtl-20240331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_a93ecf9b-21f2-4538-a381-6ce1dd304083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_e3b77941-9a0e-436b-92bb-516318378415" xlink:href="vtl-20240331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_e3b77941-9a0e-436b-92bb-516318378415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a2ed66d7-f1e9-4518-b1f5-f9783e2e97ec" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e450d24e-16a0-42b1-b1b3-7fe596bb429a" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a2ed66d7-f1e9-4518-b1f5-f9783e2e97ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_62257f1d-98e2-4ed1-9acf-f8ccd43de5f4" xlink:to="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e391b842-f4fc-48b6-b2c8-058d00876b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e391b842-f4fc-48b6-b2c8-058d00876b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_44789164-4d57-4979-85ce-0be0f592a307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_775fd074-b7cb-4aa8-bdfb-f2c325f134d2" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_44789164-4d57-4979-85ce-0be0f592a307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77c3f82e-6fa2-404d-a1b8-e85ad3735f05" xlink:to="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a27e339-5831-4ee3-b31d-2d63acfcfe37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_78197ad6-2849-4d1c-8cda-bb6cb78b089c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3a27e339-5831-4ee3-b31d-2d63acfcfe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57bd66a7-e80c-4d38-8f99-7ff2c45c7e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57bd66a7-e80c-4d38-8f99-7ff2c45c7e3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_040cf9c9-42ac-4815-9591-cbdd5ff1a2bb" xlink:to="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_7fcdad9e-a083-42a9-b053-22d56343a4dd" xlink:href="vtl-20240331.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_7fcdad9e-a083-42a9-b053-22d56343a4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_875965d0-ec86-4adb-a809-52396d0a940e" xlink:href="vtl-20240331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_875965d0-ec86-4adb-a809-52396d0a940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_c924f102-e9ce-426f-9dcb-b19427063902" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_c924f102-e9ce-426f-9dcb-b19427063902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_e969ca37-982b-470f-8268-b11a93a5b959" xlink:href="vtl-20240331.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_e969ca37-982b-470f-8268-b11a93a5b959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_91e2f625-d80a-4c44-8cda-0be4149d0f5b" xlink:href="vtl-20240331.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5454e801-4979-4546-8387-26f48cfc3369" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_91e2f625-d80a-4c44-8cda-0be4149d0f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed0c05ce-0ce3-422b-b14b-9b10d7731b21" xlink:to="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44906644-523e-4076-b772-965600058332" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:to="loc_srt_MaximumMember_44906644-523e-4076-b772-965600058332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_adcb18cd-5931-4f88-b33d-0a10b91dd7f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9dc83831-60ef-49a1-9fea-eda7cd904426" xlink:to="loc_srt_MinimumMember_adcb18cd-5931-4f88-b33d-0a10b91dd7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9845a53e-ea4c-41df-bf05-ce885e645e0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_ea43ce45-bcff-4441-b842-f01a2a58efa1" xlink:href="vtl-20240331.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_ea43ce45-bcff-4441-b842-f01a2a58efa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_881b0da8-cdde-49f9-be8b-fcc301f77d42" xlink:href="vtl-20240331.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bbeb2508-14c6-4c63-a997-35eeecf3a707" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_881b0da8-cdde-49f9-be8b-fcc301f77d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c80ba62-7609-4340-b20e-dc5c9bca12f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_683850bb-9ac5-4f6c-833a-a79db4876138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_683850bb-9ac5-4f6c-833a-a79db4876138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29130001-991f-4684-8e74-733f1c06070c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8cb1673-5356-44a4-ac25-31f9caf746b2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_29130001-991f-4684-8e74-733f1c06070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_82475aa2-4652-43c9-8250-1ff196d313ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_55bc6c15-ec8b-415f-9107-0938d0f404cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_55bc6c15-ec8b-415f-9107-0938d0f404cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_77dd77eb-200c-41b9-8315-19ff8ccf404c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_77dd77eb-200c-41b9-8315-19ff8ccf404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af1b4336-f24c-4d37-a776-3cc15bb0217d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_af1b4336-f24c-4d37-a776-3cc15bb0217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_071d050f-540b-4c70-bf94-03c45c958d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_071d050f-540b-4c70-bf94-03c45c958d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e1956e7-e933-4257-999b-7c5b767592d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e1956e7-e933-4257-999b-7c5b767592d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d634279-9b8c-4172-9dd7-2557a4f621d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1d634279-9b8c-4172-9dd7-2557a4f621d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_0455824f-c7f9-4c5e-b770-625d43c63b36" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_0455824f-c7f9-4c5e-b770-625d43c63b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_3a68f8c0-78f3-42a1-8812-05444ca0cada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_3a68f8c0-78f3-42a1-8812-05444ca0cada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f5c344-badd-4e0b-b899-38b25348c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f2f5c344-badd-4e0b-b899-38b25348c14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_85f8c1fb-52b0-4977-8e83-5f73ed1050d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_85f8c1fb-52b0-4977-8e83-5f73ed1050d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b27f909-521c-46a9-988f-ced3574ed036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7b27f909-521c-46a9-988f-ced3574ed036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_efa80e1b-59e2-4463-8469-100e121470db" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares_efa80e1b-59e2-4463-8469-100e121470db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_55ec2787-d1e3-4a81-be65-bb4924d8376c" xlink:href="vtl-20240331.xsd#vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice_55ec2787-d1e3-4a81-be65-bb4924d8376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_69ea1450-adf8-4f6c-a2cf-ee8c380bf05b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_69ea1450-adf8-4f6c-a2cf-ee8c380bf05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17311fcc-6e2d-4310-9dbd-3f225d3c081f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_17311fcc-6e2d-4310-9dbd-3f225d3c081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d06a54b2-2e22-46b4-bb56-3e5a608eb16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d06a54b2-2e22-46b4-bb56-3e5a608eb16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b480dd7a-eb4e-4505-8c61-139db4f96ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b480dd7a-eb4e-4505-8c61-139db4f96ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_9baab67f-2d48-46d7-b825-6147b9d65a6d" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions_9baab67f-2d48-46d7-b825-6147b9d65a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_796ea565-c333-46e1-a44d-48495685b3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_796ea565-c333-46e1-a44d-48495685b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95a7a40-e6b8-430d-9b96-6bb0293addb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f95a7a40-e6b8-430d-9b96-6bb0293addb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00911a68-2098-4123-99ed-dc54c49e06d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f1de9a3a-4488-4acd-a4f0-06645830faa7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00911a68-2098-4123-99ed-dc54c49e06d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9608ce8-eae2-4516-924e-289890dc5387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d9608ce8-eae2-4516-924e-289890dc5387" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:to="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9bf84448-2d2c-48b3-95f2-42f5a9d3124a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_48733a93-2b44-42bf-ac51-f1986b47b318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90094f52-d0e8-49c6-8928-c359857e74fc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_48733a93-2b44-42bf-ac51-f1986b47b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:to="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6a3312b8-2706-4372-b412-137a828460e6" xlink:to="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dcc0d394-d604-484e-a49c-6d29e1728991" xlink:href="vtl-20240331.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cba0304f-3bcd-4820-8a77-76007548ffff" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_dcc0d394-d604-484e-a49c-6d29e1728991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29cbc1b7-629b-4377-9bf6-572f893b658c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e33fbe5-cf35-4f48-be3f-0fba55c90ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e33fbe5-cf35-4f48-be3f-0fba55c90ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_94296b9d-193f-468d-aafa-ff9aed0f6d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_94296b9d-193f-468d-aafa-ff9aed0f6d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66b9c233-1f6a-4838-8e51-0c8496b7c655" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_66b9c233-1f6a-4838-8e51-0c8496b7c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_66f07f9e-dc91-46b9-b128-610d72c715d1" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod_66f07f9e-dc91-46b9-b128-610d72c715d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c46617ff-5117-43c2-8e22-3905fdff78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c46617ff-5117-43c2-8e22-3905fdff78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be82543c-831e-4ab9-9050-9e8e5b68c42f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4631f337-1452-443d-ba57-cc80e34cf271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_be82543c-831e-4ab9-9050-9e8e5b68c42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f3dee242-c1b6-4a14-ba72-73604e05c0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f3dee242-c1b6-4a14-ba72-73604e05c0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f500a4b-23fc-41ef-b0c8-f930613c3101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9f500a4b-23fc-41ef-b0c8-f930613c3101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_72459f66-4d4a-4926-ae89-b1e7edded145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_72459f66-4d4a-4926-ae89-b1e7edded145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3315c3d7-01f9-4677-835a-ea8caa1a3662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3315c3d7-01f9-4677-835a-ea8caa1a3662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76574fcf-c676-49c7-9431-3cc004c30f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_76574fcf-c676-49c7-9431-3cc004c30f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_d1e203ea-eb16-43c2-99b2-a01785682d55" xlink:href="vtl-20240331.xsd#vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice_d1e203ea-eb16-43c2-99b2-a01785682d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a22cba3a-7ecd-4a57-b5c2-270895be3f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_a22cba3a-7ecd-4a57-b5c2-270895be3f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18a5aa0e-7c1e-4307-9777-d343d54597a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e5a25cbe-927e-43ba-98b0-0364725c5f2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18a5aa0e-7c1e-4307-9777-d343d54597a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5bb57ebb-79b4-49b4-8bf1-e56edb714720" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5bb57ebb-79b4-49b4-8bf1-e56edb714720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f973b47-fe53-4f52-8a88-30562c2f8667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9f973b47-fe53-4f52-8a88-30562c2f8667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b40dea9-3caf-4487-983e-7f2034cf7b70" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0c2ca53a-4eb6-4a73-bfca-3086fec51b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0c2ca53a-4eb6-4a73-bfca-3086fec51b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_743f29c2-5485-47e7-b7e5-18bcb27d0cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_743f29c2-5485-47e7-b7e5-18bcb27d0cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b34858c-8f4e-4b60-8b4c-c375fe32faff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8b34858c-8f4e-4b60-8b4c-c375fe32faff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b5c67270-9e1a-4c9f-8f98-3c427018f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b5c67270-9e1a-4c9f-8f98-3c427018f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b39d945-79ee-4050-b265-6fa95ad0a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8b39d945-79ee-4050-b265-6fa95ad0a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a2711d2-3f4a-450d-91de-e5283585dccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_4b0aeb30-0523-4ba0-9c5e-16f0a750dbc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2a2711d2-3f4a-450d-91de-e5283585dccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c97f6d5a-42bb-4103-851a-4fc287ec0d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c97f6d5a-42bb-4103-851a-4fc287ec0d11" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:to="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0a2a58ba-97d2-4a2d-8ff9-82f368c23fc6" xlink:to="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_97dc4f8f-7d66-4856-ae2b-a2d48be0e32d" xlink:href="vtl-20240331.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c0efe69b-963e-4035-b0d5-b5a801c517e5" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_97dc4f8f-7d66-4856-ae2b-a2d48be0e32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_605d9cfd-a709-4aca-8303-2331d2897866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dc4751fb-9f30-4d33-a8a7-ba0ceb070848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dc4751fb-9f30-4d33-a8a7-ba0ceb070848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d5ab3c49-a5a6-44db-8fa8-51b84b45dff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d5ab3c49-a5a6-44db-8fa8-51b84b45dff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87717daf-752b-4d23-b35c-97e6d11c212b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_87717daf-752b-4d23-b35c-97e6d11c212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_524c3df8-dedb-458c-8a0e-0ceeed560741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a892b05-8c15-4333-8918-0d5559d63752" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_524c3df8-dedb-458c-8a0e-0ceeed560741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44816136-c26b-4179-8cc2-f010f1957318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44816136-c26b-4179-8cc2-f010f1957318" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:to="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_36c4d1aa-ffca-403a-9779-31f3b38da1bf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_8f12aed1-2b1c-459c-aa8f-19a7517598bb" xlink:href="vtl-20240331.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ce604f1a-865e-4cd5-ab38-120bb066d783" xlink:to="loc_vtl_EmployeeMember_8f12aed1-2b1c-459c-aa8f-19a7517598bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_925678e3-b9c9-4be3-9183-e757c867bde2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9ab2c06d-8e61-4859-adfa-3528572934ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9ab2c06d-8e61-4859-adfa-3528572934ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db602d75-7a7e-4182-91a6-d25291dbbfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ad09376f-e207-4aeb-83fa-ed81611126c2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_db602d75-7a7e-4182-91a6-d25291dbbfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_85aef6e2-213c-47b8-a62f-e80a247988c0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2ec8be5a-b02a-417b-a4f9-ebd3be13e326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f054e5dd-e81b-416c-8120-6c2e653b44be" xlink:to="loc_us-gaap_ShareBasedCompensation_2ec8be5a-b02a-417b-a4f9-ebd3be13e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="vtl-20240331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6fe27102-2c1f-4756-bb54-3e08b69022ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6fe27102-2c1f-4756-bb54-3e08b69022ce" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fbe38600-f917-46af-b5b3-94444f19581f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_7bf1371c-f5fc-4a01-aecd-0bd019f0364c" xlink:href="vtl-20240331.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7dc23e7d-c66d-4817-905e-8133d7109970" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_7bf1371c-f5fc-4a01-aecd-0bd019f0364c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_63ecef88-d284-49bd-b9c0-48b68fd666df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_d1221d18-8819-4eb7-83fc-da3866fadcad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a5bc674b-b879-46d4-a5ce-930ef0ebc230" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_d1221d18-8819-4eb7-83fc-da3866fadcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_4e91b15b-2f12-4059-8af2-960ef23d3446" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_43f62e31-f263-4c87-98ad-99a41e407e97" xlink:href="vtl-20240331.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_40159d0e-ed8d-44a0-80e1-4a661ac33a3b" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_43f62e31-f263-4c87-98ad-99a41e407e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_19e9df39-cfb7-45e9-98dd-bf6daf46b7c3" xlink:to="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_57113c5d-8574-4445-ae33-070cd190fc91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3ad5f87b-77c3-4742-9312-96e39018aa1a" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_57113c5d-8574-4445-ae33-070cd190fc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7807a1e8-959c-4220-a3fa-5accb3581f46" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_44b3c6d6-ff2e-408d-b536-2d584068e743" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f6b86d9e-13ac-47ac-a747-3a5d51cd1d9f" xlink:to="loc_srt_ScenarioForecastMember_44b3c6d6-ff2e-408d-b536-2d584068e743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_9188d128-02f9-4bd8-86ce-27634f904917" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary_eb937da0-efa6-445c-a517-8180d76139e4" xlink:href="vtl-20240331.xsd#vtl_SalaryAndWageOfficerMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_2b471726-6598-44a5-a5b5-e25b9707a1f7" xlink:to="loc_vtl_SalaryAndWageOfficerMonthlyBaseSalary_eb937da0-efa6-445c-a517-8180d76139e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>vtl-20240331_g1.jpg
<TEXT>
begin 644 vtl-20240331_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
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M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
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M(W.0XO)#4X,D!33_V@ , P$! A$#$0   ._PC9X@
M
M                                          \R1@ZDMS2OC-@
M                  &=<>;163"                       /:9NQYM&9,
M(                       SKXRZ-]XO                        &<\
M6;1F7"                       *)P;';7J;@Z\K"NTWLZX
M            ROAS:HS80                      ![XC)F+8U9FP
M                  #*N+-J[+@]:0                      !E;!FU3G
MP@                      #,6KL]A^A8#KRL*[3>SK@
M       #*^'-JC-A                       'OB,F8MC5F;
M              ,JXLVKLN#UI                       &5L&;5.?"
M                    ,Q:NSV'Z%@.O*PKM-[.N      !56WHYNM*G1%;:
MV]I;X              ROAS:HS80     !3.]74#8UFEJJXL[5W  !DVXHYG
M@SWU7VGMB1GRQJ]!UUH /C]>,RVM-J:HO      /?$9,Q;&K,V        41
M85E*;U=J:INJ&L*S6M/>@   >J8Q%>\[N>@Z3U3        RKBS:NRX/6D
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MM"Q];:\3[?/NM=K3O6OLLXV=3K6GO,MVU)N6@Z8     #WQ&3,6QJS-@
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M4^[>>ZC,MK31_+@O"OM9!C]Z3J[B@;&KA6?7UG3W@       &5L&;5.?"
M    ,6WG.Q3-AV%2WV/[J@^B)T_4W=&V%; ]C6DF+).M?9R#<T=UZ-COGGNF
M^.?.:;2HJW<T=Y<]TX       S%J[/8?H6 Z\K"NTWLZX      %!V%;9NKM
M2_#L9;MJ72U7;X-Z'F9=@V(1L:TQP9[)U=S\3P&7#!-C6T166T2S8.+]XK+U
M=W[?/NR]7;       ROAS:HS80     !FRTJ+[KK+F/&7+EM2W?H661;FAOR
MNM*DW='Z_,R#'F_$<]CS7/H[V>K*L_$>::\V=28X,\0S8+ZK[2'9];3-5<@
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MC-A                       'OB,F8MC5F;
M ,JXLVKLN#UI                       &5L&;5.?"
M       ,Q:NSV'Z%@.O*PKM-[.N                       ,KX<VJ,V$
M                      >^(R9BV-69L                        RKB
MS:NRX/6D                       96P9M4Y\(
M   S%J[/8?H6 ZG<V*^LF,                       9W\>]$>_
M                 \X5/'JU?7D                       57Y]6M/GQD
M                       *I\>[6]^                       !1F/)V
MMX<HQRG8R                       !C%.SD
M  024[@                       (),3N)
M@,I]                        9"3KU QRG8R
M  !C%.SD                        024[@
M(),3N)                        @,I]                        9"
M3KU QRG8R                       !C%.SD
M  024[@                       (),3N)
M@,I]                        9"3KU QRG8R
M  !UY[6I6?5<8                       !P!SX
M    . F>?B                        (\F0H
M  %5:%IW6\UU0QRG8R                       !U5VU-TY?6OB8
M
M                               $AYWJOZP/F/UL8Y3L9
M             ZJ[:FZ<OK7Q/E\>6::^W6FYH$"TM*PJW=KP !,=?;AVQJ
M2+#GXG)C^/UXEF#9B>?6%H:5A5^YH)B8Z^U#MC5%I:5E5N[6@<AXR3?6VZXW
M- 6EI656[M:  !Y1,NP;,/V-4(FU]*P],J^VM+G,>:*YM;W1/.8\W,X\T9S8
M+"U=JIMZN '/8LT^U=V";.G\/OQ]7GWQOO'8&KNQ//J\!EPR##GY+SD\".YM
M>S]*P@&UI?3'J;:VW',V"#;.G,M?;ANQJ"TM*QJW=K@
M                                   !(>=ZK^L#YC];&.4[&0
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MYG[_ !Z[*.2[C)MWSOX?%Z\_DN,]X[MK;:D[&JB&QJT]OU@
M                                       D/.]5_6!\Q^MC'*=C(
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MM/B,F.G-^LS[:T@
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MK3%C5  #055<V+J[V.[[F?"8    %SU]K3%A5          (FUM*PJG>K@
M/Q-LZ-A4^]7
M                  2'G>J_K ^8_6QCE.QD                       #
MK@W=',';_/0                       .).6
M !Q)RP                       !Q!RX                       (35
M7/?IR';C'*=C(                       &,4[.0
M     !!)3N                        @DQ.XD
M   " RGT                       !D).O4#'*=C(
M      &,4[.0                       !!)3N
M    @DQ.XD                       " RGT
M !D).O4#'*=C(                       &,4[.0
M     !!)3N                        @DQ.XD
M   " RGT                       !D).O4#'*=C(
M      &,4[.0                       !!)3N
M    @DQ.XD                       " RGT
M !D).O4#'2=BH                       &,T[,0
M     !!)3N                        @DQ.XD
M   " RGT                       !D-.O$#'*=C(
M      &,D[-0                       !!)3N
M    @DQ.XD                       " RGT
M !D-.O$#'*=C(                       &,4[.0
M     !!)3N                        @DQ.XD
M   " RGT                       !D).O4#'*=C(
M      &,4[.0                       !!)3N
M    @DQ.XD                       " RGT
M !D).O4#'*=C(                       &,4[.0
M     !!)3N                        @DQ.XD
M   " RGT                       !D).O4#'*=:^\<>RX>;Q9:KW="PM7
M<E.'/G^SJ- 5EN()LZF.[[G-64M_:>EO@498U7T1ZMG2L.2\>P  !\'KQ3F_
M6WC76OZ5[M:8L+5W*QW-&68-B18LP     &!L^#W7W-
M       1<E                        (Q*3P
M   T90]+<^#.                       ,A)UZ@8Y3J_WBZ>>\^<W]5VWJ
MF-.5%YE>YH:JW=#3M/>>Z)R+><]*<.>S]/>U137\3S:_!Y<76WUG%;.H.ET!
M5V^>+6GD&+-:^EO^L^B)D&+-5>[H;:Y[I^E#Z#\QUG2=#86KMTA8U=KZ5@*C
MWJ^28<UL:5A;NC8U?N:%+V%9Y1/#Y,?9%R?:?H  !U76M/TW_6_B0
M
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MW;T9WJ[LWU]N$;&I!-K2G6KN07:TQ;&C8U/O5P
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M]GK0Z[AY)BS=B_*=KDB\YSE/&3C?7CE_'N";.I?=9<8&Z?CP
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M<^#BLF"'9]:.YL%<;>CJ2EZ#C_>+.%K3Z4J;NZ:^T@FSIQ'/K9FN*(
M                    #^BCY']OUS5VP                       R$G7
MJ!CE.QD=0/=?.I_J[EM:5AC2_P":[:N(^@]&7T7Y9M"@Z;LIY+M>L+L.&[5^
M+[[(-[SN&NBY;5U+?YWM:;0-7<96NJ"8:^SZYCMVX;Z'YI             '
M5=:T_3?];^)   7#H6=TUUID.]YOX??@         <GXRSO5VZQW:\
M   #Z?/N=:VW7FWH@  <_BS\CX]P_8U0
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M                        024[@                       (),3N)
M                      @,I]                        9"3KU QRG8
MR,%]+R>].:ZP       8*Z7D]Z\UU@             &,4[.0
M            !!)3N                        @DQ.XD
M          " RGT                       !D).O4#'*=C(
M             &,4[.0                       !!)3N
M           @DQ.XD                       " RGT
M        !D).O4#'*=C(                       &,4[.0
M            !!)3N                        @DQ.XD
M          " RGT                       !D).O4#'*=C(
M             &,4[.0                       !!)3N
M           @DQ.XD                       " RGT
M        !D).O4#'2=BH                       &-$[+0
M            !!)3N                        @DQ.XD
M          " RGT                       !D1.NT#'*=C(
M             &,4[.0                       !!)3N
M           @DQ.XD                       " RGT
M        !D).O4#'*=C(                       &,4[.0
M            !!)3N                        @DQ.XD
M          " RGT                       !D).O4#'*=C(
M             &,4[.0                       !!)3N
M           @DQ.XD                       " RGT
M        !D).O4#'*=C(                       &,4[.0
M            !!)3N                        @DQ.XD
M          " 3$_B0                      !D).O4#'*=C(
M              '6YO:&/>[^;                       #]3Q<N3B
M                   !QJ>2"                       !VK<)]*T?H[P
M                       R$G7J!CE.QD                       #JN
MM:?IO^M_$@
M                      !_11\C^WZYJ[8                       9"
M3KU QRG8R                       !U76M/TW_6_B5S5]I5FYH7=76LLP
M;>4KSF@  /Q-CZF[+M?:HNSIP );K[6R:'I<U6U)3UA5^*=74G00G9U8=GUY
MA@ST3957Z@:II.AA6QK4K8U5[5MM#<^MJ6FOX#LZM"V=/!-K2 &AJJZNFOM,
M.]%RVQJ'I,5]#R]]5EM2EA6;XYKK:=WJZ@+2GV50=/6FWH1W-@L/4WH3L:EJ
MZ>_B7H>7^:?.Z><ZO"72<I,,&QN/G.JK+<T<>7W-7G6V]&650-84?1Y,O.>\
MWD                                    #^BCY']OUS5VP
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MG1<QVE<=W>>+2GIW?K=2TW0<)DP=?G4<?[7@
M            #^BCY']OUS5VP                       R$G7J!CE.QD
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M=?\ U''>UX                                     _HH^1_;]<U=L
M                      ,A)UZ@8Y3L9                        ZKK
M6GZ;_K?Q+RB=>4724/9U*)_9\VCI6%=[6E:^E84WOUM?;6GJ^EZ"C;&JMW1L
M:DW=",9]:7X-GZO/JT=/>RM=4'(>/>NJ/H\TVU'HRJNLUV])S6/)Y%@:N[%\
MVOZI2;#FS_:4V\.9Z_#'2<GKJBZ//=K3<!DQ:MI;^$;&OP67#0UG3 "R-/?O
M6MMJ0L:NL=VNL_2L;8TK")9L%G:F]G^SIH#M:>OZ+HZ LZF48<_.XLL)V=6\
M*VVR#?<WX/.P:'IJAWZVE+&IL?4WJ_V=2>:VU[(]<WCRSS6VZGW="N-S0_4
M                                    ?T4?(_M^N:NV
M           &0DZ]0,<IV,@                       =5UK3]-_UOXD
M             /*)_)C\ !YQ/A,
M                     ?T4?(_M^N:NV                       &0DZ
M]0,<IV,@                       =?6SJP?I^0
M     CQ(0                       1\D                        !
MLKF.PO/6V0                      !D).O4#'*=C(
M       &,4[.0                       !!)3N
M     @DQ.XD                       " RGT
M  !D).O4#'*=C(                       &,4[.0
M      !!)3N                        @DQ.XD
M    " RGT                       !D).O4#'*=C(
M       &,4[.0                       !!)3N
M     @DQ.XD                       " RGT
M  !D).O4#'*=C(                       &,4[.0
M      !!)3N                        @DQ.XD
M    " RGT                       !D).O4#'*=C(
M       &,4[.0                       !!)3N
M     @DQ.XD                       " S$^B0
M   !D).O4#JJ>M#H                       &;$Z30
M        /TBTI1                        1B4G@
M      !%92J                        H1/:2\C'*=C(
M          &,4[.0                       !!)3N
M        @DQ.XD                       " RGT
M     !D).O4#'*=C(                       &,4[.0
M         !!)3N                        @DQ.XD
M       " RGT                       !D).O4#'*=C(
M          &,4[.0                       !!)3N
M        @DQ.XD                       " RGT
M     !D).O4#'*=C(                       &,4[.0
M         !!)3N                        @DQ.XD
M       " RGT                       !D).O4#'*=C(
M          &,4[.0                       !!)3N
M        @DQ.XD                       " RGT
M     !D).O4#'*=C(                       &,4[.0
M         !!)3N                        @DQ.XD
M       " RGT                       !D).O4#'*=C(
M          &,4[.0                       !!93J
M        @LIU                        " 2G\
M    !D).O4#'*=C(                       '5%<4G75]'^4@
M               ?.GZ$                       ">ZF]WL<!].]2
M                   !S-?8V3BR@                      #(2=>H&.4
M[&0                       .HB\Y_J5^J?&@ ![O/KT^O(
M                                 %J:5C_1!\T^M^J0
M           DU9:69AR@                      #(2=>H&.4[&1U1]KP$
M0SZ^QJ'I*UV]&.9</#Y,6RJ#I:WV]+9%#TG5+VG UQMZ6A*NXJ_<T.R7D^UZ
MR>OX?L%Y?K[YK;8              #J(O.?ZE?JGQJV]"RUK1])G2VI:CWJS
MA<F+=G-]91MC5U)O5W!Y</T>9\D\'EP=FG']YPV3%DF[Y[ALN'B_>.%;&K,]
M?:A^?6FFOM0C9U)EK[43SZTGP[$/V-0
M      6II6/]$'S3ZWZI                       "35EI9F'*
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M6745->T#9U7%>\4QP9[(U+'(-[S.SZ#IJ6W]"+9]3%O0<M^3
M                       %J:5C_1!\T^M^J0
M DU9:69AR@                      #(2=>H&.4[&0  !X(\TC\/P_3\/(
M\)CSB0              !U$7G/\ 4K]4^-#P3Y")_)@!$IC]@E^H]+WYO/D?
MA^Q/[/GQCU^S'Y$IC]B4Q^1/E/D
M  6II6/]$'S3ZWZI                       "35EI9F'*
M           ,A)UZ@8Y3L9                        ZB+SG^I7ZI\:
M                                              %J:5C_ $0?-/K?
MJD                       )-66EF8<H                       R$G
M7J!CE.QD                       #!N;#:-E4
M    1&4N@                       ."CWJ:MM?R8
M      $7QY+!\^@                      !D).O4#'*=C(
M            &,4[.0                       !!)3N
M          @DQ.XD                       " RGT
M       !D).O4#'*=C(                       &,4[.0
M           !!)3N                        @DQ.XD
M         " RGT                       !D).O4#'*=C(
M            &,4[.0                       !!)3N
M          @DQ.XD                       " RGT
M       !D).O4#'*=C(                       &,4[.0
M           !!)3N                        @DQ.XD
M         " RGT                       !D).O4#'*=C(
M            &,4[.0                       !!)3N
M          @DQ.XD                       " RGT
M       !D).O4#'*=C(                       &,4[.0
M           !!)3N                        @DQ.XD
M         " RGT                       !D).O4#'*=C(
M            &,4[.0                       !!)3N
M          @DQ.XD                       " RGT
M       !D).O4#JR>M$(                       &;$Z30
M            /TB<I7                        124LA^
M            B,I=                        4$GM">1CE.QD
M               #&*=G(                        @TIS
M             0:8G,2                       ! Y3R
M           R$G7J!CE.QD                       #&*=G(
M               @DIW                        028G<2
M            ! 93Z                        R$G7J!CE.QD
M               #&*=G(                        @DIW
M             028G<2                       ! 93Z
M           R$G7J!CE.QD                       #&*=G(
M               @DIW                        028G<2
M            ! 93Z                        R$G7J!CE.QD
M               #&*=G(                        @DIW
M             028G<2                       ! 93Z
M           R$G7J!CE.QD                       #&*=G(
M               @DIW                        028G<2
M            ! 93Z                        R$G7J!CE.QD
M               #&*=G(                        @DIW
M             028G<2                       ! 93Z
M           R$G7J!CE.QD                       #KUVM6M>JXP
M                   ?AO;DNVM_!G                       $$F)W$@
M                       0&4^@                       ,A)UZ@8Y3
ML9                        ZKK6GZ;_K?Q(
M >*?Z6?COW316C8                       ""3$[B0
M        (#*?0                       &0DZ]0,<IV,C'M[SD9S8-*5-
MW"=C5C^7#\/KS>-=:1;-@O"NM,2=#S$?RX;RKK3*5U0=B7*]CA?I.6[#.6[
M               =5UK3]-_UOXE]GGWM?GNHA^?6R9><Z )[J[L"VM( 7I6V
M]%V50)?K[4?RX/@]^ !/]7=F^MMT39TX T)57=0;]9(<6;5M+?Y]LZCS31=E
M4      #Q3_2S\=^Z:*T;                        028G<2
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M/QW[IHK1L                       !!)B=Q(
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M                        028G<2                       ! 93Z
M                      R$G7J!CE.QD9_LZCZX]<OCR2_!L5WM:?A*F]^M
MVIS_ $WNB<GW?/\ )^,DXUMJ@;.HUA2]!E.ZH+QKK2[JZT
M ZKK6GZ;_K?Q+]B=<4?1Q#/K\%EPSC6VX/L:OVQ/W^/<>RX::L*O0]5=<9[\
M1/-@_3B\F+TS%KZ-ARGC)$,^M8FKNT)9U%YUMK3^]H>2/R?/XFZZ^TI??K('
MM:7.8LVHJ;H,Q7-!S6+-/];;B6?6E^#9^'UY^F)_8GV$.SZTSU]GC??F2X<U
M2;]=7&WH#Q3_ $L_'?NFBM&P                       $$F)W$@
M                 0&4^@                       ,A)UZ@8Y3L9
M                    ZKK6GZ;_ *W\2                       'BG^
MEGX[]TT5HV                        @DQ.XD
M   " RGT                       !D).O4#'*=C(
M      '7%NZ.7NV^>@                      #\EVJ<)]&NO6V@
M                !!)B=Q(                       $!E/H
M              #(2=>H&.4[&0                       ,8IV<@
M                  ""2G<                       !!)B=Q(
M                $!E/H                       #(2=>H&.4[&0
M                   ,8IV<@                       ""2G<
M                !!)B=Q(                       $!E/H
M              #(2=>H&.4[&0                       ,8IV<@
M                  ""2G<                       !!)B=Q(
M                $!E/H                       #(2=>H&.4[&0
M                   ,8IV<@                       ""2G<
M                !!)B=Q(                       $!E/H
M              #(2=>H&.4[&0                       ,8IV<@
M                  ""2G<                       !!)B=Q(
M                $!E/H                       #(2=>H&.4[&0
M                   ,8IV<@                       ""2G<
M                !!)B=Q(                       $!E/H
M              #(2=>H&.4[&0                       ,8IV<@
M                  ""2G<                       !!)B=Q(
M                $!E/H                       #(2=>H&.4[&0
M                   ,9)V:@                       "#2G,
M                !!IB<Q(                       $#F)Y$@
M               #(:=>(&04^(                       /2>X
M                 \3R                       !XGD
M           >L]@                       />:Y0/3,?AYGLB14J? MU
M   J1-MH   I]-P(      $4.:.1     !^ _00\F         (^>1SP
M *G+8    !4B;;0
M                            !_*?]H^!Q[+AWWS/6]ZWSCZK!C)*=(D1
M("6$54?2:<1D=-PE5%A'O,B)WNC/QI1&:DUFGLM><M)^,D!]IH1&,DV.5L2H
ME)GXT^9[+=.:*6-"HH)/*&N$   1;9UJXWZ\6O6V?,X<V TWT4Z;61'3)2;W
M*1++*T+^112;O*--&(RFFWC@#-2;81IY&=DWV4:3LTVBB4TN760XU(C$B9J0
M@N A1R9#"["CS3B,Y)M(K@S8GM/>0
M                                          /Y0?M7P&.9L'8#S'7]
M\'S;ZMGU/K-#(P4GGB)IGR-+HR.GWG''V&?4WPCT)]B)>9]3NY&5#L!1@E/X
M?6;L15Y6*:N/P^XA"?8<^C=R.G!ZUZC42,@)HQ.J$;"0  !%=G6K>PKQ;%99
M\UAS8#3]YI0AQSQQA1Q[ROTV$B+)WH\X)>IDCY#P+,,K)MI%W&*$]H#SB5/)
MGJ-S(P2F_#"*>V5Y\S#B?C.2)N9C3;B/K. -XHZ\'J(%\(X0^8WF@
M
M      #I2^@_,N*]X].5%YV3<EVOX8+3.3](H7.?<6VBC$X23LM$E*X)L>!S
M92YH8S23DU\C%:?H++- H]!@]-JG-GL,RI^,TXBH"T3FBYT9F3FA-THW"@
M#A<V&)[.J)MI[G(>,F;4_:6JB-G#IQJG5Z/>>)5H.%+.*J+G/K(&0DN$^4DY
M0A>A^'H-#(RXFKRZ#1:!U-/6ID3P@!$B[3VG$FDT9[32A?Q1AZC=*
M
M             !6A98         *!3#S5R  /28^3<Y<"       !&3P)2 "
MN2P#W         %9EF
M
M
M                                           '_]H " $"  $% /\
M/:"4#0Z<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H
MZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H
MZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H41A"/3E'3E'3E'3E'3E'3E'3E'3E'3
ME'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3
ME'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E'3E$6
MY0FC PZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H
MZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H
MZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<H.C" Z<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<
MHZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<
MHZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<HZ<
MH22@8=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=
M.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=.4=
M.4=.4=.4=.4=.4=.4=.4=.4=.4=.4+I0+#P;?MX@K^?$(A'B*O$D.(NOR\&W
M[>(*_GQ"(1XBKQ)#B+K\O!M^W[]BTBZ4C)2<WK [0WXY7\_OI>RB\/"2DC%X
MS.U-]INT(=K+F9',8PY>*+,AT/L%ASC.FA&RGWL0C^!ETOB\,62D/%TU.V-,
M69$4ON80YA"0',2$></P"OX(LDA^A>2F*23MB.552P*;[E&40B1Y)HHD_ H?
M@6#*+L_N4D8O61VAIFS(@G]RT:F<G))T3Q=M3-3_ (!U^7@V_;]_(/4/XP\Z
M:<RM&TH350>E0,#L6[*"TM262EK"#@,V[-V9TFE!5S*V[0R:+<QV[=F[,="*
M:CN6-VACR=-P5NS:.8K)12-]^K^?WU._SK_\GGD8P12E"1D5D$EU%46C6,QE
MY4(,I<2*:J354C/T,I8D=&E30KE4S5JTC-)=!K%!D0[:6R[J1!-DM%H@D:+=
M%FY,JA%!6H_YOO8A'\#3?\D><8U%'_AVV(J@1@W>$:)$5.G!B8TQ91:**,V[
M*#LJ4#&8H,RN&"2J007,@:2*F5!/R_ *_@8B<>GIKG^N0QA%RJW:MSS270:Q
M;I-B$,P0<I2QC!V8W1GA+F$79BE9&,_9Q:*",8Q$NCY3/\"A^!I[^=U_).^<
M$'K8BB,&#=V1LF50\.AA&:,.C/T2#5-Y!& *P2;)G8HN4Q#F&<L6.>>N2KK?
M@'7Y>#;]OW\@]0XG$$E';P[HR\>3"5PAY\ZY]13O/G)H0BBS018F\V*JM11_
M^>7R^"\)>=KYS_U50_SMO02?U$U]1]^K^?WU._SJ3J"9G3H[DSZ/_AT]R\]=
M9I [R8I*(32'_BAGZ&G/WT_ZAU_),?\ EHT]"W] )=+X.0Q.T\V:^JJ/^;[V
M(1_ TU_)">0)%PX,N:<?P4W_ #,6,7:L8LB&J3^8LQ0=E6E_2+S=1N59.9((
MD\*?_:3\OP"OX&(=NX-T',X.J2GOYW'[YG'FU3EZ2*4M,A$DN?Q9F@R;OX2;
M])4/.9B:/RNS"72^+LTUF$%OP2'X&GOYU9S!,[IT=R:=?PTY_(S:1=**E9HQ
MJ+ES2F22Y'\N@VC.E$"J-YDW;>!31+%.=KDC/6I"?@77Y>#;]OW\K=%;+.5(
M**!5Z0S4AXDBJ];/8+S%)).6'@@V3>-5#3%I!FM-G972LMF!$2MW35H=TX*H
MO-G972J+XA&LO7*@J]6@LK]^K^?WTH>$:J*F_48.GI%&[9P9N=9=FZB\.A&#
M*8I^4JLU1*W>D3;2AZ1J:5.RME5CP.9T](J@@](1M+)C!L(*,D8RZ8E1"+AH
MT,^<%66F[PCI3[V(1_ R=\1H>/A,'I%TI0](T4ELPZ12*C-*,U>E=*1Z%03-
M_!T8[]!X5<S4A A^C]31^T;0=]/ OX!7\#$3!^1=(2EV5JJJ;]1GCTBR!7R+
ME)O,F[<K$Z, B\;,A+IC%H<T&)HNSIG,/>34R/ZF(C^!0_ REV5JJL?]9A,7
MQ'"<H>D:'8/.E55491--GY78YLE1,GY5X%F"+HBAFB90Q732,6+ L9G,8O#?
M@'7Y>#;]OX9E,_((29-THN7!G!_PZOY\0B$>(J\20XBZ_+P;?MX@K^?$(A'B
M*O$D.(NOR\$UXDAU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9A
MU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9A
MU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9AU9@9Q$PZLPZLPZLPZLPZLPZL
MPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZL
MPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZLPZL
MPZLPZLPZHP*XB4=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=
M68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=68=
M68=68=68=68=68=68=68=68=68=68=68=68=68&<1,.J,.K,.K,.K,.K,.K,
M.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,
M.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,
M.K,.K,.K,"KQ*.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K
M,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K
M,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,.K,%%XGA[2QXC#B4?\+QXC#B4?
M\+QXC#B4?:5BUZI6S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"SC"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"SC"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"SC"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3"S3
M"S3"S3":4Y%BEQ.1>J_R+57I.)R+U055*E DP1/'Q;OR+G^T5TF8_P!E9<B,
M"'@> 2<IJQ\'SXC,O@@Z37\>O)YWB=2"<$7Z*T?"#\GG?;C'D&[I-Q#Q8ORO
M(1F*$(D4*I!9TFB(1Y@QH%@BX(M!=ZDA%)4JL&3\KK[*RQ48>]&X,N0I4U"J
M0.L0D3'@2"4P15BJN1* \\GZEG:: 2=IK YX$A[T;A)8JT%G!$8>]&X1>)+1
M!7:9C^!GY(+>UE5>DXG(O5"I_2FDC8Z-+K'4;J3XL3,)@F]+)?4KSTI3RZ:)
MO8+SQ) [>?D44F$R(S@RFGGG;G0BZ<3U)!1I/2+*/YB1D4]1P3BBIYI:H+ Q
M:?4BB:?.XH(2)K!J[C,2P7F,P*R+5/\ #4KZ*22$^Y$DBJ"A85$D8LOG!'AO
M_LG\T(TBVG15#BH30BO[G;'#Y^FR(A/BG-#^R?S0C2+6=%5.^F9&9F$Y*\.O
M/B%/+YNF\B[G!45&3XKLLE50,E<)3!-2"A9VYZ=O*&_D-Y#+D7)6*4&C^H&T
M'+FG74549^K%2%-$@F) @BZBSEZ;2)(]-,/L55#FA[C:BH4X)LY*K%BK-/6U
M,?\ [HR9JJ6J?XA'^SFR)5GM02Y%HG,S1,SE<H;JH-VQ&Y7+--S!_+42/%R-
MY5!&>D650.A%V[G143R^;D=F5_LGLW*W.P?P=0]JJJ])Q.1>J%3^E?252"$'
M13L9,=RFWEC)9-Q)?4PFYUCRHQS/FR133&JRP@C-&"JT6$XBJHR_L&B933&H
M8<E)Z?RG#QQ&:*"IOVS;_P -R;_SGS#^P-_953_#5'\-3^E9?Q4S^VE4RP(^
MA^B8?_9$45B^?M7;WP=LTW173=621?Q@L^,6!A#^R346B^?-7;R-0IP55>&\
MM&F$X%;/H?HF#EHNT7ETS*]+3:<%&R*SB3D07*N2JO3(?LE$L,Z+3O) \S];
MSZ%_+/\ S'-.?NF$A2=FDKQ6"DS]<#-7\8]+, T(H4E5PYH0IM& J7TLR81<
M-HO8/%W+8CDKQDI)H5(K!1O"/,?G,YTAY[QVS]WKSK_EM+I DLB@C!$@F7KZ
MK],V2*D1I_8K38T54#J'F"O]D\9KMUY9-"O?:NJO2<3D7JA.F1GB"2?Z22J5
MG:P;L7; ,".("72\[=9"7NF!I?+%4'"C=15_&6N7JCXKF!FLO657;R\Z;INP
M.FZFTO.Z--B17=O(/&";=7SB3F7G>0FC+K$9)+8L4FTO.FZF<M5.J\E+I\6=
M2\[Q.9L>L1E:;I,29@=I"2(.(%E\L5\[W>?K'TL5\Y+KE#!^W=?K/+7+^,VE
M<7(22?*FA+S]8^EBL%D>M4-,V!W*ABP-!&7NI?%A+%(*K0>IGE4N.V$KEJK5
M!9!^N1FV@V3G;;J&\G<>>WDTO.S*ZEIXNGLO.LYGDLB^3EC*#-&62T[<%3F*
M(E4K,VB2'4S'[$\8'>I<IB)BS5=MFZ<4R%I\R3N8-W)C*RYV_#V7D=))(3!N
M65RN+8SJ7G5=35CUB,6:JC1NW?H$9>=^@/)<=5U.V!WJ)8<H(,#D=Q8.&BS:
M6+P<GEYXO'$'B9Y5+CH&]JJJ])Q.1>J^Y2EQ4U_M/Y2F[-"0%/&$.7W<NEQ6
M1?PS)@1I#[ADP(T_P157I.)RUS!LM=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1
M%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WH
MB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T
M1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z
M(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]
M$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>
MB+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O
M1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%W
MHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[
MT1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=
MZ(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB[T1=Z(N]$7>B+O1%WHB<U"F]0]
MI8\1AQ*/^%X\1AQ*/^%X\1AQ*/\ A>/$8<2C_A>/$8<2C_A>/$8<2C_A>/$8
M<2C_ (7CQ&'$H_X7CQ&'$H\5(2)XN&JC>*21E3)2I=51PW,W.'TI59D\&C0[
MHYJ3<0#]B=D?QETK4?1:2M9T91.*<?N"$B>)I0X+#P9,S.U'K0S10,F"CPRZ
M!D3?>MFYG![4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R
M+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R
M+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<B-*N1:C
MD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:C
MD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1:C
MD6HY%J.1:CD6HY%J.1:CD6HY%J.1:CD6HY%J.1"E7(M1R+4<BU'(M1R+4<BU
M'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU
M'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU'(M1R+4<BU
M'(M1R+4<BU'(M1R+4<BU'(M1R'2!FY^*)*13-4A(.VU)-?UJMG*KQZ^;JJN3
M4BI M5%B5!C3:C@DPIQ1J2E&$4RG;JMGM0-XN'LUEAF!W4F,@A*I H^+(I0=
M@>2D7.LUEQWSAO22J@2I58QYM)#R\.I*9NA+I,9Z25RE1^9[(?(3$F0)+VL*
MK<0,@R/-UHTI$T*=)$CNHB1.\3I(_P"F5L7#=ST"CQV_91:*S23&8%M16)G=
M*+)!>DU$R?<2/U7^%)WZGBL@/!ZT:0C+Y?2OJ6181F<]74@[J;_O3J\QBDI<
MT3MJ._D8^OF7]E5_\\WARE[LT4Y;1ZIHBE_YY!ZYXZ/%_6"QH&FYXJ2^;_U]
M+P_\>GYN1F'\A2BD%21<2T2:4G>"1(-4E67]G$D#36J%#1<TLH91S+_[.HH?
M^75W[*I6,1!FX.66T<I&,5_W_;D?J@LL5$I)JW/'[U54J14%RK%^R@]27B%G
MB2,?!0\"%:3 CE)NY(X+X(S BJOBNX(A!O,$7$?!&8$55^VHI!.#=R1P7P.>
M!(,7L':<)NWB"'@>!GJ13A=P1 J2I52J39NF91>!4V;LKI/[$8PA"$W;QC"/
M,*/$TSCJ"?K"3@BL3&@6"*Y5BQFS>$4U2J07F"*$4YH@H9P^2;Q0?)+Q#AZD
MW'OAL&[U)QX(O$UC>";\BBW%YWZGBLDFD&"D^G97T)*_*R6/-?T.EY^T/&=3
MLK]-&H$'*3V?IE2D,T(P.V>E2<S2:P<.%JA:."S6?E?(2F?III-ZE;MC2:;I
MLU97-"-7*[TJCF?30C\[R<)K-)=/T?(3J9$A96[;IE=3M!) 26?180-.6!8R
MZHH)*-IRS9';S0B;Q[-?UNE9ZS=0:3Q--U"9^6Z<U"U-&>3DC\D[G";XB,X3
M(SD$V3815-^HWVY'ZH5/Z7W(W51IER8S>%3$.5Y.$VT"S^!#/7Q&9%:ABC!6
M9P20)/RJG>S8K<[2<054>3>"*C%[U,#SS]1U79%FWO1-HV@>$8-)N1PG[_C&
M#9R5P13]LM_\2$8PA!__ .5"8S K(BBGZ"HOH/6T@C"#*5N$HMRU$50LMFI'
MHEWKWDW*@=G-RK'$TB2+Z$K0_7,9H1E!M.?,4EOKGDW*@=G-RKG?3A-FI+YG
MU48U!!2,NFB;V"TZY*$=E<(2YTC!L6?1-"'_ "*E7BFW@C!%"GI:BNWDY>F=
MS-K%9Q+W<'24YCUJS0QBRV1-&JZ#5J1L201\E3[$W,9ZX]QMOTLVI6J;M&+V
M#)S!RE_]D)!_*\_BIKTM/2]%PDQ2@S?K-R+S%.5()&FB)5GU12]%JFA&)B.&
M23@>[T?>#DR,J(A.RKJRY5$ZRTZY&ETU(]#/^PXO._4^TDC]4*G]*66NG":+
M,C1&E$BE;MN1YE4A"F:S.)C-YDZ/,R5 7]+.5I%309'7BZ79.W2KQBN@O+)I
M!X(-W,J,Y?%>LFC7JF!)I&$OG+:+1B4SV!9$Q49I*?E*F?5L(S:)V,\:P:M*
MH_A=?Q2/T,C]!(_04N2$&Q(?HF<N]?+3N(KJLG3E8/&*;PITU)*KR_7,XEA$
M2WUTL.XBL=DZ<+S)(JC^>'B5M)"0*V3A^B9&:.)<HG,2OFTH;0<L$WKB5%(>
M!X5/^3C]DD;.E$)9*BLH,X<W\L<PEQI<A&#2G?2O:=(:,@F!W:4O_L%RF,3H
M'PZ!\"PC"'/RIF)V[Z9O+W_3H4LXC O_ -D)!_*\_BIKTLD;N5$Y;*8-(NV1
M'<P925)H><M^H>.V4)8OSY^$/[.JO3()P3))?4PFZK@TJ,>+YG_8<7G?J>*I
M-E%8?@#-E"D_&R/U0G#(SQ%$GZ"J%_463,#,D9C*CJ*GECE]&?%@H=TT=-DS
MP/-639**2;N5JD6;)O#G<)/"'E<M.WC%&8%@E*/):RUM%LC&GS=2_9%>)I(/
MT8,TU$R&ASA)6!F22,@_0[G,O,]3FDO@^2A+WBY9=+CMFTNEQVS9DR,S:25L
MY*A*Y69N9K+CI.7,K536:IO#'#MHZ*HE*EG"DSE9UCMFSLYVDN.BY<2M9)9J
MF\,=S+S*.ED2K%18/&4)9*XMC&2?IQ92J+9!I+U4&J[%Z\*DG!,M2MXJMT%>
MJ1DS$S)$-Y>9-U.I%%\==O\ J20EBB;6+>8FA+F!6"=/%\X_V)M*8/H0;3&,
M%Y*HIX'EARNWTL<&<,T7A3DE;M!1LW=1+*&1F:,FEYF28>2UQ%P@D^@=S+S*
MNIHQZU%BD=)(>[C]9.F!GJ18<H2^7G;K(RUTR-+Y4HW70EYDW7%YWZGBL(=!
M+J4:)KB3-2*O)S*T546+6+E5>7-O+I1HFO!6'(SAFG"7"GY<5ZL5^V\^;2]%
MHZ:35F=2I9:1JHY2;R9*9M$'3220ZYG&'+\;(_5?;?2U-["%/$,"$@2'X10D
M%"L&16:?X4Q8&@R9E:$^VNE!4K5L5L3V4G?J>*U1_P!C:C1(?7,7,.LD<MZ1
M:3N(N&]&_DO^]U_5H4JLL25M7#=WYC6+B>HK)KRP\O(I5#9:"D#%(UJ)(ZC>
MCH_][TOZ5?QDJ7*@XN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J
M+E:BY6HN5J+E:BY6HN5J+E:BY6HN5J)HL59?BL\_\AC2*Y$A)%BE>NWL$']0
MS),K>0."$:4Y-"LE'%/MW!Y_,DBHP<'@*9F)&ZD)"D5:;/4'SE&FT"GJ&<IJ
MFF3=&<%=KHRYI2"?Z8+J>8?V.CQ&'$H\683=,K;\ G-TT&?L?'B,.)1_PO'B
M,.)1_P +QXC#B4?\+QXC#B4?\+QXC#B4?\+QXC#B4?\ "\>(PXE'_"\>(PXE
M'_"\>(PXE'VEEC<KA>TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPM-L+3;"TV
MPM-L+3;"TVPM-L+3;"TVPM-L+3;"TVPF3<K=;VDD?JO\*3OU/M)(_5"9ONB2
M3/\ K*XF?DKOWYT7'W#1\F[@H\4*X^RY<D;$+/551+Y@5Z7PE;X[A5D\46.D
M^344F#Q1O'QG+TZ,)F_Z!(IOU05F7Z'+Y^FS)">+&@Y?F7:LG,'*?V)E-B,A
M&>JI!,\#P1J BK@,ICU*AS?I@A4"J\&,[3<G<."H%+/%5Q+YT5T>930K,)3=
M6!YK-.AA[X< L>< \J5-$P<JF2(O4*J$&\U74.';Q1)3PG3\[7V-G?J?:21^
MJ%3^E;?QS'U\U]9-9@H51!L\0.^>JJK++N)8:?3!1F&:+R!HL7RD)<\6?H4^
MW<*$0<.$797JB3V=O5$XO7BJJRJ[B6'$_P#_ )UX0@6#QR5HF@D]>$D\Q46-
M(OYI<Z5<'9-W!G;M5VR/.WYV\&C1RB<*Q\Z8U5Z9+]KK^R>PZJ8 R<(PI8\?
M)44*G#K4@5VD:(E!>I=QAS$R=0:(.)>9!DV7@N22^I7_ &4OZ6J48%3J!7J(
M$) D*B+Y*L\0425E\Z1>BIE()F2J)!0P,6!H5&W(@EX57_!SY%E[E[,2/7:J
M"S]-PI%59S+5*E]C9WZGVDD?JA4:45&LK>$<(JG@[F$U]8[/!O,%')$XK-BF
MF"TB0Y5%#D9\XBW29-(NT:4Y>72L8%3<?V52)1(5B>#]XHU*9^K(D/"HR&1.
M@\36+.URO&LL<D60E9H.'LB_FD7\TOC^E_4,>9GS9%U!/S):Y$/^R9U,E$[9
M@\(X2*>#N838W0O"N4S%;NB."TO#]1'30CDMOM0G(FR9@S6A+GB[M- L]4B]
M,K+7BA:97C DG/ KE50IB4P>!6L]<P?&J1"*16[LC@LS5A,'/5I_KJ5),D:@
M_?\ K@'TK(\BQEY6<*I-")(1A'PJO^"/[*5]-./53-RHHYG+,C8U2^QL[]3[
M22/U0C#F%:;;*19L4VA5F*:RCQBF[*TD2#8SV7)/((T^W3,Z8IN8F+ T"TZV
MA%JR3:A20MSJ&8IF561*L5DP39E>RY)Y!"0-TC!1."D#4RU-%NT3;E/3;8T6
M[8C<K=DFW,W9)MS/9*@[,K+4E(/9<D\@SDZ+4PGI(HG_ .#04IIL>+1DFU*N
M@1<ML-><S4*Q;2=GTJ'V'C!)W!*FVJ<2R],JH38)IJKT^V6,SDZ+2-LM0T8)
M-8&+ T#TTV-%FP2:0>RE%Y%G)$&IGTN2>PMEJ"$@2!B_JA;+4,94BRB'C%-V
M7]/_  S9$:%78IK'?2Q)X"2%N6#MBFZ]C9WZGVDD?JN 1AS^U&'/VNG?J?:1
MFYBV4O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>
M"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O
M!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07
M@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+
MP4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%
MX*"\%!>"@O!07@H+P5%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"
M\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!
M>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*"\%!>"@O!07@H+P4%X*!XXBX4_
MPM'B,.)1_P +QXC#B4?\+QXC#B4?\+QXC#B4?\+QXC#B4?\ "\>(PXE'_"\>
M(PXE'_"\>(PXE'_"\>(PXE'_  O'B,.)1_PO'B,.)1_PO'B,.)1_PO'B,.)1
M]I9*B55;W0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NA
MN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[
MH;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<
M>Z&X]T-Q[H;CW0W'NAL/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0
MW'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]
MT-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN/=#<>Z&X]T-Q[H;CW0W'NAN
M/=#<>Z&X]T-Q[H;CW0W'NAN'TK;D2@D4>44>44>44>44>44>44>44>44>44>
M44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>
M44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44>44+0Y&
M]I)!_-]J!H1]G)C_  PXBO\ NXK-I>DDRD3!N9M4,N@S6IV7)JPJABDWA.6"
M2323(E6<5&V(@N)?+T&K5NV:S9*F&B2X]XRT-6T72KJ+*5B:+HK'_'R#^83%
M\5DDW9.WA9<FX2BLY31!%('A)?4L6YDU5G2:(34*I!58J4$EBJP')=XZ<G>2
MR"BD';>7IQ32*\2,:,>03>)*1,:!8)O4E(QCR";Q)2)C0+!%VFM'V(F/\,.(
MK_NXK._0,OZR:0]X,9C#H&-8_E/_ $,@]54+<SAXM2[A(M/F/TRJ,.EI^9I,
M@VES"8PI]K%!Z^68$7J*4$91_'R#^855_P PA#D%#_H++G;542E=,CN2^IDO
MJ7*+!N>0J)P=-V\)DZ;2I)LH)7ZU_"$49?&/NU--0\MEA6+DE1NH?KF"K$R4
M2IO6TW.Q\J<P479RZ#%S&=.B'<S-PT@5$_ZR^P\Q_AAQ%?\ =Q6=*E,Q9J%A
M+:3>E_34CV#AQ5ZI3P9N$9HU821*6GFTQZI<SQ4T$O+FC.7-B24DOE9)C"7L
M4I-!G-H%>/I$F]6J>9$<&_'R#^83J71?(MJAB@5B\.^$O=^Z8,9F5V:3%C!S
M)BQ@YESDDO/*HG4>15-*7+&:=8<)O8,G;M\M,BNF<&S)BXBU9S5RE,H3EJH0
MUQ(QA4!#J$FLP([0.]Z-!VJ28+31([5S<"1_8F8_PPXBO^[C<8\_L<_#GX<^
M R#^;VBF/\,.(K_N]I)!_-[13'^&'$5_W>TB#@Z$;@="X'0N!T+@="X'0N!T
M+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T
M+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T
M+@="X'0N!T+@="X'0N!T+@=",_="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'
M0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'
M0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'0N!T+@="X'
M0N!T+@= \\<J0\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\
MP\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\
MP\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P\\P-'G_ (7CQ&'$H_X7CQ&'
M$H_X7CQ&'$H_X7CQ&'$H_P"%X\1AQ*/^%X\1AQ*/^%X\1AQ*/^%X\1AQ*/\
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M(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A
M;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:
M5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A 9NTZXLIRJ-I6
M$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@
M-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M
M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@-I6
M$!M*P@-I6$!M*P@-I6$!M*P@-I6$!M*P@&^D?"!U=-6G?%E82G:5A ;2L(#:
M5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L
M(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A
M;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:
M5A ;2L(#:5A ;2L(#:5A ;2L(#41IUQ72@5TD80*?:5A ;2L(#:5A ;2L(#:
M5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L
M(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A
M;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:
M5A ;2L(#:5A ;2L(# FG/%523C:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L
M(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A ;2L(#:5A
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M0F!,:94CJ4QSI2A$N8,Z:S*VHC(57U.ZK6=C!7^L?TYC1+ENM)],*NJ'(?\
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M^9AM_P S#;_F8;?\S#;_ )F&W_,PV_YF&W_,PV_YF&W_ #,-O^9AM_S,-O\
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MEUZ_1K&$-1FLOY,:(ZVEV-\ TQ]0G&%5SC6JTD:>69!5#DF:M:&!*RSB:O\
M.&IC34^UJ9 ;U_I\Q+3.I:>8TT.ZF)]F]E^/^K#Z(?3IAT\P34.J64RX\X?Y
MTQGF>EQJ3I"J)U@K5;\H-5QHFQ#0-4:E\D4]K'DU2N\-UI6<PTM84KS436F4
M*7B-0?\ KUB-RZ9UWFPB">L6<SBFY%JXSZ_U(8RGFAC'SLU.82D&I>55HF^J
M;!>8=-$HU')UCI77I.@\\YO=:C\7(:4<>U%)<.8 HK.BLWJ.5$D4W]A\&?,5
MQ_+Q#&W[>(:U/@KPT*_*\:5:=FS+4IE&13);5W]2'%DQC,M"6*UL>8N^F7(9
MG)WN4J+KO2=F/,6J^M-3DCTV82AB7&C/&-'RY>HRU3I2SSG"N*BUQ5'FS4)4
M>F9_FS+]:ZV7.4--SF9X#Q%J\J3!E#?3[P/46.9?^/\ JP^B&E+.*6!:\KG1
M*UK>9Y?Q?3^"C9KQH76*YRUI^FV'I-JEF+1WB353,&KW$F<Z#GNI"0:BFLEI
M[3\G(6&L+$.7=/1,*R"(G6)W>=L%8XP_0.ER;X_R6ZR9J#R[1+++6H'3?C^L
M=,#K2W7U*SF31T,9!:.-$\UDM,U#INPC/<-Y+E^*29IR)C.05'IOH+3S/)#E
M;$9]$M<2>$80A'V'P9\Q7'\O$,;?MXAK4^"O#0K\K_MD3(E#P,6!X$(5.$80
M- A"IP$4R1-P#ZL/HO"*18Q*6!(0A^DQ2%("D*6)2%+']$! A2QY0YP+ O@9
MLD>)$R)P,6!H>67]/Z81$80C")(&*8L#P,0IP8A30C#G$Q8'@8L#^Q.#/F*X
M_EXAC;]O$-:GP5X:%?E?Q#ZL/HO:+!GS%<?R\0QM^WB&M3X*\-"OROXAK,H^
M3UK5&R["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R
M["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R["PV78
M6&R["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R["PV786&R["P
MV786&R["PV786&R["PV786&R["PV786&R["PV786&R["PH_1]AV8H;+L+#9=
MA8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+
M#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;
M+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=A8;+L+#9=
MA8;+L+#9=A8;+L+#9=A8;+L+#9=A8332KBFCY@:02\T;>EXMZ7BWI>+>EXMZ
M7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>
M+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXM
MZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>+>EXMZ7BWI>*%(5)QQ#6I\%>&A7Y7\0U
M1_&_$:!]-Q"N?SXC1/JN(:U/@KPT*_*_B&J/XWXC0/IN(5S^?$:)]5Q#6I\%
M>&A7Y7\0U1_&_$:!]-Q"N?SXC1/JN(:U/@KPT*_*_B&J/XWXC0/IN(5S^?$:
M)]5Q#6I\%>&A7Y7\0U1_&_$:!]-Q"N?SXC1/JN(:U/@KPT*_*_B&J/XWXC0/
MIN(5S^?$:)]5Q#6I\%>&A7Y7\0U1_&_$:!]-Q"N?SXC1/JN(:U/@KPTP:A2X
MTHS>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&
MD-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0
MWAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#.
MNHB%751O#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;P
MTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2
M&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;
MPTA#6$F:-(ZM$F#?>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#
M>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X
M:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI#>&D-X:0WAI
M#>&D-X:0WAI"J=6J3Z,=82<([PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PT
MAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&
M\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;P
MTAO#2&\-(;PTAO#2&\-(4OJT29K;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(
M;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO
M#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-(;PTAO#2&\-
M(;PTAO#2&\-(;PTAO#2&\-(:B=09<E23PT*_*_B&J/XWXC09C&;\0K<YB1XC
M19S'<\0UJ?!7AH5^5_$-4?QOQ&@?3<0KG\^(T3ZKB&M3X*\-"OROXAJC^-^(
MT#Z;B%<_GQ&B?5<0UJ?!7AH5^5_$-4?QOQ&@?3<0KG\^(T3ZKB&M3X*\-"OR
MOXAJC^-^(T#Z;B%<_GQ&B?5<0UJ?!7AH5^5_$-4?QOQ&@?3<0KG\^(T3ZKB&
MM3X*\-"OROXAJC^-^(T#Z;B%<_GQ&B?5<0UJ?!7AH5^5_$->==)8R=]T:3#N
MC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:
M3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28
M=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#NC28=T:3#N
MC28=T:3#NC28=T:3#NC28=T:3#NC281^J/)H0P=49*QI?B%<_GQ&B?5<0UJ?
M!7AH5^5_$/JI?"O$#_MTI_++B%<_GQ&B?5<0UJ?!7AH5^5XQ9J\EV3\D9]UQ
M2C!5688RY*,W4IJ,U'R33G*--&J>6:D1B+5DPRSD'+N14<2T?I]S8WS[2@S9
MK7E&*ZDP=KWD&5:CU":E:9T[2Y+ZC*DG=2VL)--9%5GU%:+E=2< ^JE\*B7R
M]U-G2>BY*DF.2-*B]+TW]B:XOJB24O\ 8H3%=/U70D/"A*#GV3)U-)8ZDKWQ
MC_P,B8NJC$[Z6XIIY[BW[&EK&,ES%DFLY2A(*AQ'CIQENL)CHRIED^S1IYK+
M!#FC\54]46._OC_MTI_++B%<_GQ&B?5<0UJ?!7AH5^5XTE_[.9UD3.J-6'T_
MZD=8ZK7(2A-26IWZ7AOU3#1K_L9K+^3'TY?^,10.6(ROG;&>G.=4(S3U5:B?
MJ(8NJ%9]G;4R75[+)/@V6EQ9K,QQ3>+,@< ^JE\*CZ?E/2XU4MV=:ZCJOJK3
M?E;&LGQ"^Q-)6$JH3#^I"C],^(Z4JZG*WK?"U5,<B53B5#3_ *7\8T5G+*65
M5<#47(B8KQ?IWI"88FQAGV@<0XJI>KL-:9\'4'D['>+*9T[9^F>@\E,TOE/4
M5/<:SN<5A1V']+*>;L2T6O0:M"8OP#C]]4.'4JVUM51B>35=6N/<35/A#$.#
ML73["=%4!A+4S)\0PQ^2:XIE>G_4C-]$$I6D.H#)OQCHQ^=>?DR1R9IV?.,O
MX!QCBFF*GP7B+&%"4YBG+M1XRJ=O,\?8MTT4[D_%U!5GC7&<]PG25/5_C?&.
M3<3XFQE0=+XHR[46,ZF1FV/\6Z99!E+%M!U=C6G<>XXQ!BC+4UQ_.W_@?]NE
M/Y9<0KG\^(T3ZKB&M3X*\-"ORO&DO_9S*O\ N+K(),M/F;?IV4(N>1_2Z]?B
MNL6>GG4KK1U#4&MB_29B-U5&G>C?ITR>CY].,D85K:=:AC4O*,S:YJM?U!E7
M6GC+"U-T)I;K9\YPQKLK>GJLR;3%<TY6T/Q_U4OA4:!*[D]/UKDC&%<:::IQ
MM/JEJ/3#A&@J2I3#^F?)[W)]+83R[76#!D21T1G3#F4RF=:3?IV%,3*DPAS5
M^H%+5ZBCHM:+T71>GDL2:<< PYZ=-"G_ #F[3&J1+515[B%.9=UG9EGF-:YR
M%J2K#(=%8[U.U3B>4ZQ\1TSBV?\ U'R'<UO3?^HC3_3[Z=WS!TC8EIBO#Z.L
MVK9+R5I4_P!H,F_&.C'YUYQ8.ICE&BI$]TPZ?L*E_3I@P_GRN<",=15#T1.<
M;ZQ<T32D'=5:H:SK&BI;3M(X#PR2M7V0-,6'\_5S@1AJ+H>B)ECS65FB:4=,
M:MU05E6=$XOU)5CA*3ZM\6TC2K/P/^W2G\LN(5S^?$:)]5Q#6I\%>&A7Y7BB
M-,M"X^K"=:<Z+G]>YBP=2F=9;1%"R?'E/X<TZT7@E3+^FV@<X1I;Z?N(J:>M
MVZ31(91T6XQRQ-\3:0L:8<F&7L!43G%M(/IZ8BDCRK* D=9TUV]<.##>GNC<
M$%_'_52^%1",2QI/7#ENE9?E+59DO,,OQ%J$K3"19AK*R@_-B34)66%&F5]2
M=<9C8XHU35_AN44KJ K.C:Q.>*A\6:I\@8CE66-25>YF:TSERI*0I:F<N5)2
M-*XXR).\45"RR!/I75.6]4E=9KE- :O<BX^DN5]0];9G:4UK3R13DKR'D:H\
MKSJ6:SLHRRF666JB84*GERI$Z%Q;ENI,-33%N7:JPS.GFMK*"CRC,NU+0-83
M>:.)X_H2N)OC:?JZ_LSJ%KG(=2Y,F4@R[4M,TAC+5+7.+)+EG.E99K<8RU5Y
M"Q7*,HZFJZRY*<8ZHJZQ5):MU59(KB4XTU3UUBZ298SG6.:W.,]5F0L62C*6
MIBNLNRJB-7^0:'DF3\M55F.;^!_VZ4_EEQ"N?SXC1/JN(:U/@KPT*_*_B'U4
MOA7B!_VZ4_EEQ"N?SXC1/JN(:U/@KPT*_*_B'U#*(>9*)VQ\ACMCY#';'R&.
MV/D,=L?(8[8^0QVQ\ACMCY#';'R&.V/D,=L?(8[8^0QVQ\ACMCY#';'R&.V/
MD,=L?(8[8^0QVQ\ACMCY#';'R&.V/D,=L?(8[8^0QVQ\ACMCY#';'R&.V/D,
M=L?(8[8^0QVQ\ACMCY#';'R&.V/D,=L?(8[8^0QVQ\ACMCY#';'R&.V/D,=L
M?(8[8^0QVQ\ACMCY#';'R&.V/D,=L?(8[8^0P;Z8V0XPT_4ZO2%&<0KG\^(T
M3ZKB&M3X*\-"OROXAJC^-^(T#Z;B%<_GQ&B?5<0UJ?!7AH5^5_$-4?QOQ&@?
M3<0KG\^(T3ZKB&M3X*\-"OROXAJC^-^(T#Z;B%<_GQ&B?5<0UJ?!7AH5^5_$
M-4?QOQ&@?3<0KG\^(T3ZKB&M3X*\-"OROXAJC^-^(T#Z;B%<_GQ&B?5<0UJ?
M!7AH5^5_$-4?QOQ&@?3<0KG\^(T3ZKB&M3X*\-"OROXAJC^-^(T#Z;B%<_GQ
M&B?5<0UJ?!7AH5ARQ?Q#5%",:WXC098E;<0K8D3QXC11(E<\0UIPYT5X*:&L
M5&5V-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8
MM&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%H
MV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&Q
MK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%H5T(XF<&V-8M&QK%HV-8M&
MQK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-
M8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%
MHV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&
MQK%HV-8M&QK%HV-8M&QK%HAH;Q= %T,8K)#8UBT;&L6C8UBT;&L6C8UBT;&L
M6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT
M;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8
MUBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L
M6C8UBT;&L6@VA?%9X[&L7#8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8U
MBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6
MC8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;
M&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6C8UBT;&L6@FA
M7%:8V-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-
M8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%
MHV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&
MQK%HV-8M&QK%HV-8M&QK%HV-8M&QK%HV-8M&QK%H::(,6-'?AU*,!U*((LFI
M'PR=G?'^&B8RSYCO,GW,NS#*YED?[=#YIDM>UA]]7%<2/&\CD\W9U P^[Y\A
M^J _5#QK&OZ>Q\E^"JNJI30\GI>IY76LH^\G.7I9),@_=3K,<HD>0_\ "M7S
M1X6?>]7H^G$]<.,J#)M;ML:4CH]PNPF=,S/ ]"3.ILOZC)=C.=2C5B_DD_SM
MJ2IS3X\?ZPIG21IIJXFLR0QMD2298IFE]<!,EM,+ZBFV4IS2O^V62-2UN51B
M[4>:KZGU)97KB7YWI'*+QU2K/5E6=3,\;9<IG*E),]7U05<CHLKF4Y,RZ,C:
MFR4]5- :HCS:K,\:FZ:T\S+#N7ZNR0_#K5E-*KF.%=1$MRZ^FVLV5-:OQKJ3
M<U'66:\^R_#ZU0:QZYI"H,IYJD&&*5FNK"N:2:9;RG1__J"O,J2[%&,":M9U
M6#3#N6Y#F^E3:K)W5\QTZ:H)CJ#>?;JZ,8,_UF'ZS"GH\Y>/J"?T6>M15/Z>
MA/=8<]I>7RR9-9RSR#5Z6/Z8I_63,\G2S!N=9-G25S76DSC4D_U',Z!H)[JU
MJ:B"YJR^QPS01M64^JI/%V=*9RW1*FJ+($Q;8BRO(,V4K)]<<*Z%7Z@IM3Z%
M#ZH7KRK]5V4JUEV7J^U)5G+Z:QW6]-N<<L-6E6ULVPGG"G\ZR4VL]C,J@Q/J
M.-7%5#->?I'A:#W5Y/* 7SIGF2X'D>*]0T_RI.Q'6HQFD\Q?J8/5=79 _P!H
MLKYLF%!S6@-3[J:UCF75336#JK4U9SFDIGG[,K+ 5%3'5M/)BSQID:1Y:IB8
M:JYO4<UPGGF4YF)4^J5^YJ:GLR,<OZGO\*UC_?CZ;GS5&JZG'E6X=TFU4RK+
M#HT]>3,M0?U#FS%; >;VRDXK;7^0I\ 4$P;2^E_IY*Q-B;Z?3%LUQ/D1(C?5
M92O^V6FM7,K^H76&\T5_D'49\_\ ZDKMXUP4R;ZEVC>J\3UI@W &"6+*68WT
MS(IM\^C0CY3Y/7ZF5&1ZEY.QGN:1F]\]EF.]%TOE\MP?D-N5IJKTRLF\<U:D
MDB)9FU U0XHC4+/YG/=5V0=1$23#4"\00<H4290NBG4__J_C)BVEE(:(_):,
M-(6=U,,X[TCX[J>FTOMU?Z+PI[^N'U!/Z+6.Q;3*J\]M47N,](JIU<*:E/\
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MQ;)!IAU"1 B<DDUP666SN!COZ=2=]QD /#L3:9-'3J1(!!;(YIG!3FFESA6
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M2B$D(B69'YG=A4NB/7<"(,P A5'M1+B2;IE.T)VUZ=^W_B%E]?8$QH, 9]<
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M&5)-".H 2[4'9S"7#5'?$1&U.SRTAI$ !"2$(:-"/W#!S$P.@T5(9H82\31
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M)$_/)$'  "FBS\XS/F/YM$3O_N_^J?YC0Z%V$1'2BQP! +I*))DYV4T!S#+
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M->UT"81FU)WE9@:+TOP@Q,)TW(S7W@03A H-B.2\Q:X1;-(>@*9E9)@Y[I]
MZU_C9! ($7.(C#8.DZ:<Q_F,<8&2!:3[,K(,Q,379%0"=FD32[3,%YOF!D90
MT"BB/0IV3G0OLI%(T]-*S_G]Y6<PNPF#9!\,]:S&MS ' 2NNB6:BA9=[,#@Y
MP&$"D)K,L@%YA>,S4"_,OMI!$#&B$/8UIF8V/6>]?N'O0V!9?R_]R9E.PM$8
M:Y[/86T&.].RSRN(Z=<5%Q &N18V^(6J <T]8]F;G.ENFZ-4X[ H%.?H$FV8
M)F:,32'G3\71J#Q,0"L_YAVE'8>Q#:>U-SVR.:X0/36LG+H>03NM0 D 65G-
MG#H;1TC6F?=98O7)"-4MIV*#3!WZ3/QZEE.,P?&J"#1>B3";3[(&E9;&  !X
MD&SVCYAV%1U*#770(Q=#$:!-,%DY<<4CI)YD&Y)#12XB)U0"9YC[[7&!D@0L
MKYQ_1N9\Q_J7+^;V.#:('J!E37-- !U$!-\N4,!O&BFT+(ZTQ[Y YL =<O3K
M0#B 28#64YN:2T. +2#=C()(]17QN="-+Y(]:R?G'N3LP2D E#/SLU\LINNN
MM;J3X2_&>P)X-#_<$SY#V.3?N&SY;@>H\4[.$K6 !NT]"GMS26W@"T@W8S21
MZBA?<Z$>9\D>OV9?W($0TP-?>%?8X$=)]">,HWKI$8:B"=LFA-<TR0 .H@2K
M-SF80 V-!,EBS_G]Y6?\_O*S0= ]RR?G'N7E9L)90(P,E(3,D/+F/H,I;TMD
M]GS,]W!&%!!ZD'M(F$=1I!0=ERAC8$T1EM[4S[@X2+I-8[)>HJ^'"&F(@K[#
M$2B.Q/?I>>F]7,P1$ZP"LVH.:P1!B)3/7['LS) ^4&B>([2-JOO< -O2*R_M
M\LXOBZH21WHL=FM@1 BZ)JD[(=/EDCJ[X[EGQ('Q>\IT"#(>Q")I/:F_:Y)O
M$F+B)0 ->\K+S6CTR*I+$'L((/259>1ERAIO.(F'3M,%Y<1>GA2F/RY,PN$(
M3G;#7"59,?UCW*=!SG.$!#X3!$-+C']1BF?/[O:/F'85U>Y?N/N61M/N3/MF
MNN B)(G,\@/4LL![G$N$CG7I-,*%E?./Z-S/F/\ 4N7\WMO0(V& JL5W+$.T
M[2FYCA*V:57<P1&\;"K[1$B8DQAL4,P1A,:1UH.@21-$DP32\1NF(EI4"HP,
M)[L3=J1&6(1,3M7F$2QC(2 3L0SB/B @):-G6BQPB#(5<RQ 1CI4,P1A,9B.
MM!T"2)HDF'L+7"(,X*C=.R)@KC  -%NE1@1&< D"I7,L0"<Y@E<8F6E.<P2N
M,3+2K[Q+I!A6F-(D9 ME,D$/,$TQ!@0K[02[23$^S+^Z'(8.^4]#6M(*C C4
M"0%=RQ =NTTJZ\ @T%1NG9$P3K@A)!H&DR<4UAGA$[3+P_ANY@CVC85&[':2
M14O. ^*$.K4)O8<YH@YT\LE2+W-,28F4VHG+$(B!E)D6$^(VJ&6T#MKG4#*%
M&!&H$P4,L0[3M*CF"72)"K[1$Z28H#-$832D=BPGQ&U "82*!6$^(VHG*$(S
MRD]OLN9@B(QGA*H*YEB C'2FYCA*V:5#S!*)B)"%"$3$&))O1$TNC4A?$;IB
M)82_T;F?,?ZER_F_T5S/F/\ 4K<P"-TQ@L#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:RL#:
MRL#:RL#:RL#:RL#:RL#:RL#:RCF&2\8_]47:' $7VS['+TVU!>FVH+TVU!>F
MVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU
M!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+
MTVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>F
MVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU
M!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+
MTVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>F
MVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU!>FVH+TVU
M!>FVH)Q#&Q@: I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I
M@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@I@C_4K/G;V.
M_J-^P_F1_-FO:T!WPRTRB5>9FM!E,2=L%\ @UPB-6D=-*=G9PBUNFLU#M3#E
MM#8QC#J3'L: 3=B:91*F->(@F4=15U@ $!(.OV?Y.<V\3+#K@))MI*<6,N$:
M-,))IPGG-:'0 GZU@^GBAELYC4. 0RBR^ZF,#V]@0=D-NB$HUR\/R!GSM['>
MPYCJ)AI- 7F9F:61E#6B8:Y1[T6YQ#A)==3K!Z=:^-P&T@*+3$:0L_YAVE/<
M<R_$X?T;Y-R^-P&T@*+2"-4JB\@#68*+""-1C[,QC<PM#80AT"\PN\QE((@1
MTZ]B+LMUT.$CM'<FM+K\F+2KH<V.B(C[+K7-)T A1*NM<TG0"%*KK7 G0""H
MF0*#' ["#_1+]A_,C^;,_9V)W[NU-SA.V$?^+K4W)I?"/_)WN"R_W>Y9?[?^
M*9M/84,MLY  WHO);  F<T=2(SP/*E@3HIZM!TS(M^PA QCI.F'^[;0GC-C\
M4)AMBB,D%I&LQVRD@A%CIVAR<,UI<XF4RP&\;@@_+PNHT'5J_(&?.WL=[,L&
M8NEZ5^PNT"*=F_=&\]QF+2X 40D(19]O'RW",(& <-O259_S#M*S_F':43G$
M%SC$QBXRZA,-"S&9)^ @$3SR:=I68[-E;EFZT44V(YF6+L1 @8=L-/LSNI/!
M_2>Q.CH<@,N>[1/",NY-RX!KQ"0R.O#73LW)F2\D,,KX1FT22H^3(\2M(:X&
M(UP[4Q_W!@)"9;H)FEU*.1 /!$+L12@6Q,;I<!.1"5-.4 '-E F=)I_5O3<G
M.)&6T7B)?B-$TO0H/^V^%[2"(-<V.F,D$':0#7_1#]A_,C^;, (C\%.I.$1'
MXNU.R7D:1&HCL4 9&R=<YLZDR!!GF.Q#(>Z#@ -?PS$:=:\[-S 834>\Q1S6
M2"84& I4"YU90R6N#7 "(^75H*<[->#&@:M I)3G7PUUXR'09=13LS,>"2(=
M6H3DKSW2!Q,=0,FZ1>>UXNF$>K08TIN7EF(;&)HCH&S\@9\[>QWLNMQ"4;='
M6KGW#'!PDD$^NBQ.O,+60@(SF,_3>CD9[3 $EK@(@@HAC7  8B(#8%GDCF':
M5GDCF':4]OW#3>+HAT+UX:D_,<TMBT$ Z)(1UF$R>]S269DL1+ ]"=R(8TAH
M&(R1.@#V9KGM<080@(KR<ACF@R%SI).G7J3LILL&D;3WIC[I= "($\(SPU(-
MR&DYD1+"$-I67]PP7BS$*2-(WKX6N)_3=E67F726@Q>VFB?9*$69#"1(280#
M0#VZ@F.+21  PG;)/!,/VS3>#HN="[)K/30F_=-:7-A=<!.-?30H9;7..@-_
MHE^P_F1_J5GSM['?U&_8?S(_U*SYV]COZC?L/YD?ZE#F&!!CUB-JQFH6+&:A
M8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J
M%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQF
MH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&
M:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L
M9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%B
MQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6
M+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A8L9J%BQFH6+&:A
M8L9J%BQFH6+&:A8L9J%BQFH6+&:A8BTO,#J%BG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4
MZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG4ZG43_P!<+;E@
MPO&$5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7
M%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5
M<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q
M5Q6,5<5C%7%8Q5Q6,5<5C%7%8Q5Q6,5<5C%7%%D\##_4C+^;\R?\Q_T9&>7
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M(G5_( :W_=.[3#IUHM>(/;/T[4S)$+K@(Z:;$&L%Y[IA[ZU?<&N%+1/#J_\
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M%-\Q[9#&23^WV$&8SJ $#003$'KG3\IYC=,AZX0V:/P-?MJ_ %C)X@U)K#.
M!5['9YA=((US >Y%KI01 HC((<TF(#J.S<8%#.^Z()$S1,.[K)TIF7E2/ B7
M1F$^W37!%S<Z,!&!&C;>1<Z0RM.B,)]ZN/GB3V)N=E$![=-*+<PM:(3#F.N4
MR=?44,HSW2*XJX^>)/8F9XA=:('3,;4[+;.;4UCIP/P#MG\\,9",09>M!IH
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M0IV;E+^!;L_ W&3Q![4UIH %0]F8]T(.,E9/O0:R$08R["%Y<8&2!UA#*-T
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MUPBUPF(Z=Z8\4-::B2K^6^YF'E=,3"@]7_U".6^<&!7[3T[48Z5EAV6U_P
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M,V^UPG+8$.KF.Y,R<D$,9&$9R33))_58^5_9^:9OR^\?RF_;D"#23&F6-O\
M&<N <TSM<(A'R&,RR>9K8.K43_+#G "  DU1M_#137/A$ "(G,-.O^2T.@ T
M   0 [?]"!\K^S\T?E-@"X0$9IUB;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6
M)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q
M8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[
M%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;O
ML6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N
M^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F
M[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B
M;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6
M)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q
M8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[
M%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;O
ML6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)F
M^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F
M[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B
M;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6
M)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q8F[[%B;OL6)N^Q#->YI #A)&,HV?
M]#.+G& $I)4<IP<!H,47/( $Y,R\XN!;&$1++HD0S,LQ!F/L<S+C%L\1U>TY
MF88 =(!3.'4+5YF7&$82ZOX <V/Q& @(IK\TP#II"3N0<V4$1&P_R;SB -)D
M5T9C8[?:<U\8#1/+(AFLC QGGD,/9?S3 $PT]B&8PQ!$0?YSLU\S1$P7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7
M-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q7-5Q0S&S.$1^:ECIB
M"#UI_P!LZF(ZVS5B*;E"=YW-XP3&Y[2X"!(!@;SHF?5,FYC1<8&Q@98#WE0+
M'7?U<.*S2*1_<O*8TO<)#":.B,L3L"\IS2QQFC*(Z(R2[0A]N 1=,2:#$45K
M,#&72QK1$@2DTBK>G9IE#2X]B.8T$0,('8#[T[[8-(+8RT?"8*Y N=H$D-IX
M)@ +7-)B#K I[EE'/872"$#"$@BFYH:;OP@ 4 B1 ,:72",L (T3&,*D',!<
MX\LQ;M/9"*( +7"6!EDT@IWVP:06QEDY4W+<TF]2*)8(%\23,!.>"&4_+<PN
MC=)F,!'0/?[!]JPP:##KYG'9+5K5T7H_JC[IDQF9%QA=$!/#KD0&;EN:#3[X
M$#<G.;*#=(K":YQ@!>).J\41EL<X"F;KA [X)N?F-+FDR"-T@R@]A3<YC3=@
M(-IEUH9S00#&0ZB1[DYK6D7=-,8V)Q+3$& ;2[7J'25'S 60$=,=0FEZ108Y
MI:#S1C6.)_DYOR_Z*Y?R_FS/N6S&!ZVR.K$$U@E:R%0^(UF1?N'O3(4PC64U
ML 0X&]K,3&*SKE#3#J,BS'F5T!OC'W++<S$0#U@R'IH3/F/8C_ZV]@69^[W)
MWSG_ (M69#_?VA.\R@NAM DW)CP!>,0320(+)Z<H3/V?\2H0'Q,).LP,J>^$
ML81U0F68UL@%_M69^_M65U?\DW,R<3:--,FO:A]O]VR#B0 80E,T1-+I'L)?
M)%Y^H&':/8WX0]YPZJ(QEGFDG0/W&6UK8B!!EC R3GL3?E9VA24D@[+Y0(G)
M,:X=D$&L  OB02"8IFQGN3?W?\BLWJ[2LQSA$MFU1)080($@D4'X8]JRW 2_
M$.J1-V#L_D9OR^RXP$DT"51+'5&S^<&,$29@BQX@1./X@<QI ,T01V^PN8TD
M"<@$^T-$Y,%Y+H%T@DUPAHTJYF"!]K<]T(.) EEDZOX+N6"3J$5>S&D#3 P]
MK<YT(.C"663J_D!K923 =:N9@@='M#6SF0+RB02(3:3+!1N.\)L5UP@=!7FA
MINZ8&%?LNY8).H1[$6/!!%!5YK##8;$,IWPDF$M&U'*?./X8!7KCH;#8H%',
M:TEHG,##V>; W8PC"2.WV!SP0'"(B)PH"<JX\$$4%1N.J-BNO!!T&17LMI(T
M@&Q%SF. $\AL1.6TF&@$]BB]I TD$>P^6TF$\ 3V+ ZHV(',:1'2".WV->\$
M!TH.GVMSS"ZXD#3)&S\XR_E_-@QI <#$$S:YHIS\P@D@ 0C(*9P-2\MA ,09
M9I-@*'VN::(1%!G!$4<GS ,LSP)FU"%.B(">XD%I$!/&$:9 $<W[-X$:#)"-
M$Q!&WBA]Q]VX.<)0!I$T9I!H 36Y9 (,98Z-0*/VX(C=#8T1 "/V^; QO1AH
M=)2 BS*S &.G()FV0GV'K1S(@MA 3WI83R0WK_(^V< Z<RPET@]H5_-S [,C
M23=#:I^H!,RV$ MGC'1"2 *;D,(B+L\8?"(:"A]N2(W"V-$2(;8)S<P@DF,D
M=&L!/^Y<6W77H 1C\1V0WH_<?:N ),93 @TPDE!3<USPY\8O)C1-=DEW)N9]
ML^Z0(%IF.XC=UH?<_=N!+80 U34   RZ_9YC#=>)-1&NU>6[-@WYB9*H]1*R
MQE.^++$(FD=48&,R_P#.]L1A;1'2X@:-1ZD/M@1> :(RP^$C5'<O\7.@9#&&
MLDB$=':BS(S &G7#= P.Q-^W:X%P=>)=&6,2=)I0^U>9;H$1I%-:.2<P#+)E
M@3+L$*:MJ>7$$.A"$8P$9Y!I3WO+2'30CIC+$!#[H$71"26,@AHAO3!ED"Z3
M&,:8: ="#=  _D9OR^P;#V%&#B0"9#+&6;IU(7( N )&LQL1&8]K0( .,EXD
M3".BGWIT" UI(+B?ADZ6P1=D9C<R$X$]734O+9/3&8#2=2(R\UA(E,]>L:U_
MCL>TQYA*V:/!%^8]K7 $AI/Q. MH]R.:YP8P27G:= TKS<MPS&B0EM!UBA><
M]P8V, 32=0I0@YKP9BT]N@H.SLQN7>$0#/#2= 0RF.%Z(@X&(EA [T_*>\%X
MB8F/Q05VF,$W)!#G. D%$:%<.:P/FNQIT1TZD<O,$"$-JS/M3/<#V;1..RLJ
M";]H*,MSG_,82=4:H(L:0( F75"U!@I,$W*<08$2CJ/O4&F!BV!T&#5Y>:Z\
MXP$=H%J/FO:QH, YTE[Y12@20YKIG"8].Y9.UW:5YKW!C)KSJ3H I7G,<'LC
M EM!UBCV//V^.,L,4))J:M<)4[*>XD&<.EF.O8B6P#6SN,@'3I!',RLQN8&S
MP,HCJT+)VN[2O->X,9-%U)T 4KS6.#V1A%M!UBA',RZ'!L-M.P(77M?&(@TQ
M@0AY^8S+)F!,O7HWH7H$&9PE!Z=T4,S.>W+#L(,I(TP%":QC@3%MUS3$2P@4
M<IYOO) CIB!!7#FLO_IC3HO:=7LOF9H+JN\%7S2Z.]%N6X@0$D9)EE_<9@@\
MF$:2);-Y@LAKL+W.:>LNAO3LLT'=1NE0S>;->UK=38_$>N:I0S)KPG^40WHF
M\X-C\,"0V'5(=:\U\\D:)@!1L65]Q2YL';1WFK^%WWCA%T;K-LT>E .E7[YK
MDJFW(YC@ 3",)!,!'=$K)^S/.TW]KYM_PU)V6:">!ZQ*OW^[V?;_ /K_ .U,
M^8=H3M@_XA-;EN(%QI@#M3<_-QM= &DCIO"#LLD&_.-B+7/<09Y2LU["00X0
M(ZD<K.)>PM,8RPZ3)P;-$PV4(C+<6QT%>;>-Z_",98+RW/)@"1&)T=LB+WO:
M'  W(_% ^_I%93LQ]YI;\(_2)."#\W,8R\ 0"98&F"#B0YKIG"8K*^=W]WYQ
ME_+_ %+F_+[!L/847,RB7 G$XD1C/"5#,S)R:MBNQD $.N59=SF>;U;H=@J3
M0VF(.R!L7W#1(PAX+J&RPZ;$[[C-S&$ & :Z\7133I)_XE/+C'XB.H& W+);
MG%P%V(NPG($8S4G>5F9>67F^V$"!/+"G6A]M]Q%L"2UPHB9B.O7U0BFN#@]C
MI6N":W-)R\P ",[3";9NVE,RW_J;+I$1*CF:'2[*=T4#RG_R=4Y^K<4_-/Z7
M7=P'TJ\79D=@M0?EQP@&.D1X()N91!L=AB#N1>< 'FZH?_EN"S,PTM=VB ZA
M(G?([W)OS!#:WL:AM;V-0VM[&H@F0 0J![2@7T.DWVE9/S'M*R6YQ<!<B+L)
M9!&*S,K++S?$)0)Y84Z_9?RC#3H.U/OM#<QHC>%.WC'2#0O@I=\57 *0K)VG
MM62W.+@+D1=A R",95F9647F^)(@3T4](+.+3 W@*X [DP.EECUB4)][2=T@
MW(%\X?\ #'KXIF5GDL>P0#IVD41Z#;0F,<8Q<T@BD7IT<T2W2#](1?\ ;N+<
MPQ-QU)G,#OIV (M=.)"LV$]PPZ5(;1VH^;EESH"6\0)M"#8!K6R-:)A;TD62
M1^IW]RR?N&3N@QWS63]4%EY#,.66M&V(C9M"?M'_ !"&5]P!F,FEE,/?UUA#
MR\+A>&I9,=)_N0.8(M!E$T0O1=XC:O1=XC:B6R! -Y7&/63_ -P]C6F82G8+
M9NM'/&=EB607IH3=-*9]PT@WA D3$C1TH7_\GN]GV_\ Z_\ M3/F':$[8/\
MB$WSF%QNB4.($)4,MH#&-F:/>:>]#,9"-^$NQ>6^$(QD L6:^ ,'"0B(H$R?
ME98&6\",&2!XT0GU=8UA0/L_>OVGW(N<8DF)7V_RG^U-=]T\M+A$- B0-<L%
ME^621>,"9^:.]97SN_N_.,OY?S8![@"9HD"/X$Y8<"X3B(C5^.S?E]@S7@D
M&:>40I@BX4DE!QH7F,! @)X1W$H_;_<-O,,HA.TZNE<8(G[5KB\B%YT/AV 3
M]):%FY^9*R'Q-A&\3&'36AE.R8!Q B'.DCJ4L2UIHA&4'8)(ISQ,2368H?;_
M '326C"YL[:^FJ0(MR6O<XS%Q  \,_6@W.:YKA.6P(=XINI,RLIL&,FC.8TG
MIP\PM>#^D0+3UF7LU)OW#A -(@!/!I3LUL0"8B,Z\NZ?,NW+TD+NV>;5.AFM
ME(GUQG7F.:]I,I:+L(]?#8HY+;K: 3$]:BO,8"! "6%&PE#(@;\+I,D+HFUS
M0!DTHO>"8M(DA.8:2-"&9"(F(U%>;D,<7&47H76]0,IT1,!U(9[081$\(R :
M]2&>T&$1/",@&O4AF,! );//0*(Z$<O[EIDA!S81F!@X&2F0IN1D@M8V:,Y.
MD]_#+R #%I))DA*3-+K0^W^Z:2&X7-A$5R0Z0DBBW):\N/,X@0ET-GT2^P9?
MW##$1^)L(F.D&>'6G97VC2+TCG.GAH$.&R,J=D9[2YCI9)P=(W:$69#"2>9\
M))8R 4T1GUK+R6@Q:3&:$IHE0^W^Z:2&X7-A$:H&2'"22*+<EKBX\SB!"70V
M?1*GY!!BX@@R0DA/+JT(/;.#$=2\S/:YKZ;L(.KZ:RFY64V[EMF%)UG7QE,4
M'/:]I $0V!!.J,O8F9D(-9=@*;K3&OIK7GN:2PS@R'#=H/6O.R6O+I8!UV /
M5+VHO,Y)-:#3,X%M?$ (M/*[L*.:P$" GGD&HGV,^W -YI),T)8S2Z]"<QX)
MI;"$CII=4R&:^6#@XZ9XE'/++S3RNA-"&N6D*^&/C^F2%<8PZU?<(4 "@+*^
MVI:V+MI[M_\ "6D7F.G:>G?V7QEOC/"(A7&,%FO#;KG@-:&@76B$-6JB?0IT
M?MLP$D&+3) :8R_-IG7^/GM<?BC\,+0B,ECPZ2!)DGEI-"8S/8\EC0V2$*(T
MC0F.R&O$#$QVB:4ZT<U@(!A//( *(H/8" &@2PG$=!.GV?X^>UQ^*/PP]Y1#
M&/#H21NPC6LS((,7$$30DA/+JT(9M%(T@S]-*<_*!#28@&?=&F;5[/\ &@;U
MZ,9(0KCN7F/!(ND20IAI(45E9;08L$#&$*)I=2:?N0X/: /AA!T-O364W)RV
MEMUQ(I%V!IG+C&61,^W -YKB29(2QUQIT?G&7\OYM RMR_[/_LLORW%L;T8&
M$874'L<0XALHGEG3&9SB6Y@DB8SS3ZQ!.S3RC?1O66]SW0>081DA>NF2:$ZR
M_+<6QO1@81A=0)T#L1RRXW8N^&,F'1[(Y>)Q@#HIBO\ +\YT87H1,VV,.J$$
MYPES&Q:#)*8 @Z*4<]^<20(EH)$@GA" W)PS3$LA+208SZQ!.AF'+:)@(S42
M B.LDK_$S7%X,1*8T7@1&7:%E_<-F="/5\+OI(_'9OR_R#Y9D,X,H.T*.6S+
M8=+6 'M*+G2DRG\*'"@Q1S'  G1L TG1^&B)PO,?")A,(3?R \0)!C+*)$<Q
M\Y_I7+^7\VS'G0=[EE?N_M0_8LC[AL[8@]9)%1[5E9;)\R!(US0\4:ED98Y6
ML'U%97[O[4W8.Q.VN_XHL+7Q:2)A1UH9F;$-=*W]5ZB%&VB"YO)C'I3=^F*
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M]-:_RON 7",&M$D3K,\-F@SR)PRV'+>T1$I(<!1+,LP9E#9#+\.OO0RLMKA
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M&XK]I1VK,^<?VI^:W$\PCJZ7O8'1E$W5,FY@YF@^[L@H-!)T 16!WA-BB6.
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M1R_N_BRW @Q<UT-GQ$]-2+102/Z(9\P[?S(?FSR081?+#6FN@8?#+"29,SV
M_I,-4H,G6KSA OB3LF%O6LR\",,XVH_<9;;S22=7Q3M.C4O(R<LB]/2=DP@-
M)*&4^!)B74B)H]RB&-!'^T6)V>]A<TET#J=KTB:"8S)RR(1E.N$YF ":RX7L
MNCXA&<2:Q-!-RLK+( ,>N:),P 7^,V4M AK<)=\J_P =V62X1 HGTB$9-Z=F
MYH@70@#/#211'\@?_P"MW:SV7G82('8:>I>9]MF,+3+*9M7274FW'ASXRPE
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M/7'H(+R[K6LCRMNB*&1G-#V3W7"@Z#1JD.J":[*! >T.NFB/3M3"*6#M*?\
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M(XZA*EM652VRH E"O)V1-/<,B1,=HF,V+HR0[]6+&C=PE:0O_P!DF?M1EOR
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MBC(36U5D?X15-,RFXWI[W3I(42!I("=,7^ZY+X)UZPLL.*I#B+U2I]12AMH
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M,W:[%5N5C-6@KX=Q3A<.%8)P@#A#N=P?Y=;E.@IK=><KW%?"U5HNU/P],M9
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M$+;%,MQ81-Y,L20"=.B+CL]S0$?6%N<""XW/@W4+2%(<1, X5I((F)]HZ?\
M)12TJ%NONJ"&VVTE2UJ)D$I2)DDG< TP;R]DN]BC"<95Y(HJPRG/@Q-S<_U8
M4P\E2'$**5H4"E25 R((.D$'=!BKSG8+)7UMAH"L5=<PRI;+);2%+Q*']%)!
M5W 9GV/\=_5M5_ASRCR3ZQX,^3\/_P!WC_I>U$S%!<<S6VJH*6ZL^4T#M0V4
M)J&M!QMGMITC]([L-4-$VIVH?6EIIM FI:UF24@=LDF0AW+N;Z"HMET8"2[3
M52,#B0L!221[8((A->SDN^*IUH#B5BD49I(F"!NZ1[4X7:,Q453;Z]N173U;
M*V7$@[A*5@&1[1W#!OF2,MW.ZVX.*9-124ZEM\(F6).+0"1,3EN147_,64KO
M16RD;+M14O4Q2VV@;JE'M =LP_5Y"L%PO#%*L-ON4;!<2A:A,))W)D:91Y=G
M3+EUM=*"$EZJI'$- G<!7+")]J9]BH<R#8J^\(I"A-0JC9+@;*YE(4>T3(R$
M<R+YQ0^[%.YG^Q5]F15E::=5:R6PZ4 %02>V0")_EB<6O-&:[344-JO2.$MU
M0[APOIPA<P 21-)"AB F#[-GVT5KE*;#>ZIRDID(<47PMLK!*TX0 #P:I243
MN:.S%D_N[?P1V1LOKCEC\1:]E7K#F+\3?]AC+UB?IJ6]T%8BJI'JHK2U(I*'
M$**$K4 I)F))/?)3.+OFG/5515=UKF&J6E%$MQ8::"L;F)3B$:5*")2F))W=
M,+R-E-^DI[AY;3U056*6ALI:Q3$T(69G%H[V7=(BB_A_SX^VJH9H4L+JJ.:T
MMU"%EQ#C>-*2H)5+="<0F-$XJ-EB,XT]NV?U;JC5&D?<65MKD%AMHH2I)6/"
M1C2A7[15V\R7BX5M'5V*X,BEH VMQ506TNXTEX*;0@'#H5A*ABG+1%7M"_A>
MS!3VYFM4Y.CJ%<&IE#IQ*:TH<:=:"M*0L I[W=(Q0QMI_B2OC-YO%*XA]BD8
M)<276ODBXLI0E*&R,26VT89R)5*:39[-DRJH::HMU8Y4.>7+<0E25MX.]+;;
MAF#NS T>WHA_8]05%,B[.62FMJ7W"L,<*RA"220DJPDI,CAG[45VQK:*]351
MN2ZY-0JA6M2 S5H")!2T(.("9GAT&4IQ<,L[/<WTUNRO<U8*BJ9J'FUK:$P"
MI@()#N$D=XOMRX245>=V+C2U>6/J]RDIL2UFL6MW@RI3B>#2VGODJ.A9T%(T
MF9A&VS85<V;;F!:T/5#3KJF"'T )#S+B4J$U)'?I5('29G$4PG-F>\UTMSSV
MZ\VA2*IUT4C%($F:4+0T3CQ$'"EM#8&+PE&<96REE2LM[%;8B ^JL<=0VO\
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M3)++A93=;JX4AYU)D4L-B17(S$Y@$@A,R#)&U+*-[MF;<EEX4[MRM:S.G<)
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M:;Q.69;RTX5X<7!%XZ OM2* 84VKPDDI,C/2#+=BGOER0%467*&INRY[@<0
MVT3^12RH>VD1_C2N45U%UOZ*Q2O:=J0I(_,F0_-%=8<EYEN-LMK-'0NMTU.[
M)I*U-S4<!!!F=)GH/;C(6W/-S++6='ZCR%VH0V&U53/[U)40!X)+8< W$E2L
M,@91LJM-\*#8LRW*X6*N0Z!A(J55'!3)[7"!*3VI*,]R+WL]JTD(MU6M-.H_
MMTSG?L*_.VI/YXHMI#PP9DVAYBMUBM4QWR:!%0 \X/\ 55)S]#9!ANDSGP1M
M*[K;0X'Y<&I8I$<$E4]$B[@&G1W=$7*JJ[Q>;18O*,5C52/+:HETV$80,'[M
M:QIX1*\2L6Z)2A_/&<*A#U[J4,(=?:;2UB+#:6T*PIT!4D@D@"9TR$;--NX2
MGRJ_61-%7K!TK?IT!8)]N9<!/M =K_)S!_%?=J-FNS'PRK9E]NH$T-K)#96!
MW5+4<1!"L#92DC$8.9!G"X^5E?"<'B3Y-NSP^3X>"P_ZN'W8K=H%_IZ9BYUX
M9X=NB04-K<;:2UC"22<3F'$K3X1,HV;?PK75#6',MIJW\P!0!/E5P22R@DB>
ME8<:]L8>Y%[V?UH.*U5KK#:B",;,YM+T]I3921^6/_\ +O\ K@_D,;'O5G_P
MJ>,N_?%O^<(B]_[BV_-T19+-D;,-PM5 O+]&^IBE>P(+A<<!41+22 !^:+3M
M>VBMM+SA:KMY#3W$-I;<J6N%+:@<( DH:5 ##C;*A+3#%_R5<JFUW'_%2V?*
M*5>!>!9.),^X9"<5.7<PYKNM;;:QLM5%.]4%2'$'=2H=L'MB-I&9,K5KUON=
M+=:4LU+"L#C95P"3A/:F"1^>+EL^VB5[^9<HU5KJ%UZ;@D/(8W$I)<(T!<R@
MH)DK= FF<7.BL*^$MC-;4MTJYSFREU009]OO0(J6<@7RNM#=8I"JA-(Z4!Q2
M 0DJ';(!($(V@_XAN'^)3F+R8W#ACP_!<*1@Q?T9=J$9'S#F6HK'K;15=QIS
M<5+>2G $A26TI$\2YI'Y/T159PSEF.S4>9*2F;JWLLE]*JY+3B@$@@*\.1F4
MA)$OVHV?WG/F8S=[#=*);MGH=/\ P+:&V^])*1B.!24@S,I2&B+;FG:;G;+N
M4F;Q3MU=#2UC_"U2V'4A;;BFTE(2%)(([X]PR.B+;<+C645WR_>4%RW76W+*
MV'<(!*3/<5(A0D2E0\%1D0-GGWW5?"JNS%D_N[?P1V1LOKCEC\1:]E7K#F+\
M3?[(Y,]8%_-7/8M/]RN/]@8K\Q96V:OU6:J*OJ%,OW"XJ6PFI0ZK]\$'&/"[
MX##H[1!TQ39^SHZARY5=PHDX6QA;::0\D(:;29R2D;DR23-1)),"PU[ZW;=;
MK72FEIU> V7\2G% ;F)1 F=V0 W!&3:6QC@J2\7IU=S*#\HL.U!2E<NT>#09
M'^@F,OM6;%*K164]4A)D%,< M:L7="2D*'M@1MIL;1;H<J.TMW8J;LHH0S;V
MS4+2@DJ([TXE2 .G@Y[@T56V7:'G3+U;06V@J*>WTEFK14U%>MU("0&TB:01
MN#3)1!5)*<46&OX-+7E#US>X- DE/"4[JL( [0G*,U7;,#ZJJK3=JQA*W-)2
MTPZIMM">XE"4@ "-D]CVFW2^VZU*M@JJ5NR,,/(=J5L-K>4]PH("DJ<5AEI[
MY4XSKE/)]QS3=E9JMBJ3R:XTE.AH/);<2VL%O#(S7WQ,]"1%!_#U_$%Y;:V;
M35.5%HOU ,884Z5$AY "C(%:@3A6E23IP%.*+9>+;=*:_91S TMZUW6E 2'0
MD E*T J 5A4""%%*O:(*18;9M/N53DS:/;Z-JU,U^ .6^K2DR0%3T)Q*,Y*+
M125$!:Q*64MGN:BTNJI[U0NM/,$\$\PXHX'$STB<B"DZ4D$>V;GG]I12U07Y
M'E,B1BIG64-O@R_^K43+VHIW@E)RI5MC.:G) -<&C2J9W,)J9$GN+C-VTNM4
MI2A;:U=JT J0RVZU3M!(,]/ S,NZHP_=:K-&>C7KJ5U#CQH:/'PQ65%<\,\6
M+3/=BCS?D--7Y.U:F*.H=K&TM..NMK6<6$$Z E0$^[N:(I?[PU\,1E[/>,HI
M*>VV]FM]ND?4XV]W?!2<0]M,5^:+BVEO(-LI5YVX:7[D),U!';!":@*7A_H)
MT;D9UVAW"87=++<'6TG]AD.M)91_LMA(_P!,7\#_ .7*[^V;BQ??-#\Z1#/]
MZR[_ .%#/]ZR[_X4,_WO+O\ X47&W5S[CU+0T% BE:6HE#*7&0M80G<&)1)/
M=,4#E[FI=OS(&;:I>DAL5"DR1/M!*G!H[0C924[HJJR7_P#,1LKR_M-NE_MM
MM19$5-"U9:=AYIQU3#)=6Z7 >_!7WLOZ2N[&=MG^2;AF>ZN9JH>"0S<J2G0T
MBH0A26UA3>'#,J!42#H0)0 =V4',>SJXKH:I:0A]L@.,OH!F$NM*[U0[AT*3
M^RH1F->:;'363:?ER@57MW2@3)%0E"5%..??%)*<"T.%93,*;5V@ARS#@_K;
M,ZF[FI"I%: ^I(2ON@\&TF7<E#B*9:FP\C@W A12%HG/"H#PA, R.C1&R92=
MT.UA'O78V79>VG72_P!MMS5B0_0,V6G8>9<6IEGA7'"Z#WX*M$NTI7=C.VSG
M(]PS-=7<TTB4-M7*D8;;;J&TJ"%A3>$"9(*R09X!*-IEUL-2NEK17LM!YHR6
ME+R:=M>$]HE"B)[NG1IC)U'7MH4Q]8\)A($BMEEQUN?Y%I2?RQG%^]J4X\S<
MW*9L+).%AI*4M)3/]D)D0/;BW+O\UKM^9/)[8M??*#7#+3A23I  4XG\B91E
MO(NVNOJLI9QR]1IME%>FT!RB>92$I2ET;B9A*9A6"2M(=D2F,L9-S ZS5-/7
M2UU=#6TT^"J*==4D!8!TI(((4F9D=PD$$UFT*VLHJ*BTOVVH#+ADEQ(I$)6@
MD3EB22 >T=,7#-&Q.^NV/:#<N$KZG+MX;_=OORQ.J9<$Y3.DE"G -W @3E4V
M>YMEFLI'G*=]L[J'&E%*TF7<((C:(U2S%P5E989,]&ZO_3B*8LTO_P"/H_[5
M,5C&TO(];F#,+5)1K74(KU,L.)+<VT%L*&@#0=&F+?0N45/9<L69!:M5HI-+
M;"<(3B4J0Q+P@)$DI2E.A*1,SV:5-*LMOMWNI6VL;J5I74E)'Y")QLSVT9/;
M"KKF,T^7+P4#Y.J"B.$5+<"%)>F9:$X.T(R)L@RF0G+F1*ZTVFG0G0#4<*UP
MZC_K"24'VTJ[L9G),N^HI&<M/DK<,Y#VWT5/G+);F!AY-:VE=6VUX,PI0*7L
M(TR<&,RT. Z8IFLB%2<NWRA3<Z2G622QB64J;25=]@T!2,7? '"=R-F**R9J
M%7%\LZ1\G.H[7Y)?]<6^X9OHEW&R,U+;E;1MN%M3[(/?("Q(B8]L?E$=5-;Z
M2<UL:=E-:1]Y.:V'W:)!:IENN*9;)Q%#942A)/;*4R$^W#+=E3C7EV^K>K4M
M[H2*E:B5#VDOH)_U1/<'L6*P5* Y;:1[ZSKI^#P%(0N1]I:\"/\ :BOVMT.T
M[)E(\FL9<MS;EQ&-ANDD&4JPZ H%,UR_:*HRWMJLKM-5T=^HA15=31.!RG74
MTPFA:%"<TJ02D&>XV!'_ /EW_7!_(8V/>K/_ (5/&7?OBW_.$1>_]Q;?FR(L
MK&UG)];F&\?45(XV^Q7*IVN!QKPMJ0%"??!1)[ABVY)LEKI\MY&LLC06>D5B
M&( I2MU<DA2@"0D!( Q*)FHDPQG#)*J9-Q_Q.[3SJV ^W@<)Q=X2-.@2,#*&
M=U6Q5N%0W4CR6A2PYPC8(3WX4='?&8[<;0LXT]OHKHY176F4*.XM\+3.8PPB
M3B-$P,4Q[8$9KV990IJ?)F=Z*F56ML6%*6*>Y,2*2TI(25@*)X-8"I]^@XL)
M4F,"DE"D]Z4D2*2-!!'=&Y["/6C_ ,4P\M.Z+'7$3]I;47+,68'UU=SJZM]U
M^H=,UK45G23^30!N :!HC8NH[@M#Y/B6(M5\_B0S=46:\WJF34TEGME$:RJ;
M8.XIU9F$@: 1( &:0I1!ED2EV?5]7=+"S>GT4E57,AE\I_X@J!0/! 5, =P"
M-GGWW5?"JNS%D_N[?P1V1LOKCEC\1:]E7K#F+\3?]BDM^:;O0VZJKU\'2M55
M0VTIY4P)("B"=) T=L@?S&HR307>A>S!2IQOT#=0VJH;2)3*FP<0E,3T:)B>
M[_/LF>L"_FKGL4.T+-#%546ZF8JF7$4:4*=F\T4)("U(29$Z>^$7"\,)4AJL
MK*BH0E4L02ZX5@&6B8!TQ1W%T%3=-4L/J2G=*6W$J($^V0-$5&T#*U/54UO=
MHZ6F2W6)0EW$RDA1(0M:9:='??HBOV%;;;._>\B5SQJ6%4BDIJZ)XD$J;Q%,
MQB&))"DE)Q>$E13%==?X<;+>+AG&MIUTS-US IO!1H7NEM"3-1[HPIQ2$UE,
MTG:7M;SB4W3*--;@U=[6ZREYRXONXUHQ%6A"1C5C.F>.9$D1;,B7#9'34"[W
M4-T(JK9<7E/,K=.%*TH2$S"=U4B-&G3*4/*J55=QR_ERJ>;260VNI+=3232.
M^4A*E(+F%6E,\).@Z(O6:*%"VZ:Y7&JK&D.2QI0\ZI:0J1(F =,B1%-L+_B,
ML];<K%;'B[:+I:UI364842<,E%,P,1 ,S-,DJ0<*2+A:MEUFS%=,P5;/!TMQ
MO+Z&VJ114#PB&VE#&H"8DI';W8MUMVJV?,%KS'0,EJHKK&ZVMJMDI2@MQ#A[
MU<B$Z$]KPI;F6]G.S6U/6S(^5&EHHFJU874U"URQ+=*2H)! W HF:E*GI"0U
MFRZ6#--JKFRVZ[9J%YIRB<<1(E*%K7C"%$:1B1HW (L^W>_4"Z:T6BLHRS0T
MY2MU%)2DD)FHI2IQ145'2E.F0T"<9@S]8VGF;?=:LOLMU 2EU*<"4]^$J4D'
MO9Z%'\L?X#7;JP[2$65>7D7; T612*4$SX0KX2?!@=[@\, XHM^T'+"4./T1
M4ARG<,D/L.#"XTH]J8W%?LJ /:BHSM>+/FVTW.K<545-KMRV#3*=6<2^#45=
MZ%*).@H]I*=R'J_9G9W+'ET-,M4]&\\7W9H3);JUDGOG#I(!(':,,U*@2EIU
M"R!ND)4#_P!4#.^5J>KIJ 6VEHRBL2A+F-K$5&2%K&'OI SF>X(IMBR:>K3F
MU5.U;*ZX$-\"NA95H"5A7"%:VPE"@4@>$<1G%QS1FBFJZFEJ[146]"*-+:EA
MQQ2%))"U(&'O9$@S'<,4VT"EI_+*3 [35M+BPEVG>,U!*MP+20%)GHF)'08_
M]2MC^5;K5YL=?X=AF[J2*"W+6N:W&F@XK$M()X-,RE)E):90C;!8::K:M"'K
M4YP-0E"7R*/!CT)4I()PG#WWY90C;%8J:K:LZ'[4YP-0EM-0118,>A*U)!5A
M.'OORRB@VBY88J:>W5=PLC+;=6E"79L+;0HD(4M(F1H[XQ7Y%V^6&XI>M5/2
M*HKU8W FH<:?9#BF*A!(FE*B<"ABE/<3I)LFR795:G++L]R[WU*Q4*!J*AZ1
M <<D5  !2B!B45*4I:C.03DG8Y04U6W>,M/ONU;SJ6Q3K2YPF'@R%E1/?B>)
M*92[<6_8E_$C:*^OM=E656B[VI:4UE,@S[Q25%,P <,YJ"DA(4@E(5%?9ME%
MFS!<,P52$(I[I>GT(;I>_!4IMIM7?**04]\@;LY^Q0Y$VXY5K4W&W*=#5^L:
MTHJ'4.+*Y/C$@J*9R!/": )!,7C9Q_#!9+A1U&8$%BXWR\.)54E@@I*&TA2M
MU)(!. )Q$X2J1%XV+[8;0[>]G][6'EMTR@*BE?DD%;<U)F#A2K0I*DJ3B$YD
M&ZY:V*9=NM;>[LTFG^M[\XA1HVPM*U&G1-4EG#AQ84* )[\B:3D;9!;Z:K;N
MV67'UUCSJ6PPL.!8'!$+*CX6G$E,O;BW;%OXDK1<*VWV-1-HO%I<2*NG09C
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M1B0$I2$DDS_-$_\ UFLLO[J-=#]+3NI?::=<;0\D$)<2E1"5@'2 H#$/RP
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MHK@]3)PL5E=0M/5*-$I\)(8E=U2@2>V3#V:L]W!ZYW5\!*GGB-"1N(0D22A
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MQYP[[\QYP[[\Q=G'"5+57J))W2<">R-E]<<L?B+7LJ]8<Q?B;_9'9[]ZU_\
M8M_Y:'7FG$(<$T*6A24J'=22)$?DB0_D9C_-+*WWO2?#A?\ 6/Z^R-U_OZO@
M)[(V7UQRQ^(M>RKUAS%^)O\ L9BR3F*^5=986';TEJB=6"T@,5&%O"F7>X1H
M$H=V>;-[[64%,U0L+8I:500%*+!><)D)J49&4Y]I(A3N:Z@5.8[/4JI*QTA*
M5.H4,;+J@G1,I)23(34@F,N;(=DE8Y1YFOCP==>8(#B6E+X)E )!P\(O$2H:
M0$=PF,TVO:#=ZB[(H!1N4YJ2%K;4X74K 5*<CA&@]S1VXS;D_,][JZVRTOUK
MP%(\L%IO@:Q*&\"9:,*3(2[49FS+E>J<HKI2TK:F*ADR6V5/-I)2>T9$B<"_
MYVN#]SN(N=6SP]0K$O D(*4S[@F9>P?X<-D%W_PY1TSA8=JT'@W''&V>&><4
MX._PI$TH0W+$1,[O>V6WYMS6[FJQW,)<4S4N+=2ZT' EU&%TJ4TX)S2I*I&8
MG,8DQE"W;.+Q4VEZYU%6TZ:=>#A%#@4MXC*<@5G],)GF\2"AI^M"1N]S@XKL
M^9I)?3::,./);(!>=D$I2DG0"MP@ RT3G**G:1;<V'*F72\XS1M4SCK#:B@R
M4EM#/?K2DZ"XXHDJF!N&558=LUZ;OUS17N*HZQ#BG%&D+:,(6I:$*Q8PLZ<4
M@1WQW!_/]GOWK7_V+?L4.SVR."G\HQ.U544XA3TS>EQR6B9TA*1,36I(G#VS
MG(&SRBS<+:M5-6WB[O)67GD'"YP94AR<CHQ)#:)^"F6DVK,^QJTU>7;L\M]N
M[V=U:G&&PD)+;K*S,242H$ C<^33NJ<:R;9[A=E,_*>14SCP1VY** 0#[1AR
MU7RE?HJUK0XQ4M*:<3^5*@#&Q>4A_P"4OZ9?_4L1DVS6O(PRR_04J@Y=^""!
M=9(2@N)4&TE8Q K)4I9!5H/;*EY.LERNJ$&2E45(Z\D$=K$E)$_:G"[5?J2H
MH:YN6-BJ:6TXF>Y-*P#(]V!:<K6^KN5:1BX&C86\N7=(0#(>V8^J\U6ZKME9
M(G@:QA;*R 9$@+ F/R>QD#/&8MG]MS+=,PMOIJ'JA?!N8VR58BHI7.>@2T 2
M@[/[;E][9YG=]M9MM135!?I7W$@JP%*B$DR$\&%"E"82N<A%-8<\V)-\J['=
M U56<#A$UA'@I0"E06%@I6@%)"A*8B\7JW6#_"[#[Z96;!P9I2E"4E)0$I"5
M*(*B D":M @9EN&7;NQ:",7E;E"\EK#W2HID![9T0EEE*EN+(2A* 5*43N
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MM5VN]IF_;+#8W/*75U.$A*EG09H)FF:4("I*4O1(V':;F=3=,Y<,QTM0L*6
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M5 @=\4KFD**2(=K<\Y@R_8K0RA;BZVINV-*DI!/[M">^43+0#A_3H@A)F 2
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M5+K'^%EUWUBIK@1PW#S"I\+.>&8&B7M3E%1F3(CK#-=54CE"Z:AE+R2TX02
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M_2(\&_\ 2*Z_2(\&_P#2*Z_2(\&_](KK](CP;_TBNOTB/!O_ $BNOTB/!O\
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MB:K7'DI#3AK&BX@M$*)( !"L03IW)C^7K<[YWK$6^QV] <J:EP*4E"2H)&A
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M:ILPWQII*1()1Y8M4@/RJ,>4TS+;;U3?KXX^M*0%.*37.H"ED:5$)2E()[0
MW!&SRIM:4"MJ<L7IJO(\(TR"5-8I=KA"<,^W.,U>HEM^>1M5O&S%.4>$=SW<
MV:Y>8!7>6$LA(92/)N]X%*#^[!TA17VI1D?:)M0?R;34F3ZVJJ0JR"X>5.MU
M+!:<:G4 IPJ[V8FG_JC89_>LP_,4Q>&[>K W45UK8J220G@55;<PLC3A*@D*
M]J&:6VHV:(HVFTH90V+N$);2))"9&4@)2EVHVQ5&:JJW.77,=3<;R&+*7Q2T
MS=<EMM]#?# + EC,M.CMDSC*-#9D(11-V&VAH(\'":9!F/RSG&W9JG0EM!K;
M O"@ #$NE<4HR';4HDD]LDDZ?8VGYAK5%R_U6T&\M5RW!)S P&PP@]O"E*E8
M= W5#M1D*[6Z2<PTV?;&+8H*DYPBU+"DIEIDH 8I=P1L/M]YIVZFF^M+X]P;
MJ0I/",4(=:5(]M#B$J'M@>QFVXV52DU[%BN3M.I FH.)IEE)$NV#&16;&A"*
M==FIWEX !-]T%;Q,I]\7"J?MQL^K;(E KJO*]Z9NA3H4:1LXF<4AI =)PST3
MC;E<BTWY6+O9V@]A&,-FC4HIQ;N&8G+<G&P^O;2$U/UO>V>$ [[@UT'?)GW#
MVQ&3<ZY8M%QS36V[+-Q%YM-I9X:JI;<Z^$-U;:)C&I3A4D-#OEA!PQD*LRQE
M>^V')^2[M]?7"[7^C5;EOO-IDU34K*_WC@4?E%2")3':&+8C8[T2;0'[_6MM
MJ3^[56L4B5,$DR[Y)TH[>*4AIAVFKDI73.(4AU*_!*")*!GVB-V,[4J%%5LI
MZB]LVTS)'DJ:X89>UC*Y2T1?O5>D^"U%@M]M9;IZ5FUT2&VFDA"$)#*9!*1(
M 1M6I%K#%!3[1LQ 2(2EI$FB2.X -/M0C*-UR;FZ[V95QN=1E^\66T.5C5TI
M':IQ2%D)(+3BC.27) HPJQ2C..TK:)0_4]USSF!Z\HM!6%KHZ<IPM)=*>]X9
M0F5R_P!6<E32/\M/^]3^H^RQ^17PC[&SG_F3E_X-1&QJBN++;].O/5-B;=2%
MH5)E1$TF8.D3C.5+6-I=97EZZXD+$P94CAT@QD%3JBI0R[;DS/<2RD ?F  C
M.Y'_ ,NW3YLN,@,432&6U99M+I2VD)!6[2H<6J0[:EJ*E'=*B2=)C:FQ9@@4
MCUDL#]<$;GE> A)5+]HHF3&VF_IIV_K)>;13*J,(X0LHIT+2C%NX0I1,NZ?R
M1LEM61/JI5P;HK]56]N^\-Y#Y2ECOU*#'?EQ* "W+<5*+OD&_?\ IS]7WBB?
MH7R@7?$E#R"@J3BF,29S3,$3 BX9"OU4FMN%FL-KH'ZA!44N+8>8;)25 *EH
MT3$Y;L6^W6YI#%*Q2,-M--)"4(0E "4I2-  &@ 1M[S)7.(I<I6C,SEP=6V)
MI0X*8N5<@-U6(#0-)5HBFSYLORIEJR9;N3:*BW#,M?4N5C].OOD/+:I$8&PX
MF2DI*U$ SF8N2;PEI%>,U7WRA+$^"#OE'?AN>G"%3PSTRC,5TI*=MNLK<X7T
MU+R4@+=X.H*$8E;I"4Z -P:9;IBCV';'[$C,6?*R@7='TU54*6AM]$%\&'ZE
MT)6LXE]ZEM"<1T:1,3V0KVU4N6*>W#-#GD7U$[5N/<(:56(.FH"1AD-&$ SW
M8V&>L=P^;(C/OJY<_FZHM"J%QQM+V7<ML5"FDXE"G<73I=T=PI)!W.Y%!;;&
ME"+=3TK#5,AOP$LH0$MA,NT$@2]J-J=+8PD6Y^RV*HKTH/>BM*)() T8BWB)
MGIC;)<DLMBK<SY6,K>"1C4VAAI24E6Z4I*E$#<!4>Z8V2OM )<=M&9FW%#=4
MA%.E24D]L DD>V?8NWUTHK?MF0J<VM#FXA+M8.&6W,[I*BDD Z"H3T1GJGO^
M'R+_  [<EDKE(+;IU+;(GVPX$E/MRC8C;<Z-"I377[)K%4T^"H.L. H"5@[H
M6T1/\L)992$-H 2E*1( #0  -P#V-L-R0T@5;FT&XM+>"1C4VVRTI"2K=*4E
M:B!N J5+=,;$;E0I1]<C,U4PA7[?DCE-_P 0.[AE*<;/?5>_?"1#&PO8Q8FL
MPYY<H/K2K56U)I;?;Z0KP(<J' E:U*4H@);0G%(@SC9 O;72Y9IZ$7NY>0FQ
M.5;CN,T"\8=-0 )2 EA T[L;.UUC+;I8RQ>WFBXD*P.!:0%IGN* ) (TZ3&;
M''4A2V?J]QLG=2L5S "AW")F+LX\2I3CEE*R>WBK6)S_ "PW;Z)I#-*RVEIM
MIM(2A"$C"E*4C0$@"0 T 1F]RQ3144-?F_R)+>C@U-N/*;" -R2MR,J)V8HR
M C+KE$IVG\N%S\I45NK4XI[@>\+A7BQ8>W%[V[;5:C+J7[G8&;1Y)E_RO XX
MP\'$.N"I$\02"B85N2$AIFJ[OI NMPS!>ZFY'=4JI-6M)*SW<"4#\DHV?U+;
M:$O.Y5O(<6$@*4$E6$*.Z93,I[DS+_H6K+FU>+(ENIJ7GD@N5$P%K*A/]UNR
M,<LV/QE1J8=SKFBX6VJHEV]ZD"*1;I<QN+0H&2VTB0P]WV"A8!21(@[A$7&Y
M?PHYIM]MRY=JERL?RSF"E6_04[[GAKI7&OWC:3_W8 &Y-2@$A-MSKMXSO3NT
MEH=544U@RU2JI*)QXH* NI><)>>2 HD-*&$*DJ>B1;V][ +W2V+.[E(FWW2F
MN;*W[;=*9!!;#Z4$+0MN0 6COL(">]TDVJH_B?OUC=RI9JMNO;R]EFFJ6J>M
MJF3-I=6[4J4X4(.G@AWJNW*4;/L\VZJIV*3*%RK:VK:=Q\(ZFHI2RD-801,*
M,SB(T=N>@Y@V6V2I9HZZ[L---/U 46D%M]MWOL(*I$(EH!W8H[6\H+<IJ9EE
M2D[A*$!)(GVC*',DWZKIZVK<NMQN'"TP6&PBJ>*TI[\ S E/1NZ!/=C_ -1M
M@V8;>CZTN]Y;NEBS(V^[;E+9KG6VZBG53R=9=P)"5I$T.:%*TI BZ;<]M5WI
M;YM!NE(BW-^0,*9H+;1(7C\GI4N$N$*5)2EKDH_E*E*O6W-ZKIU6NY9=I+,U
M2I"^'2ZR_P *I:IC#A(T"1G/M=VY[8/X:;[;;969A#1OMDOM.Z];JM]H845*
M5,$.M.X9A6'0LF9/:AC,&U_,>76;#3(=2;-EZWO8:E2TR0IVIJU*=1P9[Z38
MDHZ#HC+&>=F5RI+9G7)]P<K;<NXM+<HWD/M\$\R\&^_"5IEWR=(TC1/$F\;/
M?XF'+1<'KUPK+K=A;?9IF:<A/!!M3Y4X7$+3P@6K<5AT$)TMY(RKF?)U]LE"
MVFGH;A?J*O1<$L(&% =%,O@UJ0D 8B25$348K,C[<[NQFJLNR*MFO=:HT4;!
MIZE)2:=MM!/>(22D+4<:O".F$[)]G.;LLO9/I)L6NYW:@J7;M14A)PH#;:A3
M/*:! 07-!EI 3)*<Z9FKKXY?*;,ZK:ZBHJU*76K?8;7Y2[4*("?WCKA4A*)A
M*9)[7L7;:U_#)?+7;7\RJ0[?;'?V'GK?45*)@53:F%!UMP@G$$R"B22K]D6K
M:O\ Q,7VV7.HRXI3MCL=AIWF;;35*Q(U3BGU*=== \ *T(/?)/:C9[M)H*JG
M9H<GU-T>JF' OA7A6TA80&R 4S2K2K%+1N:='L.4=6A+C#J%-N(4)A25"1!'
M<(BIRG_#MF/+M7D-Q]VHH;9FJFJUNV[AEE:F67J525.-XB2,>YW)XE*N>V;:
M[>6\Q[1KO3HHE5+#' 4E#1(5B32TC9)4$8N^4M7?+(F1/$5;0\_W*KIWZ7.-
MQH:RD:9"\;**:G+2@YB $R3HPDB7Z(V>Y]MM53L4F3[A75E6TZ%\(\BIIN!2
M&\((F#I.(C1^B&<LY$N]9DV[Y8RREZ[WRW.2JZUBK>G3TB&U M%MI6)Q2UA6
ME6 )T!45&VNU;3JW,;%I>IC566_T=*6:YMYY#1::=:2AQMSOIIPS)E%HK*6N
MJ,NYLM#[-WL=T93C=H:L)!DM!D'$'P5H,IR![4H7D/..;LI6BR52#3UMTL5!
M6&Z.,*&%80'EAAM;B9@J0$X"9HW(N'\..S$LVVF7:A;J%=45*0DA865NJ0"H
MJ6H%2U!.E2B9=J+EL8M-53L7.LM#-N;J7\? A;80"I6$%6$X>T"?:B@LKR@M
MRCI6*=2D[BBVV$DB?:,HVDYASBZQ=*"[WR^9JX"F2J?DKS066%A8TKD@@RFG
M3NQ:,W9?VDW[*]HO0=N5OL5K6U54ENHZEQ3C-,VY4H4LJ0E7?GO1BF,.C$;Q
M_#?M"S ,Y4-/86;_ $=W72-4U53!;_ FEJ0SWBB9XT*("B-.X0$_Y::=@I2H
M+"N^[@!'_7'RC?Z3[D?*-_I/N0W2ND%2 9D;FDD^QE>V62MIZ)RPYJME_=54
M)60XU1AP*;3A![\X]$Y#1I(C(68+55T],QE/,3=YJD/!>)UI#:DX&\((Q3/[
M4A+M]HWS*-$XAFHNMLK:%MQR90A=0RIM*E2TR!5,RC+>SJ[/M5-;9;934+SS
M&+@UK:0$DIQ &1EHF 8SN1VLNW3YLN,JU.Q',ECKLMWG+]MN H,V,U3CENJ:
MFF0XZ*5VE(*F5+45);<T-^"GMDW>]9GNBK_G?,U9]87R[J:#(>="<*&FFP3@
M9:$PA/MDR DE.?<QW6JIZAG-F8#=J5#&/$TT64-X7,0 Q32?!F)2T]H6NNLM
MS<L.<LN5@N-AO#38=-,_(!:5MD@.-.@ .()TR&Z 4E-DK<RY$M;:A@7=:&VU
MU16)&YC2P^L4Y7VY$89^U&:Z6N?-54M4%&AVH4D(+JTU+(4LI3H3B.F0T"<A
M"<D[)\VV"NRF64"VU>9J:I>NMN:4D?NDK9(:J U_V1>$]Q*AA2!%XV)W*K?N
M2LR(KG+Y=7 $5%95UP(=J" 3A(T8$S5()$RHXB:+8];LXY89RO;VD4%-?46^
MI5>FZ%L!+:4M*5Y+PB4 (2I6*0 )Q*TQ49!NMP%T6J[W"N:JBI2G%LU#N)LN
MJ4$S=PR+A EB)D2(KLJWZJIZNIJ[Y=+HERFQX W6/EQ"3C .(#PNU/<)W8H_
MXA=@]WMMOS4FV&RW*AO3+SM#74?"<(G$ID\(VM"I$%&[A3I Q!>3]KFUK-5L
M>J\M7<U2;):F'F;:Q2EE25%HN8WG:A:\$UNE*4HQ!/<C+V8MGMRI[5G/*5U1
M=;4]6MJ=I'%82AQE]*>_P+2=U/?"6C=F,V9!VLW&P#,M_HZRBHU6=BI10TS3
MS'!HQ%Y2G5G%B4H]J<@#*+=_#]GXIN% U8::S5RV2I <+3*4%;9.E)"DXD$Z
M00#*&]GN1\VY2N^7*) IK?<+_0UGUFS3I&%M"@PL,N%I,@E2\6*7?=R+E67:
MY.W[..8:OZPOUZ?0&UU51*24H;22&VFP2&T R3,]V0SS=;O54]2WFG,U3>Z9
M+ 6"TRZTV@(<Q =^"@SPS$I:>T,D;8J2KIVK=E:CO%/44RPOAG55[26T%N0P
MR21-4R/:G[%GVO;*KRG+NTBP-N4U+6/-</2U5(X25TM4U.9;))*5"9022 3A
M*6<E_P 0.9<NT.1BZVY<:#*=-6-U%Q0VH*##K]4LEMLJ *N#TF4I=L94RWE-
MVEMU-ES,EFN_!NI4$>2VY<RTV$ R5AD$ ][HD2/9VH[3-A^8::W7YC/=RH*R
MUWEMQZTUU,EMIQ!<2U)UIYM2U%+K9F0<![V<Z?;M_$1=[;<\PVJE>H[':[-3
MNMVZW(?T.O)4^2ZX\XGO2I6X-PF2 C+&VABJIT6NQV:Y6YZF5CX=;E6I)2I,
MAAP@ SF0>X#/0U_$'L$N]KHLQOVQ-GNMNOK#SE#64Z%XT*QL'A6W$$#P=!PI
MF98@O)^V?:UFJW55;ERX5#OU-;&'6+;3TSM,ML^3\)C==?4X4E2W5)DCO4[@
M!RWMI8JJ=%KLEEN-M>IE8^'6Y5+24J3(8<( ,YD'N ST7S978:IBBKKJFF#;
M]2%%I/ U+;QQ8 5:0@@2&[%7LFL=934=?4*MY%14!9: I7VW5:$ JTA! T;N
M[[%9DS,=335SU3>+I<<5.%<'P58^IQ*"%@&829*T2GH!.[%98/X<;]EU_(=3
M4O5=+9<STU43;E/J*UMT[U(H*4T5DD)7X/<*BI2J^\[;LQ6RYNU:6DTMMLU
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AF:\/WNM%0XE834OH0A0;DE.%$D"0.(SGWW<__6;_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915233811248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,079,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915145804544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 97,312<span></span>
</td>
<td class="nump">$ 46,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">5,303<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">102,615<span></span>
</td>
<td class="nump">52,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">442<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">104,155<span></span>
</td>
<td class="nump">54,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,767<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,419<span></span>
</td>
<td class="nump">18,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,146<span></span>
</td>
<td class="nump">24,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,579<span></span>
</td>
<td class="nump">25,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 and 130,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively, and 90,079,016 and 45,177,730 shares issued and outstanding as of March 31, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">519,757<span></span>
</td>
<td class="nump">436,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">4,287<span></span>
</td>
<td class="nump">3,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(440,476)<span></span>
</td>
<td class="num">(410,892)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">83,576<span></span>
</td>
<td class="nump">28,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 104,155<span></span>
</td>
<td class="nump">$ 54,299<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915148712464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,079,016<span></span>
</td>
<td class="nump">45,177,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">90,079,016<span></span>
</td>
<td class="nump">45,177,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915237103472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 18,736<span></span>
</td>
<td class="nump">$ 22,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,145<span></span>
</td>
<td class="nump">4,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,881<span></span>
</td>
<td class="nump">27,251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,881)<span></span>
</td>
<td class="num">(27,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts', window );">Change in fair value of the tranche rights</a></td>
<td class="num">(4,796)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(2,094)<span></span>
</td>
<td class="nump">1,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(5,703)<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,584)<span></span>
</td>
<td class="num">$ (25,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">97,299,955<span></span>
</td>
<td class="nump">43,664,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">97,299,955<span></span>
</td>
<td class="nump">43,664,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144229328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,584)<span></span>
</td>
<td class="num">$ (25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (29,056)<span></span>
</td>
<td class="num">$ (24,496)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915234056144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>January 2024 PIPE Transaction</div></th>
<th class="th"><div>At The Market Sales Agreement</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>January 2024 PIPE Transaction</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>At The Market Sales Agreement</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>January 2024 PIPE Transaction</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At The Market Sales Agreement</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="num">$ (317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 91,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">429,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="num">(342,552)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">45,177,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,177,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 28,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,759<span></span>
</td>
<td class="num">(410,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(29,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,751,286<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,364<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,360<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Conversion of tranche rights liability to equity</a></td>
<td class="nump">$ 28,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">90,079,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,079,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 83,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,287<span></span>
</td>
<td class="num">$ (440,476)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 51<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-51<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915145952016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_January2024PIPETransactionMember', window );">January 2024 PIPE Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 4,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember', window );">At The Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_January2024PIPETransactionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_January2024PIPETransactionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146750320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (29,584)<span></span>
</td>
<td class="num">$ (25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ChangeInFairValueOfTrancheRights', window );">Change in fair value of tranche rights</a></td>
<td class="nump">4,796<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Fees expensed as part of January 2024 Financing</a></td>
<td class="nump">1,690<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">389<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(6,145)<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(23,969)<span></span>
</td>
<td class="num">(19,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Sale of investments - other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock through At The Market Sales Agreement, net</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of pre-funded warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from January 2024 Financing, net of issuance costs</a></td>
<td class="nump">74,273<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">74,464<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">50,638<span></span>
</td>
<td class="num">(13,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">46,674<span></span>
</td>
<td class="nump">106,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">97,312<span></span>
</td>
<td class="nump">92,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares', window );">Conversion of tranche rights liability to equity upon increase in authorized shares</a></td>
<td class="nump">28,396<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ChangeInFairValueOfTrancheRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Fair Value of Tranche Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ChangeInFairValueOfTrancheRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Tranche Rights Liability to Equity Upon Increase in Authorized Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144330368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company had approximately 80 employees as of May 1, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome and irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $440.5 million as of March 31, 2024 and $410.9 million as of December 31, 2023.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2024, Immunic has raised net cash of approximately $430.9 million from private and public offerings of preferred stock, common stock, pre-funded warrants and tranche rights. As of March 31, 2024, the Company had cash and cash equivalents of approximately $97.3 million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the </span></div>instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 22, 2024. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915141756336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S. of approximately $73.2&#160;million, Germany of approximately $22.5&#160;million and Australia of approximately $1.6&#160;million as of March 31, 2024. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.2% during the period ended March 31, 2024. Cash and cash equivalents in Germany are earning interest at a rate of 3.5% to 3.75% during the period ended March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-240">three</span> to thirteen years. Depreciation expense was $26,000 and $32,000 for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three months ended March 31, 2024 and 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $36,000 and $1.8&#160;million of <span style="-sec-ix-hidden:f-254"><span style="-sec-ix-hidden:f-255">other income</span></span> related to research activities performed during the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2024 and 2023, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2019 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants and Tranche Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, financial instruments are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If financial instruments do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the financial instruments should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified financial instruments are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the financial instruments after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If financial </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments do not require liability classification under ASC 815-40, in order to conclude financial instruments should be classified as equity, the Company assesses whether the financial instruments are indexed to its common stock and whether the financial instruments are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified financial instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. The weighted average shares outstanding calculation for basic and diluted earnings per share for the three months ended March 31, 2024 includes 11,193,564 pre-funded warrants.  </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147764752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-305"><span style="-sec-ix-hidden:f-306">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147681088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 for the research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $257,000 and $195,000 for the three months ended March 31, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2024</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:83.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium and IMU-856 totaling approximately $3.0&#160;million, all of which is expected to be paid in 2024 and 2025.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915237131696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.2% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2024. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded tranche rights of $23.6&#160;million at January 8, 2024 as a result of the January 2024 Financing (see note 6).  The fair value measurement of the tranche rights associated with the January 2024 Financing was classified as Level 3 under the fair value hierarchy.  The fair value of the the tranche rights was determined using a Black Scholes Option Pricing Model. The inputs to this model included a risk-free rate range of 3.93%-4.36%, a stock price volatility range of 105-115%, an expected dividend rate of &#8212;% and remaining term of 1.81-4.81 years.  This liability was revalued on March 4, 2024, upon approval to increase its authorized shares of common stock from 130&#160;million to 500&#160;million, which resulted in the reclassification of the tranche rights from a liability to equity.  This revaluation resulted in an increase in the tranche rights liability of $4.8&#160;million using a Black Scholes Option Pricing Model. The inputs to this model as of the date of the reclassification included a risk-free rate range of 4.16%-4.63%, a stock price volatility range of 90-105%, an expected dividend rate of &#8212;% and remaining term of 1.66-4.66 years. The inputs used in the determination of fair value of the liability are level 3 inputs.  A rollforward of the fair value of the tranche rights is as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.818%"><tr><td style="width:1.0%"></td><td style="width:66.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of January 8, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value through March 4, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to equity</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,396)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147772544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, we filed a shelf registration statement on Form S-3 (the "2023 Shelf Registration Statement").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The 2023 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of May 8, 2024, the 2023 Shelf Registration statement has not been declared effective by the SEC, however, the Company can (i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expired 2020 Shelf Registration Statement until the 2023 Shelf Registration Statement has been declared effective (or May 22, 2024, if sooner); and (ii) after the 2023 Shelf Registration Statement has been declared effective, offer and sell additional securities registered on the new Form S-3, as well as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">unsold securities from the expired 2020 Shelf Registration Statement that are permitted by SEC rules to be included in the 2023 Shelf Registration Statement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2020, the Company filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement"). The 2020 Shelf Registration Statement permitted the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. The 2020 Shelf Registration Statement expired in November 2023 but, as explained above, unsold securities from this expired registration statement can continue to be sold under the 2023 Shelf Registration Statement. As of March 31, 2024, there is $75.0 million of unsold securities from this 2020 Shelf Registration Statement.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners LLC) as agent ("December 2020 ATM"). The Company has used and intends to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, $7.3&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company filed a Prospectus Supplement to the 2020 Shelf Registration Statement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with Leerink Partners LLC (formerly SVB Leerink LLC) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of March 31, 2024, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, we raised gross proceeds of $0.2&#160;million pursuant to the December 2020 ATM through the sale of 150,000 shares of common stock at a weighted average price of $1.31 per share. The net proceeds from the December 2020 ATM were $0.2&#160;million after deducting sales agent commissions of $6,000. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private Placement of up to $240&#160;million ("The January 2024 Financing")</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2024, Immunic entered into a Securities Purchase Agreement with select accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a three-tranche private placement shares of the Company&#8217;s common stock, $0.0001 par value per share or in lieu thereof, pre-funded warrants to purchase shares of Common Stock. The Pre-Funded Warrants are exercisable immediately for $0.0001 per share and until exercised in full.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The first tranche, which closed on January 8, 2024, resulted in the purchase by the Investors of an aggregate of $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.43 per share;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The second tranche is a conditional mandatory purchase by the Investors of an additional $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.716 per share, equal to 120% of the price paid in the first tranche and is subject to the satisfaction of three conditions:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">the 10-day volume-weighted average price of the Common Stock is at least $8.00 per share during the 6 months following the data release; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">aggregate trading volume during the same 10-day period is at least $100&#160;million.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The third tranche must occur no later than three years after the second tranche and is conditioned on the same volume-weighted average share price and minimum trading volumes as the second tranche. The third tranche provides for the issuance of $80&#160;million of shares of common stock (or pre-funded warrants) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a &#8220;cashless&#8221; or net settlement basis, which would reduce the cash proceeds to be raised by the Company in the Private Placement.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the conditions in the second or third tranches can be waived by holders of a majority of the outstanding securities (including the lead investor).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Private Placement resulted in gross proceeds to the Company of approximately $80&#160;million in the first tranche, and an additional $80&#160;million if and when the second tranche occurs. If the second tranche is completed and conditions for the third tranche are satisfied or waived, the Company could receive up to an additional $80&#160;million in the third tranche. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the closing date of the transaction of January 8, 2024, the Company did not have enough authorized shares to be able to issue the potential shares for tranche 2 and tranche 3 (collectively referred to hereafter as "the tranche rights").  Therefore, the Company recorded the value associated to the tranche rights as a liability of $23.6&#160;million and allocated the remainder of the $80&#160;million received (or $56.4&#160;million) with the common stock and pre-funded warrants to equity.  On March 4, 2024, the stockholders voted to increase the Company's authorized common shares from 130&#160;million to 500&#160;million shares.  As a result of the ability to issue shares in satisfaction of the tranche rights, the instrument was reclassified to stockholders' equity.  The Company allocated the transaction cost across the instruments on a relative fair value basis at the grant date. As a result $4.0&#160;million was netted against the equity proceeds and $1.7&#160;million  was recorded in other expense in the Consolidated Statements of Operation for the three months ended March 31, 2024.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company registered for resale by the investors in the January 2024 Financing up to 55,944,850 shares of common stock issued (or issuable upon exercise of pre-funded warrants) in the first tranche. The Company will not receive any proceeds from the sale of these shares of common stock. These shares are registered on a registration statement on Form S-3 (registration No. 333-277040), which was declared effective by the SEC on April 30, 2024. </span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the stockholders of the Company voted to increase the authorized shares of the Company from 130,000,000 shares of common stock to 500,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. </span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through March 31, 2024, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-funded Warrants</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issued 11,193,564 pre-funded warrants in connection with the January 2024 Financing, which all remain outstanding as of March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, rights and preferences to be set by the Board of Directors. No preferred shares were issued or outstanding as of March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2024 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares reserved for tranche 2 rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,620,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Maximum shares reserved for tranche 3 rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,620,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,973,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147687536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans <div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares initially reserved for delivery under the plan was 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This maximum number was increased by 1&#160;million shares through approval by stockholders of the Company at the Company's Special Meeting of stockholders held on March 4, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 199,989 shares life-to-date under the ESPP.   The Company recognized $0 and  $46,000 of expense related to the plan during the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan, as amended on June 28, 2023 (the &#8220;2019 Plan&#8221;), which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  On March 4, 2024, the stockholders voted at the Company's Special Meeting to increase the allowable shares under the 2019 plan by 9,100,000.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-452">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Repricing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the Company's stockholders voted to approve the repricing of outstanding stock options having an exercise price above $3.00 per share to $1.72 per share.  All other terms of the grant remained the same. There were 3,317,596 stock options that were repriced to $1.72 per share.  The repricing will result in an addition $1.2&#160;million of stock compensation being recognized by the Company over the remaining term of the repriced grants and $0.9&#160;million of this amount recognized in the quarter ended March 31, 2024.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2024 and 2023, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,196,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repricing Modification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan (excluding the repriced stock options) during the three months ended March 31, 2024 and 2023 was $0.97 and $1.15, respectively. The weighted average grant date fair value of the repriced stock options was $1.22.  The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:72.529%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, there was $13.5&#160;million in total unrecognized compensation expense relating to the 2019 Plan, including $0.3&#160;million related to repriced stock options, to be recognized over a weighted average period of 3.17 years.  There was $0.6&#160;million and $0.3&#160;million of stock-based compensation expense during the three months ended March 31, 2024 related to the repricing included in general and administrative and research and development expense respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#8220;Vital&#8221;) following an exchange transaction (the &#8220;Transaction&#8221;) with Immunic AG.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#8217;s 2012 Stock Option Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of March 31, 2024.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three months ended March 31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144370960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#8217;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#8217;s monthly base salary to $32,368 from $30,250 (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915236988416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.</span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the </span></div>instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 22, 2024. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock', window );">Cash and Cash Equivalents and Investments- other</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments- other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S. of approximately $73.2&#160;million, Germany of approximately $22.5&#160;million and Australia of approximately $1.6&#160;million as of March 31, 2024. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.2% during the period ended March 31, 2024. Cash and cash equivalents in Germany are earning interest at a rate of 3.5% to 3.75% during the period ended March 31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-240">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government assistance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $36,000 and $1.8&#160;million of <span style="-sec-ix-hidden:f-254"><span style="-sec-ix-hidden:f-255">other income</span></span> related to research activities performed during the three months ended March 31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2024 and 2023, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2019 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Warrants and Tranche Rights</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants and Tranche Rights</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, financial instruments are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If financial instruments do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the financial instruments should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified financial instruments are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the financial instruments after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If financial </span></div>instruments do not require liability classification under ASC 815-40, in order to conclude financial instruments should be classified as equity, the Company assesses whether the financial instruments are indexed to its common stock and whether the financial instruments are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified financial instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div>Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. The weighted average shares outstanding calculation for basic and diluted earnings per share for the three months ended March 31, 2024 includes 11,193,564 pre-funded warrants.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147787872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915236160848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expense consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research grant</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,860&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,099&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-305"><span style="-sec-ix-hidden:f-306">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144281616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Obligation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of March 31, 2024</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:83.833%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.752%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,223,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147735536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Fair Value of Tranche Rights</a></td>
<td class="text">A rollforward of the fair value of the tranche rights is as follows (in thousands):<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.818%"><tr><td style="width:1.0%"></td><td style="width:66.928%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of January 8, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value through March 4, 2024</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,796&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to equity</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,396)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146472544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Shares Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at March 31, 2024 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,193,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Shares reserved for tranche 2 rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,620,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Maximum shares reserved for tranche 3 rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,620,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,131,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,973,057&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144330896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the quarters ended March 31, 2024 and 2023, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,196,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,175,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repricing Modification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,318,323&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,224,039&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,815,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,161)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,595,841&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888,367&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.67</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.02</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:72.529%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,750,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,979,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915237089744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">99 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>May 01, 2024 </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfDevelopmentPrograms', window );">Number of development programs | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (440,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (410,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">430,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 97,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,674<span></span>
</td>
<td class="nump">$ 92,761<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915250867520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>lease </div>
<div>financialInstitution </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>lease </div>
<div>financialInstitution </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 97,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,674,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount', window );">Australian research and development tax incentive</a></td>
<td class="nump">676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 670,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing operating leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-funded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised (in shares) | shares</a></td>
<td class="nump">11,193,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,193,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 73,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount', window );">Australian research and development tax incentive | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent', window );">Government R&amp;D assistance rate</a></td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Germany | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Germany | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance, Qualified Research and Development Expenditures, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance, Qualified Research and Development Expenditures, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfFinancialInstitutionsUsedForCashDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915145677552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock (in shares)</a></td>
<td class="nump">10,318,323<span></span>
</td>
<td class="nump">5,595,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915238138720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 2,767<span></span>
</td>
<td class="nump">$ 2,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount', window );">Australian research and development tax incentive</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentGrant', window );">Research grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 5,303<span></span>
</td>
<td class="nump">$ 5,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance, Qualified Research and Development Expenditures, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915141760112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 6,211<span></span>
</td>
<td class="nump">$ 4,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 6,767<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146363312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 11,497<span></span>
</td>
<td class="nump">$ 16,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,419<span></span>
</td>
<td class="nump">$ 18,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146679744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915141023104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease cost</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option period (in months)</a></td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod', window );">Lessee, operating lease, extended rent holiday period</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember', window );">Planegg, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915253225216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of obligation</a></td>
<td class="nump">$ 1,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915145840256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 72,961<span></span>
</td>
<td class="nump">$ 34,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">72,961<span></span>
</td>
<td class="nump">34,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">72,961<span></span>
</td>
<td class="nump">34,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">72,961<span></span>
</td>
<td class="nump">34,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146592384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Fair Value of Tranche Rights (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">December 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value as of January 8, 2024</a></td>
<td class="nump">23,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value through March 4, 2024</a></td>
<td class="nump">4,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">(28,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">March 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification to Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146506656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_TrancheRightFairValueDisclosure', window );">Tranche right, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement', window );">Reclassification of future tranche right liability upon settlement</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.16%<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
<td class="text">1 year 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_TrancheRightFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche Right, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_TrancheRightFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915145939280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays', window );">Shelf registration, termination, prior written notice, number of days | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares) | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance of stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays', window );">Shelf registration, termination, prior written notice, number of days | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice, Number of Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915139722560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Equity Offering (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">99 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Jan. 04, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Mar. 03, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement', window );">Reclassification of future tranche right liability upon settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts', window );">Change in fair value of the tranche rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,796<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_EquityMember', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts', window );">Change in fair value of the tranche rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts', window );">Change in fair value of the tranche rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement', window );">Reclassification of future tranche right liability upon settlement</a></td>
<td class="nump">$ 23,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Pre-funded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Accredited Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Accredited Investors | Common Stock | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_CommonStockNumberOfSharesRegisteredForResale', window );">Number of shares registered for resale</a></td>
<td class="nump">55,944,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Accredited Investors | Common Stock | Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockConsiderationReceivedPercentage', window );">Sale of stock, consideration received, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation', window );">Threshold trading days for weighted average price calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_WeightedAveragePriceOfLast10Days', window );">Weighted average price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation', window );">Threshold trading days for aggregate trading volume calculation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days', window );">Aggregate trading volume of last 10 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Accredited Investors | Common Stock | Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockEquityOfferingsPeriod', window );">Third tranche close period after second tranche (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_CommonStockAndPreFundedWarrantsMember', window );">Common Stock and Pre-funded Warrants | Common Stock and Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_TrancheRightsAsALiabilityRemainderAmount', window );">Tranche rights as a liability, remainder amount</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_TrancheRightsAsALiabilityReceivedAmount', window );">Tranche rights as a liability, received amount</a></td>
<td class="nump">$ 56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_CommonStockNumberOfSharesRegisteredForResale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number Of Shares Registered For Resale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_CommonStockNumberOfSharesRegisteredForResale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockAggregateTradingVolumeOfLast10Days">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Aggregate Trading Volume of Last 10 Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockAggregateTradingVolumeOfLast10Days</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockConsiderationReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockConsiderationReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockEquityOfferingsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Equity Offerings, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockEquityOfferingsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold Trading Days for Aggregate Trading Volume Calculation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold Trading Days for Weighted Average Price Calculation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_TrancheRightsAsALiabilityReceivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche Rights as a Liability, Received Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_TrancheRightsAsALiabilityReceivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_TrancheRightsAsALiabilityRemainderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tranche Rights as a Liability, Remainder Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_TrancheRightsAsALiabilityRemainderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_WeightedAveragePriceOfLast10Days">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Price of Last 10 Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_WeightedAveragePriceOfLast10Days</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_EquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_EquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=vtl_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=vtl_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915254216960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>numberOfVote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 08, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfVotesPerEachShareOfCommonStock', window );">Number of votes per each share of common stock | numberOfVote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfVotesPerEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Per Each Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfVotesPerEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915147702496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Pre-funded Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-funded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares issued from exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">11,193,564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915146283824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915148468816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Schedule of Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">124,973,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,620,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,620,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">10,318,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">1,000,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_PreFundedWarrantsMember', window );">Pre-funded stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">11,193,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,131,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915138879376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">48 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares', window );">Options repriced (in shares)</a></td>
<td class="nump">3,317,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice', window );">Stock-based compensation, exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Recognized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions', window );">Weight average fair value repriced stock options (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,750,000<span></span>
</td>
<td class="nump">$ 1,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
<td class="text">4 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
<td class="text">1 year 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued under the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee stock purchase plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increase in other share (in shares)</a></td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value for Repriced Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation By Share-Based Payment Award, Options, Repriced, Number Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Option, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915141019232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod', window );">Repricing Modification (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice', window );">Repricing Modifications (usd per share)</a></td>
<td class="nump">$ 9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">6,196,140<span></span>
</td>
<td class="nump">3,791,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">4,175,349<span></span>
</td>
<td class="nump">1,815,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(53,166)<span></span>
</td>
<td class="num">(11,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">10,318,323<span></span>
</td>
<td class="nump">5,595,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Ending balance (in shares)</a></td>
<td class="nump">10,318,323<span></span>
</td>
<td class="nump">5,595,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Ending balance (in shares)</a></td>
<td class="nump">3,224,039<span></span>
</td>
<td class="nump">1,888,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 11.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">1.21<span></span>
</td>
<td class="nump">1.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">5.25<span></span>
</td>
<td class="nump">13.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="nump">8.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">1.68<span></span>
</td>
<td class="nump">8.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="nump">$ 12.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
<td class="text">8 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance</a></td>
<td class="text">7 years 2 months 23 days<span></span>
</td>
<td class="text">7 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 462,223<span></span>
</td>
<td class="nump">$ 161,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">462,223<span></span>
</td>
<td class="nump">161,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value, Ending balance</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="nump">$ 1,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Modification in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Repricing Modifications Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915148727216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 04, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">3.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">102.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
<td class="text">6 years 7 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915144221232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">$ 1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,163<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">$ 1,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139915235982208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Duane Nash, MD, JD, MBA - Executive Chairman Agreement - Board of Directors Chairman - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryAndWageOfficerMonthlyBaseSalary', window );">Salary and Wage, Officer, Monthly Base Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryAndWageOfficerMonthlyBaseSalary', window );">Salary and Wage, Officer, Monthly Base Salary</a></td>
<td class="nump">$ 32,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryAndWageOfficerMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary and Wage, Officer, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryAndWageOfficerMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (<ZJ%@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "'.JA8ABKK4N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NND8&E&7"]-.("$Q"<0M2KPMHDFCQ*C=V].&K1."!^ 8^\_G
MSY(;'83N(C['+F DB^EF<*U/0H<U.Q(% 9#T$9U*Y9CP8W/?1:=H?,8#!*4_
MU &AKJH[<$C**%(P 8LP$YELC!8ZHJ(NGO%&S_CP&=L,,QJP18>>$O"2 Y/3
MQ' :V@:N@ E&&%WZ+J"9B;GZ)S9W@)V30[)SJN_[LE_DW+@#A[>GQY>\;F%]
M(N4UCK^2%70*N&:7R:^+A\UNRV1=U;=%M2RJU8YSP>_%<O4^N?[PNPJ[SMB]
M_<?&%T'9P*^[D%]02P,$%     @ ASJH6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MN8>']O&(BQT\1CB%T7%+H^,>2>>\8]PF< ]2'I'[;$WZX4%U&4O3X^)>90"
M?@X9<FN7/")P<!#B<77!2J_CXLYD9W+V^R>6>C\BUVQ2UG3M+7@*L^/NG7Y5
M,CM#@%4 .HI]\4I^$]8)]8B4V7JPGG-Q8=TIX\'_E[.U=RAJ%KSLK#@AGLG
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M V4#\/U<2O/2L3>,^D89_@502P,$%     @ ASJH6*S#Q2XK!   $ \  !@
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M@S0!^'XFA-YLS ?:^9_^!5!+ P04    " "'.JA8KWB?1H((  #O4@  &
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ML"LYC/&@$A3'_/;Z%JS&SM_;I$K^NE(@WTV^,O"=TP](E8S/1Z;4":+OUJ:
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MI;P2FA@GI[YEP)-S'$X\/7;/ F82'_O5<8V?15)TI%R[K-TY3>=)@]:ZVFW
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M0R\2Q/6>6'8Q8<FT8X>#EP-E;J L$?:.RP\([0!O:: JA09QJR;O&,QM$P2
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M':44=%^B6_$KQ;F+T37\<:DP]YX$\'OM0/KR%S+0OV.^^C=02P,$%     @
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M.J:Q29-G%"81+^@KGOAV7& +4U5="5DEYB;-@N4NOGWW]N?KR-;BSB6>)N:
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M5*YAFCJ.\UK3XL>%K)>HC3$KK?XU$4<9D#;<8^74N\5K#A"D^BO &6*W5XM
MNT(?$Z?"V&(HQ:;\0X_&SN,%3*CQI',FT]P61__J4N/!"RH_.=-Y=/DGJ,3/
MVNZ ? I)(9/US4YH-.=AUD /4A-%4\X9K9Z<G@VF]:LX& J1FC8[//G866LJ
M;@<&5+Z'3F&:6HVWUX%[9Z*("$K+Z3]1#+68K1F[+2F7 :-)*P%HG+:9*2YC
M+Y,Q>FNY:YTU7A!)PDVWJY5-Q0<9T+![6X760M)=99;#8II#ANZ$$Q&_:]21
M=E]=TZ3.GAE'/0IC3/>HB.)([)*O;1=2URT! W:=4&[)$!Q,7?&?3),1!+$-
MU&=8N*4!1-@;>&W!C:Q,]6%G7^.O5 3QD(;*HM*I.M+?&KI]XEG8O)V5<KQ_
M1/H*_?[BL6U]5W/)O3!1@&S4G,?$H],^S.]M+2-BG9[VGTVG_8O3O1U]'+!2
M4'#B)_#@453=V=".G<E]%])W!>&)(,%6#:/T</=()KIBIWM+^63"[5N"\.[U
MN7S4S7)GS8]F(":3R?'X_'PX'3YMJ@'8_^"G$T0RU,.386V_3FW["%3H-L9[
M0&(;X3>VU1!!LX]#8YN ' ^LZB<->!@F=;O>8%MPRG< <TU58QE2;JX15'.9
MS+1J3G?+NW,0$/)R\I4)"%.7%C GJK^&J)59$]D(T<A1-,:,W62G:-JXJ!^(
M=Q*&B<.%#351DO3\)43#.3%"]_5D(':SG-I:@(KE/K"> =-\)BS9+6=J^\99
M.@[!0XAP/M.K0Z;6L^-+^SA2;MPS:N6-D:@[</;W&OO"N(>+*L;D,.7;'"2B
M9>$RMSD Q<5\XXL6JNO1#0]X;++8&)MTKD,"BHQ&_=&S2?_T;+HS<6K^2J",
MGU8V27<W@M7A2!H/B;U3[LH=0VCF,UH[1.+G73ZGK \S6387(BY>FH I5C*Z
M%>:;G MQ0DB"XK )1M<)P2;%CC<S<R>(VM'6YH<C=;6SX<GQ*PIT+7MM/ ""
MI?3"J>OPO03;@^Z''M19T-2G\"%@2#GO*U^!RE7="=X$TC9=LPAKVJL<OT%9
MQ"XO=.[NN?BQXH%O.]0)4=>AVI##C^=$9B3>H;@W]RH":-O\K7+4XZ, :J-1
MZJ)A8>-VB5=^3!LF7F56H548#?N3T45_PI^I;$O;5LO17M.S_MD8)T_/(':X
M\70']DUV[.MHH>9#WDF=<Q9.E,SU#JEC-*TGT5=04LF)Z9KT,)V _1&M.,<K
M:F0Y^>U9?-8?HR+ XF?B8U'J6>7VK'S6'\&<I\,S\=EXOE],*]2#_C "R#P[
MG_2'I^=BUR>O)\GGQX6RM_R1-66$JO3A2^3F:?,=]^OP^7*[/'P$#K^[I0NF
M7"VP=3@X/^T%==<_O%GQQ\PSX[TI^,\EFF)E:0'>+PRP._Z@ YJOVU_]!U!+
M P04    " "'.JA8;O4.@\0.  #!*0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6RM6OMOV[86_E<(+]T20%$LO]T7D*[=;H?;+4BR#1<7]P=:HFVB
MDJB24ESOK[_G'%+4PTJZ=0.V1K;(P_/\SD?2+P]*?S1[(4KV.4MS\VJT+\OB
M^=65B?<BXR94A<CAS5;IC)?P4>^N3*$%3VA2EEY-QN/%5<9E/GK]DKZ[T:]?
MJJI,92YN-#-5EG%]?"-2=7@UBD;U%[=RMR_QBZO7+PN^$W>B_+6XT?#IRDM)
M9"9R(U7.M-B^&EU'S]_,<#P-^$V*@VD],[1DH]1'_/ ^>34:HT(B%7&)$CC\
M>1#?BS1%0:#&)R=SY)?$B>WG6OH/9#O8LN%&?*_2WV52[E^-5B.6B"VOTO)6
M'?XEG#USE!>KU-"_[&#'SJ8C%E>F5)F;#!ID,K=_^6?GA]:$U?B1"1,W84)Z
MVX5(R[>\Y*]?:G5@&D>#-'P@4VDV*"=S#,I=J>&MA'GEZ[M2Q1\OWX!="?M>
M91!KP\E=-RG/S<NK$M; D5>QD_?&RIL\(F_*/JB\W!OV+D]$TIU_!;IY!2>U
M@F\F3PK\P'7(IE' )N/)[ EY4V_PE.1-'S-XS[5P!M_P(^17R:ZUYOE.T/-_
MKS>FU) L_QLRWLJ>#<O& GIN"AZ+5R.H$"/T@QB]_O:;:#%^\83F,Z_Y["GI
M7Q&JOR,/_1VQ=UF1JJ,0C :SFTK'>YA 0]@O.;LNM$S99$[A@2"5>T&R>'YD
M/%%%";+QNR\+.Q^]N[NY&5T$[+"7\9X=N&&\*+1Z !&;(S,X9Z_21&CVH$K!
M>-E(OL[SBJ?L U2!S'=,;>T2=KAA>Y$F# S[J<H%B\96V9#=PW1<E.$J,A&&
MB53NY"853#A5#<IJ&W60Y9Z!NJHHE"ZK7)9'5BI6U+;$*LM@)=*V/[?<:U7M
M8'H<5UF5<G1.P8]:I2D 25(13IG: 9"F3.9Q6L$K>& *1&F !*TQ35/)-S*5
MI005J[R$(,#K(TVJ,*!MG>KU#::^"=F[4RL+KDL9RX*3_V UU'LC+[EUK-IN
MA<8W!?Q1"8O! _%>*1 ."^WY ZQ:X"-.2X6!U$?CH_DSYP.IF1.%$,H$USF(
M ^]JFO+^]JY^3THVNJ<RDR4*.8,D&X_'J!O?[;38@?L "/5':%P//*U$QV1K
M:B\ WWZSFD3+%Z83))L&?B+D<RSJ>3:*TO3,.I<7;.5-8W&J#/K&*>,D6!<F
MJ"6,\_)YGL!\$/#H3)?7&[&3>>ZR^<EH6 N@)\BLREA>91NKIO.!A!R5/$V/
MS$%2PJ"70\*ET [U$;('2PI7*+ .L>Z@HY.OZX2YWX,/>@O@.$A/( +&%F@$
M[2E-$3_<PC[=J8HQ])TJ/BDM9[C[^)UA=X6(9;>LS5!90XN >IG9%F&]L97:
ME$SD6%L$ZRYQ>\9B(H@\%B3FNMI!OV6VU404J;9Z>S38F H&1^MUL%ZM:T-3
MN167I;JD8#<K(+18;6H16L1JE\L_0,39F!8XFRW(TV":^(P(+&"010973:1G
M4E&\\3-X%1 TLTU68)-U]M<]DN3"PS3 @!>":$]Z#!WJ_E)8C-=JIWEFV'N$
M14B.R3A:!X/5TO&YAV2+O=&:_9+E<E-!P_]4(1B^!W?FN"3!>L 0QC.K9XW
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MT=P17BL:]-!X 3K?:.T."W]!/SK._P%02P,$%     @ ASJH6)[ >)U9&@
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M*49[X^E&%/PR*/CEJ()_M@K9\\8VNL13#&GR?P:!M).9P"C#E\<(>J!_7HU
MK/YH-5@!.N>-D^NF1FE1(E,@<;!<A3V1+"!B;;EE"6TVLA%RM0*73!!82I$C
M9=!%%,D&N &ZM-2%;DCKU-T6!<*I#JS,M<V*VK:&3@D((S=1RGDYO9= P%,E
M*"-K9T^N[-?E:TIT*VO;@&9%_QB/> 3P(&F)'*GH5S6",*J 5Y",&7 1-BC
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MN\%H4JSB\38:_"%P9\\'"ADR( 00$3O*C\%D02A$&[:<FM=+K*\YU[YMG9/
M@*3_9EL=O@OQ=N50IS J(,2J3(HO#5IKFQF])/>*KJ& ]+ @H^, $=:EW".1
M6\L,<"1)H#X3[W"AF%'(.+_Z[[9&PTB<=$48"J&8SAP5@S,# F!HZZ)R]$<Q
M*)]ZD/YKYW0PU%P=ZG",M%DSJ*2$R9G*N]9K(W-(-@+P- T8@<"OS]WQWC)M
MDO@RX< ?G;-[F$%8@UA.A-($( >!R-"<4AW)_W7E++(O2AZ"M2 )E"8-D6^
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M^C0L"R1F"H])8AS^G8U/__Z43#!<=R<81@L[?QFJ^.D>LQ.^*!%+/T"#P6H
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MY28..,_&)Y,=;W]!\1\4E/LO[\1>VJ9Z#N*_K=T5&%J 99U"[GRIBTK9_9L
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M>].A&6?B,& D(QJ#$' %U]$-JU+4[,:7T+LUQ)Y0PQ.6ZY0]7H#B&&>X9C=
M5+H+0#>#C$H#H8FK"!3)-6%NR74:(=1XHNC,/VF,7J\59:,4XDZ#*NQ/D\,<
M%Q[7,J-J7-KR<44KT'[27:I)N7(O1SEDHRE=Z5_^AY@FE$1"_^&@FW0$I57C
M6-7=.IUMT7[./ G2;>?W#?H_E84Q$!4T(&7NB>C8+]3%2T/S\2L^/X-,8V%!
M?,1)?-2$(9O]%X%T<8M7@^9?N\:3L4=[RY8<F'B&QB^OZ1>RA@:&!Y'_VW?I
M3B@:#\ YG"1]M&%%<I&8DCC9R6,U6 E,23JE^'_=YZ>?A@A]EOS48JG,FGY0
MDN:*JX9_=3$\#3]:><T_U1A?YU^\A.!^C3]%4*@5+#V?/KD\X3JM_Z.IM_3#
MC>#+FKJDCQLEP<3@"_#]J@;WXO[ #<)/>;[\?U!+ P04    " "'.JA8ZJ3"
MO<L"   E!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-E6UOTS 0
MQ[_**4@(I+*D:3M&:2.U \0D-JJ5AQ>(%ZYS::PY=K"==?OVG)TT=%)7\2;Q
MP]W_?A?[+K.=-G>V1'3P4$EEYU'I7#V-8\M+K)@]TS4JVBFTJ9BCJ=G&MC;(
M\N!4R3A-DO.X8D)%V2RLK4PVTXV30N'*@&VJBIG')4J]FT?#:+]P*[:E\PMQ
M-JO9%M?HOM<K0[.X5\E%A<H*K<!@,8\6P^ER[.V#P0^!.WLP!I_)1NL[/[G*
MYU'B@5 B=UZ!T>L>+U%*+T08?SK-J _I'0_'>_5/(7?*9<,L7FKY4^2NG$<7
M$>18L$:Z6[W[C%T^$Z_'M;3A";O.-HF -];IJG,F@DJH]LT>NN_P/PYIYY &
M[C90H/S ',MF1N_ >&M2\X.0:O F.*'\H:R=H5U!?BY;MX<!NH"UV"I1",Z4
M@P7GNE%.J"VLM!1<H(57W]A&HGT]BQT%]NXQ[X(LVR#I,T%&<*V5*RU\5#GF
M3_UC NZITSWU,CTI>,W,&8R& TB3='Q";]1_A5'0&SVC=RS=7XN-=89NS>]C
M";=ZX^-ZOI*FMF8<YQ&5BD5SCU'V\L7P/'E_@G;<TXY/J6=KJLR\D>@/;:4=
M$CB3\A$^"-GX.PYKY(T1SF=QHQU<*2X;^O @%%PRR1O)0D60>W"AG1LJ_R_:
M6JC1P+ID!H\E?1+K>-*'?/F>S_9\ U $* X 78G GT+F':0B2+F'M!X2F'-&
M;!KG;R8X#5Q7%3E1V?"[4LL<C84-<M;8L)UKL)KZ1"-S6@:ZZ>+-GFH 0=!"
MH26U*CN%A?71Z:[QLK]L_C&"K[5GLUZR;FB;VL*3T#!,!J/AQ6!$MI/!Y-UD
M<#$>PK&CCP]*MT*S#0W*0KB.;17WJWT/7+2E_\^\;: $NA4$);$@U^3L[20"
MTS:E=N)T'1K!1CMJ*V%84A]'XPUHO]!T6-W$!^C_#-E?4$L#!!0    ( (<Z
MJ%A7S-*/M@,  -,)   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*56
MVV[;.!#]E8%:%"T@1*(DRW9J&[#3%ET@18TXVWU8[ ,MC6VBE*@EJ3C=K]^A
M)"M>U!6"S8/-BX9GSLP97F9'I;^; Z*%QT*69NX=K*VN@\!D!RRXN5(5EO1E
MIW3!+0WU/C"51IXWBPH91&&8!@47I;>8-7-KO9BIVDI1XEJ#J8N"ZQ\KE.HX
M]YAWFK@3^X-U$\%B5O$];M#^7JTUC8(>)1<%ED:H$C3NYMZ27:]29]\8?!-X
M-&=]<)%LE?KN!K_E<R]TA%!B9AT"I^8!;U!*!T0T_NXPO=ZE6WC>/Z%_:F*G
M6+;<X(V2?XC<'N;>Q(,<=[R6]DX=/V,7S\CA94J:YA^.G6WH058;JXIN,3$H
M1-FV_+'+PW,61-V"J.'=.FI8?N"6+V9:'4$[:T)SG2;49C61$Z4396,U?16T
MSBY67/(R0]@T%? !+1?2P-M[OI5HWLT"2SZ<99!U>*L6+_H%7@Q?5&D/!CZ6
M.>;_71\0MYY@="*XB@8!OW!]!3'S(0JC9  O[@..&[SX%WA?]9Z7XA_N:L*'
M&U4:)47.VQ(I<UAK-%C:=D+MX),H*4&"2]C0)%(]6@-_+K?&:JJHORYEJ"60
M7";@=MFUJ7B&<Z]ROO0#>HLWKU@:OA\(+^G#2X;0%QO:M7DMT5'_:@^HX:;6
MFDC#TA@DZEV,%1<Y?'RDO6W07 IBT,WE()[K#S+*NC#6<7PK2K '51NR,^^N
M@>3.#KW>5) 9%EM"[6;B'BLC2B(C69P#C9*TH4EER.5KB/QQ.F[:F"7P;7E/
M%AF*!U?5,!Z', YC6-9.0RFX.UT,-HX=6(X/=%953FFP_!$$[8_2G1V0CE/Z
MA7!W,M]K3D9O7DTB%KT'YK,PZ;+._' :NO]T"O?*$L_7,/)C<NO:21K"@-BC
M7NS1L\5>9IFJ76VN^8\F3!<*3>H:AX4>='%9Z)]\O430FY.0)_%2/V*,VL0?
M1RG<XKX3F=>YL)T58R.@'=,E.TD81"SN$YUV\H](A.E/27@1VQ/88/DQYB=3
M1X"E)/73(GDQEBA.B'WZ!*T*1[0]@5+FJBBA4$^?51/R> (L&O41L\A/V-1U
M)GZ:)D/%E?;%E?[/D^16\*V0PHK+!34(^YR3XPS_15K=(EW7(,_0J#0:7=+I
MJ(LI(GFB,>L3.:5,N__T8@J#LXNV0+UOGA..).V&]L[M9_L7R[*]J)_,V^<.
ML=^+TE!-[&AI>#6F?:C;)T0[L*IJKNVMLO0(:+H'>G6A=@;T?:>4/0V<@_X=
MM_@74$L#!!0    ( (<ZJ%BG-G"HHP(  . %   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;)U4WT_;,!#^5TX!(9 0^=724MI(M&P:TA 5L.UAVH.;
M7!H+Q^YLA[+_?F>GS8I4^K"7^,[V]]UWY]R-UTJ_F K1PELMI)D$E;6K41B:
MO,*:F0NU0DDGI=(UL^3J96A6&EGA0;4(DRBZ#&O&99"-_=Y<9V/56,$ESC68
MIJZ9_C-%H=:3( ZV&X]\65FW$6;C%5OB$]IOJ[DF+^Q8"EZC-%Q)T%A.@IMX
M-.VY^_["=XYKLV.#RV2AU(MS[HI)$#E!*#"WCH'1\HHS%,(1D8S?&\Z@"^F
MN_:6_;//G7)9,(,S)7[PPE:38!A @25KA'U4ZR^XR:?O^'(EC/_"NKW;3P/(
M&V-5O0&3@IK+=F5OFSKL (;1!X!D TB\[C:05WG++,O&6JU!N]O$Y@R?JD>3
M."[=HSQ93:><<#:;J;KFEJIL#3!9P$Q)R^429<[1P.DS6P@T9^/04BR'"/,-
M[[3E33[@3>&>F"H#GV2!Q7M\2!H[H<E6Z#0Y2'C/] 6D\3DD4=([P)=VB:>>
M+_VOQ&^YR84RC4;X>;,P5M/?\VM?%=H@O?U!7$>-S(KE. FH90SJ5PRRDZ/X
M,KH^D$*O2Z%WB#U[H@XM&H&@2KAGMM'<.NWD/:Q0,Y<.?$7Z9>%A(?B2N3;8
ME\/!*/MS>!_.5J2A"RE\2-6%!$959 9*)6@$&&=ZP3JON@>%4;L<0[\?GT=1
MY-P^]-)TZUS"8+BU!S!,MO80!E?>?JZ0IE)I4</)T3")DVMX5I8)B,^3I*6Y
MDW2*QL+IE=\X@[G+2%IX9:+Q==R1?4S(.(T\<M]KA3M=5Z->^MEB(%>-M&T#
M=KO=^+IIN_;?]7;V43&67!HJ74G0Z&+0#T"W\Z1UK%KY'EXH2Q/!FQ6-8-3N
M IV72MFMXP)T0SW["U!+ P04    " "'.JA80H\%&7\#   2"0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6RE5E%OVS80_BL'M2@2P(ADR;&=Q#9@
M)PNZH0&")&L?ACW0TLGB0I$N2<7UO]^1DE6U==4,>Y%(BO?=?<?[>)KME'XV
M!:*%+Z609AX4UFXOP]"D!9;,G*DM2OJ2*UTR2U.]"<U6(\N\42G".(K&8<FX
M#!8SOW:O%S-56<$EWFLP55DRO5^A4+MY, P."P]\4UBW$"YF6[;!1[1_;N\U
MS<(6)>,E2L.5!(WY/%@.+U?G;K_?\)'CSG3&X)BLE7IVD]^S>1"Y@%!@:AT"
MH]<+7J,0#HC"^-Q@!JU+9]@=']!O/7?BLF8&KY7XQ#-;S(-I !GFK!+V0>W>
M8\/'!Y@J8?P3=LW>*("T,E:5C3%%4')9O]F7)@^O,8@;@]C'73OR4=XPRQ8S
MK7:@W6Y"<P-/U5M3<%RZ0WFTFKYRLK.+6\8U?&2B0CAY8FN!YG066@)VG\.T
M 5G5(/%/0!*X4](6!GZ3&6;?VH<44!M5?(AJ%?<"WC%]!LEP '$4CWKPDI9E
MXO&27[.\X285RE0:#?RU7!NKJ3#^/L:YAAP=AW1BN31;EN(\(#48U"\8+-Z]
M&8ZCJYZ 1VW HS[TQ2.)+ZL$@LKAEDLF4\X$+(U!:X#)##YPMN:"6TXT[I Y
M/ADP"QVFKN;A =-*:RXWL&*&FV,\>R,YSO.I0,B5($4[Y-SY?/$^"XZ:Z;38
M@_7%!-Y&6N"ROD"\$M=T.P"RM*!*_D=I2)G%C=)[Q]82]+4JMTSNW[V9QL/)
ME8&\S0#[F@'1R4#9R4 G&I\!W69@[3( )UR2$U49 C&GE]V,-8DL7<"$=.>8
MM&78W?@!7U# L'G'S3LY'!"I ??$33_3K9I7Y ?>PB0>7(R'W8'G%U]U1D_*
M=DA^PZ6QZC'^.9$;3+%<HSYP2?XOEV0TB*:3[N _<7D=0(^,SEL9G;]>1AUE
MY/"DJ:*HU'P7.BJ+7N3CLEB")E%0H>^8S@[%W*W'>L4VOK7W#523S#1R^K$\
M?SR[[TZ\AB8$0O^#R8I:*TR;DGT+<3(81Q%<%TQND%38#<<66E6;HJGS46LS
M&DPNQN[F$'1Z/.=I+5NK #]7W.YIRTD\'207X]/O-=)_>F&G3Y6H-[X;&TA5
M)6W=LMK5MN$OZS[W=7O]MT!^-UP:$)B3:70VH>/2=0>N)U9M?==;*TL]U \+
M^FE![3;0]UPI>Y@X!^UOT.)?4$L#!!0    ( (<ZJ%@A@I,R#P,  /@&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;(U5VV[C1@S]%4(%BA90HZN=
MQ+4-)&D6FX?M&O&V?2CZ,)9H:Y"Y:.<2)W]?CB2K#F ;?;'G<GAXR"&I^5Z;
M%]L@.GB30ME%U#C7SI+$5@U*9J]TBXINMMI(YFAK=HEM#;*Z,Y(BR=-TFDC&
M5;2<=V<KLYQK[P17N#)@O93,O-^CT/M%E$6'@V>^:UPX2);SENUPC>Z/=F5H
MEXPL-9>H+-<*#&X7T5TVNR\#O@/\R7%OC]80(MEH_1(V3_4B2H,@%%BYP,#H
M[Q4?4(A 1#*^#YS1Z#(8'J\/[)^ZV"F6#;/XH,5?O';-(KJ)H,8M\\(]Z_UG
M'.*9!+Y*"]O]PK['E@2NO'5:#L:D0'+5_[.W(0]'!C?I&8-\,,@[W;VC3N5O
MS+'EW.@]F( FMK#H0NVL21Q7X5'6SM M)SNW?-!24G+63E<O\-,WMA%H?YXG
MCJ@#(*D&FON>)C]#4\ 7K5QCX5'56'^T3TC2J"L_Z+K/+Q)^8>8*BBR&/,W+
M"WS%&&?1\15G^!Z_>^[>X>^[C76&2N&?4S'V%.5IBM >,]NR"A<1U;]%\XK1
M\L<?LFGZZP6!Y2BPO,2^7%.[U5X@Z"VL&T8.X+EW4@/U'GSRSAN$)VL]4Q6>
MDG_1P6GY@R=S[&G;>^*#)V .Z#6J9GP.(!M@EL"">MK.X'<O-VB"\J&<;%=.
M'UA'.MK, DT&C[(5^AUQ@+>>G%"#02N8@BQ.TS1.LPQ6!G_9^E!7 W#/C&'*
M6<BR.+LMXLFTA*_>6<=4S=5N0.DVM#V!TKC(;N(B+^!4M%0-BE(/.9C0P!;*
M:3S-R7,YI;#?N/02[ 6[XH3=ARP<=+!7QD7HK^,D[T(@(1U9"4.)/E&25!A5
ML IY* N2GP7$-5W5OD(:B>X<>!KGDS2 ;^&K5'SC[1GD;9S1<T[2*7S3C@FH
M!LG_HQZRO(QOKXLXG5S#J<)/CJ:11+/K9JXE#UZY?C"-I^-8O^NGV7_P_IM
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MTT@3K".&WXKA#XKQS&@,D'"T931#A/-2+K.@QE;!R$%JA(I4^E8CK$\D_]6
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M1<-0:'8,C" .AH?,.9!2=0R*%H.B82@T.TQ&1@=N&?VN&M4-Z2I1077UN_W
M4'[8O\4R&CIT:^C]*]0W@#S?4:&ZV[;^>=;[/<%0GMAT&[D<NK>.Z^G@'16J
M&[AM&@)%BT'1,!2:'2(CE4/_@+-%"+IS#8H6@Z)A*#0[3$9:AVX=VJ9"K:$V
M:\7- M5ML37;>QG%4$8K&KMKO\G/*'\L7X8@4/FS^NJGZZNSJQ<N7)2O&=@X
M?^F=CJO7)AB8ZBT.UX0_LER@E$X59.]XH)0*KUZ,4'V0Q;S\Y?]#(661E8<S
M2B:4ZPO4]].BD*\?M('5ZRE&_P-02P,$%     @ ASJH6 X,MU#7 @  9 <
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M5IO/V.GQ#F9*&/^%36<;!9 UQJJJ Y,'%9?MG]UU<=@"$,]N0-P!XJ> X1Y
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MX7OR2K<UO9U85?NR>*,L%5D_+*D-HG8&M%\HJG#=Q!W0-];T-U!+ P04
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MYSU^SFO'&6VD>M(Y@"'/!1=Z[.3&E%>NJ],<"JHO9 D"GRRE*JC!J5JYNE1
MLUI4<#?PO-@M*!-.,JIC,Y6,9&4X$S!31%=%0=7+#7"Y&3N^\QJX9ZO<V(";
MC$JZ@CF8QW*F<.9V53)6@-!,"J)@.7:N_:M);//KA.\,-GIK3&PG"RF?[.1+
M-G8\"P0<4F,K4/Q;PP0XMX40XW=;T^F6M,+M\6OUV[IW[&5!-4PD_\$RDX^=
MCP[)8$DK;N[EYC.T_0QLO51R7?^239OK.22MM)%%*T:"@HGFGSZW/FP)_.B
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M2X-G>O6:XZT+R@;@^D)*LQW8@[V]QY-_4$L#!!0    ( (<ZJ%C74%KOS@(
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M_%M KP;T7**5,I?6)34T'BJY(LI&(YL=.&\<&K-APO[%J5'XE2'.Q!>44Y$
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M!?+^BE+Q<J(V/=M-[O@_4$L#!!0    ( (<ZJ%C)J\?XX (  !H'   9
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MB3.>%YOEQ8EDZWPW^)E)R=+\< 44UW#J!KR^8$SN3E0'U7]9F/X-4$L#!!0
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MY65V#^SCZ@L5@'Y%-N()9L#KPY%RK\^@.Z.:?@XPZ ?^B7,)G-7 DY2PGQ)
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M2FU8M;-:70A:Z*W#>RH$S?1I C@&IAK(YRLJ5X;UA4K0[&\O_P=02P,$%
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M((&R#N:\E%)?#/M(QA&7_0%02P,$%     @ ASJH6)GZA!-I @  AP8  !D
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M-_\W'NO[]DZ,Z3HOTD4]N-R#1;+<_AO_K+\1.P.LX9X!5CW .G9 OQ[0?S7
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M:@ZJN:CFH9J/:F+PMJ%D]MO.3 -TNR&J192F)K2I/ WTE2=TS5K]MCIG%BU
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M"S@!K@W4\S5C\F6B-ZC_PQ#^ U!+ P04    " "'.JA85[#^RG@#   ##P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6S-5]MNVS@0_15"+8H6:*.;
M+W%J"XB==+= "QAQVWU8[ ,MC2TA$JF2M)T4_?@.*461'$5(%GK(BTU2,T=G
M#H\DSO3 Q;6, 12YR5(F9U:L5'YFVS*,(:/RA.? \,J&BXPJG(JM+7,!-#))
M66I[CC.R,YHP*YB:M:4(IGRGTH3!4A"YRS(J;N>0\L/,<JV[A:MD&RN]8 ?3
MG&YA!>I[OA0XLRN4*,F R80S(F SL\[=LX7KZP03\2.!@ZR-B2YES?FUGGR.
M9I:C&4$*H=(0%/_VL( TU4C(XV<):E7WU(GU\1WZ)U,\%K.F$A8\_2>)5#RS
M3BT2P8;N4G7%#W]#6=!0XX4\E>:7',I8QR+A3BJ>E<G(($M8\4]O2B%J"8C3
MGN"5"=YQPN"1!+],,,K9!3-3U@55-)@*?B!"1R.:'AAM3#96DS"]C2LE\&J"
M>2I8*1Y>?YBC$!%9\ S=(:G1=YE2)LD'LD+C1+L4"-^0(GC],/CR1H^!H*V*
M(')^H"*2Y I"OF7)+TQX>P&*)JE\AZ#?5Q?D[>MWY#5)&/D6\YVD+))36V%%
MFI<=ENSG!7OO$?8^^<J9BB6Y9!%$S7P;E:CD\.[DF'N=@%^I."&^^YYXCC=H
MX;-X>KK?0<>O=L<W>/YCNQ-3 6V"GPM!V1;P>5)D?4OJ<4MZ:Y;-#KQOIBVX
M5.3?+W@7\EE!)O]KD[R@-&BGI%\K9S*G(<PL?&]($'NP@C>OW)'SL4VOGL :
MZ@TJ]09=Z$'=KF%=!BCLVE9\@3@RB/H5N ^\\="9VOMZ40^#W,EX4@4UR XK
MLL-.LI=9GO);@-:GH#/UN5O2$UBCRE%5Y>CE&7K4IWH]@374&U?JC7LW=($X
M[#;TPZ#'#7U:D3U]FJ');_P,2* BC F^YO$CN\?30Z[WM(UP)^IS=ZLGL(8
MDTJ R<OS^J1/]7H":ZCG.O<G$Z=WMY>0#2>[(__([BU1$\=OM[M;.TFY3S;\
M7\! T-3XG49X;DND$E2?6%M9=P(_=]?Z0FO*X-W+X+T\VY><^E*P)[2F@O>'
M/K?S5/3_C.\_/),,3\?'QF^)<L:C(^?;M78B [$U799$*CNFBJ-TM5IU<N>F
M?SE:G^L.S[0I]S!%>X@'Y6V"_44*&X1T3L;X+(JBXRHFBN>F:5ESA2V0&<;8
MI8+0 7A]P[FZF^@;5'UO\ =02P,$%     @ ASJH6'!!9IO5 @  " D  !D
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M:MI?8'IA7!_[=2PF4KJDZ:CJRNG8-#W=T%&K"QQVD2MSN1',QV)N!# L#J8
M\[%>6)S_:3X]=#X6P[3UG$@/]>FA/M;+A8S,!XOC]DGTY9YIDD11'&,9'8V<
M"D98WN(8OFXV3!MX8'$@TM-RC:\V7B'[ZP!;TWT5@LT4KT1LIGBN 7'G#3R2
MQ+W:6!SPP%8!JQV([XX#->7VB2)854P;MH-Q)$DP!&K17:-QC&0GAH][?;!=
M$D5)XD8 <RN((@R!W8@CF +0@"%19-Z#.^^C8/V>"II?>(=_ 5!+ P04
M" "'.JA8EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M$Q2R)BAD35#(FOPG6=^U7OWU_Z9VC6M5-D=_UOW4FW\"4$L! A0#%     @
MASJH6 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "'.JA8ABKK4N\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "'.JA8F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( (<ZJ%BPVY6>X@4  +$?   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "'.JA8C>%1;H<%
M  #8%@  &               @($F#@  >&PO=V]R:W-H965T<R]S:&5E=#(N
M>&UL4$L! A0#%     @ ASJH6 0]^5__ @  70H  !@              ("!
MXQ,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (<ZJ%BL
MP\4N*P0  ! /   8              " @1@7  !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"% ,4    " "'.JA8R4B/R<H"   +"   &
M    @(%Y&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MASJH6*]XGT:""   [U(  !@              ("!>1X  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( (<ZJ%A[7&(H> (  /(%   8
M          " @3$G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "'.JA8V=G N;L&  #3&P  &               @('?*0  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ASJH6"S1R.K "   0A4
M !@              ("!T#   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( (<ZJ%AVN#W$@AH  '5/   9              " @<8Y  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ASJH6-"/BON,
M P  O @  !D              ("!?U0  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "'.JA8.70^W3D)  !O%@  &0
M@(%"6   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( (<Z
MJ%AG.0Q1-08  .</   9              " @;)A  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ ASJH6*B0O[VJ#@  Z2X  !D
M         ("!'F@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "'.JA8;O4.@\0.  #!*0  &0              @('_=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( (<ZJ%CK&;[ $ 0  $8*
M   9              " @?J%  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ ASJH6)[ >)U9&@  UE,  !D              ("!08H
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "'.JA8ZJ3"
MO<L"   E!@  &0              @('1I   >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( (<ZJ%A7S-*/M@,  -,)   9
M  " @=.G  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MASJH6*<V<*BC @  X 4  !D              ("!P*L  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "'.JA80H\%&7\#   2"0  &0
M            @(&:K@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( (<ZJ%@A@I,R#P,  /@&   9              " @5"R  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ ASJH6#DZAB @!0
MT0P  !D              ("!EK4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "'.JA8]M<,#_ #  !($P  &0              @('M
MN@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (<ZJ%C7
MIW6 'P@  *I"   9              " @12_  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ ASJH6 X,MU#7 @  9 <  !D
M     ("!:L<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (<ZJ%A![P#^&@0  ,X2   9              "
M@<'6  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ASJH
M6.D/6T_  @  W@<  !D              ("!$ML  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "'.JA8(UJ^ MT#  #P%@  &0
M        @($)W@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( (<ZJ%C)J\?XX (  !H'   9              " @1WB  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ASJH6.Z2$O->!0  F2(
M !D              ("!-.4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "'.JA8WM5?Y44%  "^(   &0              @(')Z@
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( (<ZJ%CVB#F/
MXPP  (BP   9              " @47P  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ ASJH6&^ASD?H P  ZQ8  !D
M ("!7_T  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "'
M.JA8L0;) "H"  #N!   &0              @(%^ 0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( (<ZJ%B9^H03:0(  (<&   9
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M970T-"YX;6Q02P$"% ,4    " "'.JA85[#^RG@#   ##P  &0
M    @($:)0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M (<ZJ%AP06:;U0(   @)   9              " @<DH 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ ASJH6).R84I> P  [A4   T
M             ( !U2L! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "'.JA8
MEXJ[',     3 @  "P              @ %>+P$ 7W)E;',O+G)E;'-02P$"
M% ,4    " "'.JA8-=-M8^0#   A'P  #P              @ %', $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ ASJH6/TLU:6N 0  P1L  !H
M         ( !6#0! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ ASJH6";ZAZ>U 0  W!L  !,              ( !/C8! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #8 -@"Q#@  )#@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>151</ContextCount>
  <ElementCount>258</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>55</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Value - Schedule of Fair Value of Tranche Rights (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails</Role>
      <ShortName>Fair Value - Schedule of Fair Value of Tranche Rights (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueAdditionalInformationDetail</Role>
      <ShortName>Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Common Stock - Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockEquityOfferingDetails</Role>
      <ShortName>Common Stock - Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Common Stock - Pre-funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails</Role>
      <ShortName>Common Stock - Pre-funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Schedule of Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtl-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  vtl-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="vtl-20240331.htm">vtl-20240331.htm</File>
    <File>vtl-20240331.xsd</File>
    <File>vtl-20240331_cal.xml</File>
    <File>vtl-20240331_def.xml</File>
    <File>vtl-20240331_lab.xml</File>
    <File>vtl-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20240331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="435">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "vtl-20240331.htm": {
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "vtl-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "vtl-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "vtl-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 211,
   "keyCustom": 47,
   "axisStandard": 21,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 22,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 151,
   "entityCount": 1,
   "segmentCount": 55,
   "elementCount": 403,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 435,
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "report": {
    "R1": {
     "role": "http://vitaltherapies.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-25",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "longName": "0000009 - Disclosure - Description of Business and Basis of Financial Statements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "longName": "0000011 - Disclosure - Balance Sheet Details",
     "shortName": "Balance Sheet Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://vitaltherapies.com/role/FairValue",
     "longName": "0000013 - Disclosure - Fair Value",
     "shortName": "Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://vitaltherapies.com/role/CommonStock",
     "longName": "0000014 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "longName": "0000015 - Disclosure - Stock-Based Compensation Plans",
     "shortName": "Stock-Based Compensation Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "longName": "0000016 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "longName": "9954473 - Disclosure - Balance Sheet Details (Tables)",
     "shortName": "Balance Sheet Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "longName": "9954474 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "longName": "9954475 - Disclosure - Fair Value (Tables)",
     "shortName": "Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "longName": "9954476 - Disclosure - Common Stock (Tables)",
     "shortName": "Common Stock (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "longName": "9954477 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "longName": "9954478 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:NumberOfDevelopmentPrograms",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:NumberOfDevelopmentPrograms",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954479 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "longName": "9954481 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "longName": "9954482 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "longName": "9954483 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "longName": "9954484 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:OperatingAndVariableLeasesCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:OperatingAndVariableLeasesCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails",
     "longName": "9954486 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Obligation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954487 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails",
     "longName": "9954488 - Disclosure - Fair Value - Schedule of Fair Value of Tranche Rights (Details)",
     "shortName": "Fair Value - Schedule of Fair Value of Tranche Rights (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
     "longName": "9954489 - Disclosure - Fair Value - Additional Information (Detail)",
     "shortName": "Fair Value - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "vtl:TrancheRightFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "vtl:TrancheRightFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "longName": "9954490 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
     "longName": "9954491 - Disclosure - Common Stock - Equity Offering (Details)",
     "shortName": "Common Stock - Equity Offering (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "longName": "9954492 - Disclosure - Common Stock - Common Stock (Details)",
     "shortName": "Common Stock - Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-78",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
     "longName": "9954493 - Disclosure - Common Stock - Pre-funded Warrants (Details)",
     "shortName": "Common Stock - Pre-funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-50",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-50",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "longName": "9954494 - Disclosure - Common Stock - Preferred Stock (Details)",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
     "longName": "9954495 - Disclosure - Common Stock - Schedule of Shares Reserved for Future Issuance (Details)",
     "shortName": "Common Stock - Schedule of Shares Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "longName": "9954496 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "vtl:ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "vtl:ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails",
     "longName": "9954497 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail",
     "longName": "9954498 - Disclosure - Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)",
     "shortName": "Stock-Based Compensation Plans - Schedule of Valuation Assumptions Used (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "longName": "9954499 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-141",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954500 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-150",
      "name": "vtl:SalaryAndWageOfficerMonthlyBaseSalary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-150",
      "name": "vtl:SalaryAndWageOfficerMonthlyBaseSalary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "vtl-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "A2017InducementEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Inducement Equity Incentive Plan",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "documentation": "2017 Inducement Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Employee stock purchase plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "documentation": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "country_AU": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "AU",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australia",
        "label": "AUSTRALIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "totalLabel": "Total",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r534"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "vtl_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accredited Investors",
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "AccruedClinicalCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical and related costs",
        "label": "Accrued Clinical Costs, Current",
        "documentation": "Accrued Clinical Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "AccruedCompensationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Accrued Compensation, Current",
        "documentation": "Accrued Compensation, Current"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal and audit costs",
        "label": "Accrued Legal And Audit Costs, Current",
        "documentation": "Accrued Legal And Audit Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r74",
      "r118",
      "r366",
      "r380",
      "r381"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r30",
      "r294",
      "r297",
      "r331",
      "r376",
      "r377",
      "r559",
      "r560",
      "r561",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r534",
      "r631"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r392",
      "r567",
      "r568",
      "r569",
      "r612",
      "r634"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of tranche rights liability to equity",
        "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature",
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94",
      "r286"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock based compensation expense related to stock options",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r233"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r94"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r277"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r114",
      "r138",
      "r168",
      "r172",
      "r174",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r289",
      "r291",
      "r311",
      "r362",
      "r434",
      "r534",
      "r546",
      "r580",
      "r581",
      "r620"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120",
      "r138",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r289",
      "r291",
      "r311",
      "r534",
      "r580",
      "r581",
      "r620"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Sales Agreement",
        "label": "At The Market Sales Agreement [Member]",
        "documentation": "At The Market Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors Chairman",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business and Basis of Financial Statements",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r85",
      "r86"
     ]
    },
    "vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Investments- other",
        "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]",
        "documentation": "Cash And Cash Equivalents And Other Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r113",
      "r516"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r82",
      "r135"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r82"
     ]
    },
    "vtl_ChangeInFairValueOfTrancheRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ChangeInFairValueOfTrancheRights",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of tranche rights",
        "label": "Change in Fair Value of Tranche Rights",
        "documentation": "Change in Fair Value of Tranche Rights"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r115",
      "r116",
      "r117",
      "r138",
      "r157",
      "r158",
      "r160",
      "r162",
      "r166",
      "r167",
      "r178",
      "r191",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r205",
      "r208",
      "r211",
      "r218",
      "r311",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r422",
      "r444",
      "r466",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r553",
      "r564",
      "r571"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r166",
      "r204",
      "r205",
      "r206",
      "r208",
      "r211",
      "r216",
      "r218",
      "r384",
      "r385",
      "r386",
      "r387",
      "r526",
      "r553",
      "r564"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercised (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued from exercise of pre-funded warrants (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ClinicalCostsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical costs",
        "label": "Clinical Costs Payable, Current",
        "documentation": "Clinical Costs Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 4)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r59",
      "r363",
      "r421"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r183",
      "r184",
      "r503",
      "r577"
     ]
    },
    "vtl_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Pre-funded Warrants",
        "label": "Common Stock and Pre-funded Warrants [Member]",
        "documentation": "Common Stock and Pre-funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total common shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, cash dividends paid (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, cash dividends declared (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r543",
      "r567",
      "r568",
      "r612",
      "r630",
      "r634"
     ]
    },
    "vtl_CommonStockNumberOfSharesRegisteredForResale": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "CommonStockNumberOfSharesRegisteredForResale",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares registered for resale",
        "label": "Common Stock, Number Of Shares Registered For Resale",
        "documentation": "Common Stock, Number Of Shares Registered For Resale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r422"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r68",
      "r422",
      "r440",
      "r634",
      "r635"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.0001 par value; 500,000,000 and 130,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively, and 90,079,016 and 45,177,730 shares issued and outstanding as of March 31, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r365",
      "r534"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r123",
      "r125",
      "r131",
      "r359",
      "r373"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual obligation",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "vtl_ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of tranche rights liability to equity upon increase in authorized shares",
        "label": "Conversion of Tranche Rights Liability to Equity Upon Increase in Authorized Shares",
        "documentation": "Conversion of Tranche Rights Liability to Equity Upon Increase in Authorized Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r200",
      "r206",
      "r337",
      "r517",
      "r519"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "country_DE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "DE",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Germany",
        "label": "GERMANY"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_December2020ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "December2020ATMMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "documentation": "December 2020 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum annual contributions per employee (as a percent)",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r38"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r170"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation Plans",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r235",
      "r266",
      "r267",
      "r269",
      "r532"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "DuaneNashMDJDMBAMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "documentation": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r155",
      "r157",
      "r160",
      "r161",
      "r162",
      "r164",
      "r301",
      "r302",
      "r360",
      "r374",
      "r520"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r160",
      "r161",
      "r162",
      "r164",
      "r301",
      "r302",
      "r360",
      "r374",
      "r520"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "vtl_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "EmployeeMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees",
        "label": "Employee [Member]",
        "documentation": "Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period over which compensation cost will be recognized, in years",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options available for future grant:",
        "label": "Employee Stock Options for Future Grant [Member]",
        "documentation": "Employee Stock Options for Future Grant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r109",
      "r127",
      "r128",
      "r129",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r165",
      "r179",
      "r180",
      "r220",
      "r270",
      "r271",
      "r272",
      "r287",
      "r288",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r331",
      "r376",
      "r377",
      "r378",
      "r392",
      "r466"
     ]
    },
    "us-gaap_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Member]",
        "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to share prices."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ExecutiveChairmanAgreementMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "documentation": "Executive Chairman Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r309"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r309"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r305",
      "r340",
      "r341",
      "r342",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r310"
     ]
    },
    "vtl_FairValueChangeInFairValueOfTrancheRightsTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "FairValueChangeInFairValueOfTrancheRightsTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of the tranche rights",
        "terseLabel": "Change in fair value of the tranche rights",
        "label": "Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs",
        "documentation": "Fair Value, Change in Fair Value of Tranche Rights, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r227",
      "r305",
      "r340",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r227",
      "r305",
      "r341",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r305",
      "r342",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Tranche Rights",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r56"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value as of January 8, 2024",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "December 31, 2023",
        "periodEndLabel": "March 31, 2024",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r340",
      "r341",
      "r342",
      "r524",
      "r525",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r310"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r19"
     ]
    },
    "vtl_FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of future tranche right liability upon settlement",
        "label": "Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement",
        "documentation": "Fair Value, Reclassification of Future Tranche Right Liability Upon Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized foreign currency loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r442",
      "r544",
      "r614",
      "r615",
      "r633"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation and Presentation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r446"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, amount",
        "label": "Government Assistance, Amount",
        "documentation": "Amount of government assistance recognized."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r324"
     ]
    },
    "vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Australian research and development tax incentive",
        "label": "Government Assistance, Qualified Research and Development Expenditures, Maximum Amount",
        "documentation": "Government Assistance, Qualified Research and Development Expenditures, Maximum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government R&amp;D assistance rate",
        "label": "Government Assistance, Qualified Research and Development Expenditures, Percent",
        "documentation": "Government Assistance, Qualified Research and Development Expenditures, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "vtl_GrafelfingGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "GrafelfingGermanyMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "documentation": "Grafelfing, Germany"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r89"
     ]
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "IncentiveEmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive stock options",
        "label": "Incentive Employee Stock Option [Member]",
        "documentation": "Incentive Employee Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r451"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r451"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r383"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value through March 4, 2024",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease, right-of-use asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets and prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r169"
     ]
    },
    "us-gaap_InvestmentInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentInterestRate",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment interest rate",
        "label": "Investment Interest Rate",
        "documentation": "Rate of interest on investment."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477",
      "r479",
      "r480",
      "r482",
      "r483",
      "r489",
      "r490",
      "r538",
      "r573",
      "r574"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r409",
      "r411",
      "r475",
      "r478",
      "r481",
      "r485",
      "r486",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r538"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r409",
      "r411",
      "r475",
      "r478",
      "r481",
      "r485",
      "r486",
      "r487",
      "r488",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r538"
     ]
    },
    "vtl_January2024PIPETransactionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "January2024PIPETransactionMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 PIPE Transaction",
        "label": "January 2024 PIPE Transaction [Member]",
        "documentation": "January 2024 PIPE Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "LegalAndAuditCostsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal and audit costs",
        "label": "Legal And Audit Costs Payable, Current",
        "documentation": "Legal And Audit Costs Payable, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent holiday period",
        "label": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "documentation": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, extended rent holiday period",
        "label": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "documentation": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Obligation",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "vtl_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal option period (in months)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease term (in months)",
        "terseLabel": "Lease term (in years)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of existing operating leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r138",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r290",
      "r291",
      "r292",
      "r311",
      "r420",
      "r521",
      "r546",
      "r580",
      "r620",
      "r621"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r99",
      "r368",
      "r534",
      "r565",
      "r575",
      "r613"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r112",
      "r138",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r290",
      "r291",
      "r292",
      "r311",
      "r534",
      "r580",
      "r620",
      "r621"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r63",
      "r64",
      "r65",
      "r66",
      "r138",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r290",
      "r291",
      "r292",
      "r311",
      "r580",
      "r620",
      "r621"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r190",
      "r578",
      "r579"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r190",
      "r578",
      "r579"
     ]
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fees expensed as part of January 2024 Financing",
        "label": "Management Fee Expense",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r446",
      "r544",
      "r632"
     ]
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r229",
      "r344",
      "r375",
      "r412",
      "r413",
      "r476",
      "r479",
      "r483",
      "r484",
      "r489",
      "r513",
      "r514",
      "r523",
      "r526",
      "r531",
      "r535",
      "r582",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "vtl_May2022ATMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "May2022ATMMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "documentation": "May 2022 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r229",
      "r344",
      "r375",
      "r412",
      "r413",
      "r476",
      "r479",
      "r483",
      "r484",
      "r489",
      "r513",
      "r514",
      "r523",
      "r526",
      "r531",
      "r535",
      "r582",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r84",
      "r100",
      "r110",
      "r121",
      "r124",
      "r129",
      "r138",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r159",
      "r168",
      "r171",
      "r173",
      "r175",
      "r178",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r302",
      "r311",
      "r371",
      "r443",
      "r464",
      "r465",
      "r522",
      "r544",
      "r580"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "NewYorkCityMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York City",
        "label": "New York City [Member]",
        "documentation": "New York City"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-statutory options",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "documentation": "Non-Statutory Employee Stock Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense)",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NumberOfDevelopmentPrograms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "NumberOfDevelopmentPrograms",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of development programs",
        "label": "Number Of Development Programs",
        "documentation": "Number Of Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NumberOfFinancialInstitutionsUsedForCashDeposits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposits",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions used for cash deposits",
        "label": "Number of Financial Institutions Used For Cash Deposits",
        "documentation": "Number of Financial Institutions Used For Cash Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_NumberOfVotesPerEachShareOfCommonStock": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "NumberOfVotesPerEachShareOfCommonStock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per each share of common stock",
        "label": "Number of Votes Per Each Share of Common Stock",
        "documentation": "Number of Votes Per Each Share of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "OperatingAndVariableLeasesCost",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating and variable lease cost",
        "label": "Operating And Variable Leases, Cost",
        "documentation": "Operating And Variable Leases, Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r171",
      "r173",
      "r175",
      "r522"
     ]
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incremental borrowing rate on operating leases",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "documentation": "Operating Lease, Incremental Borrowing Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesScheduleofMaturitiesofOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of obligation",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r534"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12",
      "r97"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange translation adjustment",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r18",
      "r122",
      "r125",
      "r130",
      "r314",
      "r315",
      "r320",
      "r358",
      "r372",
      "r559",
      "r560"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Liabilities",
        "label": "Other Current Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r534"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Nonoperating Income (Expense)",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherSundryLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Current",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r39"
     ]
    },
    "us-gaap_PaymentsForCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForCommissions",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter commissions",
        "label": "Payments for Commissions",
        "documentation": "The amount of cash paid for commissions during the current period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sale of investments - other",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "vtl_PlaneggGermanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "PlaneggGermanyMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planegg, Germany",
        "label": "Planegg, Germany [Member]",
        "documentation": "Planegg, Germany"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded stock warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r204"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r422"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r204"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r422",
      "r440",
      "r634",
      "r635"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r364",
      "r534"
     ]
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid clinical and related costs",
        "label": "Prepaid Clinical And Related Costs, Current",
        "documentation": "Prepaid Clinical And Related Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from January 2024 Financing, net of issuance costs",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering of common stock through At The Market Sales Agreement, net",
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercise of pre-funded warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r361",
      "r370",
      "r534"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r104",
      "r107",
      "r369"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r221",
      "r229",
      "r261",
      "r262",
      "r263",
      "r343",
      "r344",
      "r375",
      "r412",
      "r413",
      "r476",
      "r479",
      "r483",
      "r484",
      "r489",
      "r513",
      "r514",
      "r523",
      "r526",
      "r531",
      "r535",
      "r538",
      "r576",
      "r582",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r221",
      "r229",
      "r261",
      "r262",
      "r263",
      "r343",
      "r344",
      "r375",
      "r412",
      "r413",
      "r476",
      "r479",
      "r483",
      "r484",
      "r489",
      "r513",
      "r514",
      "r523",
      "r526",
      "r531",
      "r535",
      "r538",
      "r576",
      "r582",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627"
     ]
    },
    "vtl_ReclassificationToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ReclassificationToEquity",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFairValueofTrancheRightsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification to equity",
        "label": "Reclassification to Equity",
        "documentation": "Reclassification to Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r335",
      "r336",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r439",
      "r441",
      "r474"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r619"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r448",
      "r451"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r335",
      "r336",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r439",
      "r441",
      "r474",
      "r619"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r336",
      "r338",
      "r389",
      "r390",
      "r391",
      "r449",
      "r450",
      "r451",
      "r471",
      "r473"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r200",
      "r206",
      "r337",
      "r518",
      "r519"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r279",
      "r628"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "vtl_ResearchAndDevelopmentGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ResearchAndDevelopmentGrant",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research grant",
        "label": "Research and Development Grant",
        "documentation": "Research and Development Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r94",
      "r367",
      "r379",
      "r381",
      "r388",
      "r423",
      "r534"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r179",
      "r180",
      "r270",
      "r271",
      "r272",
      "r287",
      "r288",
      "r293",
      "r295",
      "r296",
      "r298",
      "r300",
      "r376",
      "r378",
      "r392",
      "r634"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r533"
     ]
    },
    "vtl_SalaryAndWageOfficerMonthlyBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "SalaryAndWageOfficerMonthlyBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and Wage, Officer, Monthly Base Salary",
        "label": "Salary and Wage, Officer, Monthly Base Salary",
        "documentation": "Salary and Wage, Officer, Monthly Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SaleOfStockAggregateTradingVolumeOfLast10Days": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "SaleOfStockAggregateTradingVolumeOfLast10Days",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate trading volume of last 10 days",
        "label": "Sale of Stock, Aggregate Trading Volume of Last 10 Days",
        "documentation": "Sale of Stock, Aggregate Trading Volume of Last 10 Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received on transaction",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SaleOfStockConsiderationReceivedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "SaleOfStockConsiderationReceivedPercentage",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration received, percentage",
        "label": "Sale of Stock, Consideration Received, Percentage",
        "documentation": "Sale of Stock, Consideration Received, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SaleOfStockEquityOfferingsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "SaleOfStockEquityOfferingsPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third tranche close period after second tranche (in years)",
        "label": "Sale of Stock, Equity Offerings, Period",
        "documentation": "Sale of Stock, Equity Offerings, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "SaleOfStockRemainingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, remaining capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "documentation": "Sale Of Stock, Remaining Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r230",
      "r570"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario, Unspecified [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r230",
      "r554",
      "r570"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares Reserved for Future Issuance",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r447",
      "r448",
      "r451"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions Used",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r92",
      "r93",
      "r94",
      "r115",
      "r116",
      "r117",
      "r166",
      "r204",
      "r205",
      "r206",
      "r208",
      "r211",
      "r216",
      "r218",
      "r384",
      "r385",
      "r386",
      "r387",
      "r526",
      "r553",
      "r564"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r405",
      "r408",
      "r410",
      "r478",
      "r481",
      "r486",
      "r491",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r527",
      "r538",
      "r583",
      "r629"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized, percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under the ESPP (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r234",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited or expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited or expired (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weight average fair value repriced stock options (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value for Repriced Stock Options",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value for Repriced Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (usd per share)",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r241"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repricing Modification (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Modification in Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Repricing Modification in Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest , Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in other share (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price of warrants (in USD per share)",
        "terseLabel": "Exercised (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "vtl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repricing Modifications (usd per share)",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Repricing Modifications Price",
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Repricing Modifications Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 3",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche 2",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options repriced (in shares)",
        "label": "Share-Based Compensation By Share-Based Payment Award, Options, Repriced, Number Of Shares",
        "documentation": "Share-Based Compensation By Share-Based Payment Award, Options, Repriced, Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r239",
      "r258",
      "r259",
      "r260",
      "r261",
      "r264",
      "r273",
      "r274",
      "r275",
      "r276"
     ]
    },
    "vtl_ShareBasedPaymentArrangementPlanModificationOptionExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShareBasedPaymentArrangementPlanModificationOptionExercisePrice",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation, exercise price (in dollars per share)",
        "label": "Share-based Payment Arrangement, Plan Modification, Option, Exercise Price",
        "documentation": "Share-based Payment Arrangement, Plan Modification, Option, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofValuationAssumptionsUsedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term of options (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Aggregate Intrinsic Value, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options vested and expected to vest , Weighted-Average Remaining Contractual Term, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock (in USD per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf registration, termination, prior written notice, number of days",
        "label": "Shelf Registration, Termination, Prior Written Notice, Number of Days",
        "documentation": "Shelf Registration, Termination, Prior Written Notice, Number of Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r136"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r115",
      "r116",
      "r117",
      "r138",
      "r157",
      "r158",
      "r160",
      "r162",
      "r166",
      "r167",
      "r178",
      "r191",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r205",
      "r208",
      "r211",
      "r218",
      "r311",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r422",
      "r444",
      "r466",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r553",
      "r564",
      "r571"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r109",
      "r127",
      "r128",
      "r129",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r165",
      "r179",
      "r180",
      "r220",
      "r270",
      "r271",
      "r272",
      "r287",
      "r288",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r314",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r331",
      "r376",
      "r377",
      "r378",
      "r392",
      "r466"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r405",
      "r408",
      "r410",
      "r478",
      "r481",
      "r486",
      "r491",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r515",
      "r527",
      "r538",
      "r583",
      "r629"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r165",
      "r345",
      "r382",
      "r403",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r539"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r154",
      "r230",
      "r554",
      "r555",
      "r570"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r165",
      "r345",
      "r382",
      "r403",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r422",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r441",
      "r445",
      "r446",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r466",
      "r539"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued from exercise of pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r27",
      "r43",
      "r94",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock (in shares)",
        "terseLabel": "Stock issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r94",
      "r384",
      "r466",
      "r497"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r94",
      "r245"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued from exercise of pre-funded warrants",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r28",
      "r94"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock",
        "terseLabel": "Shares issued",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r67",
      "r68",
      "r94",
      "r392",
      "r466",
      "r497",
      "r545"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r87",
      "r424",
      "r440",
      "r467",
      "r468",
      "r534",
      "r546",
      "r565",
      "r575",
      "r613",
      "r634"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r137",
      "r203",
      "r205",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r220",
      "r299",
      "r469",
      "r472",
      "r501"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Tranche Rights",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r470"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r339"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockPrefundedWarrantsDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r88"
     ]
    },
    "vtl_ThresholdTradingDaysForAggregateTradingVolumeCalculation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ThresholdTradingDaysForAggregateTradingVolumeCalculation",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days for aggregate trading volume calculation",
        "label": "Threshold Trading Days for Aggregate Trading Volume Calculation",
        "documentation": "Threshold Trading Days for Aggregate Trading Volume Calculation"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_ThresholdTradingDaysForWeightedAveragePriceCalculation": {
     "xbrltype": "durationItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "ThresholdTradingDaysForWeightedAveragePriceCalculation",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold trading days for weighted average price calculation",
        "label": "Threshold Trading Days for Weighted Average Price Calculation",
        "documentation": "Threshold Trading Days for Weighted Average Price Calculation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r572",
      "r618"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/RelatedPartyTransactionsDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Entity [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TrancheRightFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TrancheRightFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche right, fair value",
        "label": "Tranche Right, Fair Value Disclosure",
        "documentation": "Tranche Right, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TrancheRightsAsALiabilityReceivedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TrancheRightsAsALiabilityReceivedAmount",
     "crdr": "debit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche rights as a liability, received amount",
        "label": "Tranche Rights as a Liability, Received Amount",
        "documentation": "Tranche Rights as a Liability, Received Amount"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TrancheRightsAsALiabilityRemainderAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TrancheRightsAsALiabilityRemainderAmount",
     "crdr": "credit",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche rights as a liability, remainder amount",
        "label": "Tranche Rights as a Liability, Remainder Amount",
        "documentation": "Tranche Rights as a Liability, Remainder Amount"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Equity Incentive Plan",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "auth_ref": []
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r101",
      "r102",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValueAddedTaxReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAT receivable",
        "label": "Value Added Tax Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockScheduleofSharesReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r162"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r162"
     ]
    },
    "vtl_WeightedAveragePriceOfLast10Days": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://vitaltherapies.com/20240331",
     "localname": "WeightedAveragePriceOfLast10Days",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in USD per share)",
        "label": "Weighted Average Price of Last 10 Days",
        "documentation": "Weighted Average Price of Last 10 Days"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4F"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "51",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-51"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001280776-24-000009-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-24-000009-xbrl.zip
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M]C?7MD)$SYKR$]%]J&T[/.$,(*,VGE7ISXTZK+DI355'>E%-?Y>0[TG0T.9
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MMH!1[&(G>;FN=.<RMZ[+/)=2@::A/AGF^\OBGI$>I7[B(C?AQ7$[==A4-?1
MQYY->^HC)BRN+<UAJLN^,/[?:^N. _D+&S% @"ZDX]#2"2U#PD::3%0J Z57
ME A$J4V/D;K(CYA:8)QAQ78AB.G]1(N&F@;[\-!SF>$QJS(NM*V+LL@* 6SO
M.&@S^RMM]%>Z_;Q:[Y7!H2)1TQI_90-J6B283F70[Q4EEOA^K%? C(/S5=ZI
MD;J7LPFI](]0_A9Y>YD%:K<RZ%2;K<6.B*=X8N',J6K?LG176NIA#K^14NY?
M6JR'B!7$@C[OS&0]D+@E,-\&\;8$IRPR0Q\/O^S>Z*ZT4$]:JF8AF7XCCSD:
M!315.\UZMUUD^7FSR7&H74S8DYF?<>2SMWA>_\ZQ7PR=Z;_-?@ V@(4"7 Q#
M5&2U3/IX,%>I]CN+D=G,9FXA6@/G9 ._:[+,< 9V7V0I5P;-?K7=7(SQ%HLL
MWUV?$,-Z86[9)R1U<:=>UUHN\*#G08I=2/$ (AF+TSC#\U/S-<E&J_V=A2QS
M3/O<J3."Y%?; :T),D9WOX)4O8Y@G*',J*\4K<RH#%0>(ZV>E:@V,+]P;F6U
MI12E7./]E*_=^8XV5EU&[7"G#GK;WHR*F]@?OC%%;)81S)W%[Z,]U "<#KL3
M$+XS5<L;6OI5 .0TIL##UXM!J#)N>=HDLR9PN1O)=,"-;>S2\ZP\9YV371T?
M)=%JU-,Z0A\_R#H5D13I:29]$!'7CZDN=QER/4[(]3K 13RVM<CWW1U511E1
M+3S5Y:ACLM!:1D.^AX:\HNP\UK.,I>XAECH*COJ5L=2SBZ6>420P""IPHIWZ
M3Z:A@7LZ@J<!Z8*?JMF3B8W+LK6?DC>&73^/)6GH23@XZ[OJ_ 3[!L.)KC1\
M=AB=JZMBH\TRCKBU(QN/\[BN#V*$W8XN"0_4R"=-%_0QI[9S%449*BP@N:QS
M8M>3RZ919[F17P>!,CJXDR3V0+JR-^9HALMXN)#51C[-=7E5'4>URL8M^4C8
M?W!H7@E89\C1R(UFT?IME.'#(PG>12I:I!;Y3.L<3TFLIG=C(8.5\N%"?P),
MW"T%["G8).D>[)X$[!?VY-TP[W84&">7"-N,P0ZYH50&W595[BX6C05H.@9U
ME?;UL6GYH&)^$UI>;3*T3LS /L%83%8/X.2R1VFAQ5V<@:7!NW/G_#5:;$GH
M/C0;M@[=RXTV:;-6)Z\3_9NA\ 1<BG=+B]NED5)I<9'<.CFZ'OLCM9R<DN+Z
M(E>C$=/(T6!O&F_.ZZ@>>!NBKQF0" E[+ FC/[ N[ 60N6VTITS/KI/Q'"6W
MHRN!D'O QZV%K(;_?Q7!_YZYGF-H'M/QAZ&E)[^(79G&@-W*H-G=6=B7E0-G
M19IK1/Z!2!/[Q[?R:K=5UA#L;.V'3=OS507O(V2[1MKOQ#QWL'Q;7SSLKID^
M@C3.IIQU,WL%?3#3&M6.TBM(E+A,)QSEZ&VQJ;39 (6A5/L[C7LN5AJCN!KA
M<ID.J$I/[-FP+%&E,R6LGVW"8G?%T-JC8LC,0<W*H-6I=G)S"$[,YC]S4I/[
M1:(U;+;0Z%2[*;WN"IEP.'TK?H7,9O#M4FF=2XWM4IY*@]%16>K/^]O_^<@2
MI4BB1*D,^MVJTMRYTV%6A![)=RD9LF3(!8;L%8DC6\"1<K7;V7MNYP#AN\)7
M&A1^@:?D[J:7H#WXTZE)9TA44X+=:Z;M^@X50 ,,R)Z*'9@%8RJ_4U:+ 6P%
M:%RW_2>3[7[,:A//*?_5G3I!%WZ!9W3\X-(&QG)<U'\+(V+#'LLSR;/)HX&_
M_"E<:H@X(^8K5-\;VPZ.II=<'&V\D*?8.?Y[^B;3F5I%JP;EAG0U-]@TZ H\
M>[2OB*)^ $$%<>MK:QA2$\W)SFX;M2L#N5=5SFFB;LE Y\I JP8$[X6!5E8I
M-SM%.]CT?LZKA UV)9,4*P&F!BK9AP\T#U&RGSP5[J.6W6$A&2!7W!$JZRV+
M-SC4YPW,LQ8NV0%P/J)G3<D$R9K;T0^7T<2^6T%[UU:02?YJQSK](P&&<BF+
MQ.GF?2YB<UP>*6-6<F/)C9EK G?BQD6NPPY"K9S+4O?$<:<>*B@76"[P, O\
MY.%42/BO;KP,?H%_@JLGJO-L6!0]["25A<9 !CF'%X\RBD=L)*1JFCV!=\_0
M\+5L#YX./HND8H3)8\^.:DI3U:&C$]Z8@9'K6ZJO&QY#L.#1/9?_11D+%;\6
MD6&XT?7@"^KS60]%VCQHQ(+D;EU!T$QMUT!)>.$P$T3I"_O\:NC>.)#GL1N%
MM&M$MZA/L C?6WY+4>#>34(C_B^N%G6$T5!T)C?5EMKMJ2V0_"K39?;4:;3@
M+TW6V/\JS4IPT]@)=C!5GUGM"?S0GS5U!!N\4,U7=>8BA<;)$6A1+*@E\U%)
M\R#C@!G\\N1\&J2M]JA074AA$%2OOW__<7-]696N;RZ7TUN,%9OR47@Q??4W
MQ'J>+5V&7'49YZJO(5<]A%RU=)-%V=2''X&P^+BXU@W)O%59@\4>&/;'V5ZS
M+@D+\\:?P".T10<O:43^YKOP$-?]PES-,:8HM8:6_IOJ&N[MZ,X!\6H!<N';
M1WC(;R:UD HLQCXW6 W+9_K0$]_A*^!9ZA21[OBL,H@]&F5V\$;*V=&+\-MT
M8DIL98[KX3?Q=EI?M"I<0<JZY,IZKA,GOV493W[O#X7TQ O# W[0-D#J$@!F
M$R@'VMI*+7,]F8"_HX$\M+2Z]*$B/E<DVZ$F5Y5+KO@K'R6@"E5Z,D $:6,+
MEO<\DX15 #[1"S/M*25Z)0W>@CZ"-#6F#-^($'*9R3 %#!_06C#P-?P9.-5$
MG1JPI9&M4>-E@*D'VHFB;-K8L>%I8&>,3'4R43W;X3WY5=^SZ2D,,]'H2KEU
M:GHH%HS+'3-5_\,'PX0Y/!R'0/NG[?R4+C%%]FIX8\GP7&FB1M/U0)SBE;\[
M__4G6>Y]'C%S1$8/4QWI.X)F7)5^9PX ?I9\WUB%14VGCOT&[J''S)FTU+%D
MDZEISQA;J%Y)EJ:&DD%GQL45<(\W [Y[8L[MZ$H\P0U97VY4!KW&@J\H!>\"
MY!%7?U=G4K-*'7:VTG__\EW/&,T*0<%-6=BG,9Q/?<?UB7(",A3$B?(+ 8#T
M!\A1=3!P#)=(HRJY ')3FMA I#ZXQ(!%,&HG6!*J:F.\ZW4,F <<NXC%/WPF
MC8! ?1#&9 %3XS=0R[KA )73TW4'!2JRD&]-F <$A%V.L+H4B(PF^A#YX:9M
MW\U.YY34Q5,CC%[R8NCV",^03/!AJJD9_D3Z</W]1ZVG]#X&&ZJ*?1A$XW<X
M[4)2TB&% >OD4B>^Z1E3@(ZKF<RQ44M\P*"@W/C\_8'^:'[^2&N.@.6.[5=+
ML#CS/=B@* 2910N0HP5X#J@;6EOX:M</NIU2ARBT^*<@;)]K#IL8'LF([P]5
MOD& .$J8[P^TBHFM(T<S(&.@K1= M.2;&C'Y"[:0PI&GT19^7 9;^$P )="U
M.RF0\X YF,<1[K!G9M%;I"?[E9D2FP*H0.H!]'$-L"3 )",BP;(8V..3ZC@&
M<Z21;Q&+!D_6;-_4I2F(5^!T(M$GA@(%%!(ZC @4"[4N4LNSZGJ.'7MH0!I
MR3X\"R"OP2)4+?BAFB0LOM;P-\ 2.&_\2W=FZ0!H1LLW8*GDKL[_2 2A&[ 5
MD+&?Z=H :$JOF0(T%1C@S9,$M% :ALSVQ!")@O8X6-TI2,$1DL0<+X5<M!0"
M)R_40J=;"#6*NW<_N]*3,#*JL4&P !C@2O@J\J?1X297E[#R[-BO'O6G09AZ
MW&]W_:=_8:<#A#1LGR -+.\8[D]N P)I,@=CEUBP516"!M^'.!BIABFJOE!Y
MSC,O/'3"0.#!I8:#)?531!,N4=P'%_ 4&7*/;PI1AYKS!9Z"KT<LDRVA\YW
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M0M.RR.RX%F_#Z7,A-&MR!,YV9=!.D;K_&;=)A27*ST3/<^QR/1:+/"'X\@5
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M&*8**65!DR0<T2@X]KT_A4=;(L'%5S1BS/T<5Q+51)/X1(/W%&7V.?B+I 9
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M!LT&XF9V.H.=A[BZ]H*!L/-N^I0LBGA_"^2#,'%'D C"Q%$*+U -T0P1])*
M^'B!?ZP4("6[Q^-40:UL& GC;,Q[HBPE+MZ<S 7X<AS3.]B;2C.'J*G[C"//
M!Y'KI#38#3G+7;;XH"$L%4',:!1DR(RQ);HI9=HQL1>6:$O+#0 Z2#)B.E:#
M5 G5_[2=GU7I$BMW;<<RU*H$MI[J!DH_J?.MA/ZH;_@BZBOMS5D=JR'(12/9
M%Z!++!Q+;C(](3!=8,R&0NN#KZGB)=80EUK"!=\#G&YNO[G<8@GN;?:Q_M/V
MG\=T8F;>2"$=A"M+A\-*C(M)Q=%X)GZV:V[+=(00'A,WE7*=/?X0\T^NR"]9
M:LRGY XZ&9I"%D 8933Z_T$G<84JQ*GC&N"/HI[GYP.$':C) '1=/V%-&=&P
MDZ ?/8F9R)B,2I&HI3R&C+C6QI@3GD-N]1JU9J,:/^J/KPIZED0=+F*#5<29
M^;&*N1#8(\!/(PW\!&ZZ]"UNMXFVRO#^J%] \-*P;0"\#[_M-=NUUN)2OL ;
M7GB%:OIJK@%G;Z(RE0;/!Z=P@7L?F.>9I'K@MP5U=OMJ\9*PQ.KX.J(F2?R$
M7!Q8Z1B@[EEBKB89%+&Q(B->AX673+"1 HYSIB8L.F,3'GGFRG(6^4BT], S
MPN:;0>_RH#TREM>!P2("E/PX#@4WL(#5Y>4PJ2L58?8)8UY*L9E( ?D+VXY;
M3M$ T;#,T(E.SD=@1'D<6NZA^D[:Y_&EN>.@L":9/YHC:OB&TW4</0$!18U;
MPI$D*4"EIGC4)MYA<8NZ*J+!9FQP("\V3)1'44D=F?G!-YYC/#\S"HB1KU0/
M66%6BVUF.?&(8D#*Q,0+P43" KB?>)?R$2+5Q\UE4I/DN\\/(JY+PS <'E8E
M+=28+5D2)L-37AT_?&8$;;YBWIZ;F+6<;"*GTIAH"F;;[CR)EM4-V:H;Y!.I
M;FB?2$.<95L@<VJ0(D #J;*!# UDDR&F2_&0GLBV91.%7/ EQ?%"!ZL5;$UG
M&@.5&2:<@VI.DBR;/25M60M;1EX7:HN']5!7_3X<WH63I>K"1-A,2 J+2'@4
M&TA*,E8L.QYDB=T2SW^GR[NTCM)SHBJ3:7_%)VKB<58Z:;+4L&^G&/;M<S;L
M;\ <P=2:=(<]+!$V[VH2!R%W\)OJ @UA:@@U)!V%)7L.2!T,C">?=WH190$!
MTPI/D>9QJ*8FDF9/,UX7'N2UPX>*/C9\E4ROJ2^@HY_C)F3P<+(DJ9UL,.4X
M.4ZH2NP%OX<&H1IVN4E(E<0L^"^&22-#=MAE,'4DMSW"]JIHI^NX-CIKMVS]
M*\ 1#U)'1PZP!Q 8=K,:?Q0/\--)#@PR+@YF(M'N,!Z+B,63 VMKWM(/I^V%
MN*< MR:JWSFL4U 9B[G,>T819H19Q*,D 32E )HI3PT6$9#!XE+$3.$XVC>?
MR1$&L)<6#?(U+9RK;JSIF'^)VN=V)*(+MPY%%(+2P0=L>$ONP26@C.F_S8(H
MA+C0S7IHO-/!^M1JLZ]4VYW68GDA4$,-.W1B-U[QJKPUT8,V9KIOLMO1$!X9
M$'ZTU2M>9Z1_=>S))3$</PDYFE=A*<HK>V?](HCF>.@@@ ?XC % JJE5W7&"
MMT<AE6\IW)Z8IE)1H8U6IFM'@TV!!(Q:))[H@:YH]^IF'*LY#VR^I- G0@NU
M1NWOIBZ["/[XK!ONU%1G%X9%H*.;/HOG"T<*/0>0#3244"A@>B'_63@5_5Y=
M;K51%7H._+\>O%BX''5 Q:?%[[LX7+N9^E.CGO[]LD<U&_5^6\GTJ.7?]UHY
M+JJ]\E&?"%X<9H 5Q#CU6 E]/1U%\$5#:@)6/R4OZR]<)D_?\,+/"P[M/ 8Y
M\O+FR=X<2RX8A>1ZSN7V0C+W]-W $5TFR)T89(H92=/0I6!?)P4K5) ) .VP
MX?<$-"4+53VIVD_L$VGI-;%"36-L-%JU:Y.-%L6B/3V\EJ,=WT;%O5,?^(H7
MMD:J:"D)R>N!L)0N$N!I2"E HE+IPU#&AH#*:F(F.@XUYLVM'8VL[7H3=7K8
M;;NJ-'M5!>D\M=G//,+S03+^1,C>%,G+A<TZEDL55KM0ZSLA6+F !-NO#-K5
M=K]=!;MJW_2:!\FN41>!S0R[8,LI?)]7T0(_D;&>2VT"T&IL4HEC6[8O3J>X
MJX\%=!M%=0HS!BKOF<:+0ZYY1EZU]$^8Q-;M*7I^:6WS=W//CE2&$'5'=H(=
MBQJ$6&FJ&TX&H&PK=U>I0%1-U/GB;$ L=TR<S/N+NT&EZ#9Y020YHZ'H3&ZJ
M+;7;4UL@'52FR^RITVC!7YJLL?_%@<%K45)9GOE:>]/^D)9.F4I]]1GZQ1@0
M3F,1Y^7$P08ZU_#%<#73IIY(*8S<7$Q-=)N+J8G$20GI"_-4PUR8@[P0P$J+
MC?.GI[Q3/EDAPONQ78HY6L.HNO=.S*%/;Y2W982/WB9>QM_UB HA!;<;G]TJ
ME+3:%)KQ"8 ?*(!G^_!>W?T81M .&PL#PZW>X,9;QF"8TEP=+,H0=VJVNSD%
MP_J=?CZ+DNN-]NI'"<-KK@2D*0*:NT2$]GQ9/F&KDPJR)),X&\2HSA$(7\"(
MHLR=@,,["SL%DC@<B;G0^G1O?EVJ^YX&G:-Z[W_>W_Y/-&R1TA];2>_JC<U?
M!(%="OH:6OH]IZY+)"YA&VP6CU B>TBI#.1JM],]A5A$#N&SDN=*GEN8)G!H
MGFLASRG-Q;*( O)<9KT]HO^=CM[^^_!1]#E&'V>KY%#*ED\]HKZY:@J<\;]C
MP>E0UYG^J+[=AP ->621#=J50;>[.%0B(Q.DT]O>=,O<ZS*G9MX'K2P1J=O3
M2@=HI;%S@B\G6CE[7R9VG'3I^!X\(!KVY=HEIW[FK+#"HL]W5-$BTW0K@TZW
MDY.540#CO:2J36S6?5-5#ZEJ9[6=$U6=O7D:((S/:"C-TVWD;#K1_XX 3?IN
M(^.-Z;5_,\=.(_P^'V+>E#\7Q XI;=8#B=2-"6B]\]]K5 ;-ZO]C[\V;VT:N
M?N&O@M*=/)&K((8$=[NNJC1>)LH=6WXMSZ3R5PHD0!$Q"#!8)//Y].]9NH'&
M1A(4)9$44I6Q31)+=Y]]^9U.^]'.?V/+;ED.BJG3QC[=U:VG[>.$\X[AKE$'
M*;X]/A23H3%$G]'3WP/Y&$0^@_&!D,_)6YS?_<ATZZHA$8,6I2%=V%?+C['0
M1+[OJTVL['^#3D=X;- ](OLB:IO ^-J#-.EB_75W;Z'$_1WK"SD #6,WC/WL
M5L%3,'8/&7LTV%<^Z649>XNFA@,I6ZU9%GPE$?^^FJM,OO51_?WBIN*>.*J<
M<4L5L+Z*>N!1"0S-:!<8FD.H$LYO[LE4 _=:[=Y@7]7 [4[=JM\GKP;NM'K#
MWB[5P)VF&OCP"F&;:N"F&EA6C#65OTT5XJ/S5Y*8J.A0Z/9=S>3!V>5 -SI'
MT7O<U/LVG/:\B;Y]<MKP[+*G#XU]U=\T5;Z/H8_?[3O1DL/C$TK5<I,,WT8;
MT5:BCXT;6<HH15Y F)9._T!2WDW9Q#-)TUTH90R4LK<@7E,<T11'/&6"*A=X
M5%$(2FA[W :+8&^H/P=@7#>$LFW"HR:A=,XNC<Z^X,P:V[ I>&CRHH<A)NKI
MDQT]S[&!,9X]]'0?1"JTJ7%H>/D@>;F>RM^5EZE>J3U^=/7C0?#R%F4-S1RL
M_!RL;K9&XC#G8!TU5IVH%JF&I"M;,56)',R*-]6%9-9W0G4AO='ZNHEM;S5N
MC0;U[E3]>;];_HP=RD(&AK%+68C1E(4<7D5$4Q;2E(5(2=R Q#4)["=)S@D"
MR^2Q=W4]>C3"JS=NL.$:5GNMK+8FN[E/5NMCUE,?#9Y\A,G>O/A33@A(+>TV
M12-[UDO%BH U6;#!V:71/12<A*9HY'G%:BU*&6*^]-&%=DW12$TGQE]@/(FB
M8DT-R6.L=64CUU Y F]U&A2-4Z21+<S,,AJI:65B;9W>>WQU75-84D]0^CM7
MV;T.:V K"*)"1V^EI.RVVV>7P]&!F .-X?B,2??ZI(+@5,:A5*:?O.E8K]0N
M&\QHRG.>88-.1U)L+K6K$A*UK*IN&_')#+W7V1= V7&4VST^CM[P<\//>RVW
MVQ,_=X&?1_I@L.?Q+(=5<E=98G=$95O9H9C*R3\"5$CMS-B('M1M]XX2)ZAR
MXPZN,&P\;AD(LE.S+LQHC8?[@>89M\:]_<PA-5K&J-X8TC481MU1,SST5$JB
MFKJPIBXL\U"XR?3"^7DQ=RS0%6]1S_0W_V2 ( =F:&MNB2+,_M&4EC7U+CN&
M8I=V #:C=T>D)BV'U9KX&LX@:BK(&HYZM1RU*6)=FZ,P#3Q^=,2Z*11[4?B,
MUY&MV2:Q=PN[$JRV2]:,SRZ-Q]=(-HF] R25;1)[-4BETP92&3X::Z7)ZS5Y
MO1<WEYH\0%V=LIV(Z)Q=CO=6#-5D[1IN;;AU)[6^';<:R*U[!E,]K)S<UC 8
M!YM8TK1LZ@W?&<_/:7<MV^B8/7,X,GMP*J9M&?9DT.[!WZ;&U/YWKWNF7E2^
MT"=?57F>L=?2ZB41W_N+A1/AB-#PRK/>TS'>V=X4"/R#$TY=/XR#DFQBIUN8
M10*?%6>1*+>GYJ3, XJ4M!G+0CREY-G'B^F1Q%4T"JP4Z7+=DIAA_Q.'D3-;
M'0Y[?9_;&M:!F]Y*<W%5H38%&6,ZGN;/9L[4UN"MX+\@[^Q  R*XF.+P;Y=2
MMGZR(7QI2\/;B=M$=K!P/#."GWG:/V)W)?,P?:R>T$!*TQK^Y0<_M/=.M!+/
MT^&WGJUUV[G?_A;\S_\QC-&[F>W.X(FZ]AO<']]:O"92[1?_7F1\^.I1<G4@
M1U[#B_OPSGZPTF")7UW3L^_2F[4T7$$(=[L+;)O9P?&F;FS9&LC:.:]-.[=;
M=RU=H]'.&BJ7-_1XW!W^ ;:Q^!Y=+GX+GRS@:S.P3?HMU6]K"]CGR/9P1[D3
M\ UO8>F=X%I0?/!6EA;YVL36[)_V-*:ET+7<50@_PEO;L'+\!;V[I<T"?T$;
M 4>"H]C%0I;FBA<9AWQ7R^9CHYMH2]PV+]+N33>V,8&/'^8.7?,G0-G,^BKR
M .FK"W]V$>-VXA@N7EKVS/D6#V8(KPH;@:\*]TDR=X9!YVC0.0)SH)+$)YGN
M>O'9+U@%O]OP"G8V,OK-]NP'T_T.*\Y4]& F[*T5!W!@T3P5I3UT__.R4*,?
MA4A@L4N[0C4.<(2P3EZ=9 3<(8OX89;EA^J-F</&F$AA^)ZP\W@/79O$$3S"
M"6G?/#^2)&KAL\$XF,8N'Q!1/IX#/C(Y!SHF):/7TFX\[6H9.*XVI!<"YHD4
ML1""X()[FQNVO+?-EN->W\Q0NZ"Q5;KK#V F =6E^]X_NYPY][:V @XN;#_O
M$Y*' V0\,Z<4ZL:-J!(8M%Q.D//^=VA#KN([D,WB(R.S 4!UN/Z4]OBA+!C-
M:!OQ!(+E6^84X?" 2?=P>D+$.>GB6]JUIWVR)T%L@FC Q'?V/.GM+?'ZN%'B
M38G'RB1E1JQ;/KWTW+RG66!3.&1<CL[?SWT7UK%8!BB)473 XN /.+Y0@]NS
MU)O$CFM=^$#%4]>,26]\B@/\BE\T^R0D,U1'4VF21"1R-7R&0\]>QS^;Z;:?
MA1<OTNRO-FAS#_YU,Y-B(_H[&N_FZBO<T+>V(^/!V67H_&1Y42!C6M&<;RI)
M:B*?*R4OK\E$TG%=C43#(Y?V$84N[N'CEC8\NXSFH#"W65P,ZHQ6\_P"?%0M
MP%G]X$Z  68&Q'^?3>8>(B_@5698Y$ A"4(\F%_JN*[]0753WK4W#7!1H/SH
MSVLOMU@4!3>S/T*;AEIN5X/:3E<_/KOL]WHZF),%AS=1VF !X-'(!>+Z2(^E
M1E,B-?*F$WZ6$3JMD["/.190E'\D?2PT.U'<@?_@@%A"Y0[B6=<L,)?$7KKF
M] ?NHTDFH!U,'=,%W1^:;$+#?:QX&F4E- ASD'-P^/A+JI\$XQN.)_;H&KBS
M/Q$R4=Y2 Z*!0Q.TBL9?]I8V[.N"SMAAFS8@^0P7H@4*0E^\/EN6E30-= 9V
M68&L,P'4#%5G:?@Z?>ZO?A#X#_#%-WAL0J_@'4J"-=IGE\78S%\2D]X'W>@D
MVIBMW[KO/7R*]^Z<718;!?]2X?2D<@??GWE)X3<].7YI$?PW]LF\AJ>'R3U=
M_P%/T/% SY(7?W$7F!:Z"Q,V&/!'F8,.4[(%.@ILU-+@T* KHOISUXL%[.&4
M_0.D'(6.%!J:R$U)>$"H>L=C*44+O#<=)GJAX!(/!^XR97.![&-X(>F'R%67
M>B)9'^:4Y(W8]O_Y/R.C,WP7%GRNU-^[-P.']E3]@C15+<74J=9+"2=<>=:?
MXFG$%"%":-150X8!2K@_+%=#N*!Z^O397AL[.,;]\M>67*C80, HY,QF"W%I
M@6R0 STO[2D:QB[8UW^6G:(LG ?/#"@82 WIGN,(&L41"M$#'5@GC /Z@+C>
M_ F4^3!WX!TP,( #LK4)6?]DAL$"8CE/$OD9(^7P@Y7@KC#T@XU<)>+= Z#N
M@XTAYP+ZFSM67B4H="^W08<("BT#R+5BYV6N0U(5]]F,X@#^K&C',;9IQSD&
M'A#KQ(C!%H&\@/S,F>^"91'B7^&:BJ:"VG+AA3;@I=J-1JWQ<%"WW6C4;8VZ
MW;V 1QNM=F<_[4:=#K#R5N#13UV5]**YZBU;:DYBK86*A09@:=NJH;5:YZMP
M6K[9:,2!!+J9?7+0ZOR7;0:UC=/^V66_WRDU3D\:ANFEQ4!_)S'0%.\^%W=]
MB.TO<,?O#[9[;W\FOZPV;PW.+GO=[CYXZ[@*?U^:MP;[4+$--.!3\A;JJN\/
M?FV6&B*46J.MGINCAHVV.@J.PBAB;9X:G5V.C$9+/3=/C1HM=0P\]<F/ZWM5
M8U!3XT9-/6_3%V:O*;#<**N70 _?EJFN\(C*.8NJ8B_^UP[\$J;JMC$;,S(Z
MQKM&4;UL*^5S:JK*UI=7RFIU=5A=W=5%"&+=,/82MZAUAHUB*R>::U%\TZBU
M6MMV_ES,]H=G.2%-U[:MCS^QJOEJ@?^JS7G84UC.=F\:U;9_ OF:+PQ+L]A-
MCFY[S5S>M=KH[7H(2[6%!5:5Z9UN>_]J^E$'^D0-R,?9]2F;E;!2[B81+N%)
M5)M>E13V9.O&Y]1BENGZG"H;DDK;4+2(RNY1I8-2Z2[ $F++OK==?[D033QW
M@;D(M7O'\F=N;#F+.*0N*"=>4 WC]><_+D;] 5R,!^;=:>82+OI)1<CNJEZY
M:):K^\4>ZV1AZ4%OQ].#E*=[9Y?=5A4WPQFZU,-GNBYN/==F.MC^B.6@26LG
M56K"+JI5H_V:%<Z'R4X"*#K7;WZ$C%5SW1],!X[:T6Y-[\?*UZXD>QS+<M>C
M?WO:/TR/6G_Z92VD]D_L4I$]!-P!J;2QX$^I53G$/L\'/W"M!VRNX>Y'^%W:
MY^+\KRD[DX1D:&E@J6.3'!%6- <9$>JBP)%^*A^N@:1!>I,]#5>_I2V6(3XE
M>T1)\?T2) V(*I [<-+\=$6BB;?0J0J<V5E=.796P**P#='S(VQ4QUX@+*ND
M*NVD+_N/UFU+^\I/^A]SL7RG?<<.#B""']H-=[C#1HDF5>Q0I2Y/$&^>S7+O
MP8GF9:O.'@3)%5/SL:(1"$"+E_ &\$A8&;:AP#;.;+NX%RWM#Q+N>*LJ0M;S
MWX!4 T'K:S;0K"/ZEL1V:+,XBJF=/5$%6!)_AZVOV&6&(B$$P1IJ0*S@-</[
M)GT>NMH!&?@KTZ6BUN*1M$J00XY/7M+04NUKX(-YAP;:T<C'K6$G'&YBGS).
M#^AT$\XZB%9XE-2O[$1"-^CPPP!_[P [/F"1,C(3DK7M6=0H&U 3!K(1SEI6
M+HSF9H2738 :;>Q&?O!CU]+0B@BX(\^<S8"52$!-0!!Y=@BDEM9(<X-_J,LF
M*>J;\&2?)-@]9CC79E@NW=+^[C_ ,P)=]-I9L/L!K7,Z-]$>@$?^+S=:S +[
MOS'R_-0UG44HFKOE:XO6<'Q\:$]E^;:Z+'$9L(X9T.^DL%(ZL,!.<FTVU\!R
M@@7!U@JAAS\3MT#Q)9H1D_;R%<A6!B# M>L2VH"9-RM8%N8*[1;'N_?=>^YE
MQ]8D'ZPY'GF]3"E82#V4/]@D"7^VFMZ,];T9_>K>C!J 2(,$$.D%&CH.#H.I
M7Q>#Z9/I!']BG"E%7 J+'2/=?A'VJ-LO0B[AW32ZW4[X2GS+D@?5;H^YG<YM
M*W;MFUFR0.HP1Z I!4?MLVWBBJT;[QO*(FQ(_=4,G:HY-MW!B33.H*KB1A@R
MC_#4.-@X=T W@.<,B@JW($R:5#--KQ/$N;!-, L7YG](3T3V'=HXH@M'"-#$
MVDS5"\%]A 6\CX4X!^RB5=X&GX7F%9\,=OF!OJD8N+.O7KYC&-S3;[=&H]&^
MAN2TQ^O[7[;_?-0M?\BIO)31JW>K9]JI]92PY:B@8\@*E$>/T]1 Y]"&^FS6
MVK2N5&UJ0B-1(!&$X9JA1Z_G7)7<5@VXT2,X<UZWL)?VL_@-PZY.: -_QSB+
MUFDV;J>-8](SFMU[Q.Z]LN%K[$ ]I@)A+Z2T4SU?\W('\W)[JHSC^HSQ(3/,
M9]^S,8H8_+#!K845%9CGT=5M!V?*;3\.H&R)IU-LTQ]MF,--PK0D^E9W#G<7
M.P\-?3PXE"$^>R@ ;=CB9-EB_%QL,6K8HF&+8V&+07LO;%'2IJ1PQ/C0VI0:
MEFA8HIHE*N []\D2O=?:N??"$Q"3-*":[7NRBO]VMD:\Y-L3+_P?&,]D=/4Z
M^S*Z]G^N+S0N\*FH^'6UK@PV]*[LCX*-%Z3@/7>OO/2PR\>0ZQ&;9?O<FA/B
MX T3+O=BSG7W9LZ]<.-9P[H-ZQX.ZU9,)-@KZ_9.A75+>D;K-FD\;PDB$$2K
MS411JP:QTS*ZX[T5L77J5M!55M89]2#&C^VE.OWAX;U4N[/^5J^G5NT$:Q"3
MR:6B#+%6V<L)'>U)EC,U98A-&>*+%](U98A-&6)3AMB\7%.&V)0A-EGTO<9N
M*H8S[S]QTC^[[/;T]FAX()GTIKBD88MJMA@^%UL,&K9HV.)HV&(_1>OK(_W#
M0ZNY:EBB88EJEMA/P?IZEA@=&DN<?!!A^S+$ERS:.F*IL.?=.1V!,MQ/J?\6
MIN=X7Z9G4\K6\''#QWD^WD]_PF8^[K<;/F[JVIJZMOUS\'[:(M::]OW.J=2U
M-:S;L.[AL.Y^^D'6LZYQ*JS[1&-,RF!QCQ>Z.["U!_R/YVM1 +>:V4&H3>SH
MP;8]3:FVZ.CJOPR$R59K,61,P8H)LA314)?P3KZ50*G:5DNKB>)^H+OVR0]*
MX5X7A82S&"* Z.8,_XU0KXC"/85+X==>A-"Q!#=.\-WX%_N_L7,//(GC#7P&
MZ08A0&Q!H/@3TZ5Q ^'<M@EI'W8)$<CO3,<3"+,^G$68?:KC$7HXCJW##_V%
MK9WCG!(OM-^4/B:,X \>ZH&3N!@['7Y0%XG_0,_P)@Z*YZ694QH;A_#N<]NE
M7?/AAQ/3^R$!TVFX ^[R QRD;08>DGNRM6:$R+VP<[AIE9(=G)^)'>2%>R_C
M615D^[5W#T_ $Y'S![_!<Q(!?F&D$KR+@-A&07K_!==@\@I^\T%L>E3J6MB&
MFK-I#O2$O^<F'Q%S">9!)'\Z5?J+33,")8CSPOSI+'!@T8))P6.$YLF*OOWT
MX?I]#I$_\(@S,*YZ9WM3Q'4V2V8QM;3\&^&DA+D31GZ ZLM=T>"@P(%[H)B
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M X74DC^;V6BYZ9H3AC$UK*'>"\$T0XT7+U%C_F+TVZVV)LNU<@6-.BI N$M
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ME1VU?*LS^N+L3>)LIVATTGAG3YYT<&?,UG;R9,(U?4C1W!F*%#F$EV:B,&5
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M.3T1ZQ'7FZ&#):]W9$3\,]6NM..J)'C NC:X]N]H:_WMUC0QL"[/6XH.C"Z
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MO>AP[2>^]I^)S VHO ?<A9![;1=8LL0R$PVHY/V2M^("@<AQY75L^<YB=TW
M]%66NO2/I]1ENV:CIXYY[77[#RWZU6-)^SWI(A<"),%6<GV1?I1"<22%8N)X
MBHJWA-O%$.Q4/A%"*,BS.T0B93/DEU&;9WI(\RTG&[1S0F4NB)4W2O>_E).$
MAQ$X;,_\TFGUNJE@>->0S1.3C8 6D(J'ZM&3<B_,76!%!-5,;220-.'QE.0Q
M[ Q2^M#10.<Z#ERF5(_\^Z7I)-2=X0[V\D.U9HVJ/T!KA#-3Z5?!DJQD,]8
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MZ(:+GRCO_/7%*M*RCMQ+'.OO-AIM/]+=,"F(++Q[MC2RQA-MY>\F4.0D#NY
M+)@NO(677F@6KB@I%54MQI;VU<' PBW<V46#^=>6]LUQL50F.]W^U\#W?U#
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M.J=]ISMT7$=X;3$\:77AD]MVQ9^GK5=;.PCY5Q_8D8><&.%[[DQQTK#U522
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M\"9_A/H0L!1-F$]+3^V5Z&FQCW5'N *)]H_('W,!HO"GK'3?27$2.SYJ0Z%
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MN>"+4T%/B:WU=;'[L=Z<5% 82&"HL5SEQL.ZF/7.S2G8M<:3"WPVH]'QCTY
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M\D?F'#1Q/N:.5A0CYER7IO4CM4W%[E+8\B<_J<9C <F<%Z DP]3$'U>$(:J
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M_8YU>^+V.LUN9]L6==(\Z?:W;$V]9F?KX&2?-'N#D\<T--Z*EA']%7L^535
M6+*GRF8M![QUN[?*WF7G\8WL?DY<R 8^;A1/<:X .U6^"BK2=44!(,^$Z$^O
MI:ZV:2D6GUME7FTQGS,L%2T%2)Z3 +</">5Y6+_Y:2">C@DM[,#2FF_"LMT
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M#2HNOKMC)[P1UIF;XL^@DW9YF+8735'+-)\/]]&2.JVV?I03#YU0),=?O@?
M@^13VJU6NV8W3\MN-C<>$WA-N^8U>\9KVO?RFH]^Z,!'^%3SFJV_;&]X31OT
MFIK9[#RS^=ZQOQOLIOU8U<;N6[\WKYOG3<T8[$ZO=2_W&+1.:NYQ4-RC77./
MW><>!56E_5A5I>8=->]8Q3=N-R\_7V\!]]C$[O_OQZ^_6I=AD@(=">M#Y&88
M:GIZ6.S$9?N$TM?G/Q\R2O_F?(_":#(#]3(588)\_=H=BXFC<;Q9(_G.(_GY
MV:\UDA>0_-P)W"Q@5>E7/_PVQ";$-<KO#\I_N/A8HWP!Y3^(D1_Z)8QW4@<_
MU!B_^QC_Z]F/-<87,/Y79RB"FKWO([)??;VHD;V [%>Q2 "Y:Y5F'N?K45)+
MD(I'29V4?'3U*"G%YNI14B^\J'J4U&IK>O%14IN4^-T#E?;G$:S&N@+&:UTB
MMP/A@2%@M-NLCWX@:K%^O\QXM5C<K"EHECSFI:708-#L]SKK"J$NR./E+&-E
M<=9IMKK=@^ ^_[4&D6W]9BY##T/$\$#'@H<!8Z'J*1=N1.:"B6IN-)F"4>&D
M43RS %E#_-*)8\Q-F[<E]N64UQ$P6[\9% V>-1:QN//3\7Z>UUX=V&5H.:X+
M0H/BRWAHUF4J)M9)RSX:OCGJM-\<^3XEC7X5-RIP<7W\"U4O7E^<P]>!0(/_
M<]2T.IWC?KO3I]\ZW>/NZ:!_TJ DD("R4-]9GS3E_\??^FW[]'T"#YA&<9I@
M<0QI&GCQ.7*%*+"^H!*2)Y'PI0!7>L-<WLD'/W&#*,'"&C\L9K5> 70B8$#J
M;0U*'W'-)R36*(M#/QD# M/ME.626)CYR#MJ-]N$VFD$7$E8'I9]>IB9@A#D
MF9#IV$\LF@MFMX[_AVZ[\X/ "B-LL:QNP;VWX5216.BS_=X:190< W8]'"YL
M1J?$]%6RB[FAIG6=N>/R!BI>!:L;(CC@B*>8W -?#6=6+$:P#SQQ/\3UP\IA
M,0#8Q*+,GW*&\!DSZ/(J&I;X[HHI9>?@;P*=0O#7V$GI[UC<^ FP=_@NF0J7
M5AH$,W,YB>6GA155,/DY?6LEO:KVL2@?R^EB'PONP?=^>+5B<=M6>&9>'JZG
ME7"]OOSI\]EOOW^]N%Y/M_>!PD* Q*#9TS;"2^/$E9%7QY3Z5^;'Q)B3E2L$
M2B0^=A++PU;9KI,ER'J0%\;$;R4;PL)'+H-$QCH48R<8(?'C@XCOR M2Y+(9
M<B9ZGI.EXRB&W7G-QT/Z'JYAWM?N]U_@@*J1Z_+3I]\_7YXWK,O/Y_.[7GLK
M&T6V#\#G4?3/_N-O]DGK?9\'Q?(?+___/\[>69:EH/;R\%B6#/PV>5N8OG#?
M?UN$QM5'KU>ZZ#2,W>[^9L['OAA5%$Q0IX]8)+YGYFYN[3:?G<D^*;,V&ENL
M?=<J#K9-Z)-;HSKV%ZN.;X>1-X-_QNDD^,?_!U!+ P04    " "'.JA8VC,W
M=#<0   7IP  $    '9T;"TR,#(T,#,S,2YX<V3M75ESVS@2?L^OP&JKMF:K
MEK$D.XGMC;.E^,AZRM?:3C+S- 61H(0*16@ T+;VUV\#/"4>('6,N2/E)1:)
M[D;C:S0:C8,?__4R\= 3X8(R_Z33>]OM(.+;S*'^Z*3S]?'".NS\Z].;-Q__
M8EF_?+Z_0F?,#B;$E^B4$RR)@YZI'",Y)N@[XS_H$T9W'I8NXQ/+^J3)3MET
MQNEH+%&_VS^(B\5O^?&AW=OO]MSWUJ%M.];!X0?'.G(.#ZQ#9]CO]X_Z9+_[
M[A^CX_=]Y^C=H4VL WS@6@?O]WO6X?OND=5WB3WL]?OO#KLATQ=Q+.PQF6 $
MJOGB^$6<=,923H_W]IZ?G]\^[[]E?+37[W9[>[]<7SWHHIVHK$?]'W.E7X;<
MB\OO[ZG70RQ(7/Q)>DGI)RJQ!^W \902\=9FDSVE;W=_OQ<75\QH!7OJ"XE]
M.V'O2&[)V92(7C$1O-]3[Y6@KM7M6?U>CM1,V;>Z^Y:J)):2TV$@R06@=T9<
M''CRI!/XOP?8HRXE#IB&1Q3X<P4RKR7F(R)O\(2(*;9)K;;Y] 8AA1F=3!F7
MR,\1NU@,=:4%EXILOX-"?*^8C:4V6U520%&M7Z[\'O&D4+\L]>OMBW Z>_6E
M!L(:83QM)#E+$TJ/GC2I0<98>T='1WLOROJ*:U!H3;J\I?ZT>GT N('8,K.L
M+QM^63'=.NJ0]KQF=8CI5JQ#84\KLP43I?XM5JU&TFT;5R.B;%0-S4@0^^V(
M/>W9+/ EG]7I$D4D\8\FG6&.F4-H$]EQ<?5'@4SL^TQJ>O4D>C:=4M]EX0-X
MI,SH.+:E>^+&#CTW7A1T6/W?,>8V9YZA=^]-.9L2+L%)9L<:S6#,B7O2@1''
MBEWG;U-.WD)%XA(Y_O/]0;T& 42  ]?J7J7ZQ"R429QT!,#@D;"%6JR^0]RF
MZ@,)]>F?07D/#YLJ#R3$^W_7V\9>4[V!Q Z\94Q>D3_">T2=D\XI@S#Y#H^@
M=NKYU_O+JOA&2TY)8KXQY]00/W7UOQZRTMC:0IH2*=*/>XL$"ZP"09Q;_Y/^
M>[%[1\11D0K"A3:J33??H0K)HH=Q6U:VL.\0'XCA#\$\ZJ@)QF?LJ2#B84R(
M%$V:WLC+B$D?@'B QB0)*!%/E&6*(JXH9+O#*]/&=YB#>F,B*51XG>#-,S8B
MN;\,DNBG.2E_WW9DDP84S+T%EZWKN&J7+&%J1/2@'J(I>\1<E K889DV^RF;
M@(9C*$.?R!43ZX0TS]N([+MED)V3@Y2@'<(I"@^2V3_&S',(%^>_!U3.U@AQ
M 7,CQN^7P3@KZ&]_/>SW/OP3A0)W6%?!L<Y!N(DDHQ5\6*\5[,;K$JS #6,Q
MOO#8\]I<>Y:E$>?#ACAKAP[LD>:_13">$6%S.E7<F/LY$-0G0F ?0E]!H<-=
M4!_"4XJ]M$?4QW,)WD9@C]2DE0K;8R+@1/U(A2@08S$(Y" M2#U-1&5Z]A:!
M_!!,)IC/P'_2D4]=<%6^'-@Z)TK]T1UT!QN JP]L37XF,'O=13 CQMKIIJQ1
MRAO%S+<(O>PL](Q(3+T&4!41&W'I+>(R-TM%$9\M@@!B_0F5VFV 7X$A1-DB
M\9OUFBHF1DCZBY!DN&E?-\=OBZ"YP)1_PU[0($>:DAB;?7^QV14MTL1;U,;*
MUIBOP^!FYAX3&=OYH,B\8437Y%O4TEI?"%M4##R90L2JZW,'WK?)\%S!Q(C$
MN]R8K+A9FAW*\D.:X19A<T\\-6F &9^</7+0'=L-TY&E'(RHO%]$)6*%-"^4
M9;9%B-2+0S<5W]:)<X^.WAT<?,C%4_7C7/13_-<V)1?J ?"(A][Z88VX&D'-
M161-0 V%;!.D!1.1IOB5LS""E8OC"F<TVXA+Q:RD*3YF5D:<"N/ TFG.-N*5
M3%Z:HK-(:,0B%PFF<Y]M;/C,?&:9CC%/:FS\7,"7G1!M8_-73&H:QP%&5D9X
M/C2;)6TC8,VS_XV3F\N+, )\N+9U!O13)'2;P*\7:@\<1PO$WJ6OSN_H2C>V
M@C7(,II#;MFI0;!OH50VR@C?&48I6.J(E!-XA+EW3(*RT*.\V1GU DF?R .Q
M T[5[MT;)B]]VPL<XE#_-%6/N;HL<6Z(5!MSIH0_C#$G&S*M#=?69)R'*RRC
MJ<)1[57I3/U1K !*-4"@ HIU0-1'&2T4>:0' D7TAB@$JB"MRU;:>L%\-365
M6V5NIP%7VT<&0A ]9[KC9(JI<_ZBX@<2C58K39"7$FBTN'H+A O&I2N HAJ@
ML IZ^(PJ@>):Q,:RLY4(NJCCBCL\4V'D6LVBF+?1 G+9KSH6$,M"D; =T'DP
M>$ VT_^+>1N!KIDYRP&M9.UZ=!UG?$7QD'IZ@-V8P\_+, *?2\4U]_$9J=MH
M 17YT/7,?)858,0^E_JK3L/N9CCU4$_[YC6644R=G$'Q1U<$"W([].AH[>:P
MG&2CG11F*:OL).LKTIID#LK W$17!J6UV5G1&K#\K?=Z=O1;;V=)KV=)R;I/
MBEV2IDSF@9F1^AH:#2!PL$PHF7^O<@ <VE2G.AM[I@W6P6A9N51]9AEKWHS2
M[&UF<IJ-8>)J(2RS7,"PDKI%N>"=H84@)^BY:HL2/+]7US*MQX ,O(V&D4OQ
MEQM&!FL71=)0*&Z[H:X(,Y< MXJ;$<Y<BGX.SNH =9NPRRQ&PTS.<^_)B H9
M'E).5JV6BCUK<S5A>93+:,^M?EM(BT!9&9FC7-O8(3/-'YY,O'5=HL:C58 L
MYF0$+Y<<7@ O.CH9\]UVO#)_K@)6 1LC4H6'2C)(S>\YV6Z8[CAQ ]\ASG?,
M(0!8(H:IP\P(62X=NP 9<+9"UBCFO4..@*?AZBCQBGVLF),1L\K#+2%F(=M=
M3]/Q0Q+BZZ5C<0]Z\2?B0-1V$<!$GUP*$:A,]$I!2E,A1I0+<Z;9F"4SH0AE
MHE@H JDH%(MBN5MI!14[\]:T5VA) 4;T<_DKPX; 7<J\'NR9?JH*W>H-> -;
M4D!XMD[X:PDRFD'3?:$+;D&[BE TBF7O+*(,*#6WU\\'X#,GNM7$5R!IFG]8
MAS"C9>2R38TL(Y&.,N*1DK^-*8SZW7BX6"C:D0#^5K\?/&/NP.!OLY%/_QNC
MN1&/LFQ5C):5WYO:V.=8PWSAJ'HZ-@D=4UA#E%9Q*UU3V2'>QJ9C8F0 _ETW
MER4K/Q3\9T?JX][\%=KA[[EKMM4EV]''!#2.3]+[[7$,"JJ;O:"MU/<GSO!,
M7##^G:C4/G$&3P#:B-QQ:I/,5M<.PD.5=[3E2<?%GKH\6%T??M)9EIU//4_M
MASOI2*XNLM!?;3B>$DZ9\Z@O"W8"'I45 <BF,E"_OG 63$\Z87$JR:2#PKN%
MPR<QT26\46S2"\@7VT'/1W)>;*#R!R-=\O,L+7*'9^J1]@9AK )>:PI*@<;7
MS-&[C;58_TYK4-I<&Y:ZH585>NYF;M,OZCYE?Q+NMJ7A=PG^$W^X0LW\,+?'
M Q_\_!/QV%05U"X79@70FP5H8<.CTL9;%_NUMU+Z"1'%10DQMU6R9 \5_H8Y
M5172B_?BE(GR-C"1-=$M?#<,][C!"S*DLI%=P%P?7"R?U>AMT?![ZV82$G$N
MX&(Q :%/CCV2%_G9T_>OE'6FE9ANT@ID+,;<,C?!9$CX;;HYX-)/1.EH&Q11
MU_2=D2D35-U%5](:S1F96R#\N$@SHZ"^)"/"S9H/^MU^[WPR]=B,D##9&$ '
M!EM60=LU4>IDM0TK&2I;CW:3$#ML@FF-<2:[4)^L^J8A3/G :J)K@-X?V-$?
MG]GCF 5J<\L-!2)"_-N)3X=!='GII:_<(WW2.)V#/Q]Q*'+'V1-5'\>J1GU-
MS-M@%F?@D\@-=,?KLY_/KC\/JA4O*]T&351;D]'H"^$3[,^J]2@NVP8M?L9^
M  :NOH!Q=WEWGIE(5&MDIMN<=K65.X7I@[JL5X4(\:F7:,-ZJ?^II%G>]]B<
M.)N+,K *!J(P0#4-Q$FG>(IM?1=W61112=1230?R<4RN,?]!I*J_&"A/ITH8
MADT361NZ(HSMO0^7OA/8^GF!:S?&!C7IVZ#M*?.C#T/>SF_JBW=ASAY9J,+7
MJ9KJ@5E!E'/I#P(Y9EREI,*5M?*.O#8!+9U;?.'8)9X+W;;6&%1:O W6D)_\
MIZD!;;F9:7^8$CA_@1DG%6&*I4;>84F^&QS%XL/?YM8IRBK=NE=8R%Y7)9Y*
MU3<3MD*_Z%1P//3"%#]*;^I!V#1BUZ1NY[P!*G\QMSW($$B6%6]#)XZ.@EZ1
MD49A$$ <4 M!,V%;PQ$8<H_*IV+F\;H&<1N0C4?',Q*/DO/G@/3 >NM^%40?
MIR@%NC&?E@Z]F;S;0-^LT*0/UR1NP?SIB@ *9!ZB\Q>IOH.DHJH0,B#X-U-?
MV9@9U@"6Y/;J*R;%&?8O'%=XM$J:=HY$D1.>F__6=-S%-"WUV?,&J#V2>H^]
MSXQS]@PO[B%X,"]$&,C7G61>9JT%YKK0)&"#WR'XNW4AT"7\FOER[,U43!R^
MKDH0U*%NJ8N&(48[4O5E[,'CM2'/6%RX#4.O6KH #-1_*DAXPIXZ)PM/]/T+
MES#'%>'167W/T\R\>K0\PY:L'*VX''J-7^@DF PFZGZ:3:VY+@AII\?/9 #5
MI[*H$WV_\AYZ P2A3K1PK#]*;$XB&EELS"/6=XC)@A+4S\, ;#+W=\-%TVRB
M*,D3J?S0 Y$R9%;:%NMAWM)1L]$2U!I7L]KDBE6THYJ8.*&79-P0Z5<0M""Z
M-^[)$89-.7&J3,0;<1;2386;=D3=A-UK5*H5V;#$CYR.E=*7?O)@(9&=6733
MD;?9,S7GV-+H#E"V]965H!%5V>R:"T%FNK8XFF"^!]2=B161M'1(N2'/OS+^
MXQ1<?C5H!07;@%(^75ESB=E,V%+$YGS%0 R2("8.]PQ!=6WZUL?+@Q'XC1%,
M]*/MO]^8%TSJK<DTY-)2!QSONOO&I-YA>H[ML1[?YC8E&C?MF<A?>:M>!JOY
M&Q*$:;^SD?#5TYK%D5:M?=C$B?$SK,&O5<8K;_*N<%YJO("9[_+>;X%!2]U_
MO._4$&(ME&K'4)U?>OA,1M17FY[6LI!1@]NK]_BY?<-19TL.P>NUB7K(FNG;
M@/DU5KL3^\;<;[Y<&VJ?NUDIF:CHVQ*%6C.+DFNW+@@6,(5E-B&.N/7#P:?.
M,+QF*:TX8+*8?8MW>56LU941M#3V6O4PE>ZJ9?D1_?(,8M(D1W#!>#PD9WO^
MQLYZK:MZK4CFQ$%,9IT NM"(XXGY1$LAS2M'Q*8,4OFRDY&PI;VM:+1/0K?(
M?,590 :N)/Q7@OD%"WBCV*$&MY9&A"6G8(OGM2L<JZW!\-6CJYOP]L- ,CXK
MB)0,*:YZQ&V(3#++-\HVU?+-*DM -7BT0>ND8HVAK4/9!@V+/).(AZ+S%P@1
MDZ>-O%LIC]<>R=+(=3[3$,;#A.N3H_=$0)Q;<<B@"9/-:%PW@1'O28A]:9R2
MBG:%I]_^^JIR$;FI06D;K,RWI8-;KJ:/A$^H'][Z G7CWT$M2?P;)D'1)&BK
MS/VNP/*U4Z'+1O7IY6=ASTC/UYCN/=BDR#]XJJHO*1$0[$[PIS?_ U!+ P04
M    " "'.JA8!"QL?<44  "5OP  %    '9T;"TR,#(T,#,S,5]C86PN>&UL
MW5U9<QM'DG[WK^!J7S?-N@^'[0E9LAR*D"VM+._,/B'JR!*Q P(:')0TOWZS
M )("29 $@6JPI1=1 )O=7U9^G5=E5?WXMT^GHZ,SG,Z&D_%/3_CW[,D1CM,D
M#\?O?WKRU[L7X)[\[>?OOOOQ/P#^\<O;5T?/)VEQBN/YT;,IACGFHX_#^<G1
M_ 2/_CZ9_G-X%H[>C,*\3*:G #\O_^S9Y,/GZ?#]R?Q(,*$N+KOX[?0'E[AD
MO!AP*650SF;PV2EP.0HAO$#)]'^]_\&([+5+""JH LI(#LXP#Z)@BEP([=CJ
MIJ/A^)\_U']BF.$1B3>>+3_^].1D/O_PP_'QQX\?O_\4IZ/O)]/WQX(Q>7QQ
M]9/SRS_=N/ZC7%[-O??'R]]>7CH;;KJ0;LN/__'[JS_3"9X&&(YG\S!.]0&S
MX0^SY9>O)BG,EZ-^+ZZC6Z^HG^#B,JA? 1<@^?>?9OG)S]\=':V&8SH9X5LL
M1_7G7V]?7C[R;#@/(U+>-'P8XNS[-#D]KI<</YN,,XYGF.D_L\EHF*NJ?PFC
M*L.?)XCS&4FRO//\\P?\Z<EL>/IAA!??G4RQ_/3D;#Z"JG$F5W#^<XN;'G^!
MG,(H+4;+$7I%G\]O7=$U1X^?YDA_L1JPB^>/)NG*1:.JKLGTXB]'(>)H^>U@
M,8/W(7P8O!J&.!P-YX3EC\DX+:93>D\&@:7"@XS@2B5O*05\X E$LI@$1I:"
MN#IP5;H9B;?4= FSN%3W^5-([4(>XV@^N_BF#K)<#O"=0%9CN[MTKS_0.,_)
M++Q"HMK%(SZO2>ID*;8H"]DP#DIP!1Y] 50>LRM%\10:2WHOJ*M2KW'JZ30=
M3:89IV3TGAQ]Q&J@SNW?"F&8IBMDN_GNG5]Q/%N<GB[O"<,YGE[\?9E.3EOS
M8S[I4B<K)I!4^U)E3="GX_SG?)+^>3(9T5C/?OW7@O -LDB^Q,(AH4IDR\F@
M.Y481,E#"EHX#+Z[=V(CIGUEWB!EB-))*1-(9 848PR"S0C:>FM,5.B#;2SE
M?7+UY@78GQ?7WX4]%= %^0?,,9&CTI!<=*"D"."9X! 3TEO)//G&UA9Q[?';
MJ%Y\"ZK?=<B;Z?S9Y/1T.*]A<96.HHYJDRF,KH \"2!--F!5J(#(OCMC.&!,
M223&43'=F -WP-F&$_);X$0KE33CR ;YF/><96'!%TDX,B8(+'#0W&D>I2'_
M?V@'\7"YWA PI&!CI<#_":,%#C3RP(.C2(;;2(JS%H*.&;C4R:%2F5[2QH)M
M@-$GU[>G]J^S>]]!;VKY)N,U%%;&R.DZ"(I1-B\4A^!C@1"3,IRA+5)V8.[6
M,?3)[S76^U[#W4SI3W,>5MG#Z$T8YI?C9Y1_4R8^,,QJ*2T#FR.C5,8*"")[
MXJ*6RDH>.;:V9[= Z9.;:TR!%H/?C@DI+4[KT&)^70LQQ,\/4SS!\6QXAB_'
M:7**KR:SV1\X?UW>A4^#7$(@,^3),O$ 2@<!T;E,F+7+5IDL8^N ^($0MV&.
M^DJ9TZ&RFC'J+<[#<(SYUS =4\0V6P/]',LP#><#DYG.WB,8FW--ZS1XI+!0
MAT &+Z6LO6I,HOM1;<,;_77RIK%*.LFTT3GN@M%@D2&0O<L0L/K!'*.3S@HM
M.JPH-93DV7GAKG!ZRUQ*E)G0L"H? SA7(J4L0MM41,FZ-<EOHNA3!+VKMN\H
M%NPRUEVP=ZU>ZPV95:L51&X-Q7,&(2*]3:Y0ALI\T"YVR..'U<T?H7;42O,[
MCGB[N&DVP_DE_T12:#5)P;*J0;PT))2A1,YD'9-.J'EN'16M ]@["0RSDUID
MH1_5W9R%T;+L,G\6IM//Y#%6J4J0EFN%FK1651>\!/K*@?#&1J8CY:^N=6:X
M#; ^&;G=>7$C4VRNDV;D?S/%#Y2Z_/KI0YVD)9#+:/2JZ$[([%BJM7J*4I2-
M%+EX"D"-X5)*BCR=;%TUW0)6GZQB.ZJTUD=C*SE '\D-*P$V%++0Q9-8.9+A
MC][9PH-KSX75D]M.F;^MI'A=_J(AKG<?.,\38D'@,E#"[FK,G'R$(BEJ)F>4
M8S"=3I=? ]0_._@@S=\]-[[/X#<T?!,"-?_\9A3&<WK/JF'^4*<H*.4>B."=
MJ3F3H%R-,C1EP,O@(1(L%Y4I+K<NC=R%IW^F;B\V-!OZCD) &V6B>%.!4"*"
M2E%"-(*B4,=U3C$)%UH'1P_V;(<JF#90]^Z#VT5^=X$C<DT2* 2TSE&>R1PX
MF2-(JQB/1D?997+7*-A?!@<;A.-)4GR@<YV=K?5GZ:#6?D!K&6VM ?G4>L[O
M%BA]<F1[LN"&4VLP^"V+_],%YDUPBA!9,LJIO:5H5.< S@1%?I;>Q$@1J2ZM
MB7XKF#XYLL9L:*. EGR8+"C)?!,^ASC""RS(F3>*:&E*I-2!N:7U#4!2,B53
M8;JT-@R;D?3)Q[5GPKY#?XT&/QY?'Z57]+EQ1_F?<_IWV:,S*>?Q.OWV*J+=
M6\MON7N'/>;;R-.HV9SBUB]3=H/ 41-A%(3$Z7W/Q!UO7*'TW*!E2EOO6^>2
M5P TRY379(K&(6.U(F64))D2O0_+3C[O4PA22XK>NLJ/;Y/L<8.)W75^:W*\
MXW@W\QE_3,:3JUC.RU #E^B1VDCP* 0H80NX8@K9KMKSHISVLK7;N!5,GV*(
M=B1H,_;-J'#)R7,4))Q70H5(B9J1!",@B>F3 <+FDL\VA=29!;@ L7\_PPQI
M<&HM_CF>X6BRK#I<##1+Y(8U*X#9DX2\YK@Q"/">LEO2K",5-F]EN -0GZS=
M?GRXV<302@_-"/\;CDG"$2%ZFD^'X^%L7N4]NWP+"RK!4#'P0A$H5@VR$ RR
M]P)SMLRRUA7!>R#UR0ZVI4=+71S .087N;'>@)5>5SB2?+65(&R0145E='/+
MN*5SW%Y*"N('+\)PNIR)?'82QN_QY?CRB]?EW32,T\FJ<C^K'V8A55X\F\R6
MU4&C<YVJY#$54$49")RBE2R\],R20JXOK;F1-.P%X(&6$KJ-"9H0Y>*=.)QB
MVL4.-4.[(YYQFC/E$A@F V&JM=\2+2AC9.!1L-)^9>J=B/ID2-N2IP.--&/)
MR_$9SI9K@E9@7H[G.*5O!B5ARCD@H,S$V< ]93V) _/19HX^2Y,:\^,V+'TJ
M4G7#C"9::)]UK"55OG:2%33@T.6Z/BQ 0*F 96.$TS9QPP]=>6B13TEF37"6
M;''AM7F.2XC( UC*&',VW&36>GW&/?G4(_O-?95_:UEEIR%_[ KLE?4 2P9V
M4(B]^9 #U6/OD:Y167;#FHK+]10<K15&2\BQ+CO-CCAFF2)J)$?6S48;L?'K
M=P><O9.3*W6H(LAKZQA EL1 Q:C N[J^P$FC(L\R-\]5[RA /V[AHA4';M3K
M=A[QMG'V!OE>3*8TLN/5O%/ZO)844$:]_'2NC?Q_BY7OOQB1-Y/I\A?S^708
M%_,Z>_5N\B:LFAIE8"9'"9YG2KHI?R#C*2UXJ;6C["(:UWH:^: "]BD+Z(JT
M_67,H[I;\D=A=O)B-/G8WLNNW_L0SO566=I-==8'O)E.SH9TMU\^_T5(7HY7
M>00%6T^)-F?GRT-JGL"X@5A<I+22[*&/#H%&SDJ&SD17VKNA+='MW3X:/B]C
MF7>3I^E?B^$4;VUJ'(1</!:KZZI-!8H'#W0_#I&1BPB*+$3S^N#VZ'J5 G1$
MKAO]I]WHKEUK\CD^,LN$+"'FV0L:JR^Y^FR0G/(E. 9&4;JO8B';ZGP$CTKK
MD%5BLG56?#^J![K0;XI+C735;KIBL_B72?&:^-HDZUET=8*YUH^(Z*[4K4LL
MQ;1:&;3-]P'8'MV^XW![:/-;&(YK\/[7>(IA-/PWY@$3#(WW >HZ:5 F:_#"
M6 A>.8>%(A;6>NW?0_!]#;9Z7X)=?[\ZTU_+-VV]!R0D\@DA $=)LL;,(>20
M(//(.4/-M3M@\]>C=\<<@B*[*Z#A9$::UI5-SW'U\^7X9COPP KKC3 >N- <
ME*NID*K=/,X[81@&AZUW$=@&5Z\F.0[#F.;J:D:DYTBY>1HNQXK^/\+S)/SI
M:4VT_[W\?A B,U%X \PJ1_%*-."DXX#:25EDR3&U+L5L@ZM/N_4<B$C-U=6A
M15H6?[XLQ%QCNF#>)E:0PM(B0"E?Q\(ID)%+E[/@4;4.>QX KT^;^3R:?6JC
MO&[]W?JBAX'"7*S#!-9$2GHX$D#K)3B,EO$@"%CK!/5>4-LPR7SK3-I'41WR
MYWS?@^?G6VENW/]@0)DX2]$1UD)!/F72D4)[BN^M0&^]TB'IUL'U;DBW89K]
MQC*U ^BTW?Z_)V&*OX1E$?VTHEIY:J5304-O0/9HJBVU]2  2B!L2:[VTHC<
MNE*[&<DV_''?EJ5JH)*]Z5&;+>_KL1R$HHVI,VY1.23"*B)L$1G0>"8YXU'8
M:],:&YM=[WO.-A3PWP8%F@][,SOQ>QB']\MYM1=XV6]G/7J,M7FHEG)5=J$B
MJ3N5<6U0)6%=Z\ZM33BVJ@:R;X,AS?31=7W]Q7!,I+TJ<-(H>%%U%\ZZKQ<9
M-/#,&(B! O2H!5>^=:O1]N@:;*/S9=)C-EO48YU>E[6ML0>RU.VPC:0 4U=]
MFPR.3"$8X2.-"#&AM!;_7E!]ZE#JB$D;-MUIJ*B6VS!=POI[F)+)G__Z":=I
M6!LVE9<FR6S F1Q!B4*()&$+2,F)1XZ:L0ZI<QW/5U!;[Y(U>ZFG$\(\Q[CJ
M1+H@]&K5B_,BF4ANH,A<4UIG(#!>@-O$@L88K6Y='[T?U5=09N^2/ U4U>Z<
M#)+]VEZ<;W$VGP[3'//Y7IU7OUB[\@U.AY-\,]E-HT5>-ING923[-LSQUU(P
MS0=,!"<S:F!*87U-!$3-/&BF$6W)3N36=#RLA ?L51!,,B9XA)**J\<I%+(V
M08"6/EN>9#&R@^G5G7H5'KGON;\<WS!_VX7ZNP[U-W4291:EITP5%-;U<[D>
MG^M2 &:+";4/7,36J>&N+8^/W.'\U=-S7_4_1B8:5)+*^ )"4-2F$D:(UC%@
M4:!0]"7/!Z+GO9GHXP9(7S\]]U5_,WJN1'Q=UL5^/=YK@ ?"\+K&1H'VM83D
MHX,8$X*,:%*RK.[/UIC''8C1IWZ)KXCPCTVHCI>JK!^-_KP>]C.:U7/K\V*$
MD[):P+/:4' U?Q;&^>J6\;/5'^VPD*75D]LL<^ED'!HM@MEFD_Z<-)>.C*W-
MR*"N% "?N8)4BG+.,:F:GR?ZX$,3'C8S=G[[9_2[85INS_,6EP=/+5/Y2[DI
MULF.HG-C:K>[# HB,0R"2R[;9(U7_!XB;OVP/B5<K3FQ/CG6?N3;+D*]*B7R
M@C92<,%DU'7-C 47? +M4F;&1*N:MY/U^W20KJC12 ?-N+"<MWV:R;Z^"Y_>
M8D+RKVL;X!9N#?KDH5A-R;O  $Z3Q#EK1EX?E7:M>7$WHCYE'%USI*%NFK19
M_#8YP^GX=.6_A[-Y]?7_O0BC81EBOF-_P#R<+Z8X^SU\&IXN3I^>UEZV@;/>
M6YXY>%XWW@R!T!?/@#.=LPB91VNW\#DM,?4IN._2-3V:'INP<#/ W^HTU\!K
M0P2)Y#\YBZ"8#1 -)0:&)30VAYARWH)4=SRB3YW-77*DU2@_9N9UK6VVFR1K
M\T,.D$]M(5VCU.F6S?&C)PJ93*Q*18'2',%E)\'$)+C**;GF,_W;G$OPP-;!
M\_A\&95?$]#I.L^I:TFA'FO$8@;GH@+)DROT&VFN+_[:W#5X^R/ZE PUT/*5
MYL!& ]O$9[S"]ZN]:1?DPS8ALBRE8NKVM$6229-US9A6 J0K.7JK94:WA:KO
M>TZ?,IS&^FXZQ%T=J;)>@QHPR84LR0(+AB2U-I&DK![\DZ1@CJ15L5O[M0ZG
M3XE-0VJT5L0CQQ-UP6FW1=O-#SE,/'&?=.WBB5N.78K615ES6.GK'(/6E$P(
M5R H2<-GA'"F@U=RFW.O=JVRW2JJE"BX$0PDZKH&T'$2U9-+3-$&E0(OH9/C
MWO8ZY^N L4@#AFRNN3712).HY!S*E4CI DRRS@5K-4A9;6*P$9R,$5+4AJN4
M4%\_W'9C0'+'(WH6BS34=\NQ;:KHM452EUB\B3SS D74"8"D$T0M-7!AD2FN
M0KQ^N-N=>K[YA)[%%1VI><^1;:GEFX'P!2*=-6.U4!(]HR!*1@$^J4@ '<,H
M#;'R >_TK<_I4QFS,XVW&>6^] 6LC4_WK0 W'W;@V?][I&T49=Y^U&O6R'/=
M'K!V5+&2:S]J $'Y# VH$;'Y.>%;G;.[@X173FB_N/_GR_FAR+WWA2Q>J+L$
M!$,)-Y,"2A0R8>&*\K;6@MZ)J$\19@MVW+I[_?[Z:#O7_^=BG*>?-T@KC#?2
MD.G%7/? =IE"WJPX9!555A00<]MZG=^=@/H4DW;"D&;:Z'SSY=/3X6HOS#"N
MNQ976N,XT45?;/KO8;Z8+B6X/*WUG/NOXVCX_GR'I:4CV,&?-8?0:BOG+D>F
MD>][A;,9XBWVZ&+[T^<+'%B6?8B4"HF2B,R^;JAJ-0/#0M&9J\A*Z[4YVV+;
MU_+=^9R_QGDX6U8D:\4KT:47T]G),6XL0K!"UM.W*"QU28&(TJ.C06+-5S[O
M!+1/OK03METWG=VKL_V12%=!#J(/QDEFP?A"XCM#L-0R034RQYB8D^XP 5F?
M_.Q!V--")5^9RQWP'CA= M%/MWM]= [M>+5E*M43<BUW!93Q#*)C'K*UPM9.
MT)1;+X?IA>-=>\[_8IB^(]GHS9:H-(\".*O[(7J7P.? P&&2W!AOO6EM&!\,
M\JMTN ]AV8,<[MYJ;.9L'P3SXV009"Z96PO2.5L7?28(/&:0F:/QTBI36J_L
M?R#$K](Y'XQI#U3AP7GV!WF2=Q]Q=(:_DY,ZF0V8X,[&6(\L- D4O0DU!*67
M) 61(R+Z\%B$NXZU3W-%O6+>7DI]%%/W8K*8#KA4HBBMP?%2Z@J!NH&;]<"0
M!L<:YS"W/LWIH1C[-%G5*\KMI,3#4NTMGH8A!<W3U^4%I=]A5#$/A%;&&NGH
MK4@(*GD+$8N$+*5U$57&U/K(A-W1]JF=OS_TVU^QC;IVMQN0IV6.T\OWQ0JE
M6#3U=$4I0:EDZV&+ 43(@H8*A>?7>LAN:>7=X>%]VJV\4SH=1CU;5ES.OZ__
M1,+P\W?_#U!+ P04    " "(.JA8(H#R-L1*  !V5@, %    '9T;"TR,#(T
M,#,S,5]D968N>&UL[;U9=UM'LB;Z?GZ%K_OU1CGGH5;7Z45+5K5ZV9:N+%=U
M/V'E$$FABP)4 "B;Y]??2 "< 7(#R V I'Q.420(8L?P969$9 S__7_\^?GL
MNZ\XF0['H[]]S__"OO\.1VF<AZ/3OWW_^\<WX+[_'__Y'__QW_\?@/_]XX>?
MOWL]3N>?<33[[M4$PPSS=W\,9Y^^FWW"[_XYGOQK^#5\]_XLS,IX\AG@/^=_
M]FK\Y6(R//TT^TXPH2[?=OG;R5]=XI+Q8L"EE$$YF\%GI\#E*(3P B73_^_I
M7XW(7KN$H((JH(SDX SS( JFR(70CBT^]&PX^M=?ZY<8IO@=L3>:SG_\V_>?
M9K,O?_WAAS_^^.,O?\;)V5_&D],?!&/RA\MW?[]\^Y_WWO^'G+^;>^]_F/_V
MZJW3X:HWTL?R'_[W+S__EC[AYP##T7061NGZ ?3X/+OZPYO4Z!\6OZ2W3H=_
MG<[__N=Q"K.Y@AYEX;NU[Z@_P>7;H+X$7(#D?_ESFK__S__X[KN%Y,(D3<9G
M^ '+=\MO?__P]CZEP]'LASS\_,/R/3^$LS.B>/X)LXLO^+?OI\//7\[P\K5/
M$RQKJ;]DN1*E*SG_K7[:#SO3](D(F:3SB$"OXJA"O"&-JSY]=YJO/@LREG!^
M-FM(\?W/;DKO^',8MA3PO8]N0.W\@^ S?HXX:4GJK<^]0><ED7<I_#J<A3/:
M-2?ARQ"G?TGCSS_,"7PU'F5B&C-],QV?#7/=8W^;T=>ZZ4['Y;?9./WKT_@L
MTY;]T[_/A[.+Q]GX.CN#NO<RN5CM_VV;I]Q@BM S' WKAO0S_;A\5"6_?_;P
MSQG21RPVK$MZSL;IUIO.ZG8YOM+O68AX-G]U<#Z%TQ"^#*X>20S@6_IV.G J
M:&U#@*R,IO/%6@C:"C"!*^\L3S:;^^B87J*MA&F<XV/Y",*)D#_@V6QZ^4I5
M@9R+?ST5"RDWX.MCB&<X<-QRB4Z"\C& $L23SX)!UH:.3$__QUE?/,TIN,W/
M-6Y.)I><+5?F1@=,F8P_-]7G;-Q,C M-$='??S>>$(K)IJ)?S;>+OZ:S,4'_
M;]_/)N=X_>)X-"-4_W0V?R M8#RMWS1#PF(5O1I__C(>U35V\N=P.O!)E1*"
MAN*B J59)',K9S E!I8QJLAR7\!815!#G#QPZ#^ FRT4O0XS.PM\%81V1,,=
MFE[/CZM.1 WNF"&-T+"2H(8H6&M&/8"!W14W[DOJ>X,$#T4(+B0XGQ@HY07$
M$I#<A.2,3=)HHY\N%&Y9J(='PB;"[@$!1,[G\6AN<?TR-UP'46LTV45BT3IB
M41)!P1<@TY%Y95AB2C;6_CTB6FI^E;5_7^T-E#-N*=G[JF:[JOHDY[D0P]G[
M,,QO1Z_(+B<+?4E<P,*Q: >I2#K[&!E-WEB"M^"!>1W1:=Y8[0\2]!P@T$[B
M/:S\DY3./Y^?5>?K7?72*N,3_%2WR:_X=D3N&BX)98K'[(L'%EP&):.$**T$
M+X,2,=L@2VM#L3-QSP(FO6CB/F3$KI#Y@#/B%?-/83(:CDZG2ZH<S\$[VLV<
M,9Z\K$Q2$#H"_2]&KF21QC?&QVI*G@,8&LCXON;ESI[D>9P.\S!,+GX+9_AN
M$:)96$0Q*U%/,4/;%4&2!:!SC@ZUP BMUAI?4FLO<ATQS\&#;"+H'M;^#7)^
M#9_IVX^3,)J&5.5[Z=1TH+ G5_)QZ@[D5[91YUV0]*.+'HR,#I0:H;/0TD*.
M08 *C@.=<0FT-?0/DT'SUO[&H=#RF.MY*+!LHH*&(/DZ.QO\KS Z)X;KS<3[
MM^]_ND';I<EC;8B*2]!:)=I,A8%@@@4>O$ C74K&/G+3T>4Y^S<=6NMEW)-0
M&WJBE;:3V<=/^$N8_ MG50+3D],)SL_.)6G(4"#G E!& PK1@PO, #JCA%9*
M>.DZZ/N1QSPK=;<4:0]G 'DP$PQ3?(V+?]^.[E_P?1B?G;T93_X(DSP@%X=,
M9*' :(Z@=- 06%" ,;',A&/(0N,#84,2#X">MG=;?:JDA\C5C5#:;Y_"!*?O
MSF<UEZ8F* VP>&F8*^"LHU63=8* R""1HX5*21.UZB]>>8^>_6.C5V6N#VKN
MIHD^;,U[7 \P%%ET9."E)T?<>0E!Q@32AFR1T9IQK2,3Z[(FGBLB=I1Z#Y[J
MKSA;!,U^'D^G V:*,C5<DF)2H%)P9.IH X4SPRWRXFQK"-PBX'EK?WM9]Q"D
M.LG_]WPZFR<1?1ROB;W/=ZV:_)AKT(X<LWE.Y0<DJ4R',_P-)U^'"=_C9#C.
M'S"-3Q?:^D<X.\<!9DY_JRU$GLF0LC5!5:1 7R3'(%TI6)K?D?3+T_.&YU$A
MXC[BU:Z(7W==0++#X>GHU?ED@J-T<</5.!GE^4]G<RZOY4,+F5R2\.?[\63^
MB]EL,HSGLQK/_#A^3Q(:S0;9L)RXS2!]H?.]Q PA"&)6\RPC,S*EUJ'>O3+X
MO-?"\6+E_L+036S!M]/I.>;7YQ,R3A?K=V&S_HI_S'\UG4?J2XD29"(I*IX+
MQ$3GERG>2.Z\]T'T81\^2MGSAF(/VKF/(=,3AN8;_S61,J3"DO8@<@F@%'T)
M&3.4[$()J)5H;A-T(NQ%(F@'W=P'D-V'/?IJ//J*M(W2WOD:X^R?P]FGQ4OU
MQN -AMGY! =&H<@8+&"Q)"G!"OB$$1*3Q8G(F)7M<W/:T/Z\87@0#=]'JNO+
MCJQ>W>5I/P@E>AZ%@522)QI=ABB9 ":$M!:%SW=O8GHS_V[2];P1UEPS]]'C
M>S6VKK'^KMQ8"K]AHK?.AK1+!YT,$9^ 1T7BX9@@UMI/YJRPSO.4V8J2K/Z,
ML$<I?MZ(VZ,V5P2!=[XK>,@R>)QZ';E1BL25/1&NHF80 VW&21L=C,ZT,;=.
M?=^)X!<)Q1YTN0*)+5/K[]^59*=901*+U]&"RO1=D%F#B=HE884*HG58NONM
M59.[%Z6=\44C1"M)_%P:\*0$8CAG)YV,RC5/#%Q7L?K#G>7Q,_VXU_K<153D
M$\Z&*72HD6]1K'O[D8>JW'V \1[+>!T7:*NC)YRKT,L0T#,HK,:>A$M*M _K
M]%S&FU!%9FMSC"1#[7\A($11:'5IQ0.S+O#>>#IX&>\&^GRDC'<3,1Y-&>_:
MO,#@1>#9"/!2T.%JT$-()D")+J4HE$75O+;[R).O-U)PY^3K301]F#3:+A1^
M2[[>1IV;Y]-NHXO#H,:AP.2- 6MIC:C,/#@G$J2:5^RS=SDU[P'PU)*O>P;+
M)BK8=_(UAN)R).\I\T [*CH+D5Z B)[^4X%E+1ZQ7)]L\O5&>MDD^7H3H>X[
M^5J'H#E+X$JL&<AHP-%+P!)190(W08<.^GZ*R=?;JKNE2/NH\NV2 7,=9JE?
M:X^Z5^/I;#HH/I48I0"K^-SN)J0:E."-ET4[Y;"TCLSN0N]QI&7OX*OL35EK
MMY7&D9+7.$V3X9?Z0>/RX_F4I#2=AE'^,4R'TW%Y,QP1_</*U&4,X74M?SV;
M;A$BV?Y936(CC5AM%10A:P;_?5[;F'R]#4_M50FE "<@@F+5/7*6 2KKDV/<
M6-4\P+V&EA9N\8W/7;A_7)L4%4? E SQ9VD!9,E!\(R1*_3$8+_\[3=8TD+/
MJ]S@G01[3(&3FXS0G\TM^AQDX-H%,KX*;96%+'J?:B%<Q$ ;-)W+NH^:]16D
M'"QHLK.*'\',-J+NPP6^3];2WNM"6%_QDG5$'2Y,LK/J'H?##G+?*S ,MU9F
M%.!B)D= TGKP$CDX9F*R.03D/9^0?0.B0R1D?WC81-S]XV#IM"7#-$KR Y.3
MU9:NWGG)&6J_)A5UP!2;UXVM(N0 'DT;13VL_BVDW# 0DG$X^&DT&\XN?CVO
M=+PK/Y%[,;Y )(R77",PG#">D3#N- 3N!.2:UI*%18,/*7Z*Z2^GXZ\_T",6
M.J=OKE7]P(,/KNC=+,=6(FT<[KHDYC5^Q;/QEVI2OI^,3R>!V+2LAEY<K4XM
MBMA,!0)S%B33Q@:5M'5W<FI7AKH>>,03UVE+ ?:P<=_MDW6CB=IK$G4:S@:2
M*. FU8(!:6E_$0RB)\L6=2QDRP;TJO65^>-4/7%4]"3^'LJ ":@),4_?D$ N
M(V7OROO)\"L1^?XLI+FO.4#G X9B0%LF:8\R$B)62?CB6'8ED"P:@Z0;9<\$
M*#VHH8?2X5=A^JG^KR8M?0UG-3SW :>SR3 1H.LO3D;Y]@LWWCD0092$(H#A
M]9Q+LN9?&P'2Q!A89!YEZUO4G0A^)M#:G]+6ENXVCI?_=O[Y<YA<C,MOP]/1
MD+;1,)K1SCH^)]MJ=/I^?$8;*TZO;P;>CNJ0I7EYYO:!\P8/;1)!;\U\HU Z
M;6!?<#*[H+V*Z!GEBJ$OM^]\LL5Y>E'MJ*1!.6;!>1LA>13)N52R;5T#^#A5
M.WO&Z1/F\[/Y9KWF6<N,JRP]<]Q *=K7C*L +BD%U;07W&GE[EK2NSO+'6G;
M5QB^,4;NN<]]J.+00?KI9#;X$$:GB^ 268<\%Q/!8$Z@)#F(CK$,HIBD8E19
MYDX1%_K4&P"BGZ[!<^N!!PN\]Z+*\:XB;>B@71&QC/)T(6.30'L7#;>/GCT>
M3M]!^'?5MX/D>E2DM5Y'EP,(I\E44S)"Y%&!+<[S+$TJL=-PK$,K<$WXN[W^
M-A%88[W]$OX<?C[_?-D\7 :4*0K(QD50N?9EDHAT /F0BR_,:-= <[<>NC\?
M8R>QCUO(K&'8<DX(B>J:D**<8KFF"Q8]C[-9"$@F!'K+R$4.QK-.YM5CRKOY
MT">HO*UEUGCE7>7W_!UKH/3+IUKXM,@C9J[H:"V(V@Q>,8?D<,8(LEA?@G2<
M=8L2/*+(M00\6Y.GC<@;AB#G1"VLXYLD758'=""JH4&TEI#]FT>-%#7N2\JM
MMX*UQ-E0AT HLBD4H\/%, <>.2&=V1@S,XZ@_O14_X!AM4_-;R+<AAJ?!ZHF
M%X/??QM$6;*PY.MK76>5:\8@>*_H# HFN&BSCP^5Y5W>(B\_<:'AY0_7"KY^
MWGY/ZT:"'^\DM886UR4%KW\:L)B$\Y:L#94"D)DOP#-/1C]*D>CI5NJ'/)S-
M]/;ZI^>@MPVEUL-Z._E]$+QD6&*I24GT1=%NXG3*8)@IV3J!3#XT0F0SO9W\
M_ASTMJ'4^A@HM+;@SAFM1':27"]5$\TL Y]=!NV-- 0TAMB\(=#1537W:32W
M54$?X\8ZU&MUH/!;O?,VZMRBA'4+71RFWEE(&US6$IA'VC(Y4Q Y6N!9*NDB
MEM2^X>M3JW?N&2R;J*!QO?/[";XYKU?"_PP3HFMV.5PQ*ZZ="1)2+<^<]PEU
M<XZ%X9%S:P*_DP.T,A=PS<<?9;GK1EH8MQ5A'Q-B%MD>=W(\YG!.2C!=AZ4E
ME'5R)H_@N/!$7F3%A)2XC#TDYZRFYEF;$XV4T$.?_'MI07=H7/WJ99IZ!]I[
MLC1VH?LP-D@K#-Q+-]VS GO)6-Z!!\PAN9JMIKRL'ANK=1BL0"A""B.8\ZQU
M5=+Q@>\1D^88L;>)WGK W"_C$5XLNE/48_MJFG3@%E%F\*[DFHRD:_<1!K;H
M'(LTCLG6'O9J2O9O&^U/F^/FJMB?X31[1>;=Q7!TNAASPU*0(3$'N0AR":24
M$&+2P+WBT:B<I6T]H[<38?N'3\^9?NW5T5-)U54_B[>CZ6PX.Z]2G_X^Q?QF
M/*G4O\8OX^EP-AU(Z40=7UK'@1&^N:>=-R$'X6+.P8E,!'?PK39][K-!1N]"
M[V7BZU=<]+%Y.YKAA+[_$&8X<(XE:^JP+%7G0W)!5$621DR")RLT$[Q3 MD&
MN\AJ2IX-.!H*O)\*K-5,$V3+^=G/PT+^IHW1,J,@"/)DE<M$G1()8JW](/Z#
M:3[]O0-9SPX@K5710\R?-J\)TN96Y3PPT3M$Y2'+&*JA12=<D+HBUUNO<K#8
M*4%B UC<?/ZST__6PNTA&/,QC$YKJ_Z3Z11G;S]_"<-)9?35IS YQ>D G9-2
MFSJ1/D50->G6E800?&1<"RYS:EU.\C!%SPX,#170<'1?-73^/OZ*DU$EAF@;
MUN$$"?^_\W V+$.LI7Q(3ZKV\8UZ])_^_(*C/*Q3E*;O<9)J,:E%SH+5E8,Z
M<R+; +5W";E80JN00O*I2]O2-M0\&_@<2$$-)_LUX&"9)'[RN>91#+S,VG&2
M(,\U'B"(!>*#G/?$C#!U*M/=8ZH/H-VBZ1O<6BBKAVF JWA94F9=O5O)2,@@
M3TTA;;LN> 1&6[$K3NIB6_<@6$_-LP%08\'W,'9O%657F;+ORF+2V[M5X]]^
MJK7-TWJ(_S0Z_XR3A6''>*U@)W,N^F)(2EY M*: 9\BX]%SJYI/4&K/P(L"W
M+Q7W,.KO9R2;$=]]F9,S.OVY3@#[B)//\QE<LTE(M*:2YR4Z"<Z$>H-<& 2M
M+9"43+ <2]&MQT0^3M6SPU5C1;2<Q%</[E7D3:]Z@_U)"^'JU0$3.K-"6Z^1
MM4&8KRWF="9(^Y)<[5UM[X: 5AI1&SSRV:"A3U'W,A+O+$RG[\HR=^C=Y,/P
M]-/LDM;KT7VOPMD9YA\O+G.,EF^<#B1/C/8]#X'5JMP<$GBA-?C@E;8&F3:M
M#[@=27XV4#N$"E= 4!RP[\YE$M6XO!_3V3P;$H\7KX=GYS,ZM*]9_W4\HQ/\
M[#QC'HY(#JFV19NWA9^_%_.O.*OC>TE+\SF,?7?NZ9GL/?;^V:<"&G4/.B$J
M\ST*?_IS05YMBE9-O_/9G$#:KY?M]-XO2;M>L[0H&09:,I)5PX\E =[:#&BS
MLJ%.T]2M&]NWHKU=)Z(=*5JD.&J.+#GA(6;/:??3GG8_7;M_8?9),4RB>8/G
MIASLJZO10;"[OO?1WI5_Z Y)C?3PX\7J#Y@GQGD38V0Y0HZ,3 %6)Q+7\%A"
M%NH$;S2YM;?6(SN'3Z_>/TCOSA Z$K#T,<MJ)66UPF%9U-"%OIXRM1^C[3#9
MV$<#ADX@W5&3AT!<5-SQ;!"TKIEXT9 WHW@ X05+R>5LNC7G.7JD/9)Z_62!
MMHD"^RA9K#5:[[[<F YI8^1*%P&<"_*/=<@05%:@C6!D.(F OG5"U#TB]A^T
M:*NG>R/ =Q%R#TG7.ZZ6R\NK4')&6Q956DHE0P:"2[5_LC'!%[2F=2UK$\*/
M!5U[=F3VK_1]37DDNC\/%V,KPRC7^P<B'$<]M*K>]DE-8E1-V&P45JKAJUL4
M7&-4%JNT5 BHYX-L;:UR"A)LS"+(9)#9UMO">FIVOF^\^\D+!XF5++F)#EPT
M"A0W!ES2]"/Z6LT5.8;6A^1J2O85BFFD[WNWB+N+]]!!DH>[BQGAA.;S>;BB
M%D+( $XE"4H8*661+LM.F35/K>=B"\5VZK"XB8#WUEZO"U$OK</B1HKJU&=O
M&RGO#0)1!Q8,\V0B<2).2P*Y(V.),1N=B,R%\E(Z++;7_";";=S"Y>^34/",
MI'GZ=R0[:W2Q].BDR &1N!+6$TE()G%4 L$DLLT%ANABER22-1]_+!W?-A+\
MN*W46A>2XA__9SSYUZOA[)(8)TOR3-5L%&9!F8 0)'UGZ5#RT2<5@NF@PGL?
M_-25MYND6K=0.@LC/+T#(Q^TUI[,BGEC!>6] <]$ L-U$IB9*5%WT-RJSW[J
MRMM97CW49:[*&/N (_PCG-44PH%+M >4F %K@I@2.H /PD%2T1#B=#3-^R\^
M0M+^0T9].5P-1=]#8+)#5FE1GK/:D=_I2#:$]@PBMQ*2,\H90_^PUD7<QYC>
MNT=\[*" QIO_*NI^Q-/AJ$8JWY5+-,_^Y_ALF,/%>YP,QWE@I-+,.@XFA  J
M< M1<(3BT G#"=G2=C@=MGKXDP?&?L3>\)!91_"RG*&&MM<0'$S2Y)=$B)[5
MOI/&UX0'!<5FQJVH\BI;XN31AS];G+05>\.R_TKPVU&:5*)>X^+?MZ,[)V--
M&7Y7?I\N2I4'C.4Z&I[<%5=O0&1MOZ3HB(Q\?COH!%'? 2$;/O998*-/43?L
M$5!)O4W8G/!JE(>S'\>3R?@/^L6\N0E&)VTN&J(A.UQ90^=@9K7#"1=:EX0Q
ML0Y@Z/:T9X&!'@3;N/[_BL*34?Y'F QKT'I1NO)J/)T-4O9D  L!S&$BZSCE
M.FD@@98&%1-9=.LE]?!3GI>J=Q=DP_K[JQJ2I2U['L[>Q;/AZ:*TL=;B\GGU
M;8ZU*L5P@AS9N5[HE((NVME.(T W*>Y91<B3!T [,:\M@V^<0? F#"?SUG;7
M%1Y7O<[FYU&]<?^94#P\FV=-_$)0/I]@#K.KOQR//M2DB@G)\,<P'4ZW3S+H
MD9@F>0C[$E:C5(6KARYH.UE)V[MK@N@-OXY'DUOT7:\'RUU 3YL63R*"2DY#
M,)I#]AD=\T6%T+H,IBD#NVZ=+8A9W 5[+VS**0)34I#=7\M I4B0 TE5<)FB
M:3VTO!GQ^TJ[.!QV[^[EA]'[H9,[[G'_X\62U_JI;R;X[W,Z,"_FUYQ2T :N
M!8)/6#-$G:EC*SPP:Q+3(CI]-\S4#L_KR3I4 LB!\+(.M8WTUD,&]A6)JPA<
M7OYT(;&GNI(.Y!VFM*2Y:M=!I[%>#@0A[FSA*170V5E07$7P(=4">,]E5,7:
MW&GX[U. SB.U(L> G$W4L2?$3*_VXLN1.C8+9\DS"RIP4"%*<+:V\+6*T5ZL
M4Q2MDUR[T+5_][BY0CL 9B=M]' S>]WA^2/]Q6)RKHR:FU! ECHY(+I8)^=F
MX%PKYP,2H:$Q/NY3\;+MFQVUTD-NQVV*7H49GHXGP_\*-XJ?NE#8DS7S.'6'
M,69VU>.#L&BFA%X[]:^EU.B2.0L. FI#ZR/)&BLN8&QR5@L74[<4^B< DT<,
ME_VC9!/9[V]Z$,N2)Y,MH'*!SEJRT+Q+'&3D3#N3,?+61<_',CVHM<ZZS0C:
M1. ]V!XW#/:K;__G$"?TD$\7/]?6NXNUP#S19PKPQ'C-+M?@>-)@13$VA(*6
M/33U?L< S .4O6P;I0?M]3#]8:4-?I_>I;7?A=@]!F36$GKPT$PSC7=QF9JJ
M:U]>]UJB<TR*U?KJ[*T#Y<FC= X#<*$D=T7IE%N[5T> K>ZQF^. UB9:ZA-2
M;T=?SF?3N03X=96&*8X3+5$I4,A*/;4S,".551*9\;U=2-PGYSC"-HT4N0XR
M.VJA3]OI!FGBTE(LV05O#;",DD@3M:>)$5"29>@=M\FWKM1_@)R7!I!MM+"G
M'40N25.."8\:ZVQ079-_+,0H$%C0D@6C4> ^=A#Y,@&RC19ZB.@MG(<K E\/
MI_7FG:1Q$J>+BA!R+[E1RH'&$HE '2$$SNC(16VE-+PTORAXE*@#@N7@N1IM
M-=9'_ZEU! Z"TK'VB !GZD 4&5*M%><@)+%M%9.>[0U*!^@3U59Q76&QD=37
M'D%]I60^T-MHE^3*ASZV;9ID9P:.,N%1"S)@M27?*6FR7Q42XFJ$.>N2+8^"
MF=PZV/I,$QZUY *=D1!T(:=460Z!A0R%*2$,^NA4Z\K5%Y[PN EV^TMXW$3O
MATYX?+B3B_)6QH(,K*[W "IC[0O-(:7 M!8*N>ZT%SRU;E8'PD*G!EB;Z&1O
MW8^Z$/72&F!MI*A.;9"VD?+^(.",\3E4:F@#)INRD#<<:F,)E5GPM6ZH4Q./
MXU+]5@VP>M#\!L)MJ/'Y/)S)Q>#WWP92:FULT%![]H&*28-/Y#QPYIE@*)5Y
M<-3C%--?3L=??UA^XD+#RQ^N%7S]O&-IP[.1X,<[2:VAWUUY^A!&IXN<$16Y
MU5Q:HKPF" B"HX^! 5/66A^MX;F3'?K(RKQZX,L]M;>3><,8WA41EZ'$#F0T
M/)=O/'K_)_&6PK^KOATDU_BLO4F."3$&Z23$Z%R-"6L(/-:\8*+,"YYM['0Y
M?&@%/G">MM7?)@)KK+=?2%*?SS\O"8G..UZ4!PPI@F*20YSW=0N!\\A2\'=[
M"&REN5L/W>_IN;78QRUDUOC87(YP7Q*BA>2>"PG<!@7*!P$AT)$@++)$<.0I
MQ!;*N_G0)ZB\K676:X;QV]$,)_3]O,F(5Z)X6[<3K,.)E8S@C6:0B3>>HPE&
MM+[[7DW)4[^HVB7&UD WC;O"?IR$4?JTZ$:TZJ;$D $8C)1U)ZKYUMF!DS9!
M9"PK;KDI^4XR^LH.,(\\YB5BHK7T^QB6-!\5%::8ZZ04,F'"0BF3NF=6%/]X
M<?V6]^&BOG3R1YCDF](]_SP?!#3],)S^Z\T$\1;R%4K+HF2 15?WLK;*+DY#
M(4\#,WWGFU^V],[42P3S<2*FA^20I@S^].<73#/,_QC7><FDKHO%<:"#H(U?
M@+&*C _N-3@R^<%D[Z0J.9OF]V9[8.O;LC@>U/103] +BZ^'7X<91WG.()G3
M@8<<@'.EZPRY %YK6OZ6UGTPO(32NDMV[TQ]6Q3'@IB&/35O,1@?9S!NPF!M
M3LT'161E$0OX5&K-/2H(*7E (9A7R2O;?.98?]R\^$5P>(PT;"MZR5F=WC<>
MS4>!SCF8GIS//M7:3<P#P;)'SSE85>;-(SC$8DAL,<=D!*)/K?.L'R#G)>.O
ME98:-BVMCO&5@$@$9V$Z'99A6L[I?',^(^G<])PO97?Q^Q=B!6>S16[00#/'
M)7(':=YTM8XP#A@XB&R<(&ZL#:Y#[*(%+2\18@?1X[X:J-Y:-WA6/N#IL*8L
MUT^^2HS8;>YJYX]O-FQU.X8:9?&^JOAX5^847 //HC,Y6 FA#I]6/&?R:I("
M.KZD+YBD;M^C>!4A.]N"R]:QR\_]\6+^E,5MNTHVZ(@(.?-4P[\:0M$.C'8"
MBZ0%ECI=LFQBS*TG9U^9K[OK^YXMU4C&A\Y)O>+G/$Z'>1@F%[^%*Z[F%\2:
M6Y>B%>3.6 ^*.0=1%00OE*1C6<D@6Y=*KR7F4-DNS;1]%T5-I-Y'-/Z:G%_#
M9_JVGIW3D.;5%8MLK2X4]M2FX7'J#M.;H9$Z[X*D'UT<!C5DY*>L4$!*)M4D
M/0]1*P^UU5*R.<?P8&KC4T++(]T6#@:63530>,;8:TQS5X)TQ$X^_K),8K N
MF^RS .U8'5R=$4(6%H1.+(KHG0]=)DRN_/#].T.M-3!N*;[&-_J_A NB15S3
MXIU,3EE&VE%8DSD51#+7 4,NQ1<>)8\=5'GW<Y^5%G<26N,%N<PF.CD]G> I
M.5[O2L'JDK^?#%/EO[KH<R_^=_*Z)O><M8$0(GA6. 1KJ_&3 T07ZS Z+:*,
M5FO>)>RQ(QG[AT<[AV+?6FB\ ]PCIL:#AZ/YMT3^>/)/HIQ\]E_',^+EU_,J
MUG?E=;B8#AB&R'0E&.N-B?(%G"BEQGD,US%B<%VF>F]/P5.'S9YDWWC+N;&S
M?L J-0+ZJ_ EI.'L8E"B%$7("#S2?J@8'6.1AP255DN[*^VT7<:)/O2,)Z_U
M5O)K/!?T'AI/:#>;!REJN&\XK4;Q>W*YZ85WY>^3\73Z?C).B'GZ;K3@Z498
M<!"UTR:3/6.3-*"<EB0=,H0M%\E:;00S7:9!-B7JR2/G8!KJ(P>D$O%V.CW'
M_/I\?EC.)Y[.+P!^Q3_FOYD.(HM1ZNP ;<B@3'$0-')@*26%O!3;WMWL0MA3
MAE)_&N@C+V(UD8O[QVLJDQ<R12%J/RGRH2(93XX(!UFB"1)3)+3O!R=W*'O&
M0-E%!SWD$"S(69 Y-[S?5U.;7AOXVF(PDE'M/-8QC3R2H1T"B%C(N[9TR&+K
M86IKB7D6>&@BZ1Y&EUX>=V](")6\,$IW#KW,N=&.V':$3U!%)8B)'*\BT6A9
M+-KF71T?)>HY0**MY-=>S.\ C44ZU/3->')M+-&>);.VD6NP]6!3EK[$0!N7
M-S[PDLGQMJV3BU93\BQ L+N,[VO>]9V2\=._S\GSN@S9-$G#6/V1K5,O.A#>
M;[I%EM%YJ\ SH4$)7F<52P(-;?($%OK_T-HVWWNZ!9U@(@MCP11E0045P!=&
MV$VQ^)1B-K)Y[NS1IEMLH.]-TBTVD?$32+?0QN<Z;R8(2R:0UP%BC>6X**+Q
MD@O7?'+ODTJWV$C;W=,M-I#Z@=(M.E#X+=UB&W5ND6ZQA2X.@QIEHTB*W.GD
MZM6BCT1I3HEL)R,EYL1B:6V?/KUTBW[!LHD*>@#)#8/OJMM.,L%)#^AKFV-A
MB?/L,D@R](3 ((1H/?/M'A%'>:&_D:;6US9L(>;&E[+O)U@GC&'^9ZC%/;/+
M46/6!RF=CU#FTQ!\-!!\R&"D"T$K1<QVR<Y8\_'/1J>M1-C#:GX_&7X-,WQ_
M%M+<(+W$&A>ZA& ARUJHKIR"4&($(T2H50O.-1_:MYJ29X.!A@)O?,]Z8Z<Y
M&>5U.)4N8]3U=HZ8!Z53A%BT %=[&DAEBKW;ZW_E4N_TL&>C]'[$V_#RLS:
M^CB<5>;?CG(M/SY?MD%ERBM+YPIH6^OG-&$QZ&3H\'$B(O.>FTX76(\TSUKY
M\.?B)K:1;N,.D_<(^N=P]ND#GLTO\*>?AE\^CG\:S8:SRT$Y74AMV(5R0_+V
MWZFR@4(?@D</VFC<(7%3DIWVKEB1P>I<>WN$95&WQJ"#YDRJT"ED^12 \T"'
MS,/B9A,E-,[/.TEI@GDXP[SH(#>>7!YZ26FN>9V"[31Y- 8SQ*0D&._(FTD\
M",\ZV!1K'[#?9HR]JF3<6IX]#(JZJK2]&:Z?HSS++&+*$FJ\GFRGY,%KLJ),
MD<4PQ@O/S8M$UQ'S7(R+ME+O(:'N)CV70_<Z4-13S/D^-0>*,;=1U]UH41M9
M]Q$NO$^9+L(R+W4M1\.:P8=0YY:!Q6P<MSHEG9^H]A^+&>]+^9N(>"\Q8I--
M,(I;<,'77#QD$+RGLP_1ZXQ&H6U^-W_X&/&NFGDT)KR)6/<4$U;!>"-R3<VM
MY>O1*7!2.7"QH J89!&A@U%W-*&A1CIL);+&QGFWZ)0U1>@H+21C:G2*+)X0
M#"-3-=+V9!2+DG?0Z9$&_QIJN+TX>V@#^P]R&FK3I'KN.!LB+UY 4A5ZVD?P
MT2K0.:5DI,_V;HOLG??E&X]_;K;XMI+MH4YA2<JEK]F!F)X,[UN$',;FWEHM
MJ]6[@TQ[L+5N$\5LML@]68_D[X.RILZLRK33($LV!U5D\[OX/2CX$;.Z'_UN
M(LK]]:^O[3.7?>?>C2YG?Z!WFG/'P49)QQ4+'N@DR2!L\+8PEA![Z:C:C;S]
MG^@[*+);G]^=M=!'^.U14C_^,5Z2&A39,26Q6JE-9F>J(BGD1G@A>+$Z*VE;
M;Q,;D/>\ ;.=%@ZRPWPDW5^B6\>0G9$94KVD4%$SB%JH.AS31J-R1-6\HG$3
M I\Y:+;41!_C"1<75X8,XA3IJ8QL9:5, F=8@%K$K6M]+E'3X%;OX',I^\@)
MV$Z*#4M4[\X.ZT+&\YLTN9'PUTPJW$9R/4Z:5,8IBSF#=P1OE7VH]:X2E"S1
M6<^$B?(I*+#3I,D6^MM$8+U.FDPJ22%%31KG"I3+=) 87J=0"^^RJ6,460/-
M'<FDR8W$OG;2Y"8RZW72).,VZN+I'/:.K#E?-#BG!&B9+)=HR8YK,3[]2"9-
M;JV\K676RZ3)-/Z,5Q=R/X\7K=V7_3)3UO0?6!9#':69:_2W@/=DQ'GMG,VM
M2^8>(.>Y6#ZM)=]#OX8UI%TUQ7V<N)Z"J \2=IB@:C,U=H/'#CK8W^ZQ)#*@
M5T&+!,4H0WY]J4W3>.VAEGB(2=CL6E=/'  @CP1E#X./343? R[>U0X)OXY'
M8]IG0PT.+*BMLXU&TRO_79GHHN.T>6K:/#/S$*-A=/QE*PQ3491.0\4W@$<7
MNO8?0&FHRG'/>N@A7OMC.*M=:7[[A'A[=:"DTU7D!$'6ZV&6#=E79!Y)R]%H
M+B.7K6MLU]'RW&R/)C+OH1O0*KJ6RZ +93U9'>NI.HS)T49['2"Q@^A[.%0>
MH%#$[*VF%9 RUJ(T<LI"B0J2-=%(%6*X.R7LR8'B$3-CWYC81.(]8&'18^DR
MCRBQK',DQSG$6D&0Z.SRUH/EUNF<>?:Q]2W>S>?OWV!HI9=Q(Z'V8!6L;EQW
MMVJ8J$PL1N] )$U4:DW&LZ0S4:K"B[0E:-=ZM%@WRHZF;]P.S:%ZT$$?]_W7
M-<NWFUXZPX1G*@.S=2D$HI D$<F[$KZ@XCKZUOGUZVAY#FAH(N=^N_6\&M-A
MF7'1A/L#)AQ^K?,Q;Q2Q#Q+Z$+240.CUH")G$'--/(U&E)1%2K9Y"=8F!#XS
MI#362.O6^H\0NFS:'D[)VR*/F&,B49@Z.\H5 8$+#FBY,T9IGK!+C6;W)SYE
M(/0HVX8%>I7*FD\R_30^J_DEN2:QA(O:)O6?6&?98C[Y2E2?XGR_>Q7.TOFB
MBG5@1;'9\@)D()$HG/?@)%G6)4DOG&7H>.J ANV>_M21L0>9-TPDKQ2O(NU=
M^3E,9YS-Q[YXSV6:CVN@S0Q4CAXBZ@32D3D4A)"HNNP.CSWGJ6N^J1P;Y@$]
M@,JKV5'+E_\Q/CO_? N7&K6V19)[9!D)8WZ5:UTF87 R@\GC4N:Q%L6[//^I
M8V(O<F\\V?YFI\.5=-X"M>0,0XX)$MG&51X1HN$2K \B(NUA+OK-3(?''_K4
M4=&?A!M&K>\0>KOO]W0QC&.0E-,*:^#$DUVCN"/+UA-,3>;&V:2,8UUZ S[V
MG&>D\-WEN+9;_78Z?A.&D_GT';)=*]/#,ES$W-Z5-^>S\PDNDY,_U-/MYV&(
MPS-BX/<OX]%O.)LM.EP/D$ZVG'2]P:N3X4KU<!RC+^@-R<L8Q[L<$RUH>>I8
MV;L^[N/)[V1JW"!O>C(]N2)Q,7>.'G#R>7Q.-#*/)B@1(":RA)1B"6)4&5(.
MTI/7[$+)74R+CL][ZKCH1:XK(E8[]0MX@,B%8WQ%(VV T2/8*(A&35M=%!EI
MOT-)M-//G0(.'1_WC%6_M517:+YE1Y#%M*:3\]FG\63X7Y@'+K(8 MDN7LQG
MARH%]$H!*5 7IQUS=QV)EKU![I+SE!'16MHKD+!S]X&.4_Y,]-D5#RA-K7%B
M'H*)$IA I8T24<=.Y46;A*N?U)S%7<+4S36P B<[12>O#)U7GVK>^=O1U0N+
MSKQ7.]Z->/JK\71&<K$L*QL<*%9SNC2S$/B\0,[&G+FT^NX\M8>MS4T)>,KX
MV)_D5^!EISCEC?WN<BKU8M];#*?%">8WX\D'G)*S-5#*6">C(2.(I*)\H TP
M2@<E8 JJ!&'O-B-\K)G-H\]\ZJCH3;XK@*#[GJ]VX]LFP]56?%[KR6J/D=SK
M6+4L-4J5.'@9:F$S,^!L3:F2.DFN>!"B=:K)WL>JU2S28KD$[7.HQ4@2'+,.
M9!*UE9J46C<?DG6L8]4VT?<F8]4VD?&AQZK=+C1UB@M;)Z\89FJ?!L=K[)V!
M$,G6EC(\=&M]\)1KW3?2WLI:]TVDV&.)=!<RGE^M^T;"7U,KO8WD>E2D+S;%
MH!B84A%IBH+@:EF B8Q++%GD%GWECZ/6O87^-A%8K[7N(C/E CF41KI2"_<S
M>!4$%*NC5%89)SN=MD^CUGTCL:^M==]$9KW6NJNL'1I7LY3H\63>:W"),U"H
M!#&:9<'00GG'4>N^M?*VEEF_[9COA0-MR38&F\@]8[(.GO+@LR!^19;"2\:3
M;%V,^ 2"K[O8P*VDW4/*^ W2WH?)N\F\]'(1^+O.:HXFUTYUX$5--T.>P =;
M33X;"^=,Y[O]FUL"8AU9SPP83:3?N!7T963G'^,9UN2#GT+Z-"?J7;E!^4!;
MH2*+'EBJ2:M<:(@U[*<U;8G1*1U3EPAKMZ<]9;7W)-,>&D+?#"_5V34XRM-+
M1+ZNJ083VKJRTIYEIT'R0B+ 7"HR':#6V2J&.IO630VZT/64$=*;_/N8YO(
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M5VGXA1P%9QB#XNMH5!,*1!W)=U#T7^%>.][BYFC5LP\?ONE-V^.&4F\<UO^
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MZN[B\:/L^[0$P  0 :@ +  >@!A #J !, +8 -P ?H (0 (@"U "J &T 08
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MSI==W=V-/:>]F_W7!^@':8<TAS5'(D>#QUK'&R<N)P^G$6=X9P7G'.>=P&?
MI0O[BYO+L&]XWPJO>*YZKS6OMVX\;^%ND^YH[YKNY>X7'NP?'AX. 4]$S1Q-
MS %F(M_S!R@ &A0D%.RO$XB'>4 P !(2M/="04-"0L- 0T'#P,* "!8>[CO!
M/T+X@1[]1$B_1Q!04%!PT'#(<'#(J* ]!Q45!42HJ#_(?OH'"?5W:_Y$#YT
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M<BJ3F<GD"C )%-WJ4$G5"C 73(*G"VNOF@D/AK/CE(T87^- E=,C'G!7E_V
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MF !&<VNR5.BY&9@ L:"W67<Y$ Q73CKUJ ^AZ:6=^0PF@V55'!8!0Z$Q5!O
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M&-X_:F+T1O*+Y_C']D#-8U9,N'7])[0>&L7%CA.64=)5,,_#XU('4^OI,7,
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M?[ZJ:+[EC9##5(E'4<>@8@\JE.\RJ5C2)U?0DRXW?,*;2ER)I^,0BV$!9XU
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MOY[3[^Q2 AYA595V3Q@287TF_-C85,A4;7G_DMK%W[CVS%Q7XX78[WDDQJ9
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ME,4PJIOO^"_%&J4&1H$EK][W;^\%C?I;AL<0G^B=2MU[/W;-VINH;/-_&M&
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M?2*_-PL8LM1QUW5%^X7+3J*5LI>"#OTP20VVT&6Y=8DWL=\AE&;[Y-!PPS,
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M'!E3W$,43.7F6%QU\]15>'48/11,;F-:2?JTZ-IS@GFV<.!!JNDW7F3 O3.
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MD#X<\8'Q;/%NV7VDHYG#K@E4'M^1GUE2%[AY,"A6GD#.6XQ%4K_X,L-R"&V
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M,4Z.M773 8>@>53TV*M72WY/_SA0;\KT!26LY _*[B\@$+*>M6P+(U5M@CS
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M]B;?7L\&/RFPAYQ2!&9X<?%6>OAT_HB'#W1D#GIU/@A/[SW@B::#K5U5N,=
M!#2,R3YJGHJ>^.M8=2X5X$^^49\$9SRW=O&V[*KSO'A0"YD[5(METAU_G_%=
MPB5965/#7[6^84]<CK< 0JEE(Q+M-Q@ Z]45_YHPF/=]_Y9?9>8'";=5U#&.
M2*9]0EF85S9EU8XY^QS2I>Z.KO]-C7HT]![0:Y\DJ+T4X, PO4FQ['IA)J2R
MK+(#3\N@)K*JD7O,^./19*:]^3!+@$RR5&7PH,D@X8L)E=?2=3JW5*(#A&8V
MZ_> D>X__4T]*BJ&%. >8+%I/M;^C&MSY6V.U[?_HBGS#S[_FVF4//>/%L&U
M(5B_3_*/%?'+3%O^1WELKI3O"K4ANL<55\>39ZYB/UZE?;Q*4:?_.&.Y1>^^
MI02][7>]'3Z\'4*D'>XV?$?C(%7D.S!\,3\DGS%?_RXW%G8G[GH7U&/-H#\-
M7]Q)G_/]J1AQZSY!OX8A1YD)C@VL[W&ZW+E[",F1Z<LI;[H'8&(*A*,2S&AT
M;Q=4?F<L[D5EPYF BHH^\3S])O;4%,[HD6W^:Z%A0R$1_Y3.DW^^HWV+^?$'
M4]=56%ND_9$%Q#2BI_#1?K\\UO1B+#'1Q]OBVX5H-)X*_W8W/'<5WSO,PUN<
M?^42,+=P3L!K[&:5U6OLB[=IY@JQ>O(>_KA%VJ1>,GCZ!Q5<Z5>]>W"BI+8D
M7G)($>=!U">8B'(H9?F94MKB&'HBVE$*53RS<<H0L][!*[G,T*)*)V[_"%,1
M0_+G0#H'F7;/2"M;<5O4!DB&SU?B#!4-+D]L(ER'9]R<.7!'ID(X2?8>-H[3
MA;60HV._S[E//%DN;@2T2_IKB3^8JTL&=+:G$.UA_0.E[>H>T'*3MAQH8!3,
MHJ85[^:<B$ZWC^HLN<SW 2C0P'F9+[\!%O4MR<VV&5*O]K_:B)Y"WR3*5#-#
MM]H+<-TSSG/1P$L,YV-/@6/8>POGB/UL%G)[ERHSSNN,T)SD30##65I)Q-_7
MY=]D#>: IL"?V)0F? #38J^Y.=O@X'YD/1 ;_RIH^VH;>OOXG65 A$-BGH&1
M<+'MV\]-GV#[=8X$2!OT,&J:U*TIZ)'6N.^TRB5[$463A83$Z,994BSV_J0G
M0;I53+H*NJZP*/X]@"9]G7-^NI7BJ(T)C0B\ODBUU#OA'<=$?%[R@Z#MN[&I
MQ'OADUYS@F^*0#PG>N$<X73UI3PB9#]%W],..VKXFLJF*[ENL^1GFM<> 7I)
MZQAAA-HXG3,R?!&MLCRH.C[LX1<)LSZ_&LY$!BF17MD^0]I;Y??;2\<[E-PX
M@EW4OKHUW<JR[Q:8<I;O $NGT@6O_(FX3+V0 K/LV^.B2^U/L\78,@18]1_B
MN#)1I*4W,M"$^2.I+]$'9D"!T^,WSP>:6VYH6.6^TJ!B,2G+O" ,I:4,"=LM
M#PQPO@4LZH:.N<CPW6Q=OOP@!L*)ZQ;J1"BI^OCZ,0\Z8AY=<KS/I<=FG J0
M\:\?QXVT(A=]!_5YUK LL;/UJ_V+5-3)K*<3(R?XI'@NN9<E=N\!0EW5>4$#
M4NY?,%:W[V:^*7XSE4$?FPJ<NX053B1PN]:88V!^MBTC(H,FS_)Y+4MC\)W7
M5JGW=2_EONZ_!^1\[HCWFUENZM!J%EPLPF$22+$.' <NC3I:O;"EE3P[+%N)
M&3N2^B"F^<7\Y&;6.'O*YPR%I+,_*Z-YA> JZ.M3- "=RA1=?<(61O"[?DE+
M?YEN+QKYL+[RO%Z[1N=8FO,J2&M_CRIV:IU(KJM')RWK'([DRD3VO[Q%NQ91
M&DWYO$<GRVCDRH^K;C)>%\YE!H"CW?REB"=<]OE'<*FQ&Q?UO]!AA@&U1=!;
M>TT1;GELQCEAHM*%^$=&E);$CV7P\7.62LH(+ET/Y-BY% 5= RX<&[XKN7\)
M@5[2/^-L_+>&8'=XP_SBW?GF:Y7-*0+K=VO,=/8Y6/6+T88K<0B/LDJ+_@70
M9]O8L-UJ/(%Z)D+I$<Q#I3';"OS,XPMY#6*5V')\1O4)JZC=(;T0M!GEB[.%
M'X#+"33!EFVL..;%E33RGB&]K5D*9L)(7 ].CW+=CXO)FA_#Z<42-R6NPCF8
M4%[EGQW(U(]&VL5*C.[ Y>HL[:P!C!JC$^BMRRPRX[B>2'_%.L<MK 8%2[LI
M5+V##/+^?L?2_H4.*]W"I;A;P,?;FZ-$&OG8-!7)07O,@>8CF<-\G_!W-Q.>
MA9A"#)1VR,[$[VJ.=,F9Q(I:7)[X"56[S752#(-<?+\*6?LQ2DOW[JH8HM";
MKF[/SZ'(6?!GR.CXJ:A' TAD,!2R^YIU?)SZ\784IDC8I.B6XTQM&6PICKPX
M(I=4EO >('XH%>9=1";/<+'9V)@@WRI#(LD3R:#0+T\:T<1KN$RQ+@R%BUX3
M4RV%$B0OIC:03R _I\E^B3"EF6G%.T'!);0@/IN*'</U3F*R/J"R<YO!FL;N
M/M;$#QWIHKYT_-/4S/M;L7)+0:?2<01TZ1IGXXVDKP.*\W**\$UYL99<,-"I
M8R?7OV&V"1.12L?U<HUT;A-@03#3Z2AC?_F"G4Z[3O> ?II/WH<7V!G/L>A1
M)&? -0[54JA^=Q@WZY@$=%S$Z4&YKBXVTYS2=-N#Z+(*6[)T1DD*%.^?9W N
M1?KN[:MSIJ.:*^G$=?8I$_EJY.5DT\Q/D(UBWX3:+.438'>N8]'3 '<NJ 7:
MPO#G!:("UT13- ,P\%&MCV[Q_K3*?9TT7::8D>W*R6*!,[G-6EQ]6,/XSY?"
M4#VV)X^B9$NTJOXNX^+OO/]_&=H'?^\/_<E0:OK[&?[)H/LO/24;=@_8B&O7
MCEK'K+6I9R=]&3_(MM88_^:?F;\W<_[ S(#7\$FB_H#M$T^C@7]F_NX,!7*G
M)PQ3UKOM%-R=]U-1BC\P!#1VU963+PT$QZ,<2MC^H,Q>'(A^&'.<_TKAJW#E
MC](3P+Q5*;;2JVAA4DU4O!:1XS">C&4-8PQ"TL 7<>ZRHB6W!)ZA2#W2BXQB
M@L,3QB[,O9@3=_M4>60(BC<]P)H(#'+2XG;QBWJ:JEBMA>=! &? LU--P!3#
MUJ/Z(IC:P!,.BB#>;WR 0">[!T2?#J.I\!A]7'MT1?<--F+2B<1$XD-IB'@2
M*VWB4MEK U6F,+7]4>/ C!=FL5WB]!R"W$D]2BHH+W ?6C^0AZ&H#J[B&\)D
M@#+Q"</DX*>"/\(C*+!F92XH7GU]KL%ZD1CG3D"IM2/U4G/\\^H$WYV[];*8
MGIKT#UM*0HUWK%;*#_5BVUB3QR,W2Q7\,Y5E\BF=I;8H*Y[:-QYQ\@C)A^[$
M"]E@%B \\H<&.6.^,45'\GU>X,EMP%1X/,TP#&1D]'>SA5E3QVH(5K;61?00
M^.6V'I2(<4XG6-_$E;P<#30;(OMUK\4+^U04$=%4YY//6##9H%A1='E%#,]6
M^PBUWI#E#C_2E,RS%!/:-P7?D]]A7=E$QV\P!]P#J#!X$AUEOJ'WAS&UK.;[
M/?$LZ8&1]V%F.^Y*4W3VT60?G&B*>@Y#79J&U.T52@;Z4X'HYHRBX1QASI&'
M/OL7-#,DPN/SL>G1NLM;PN,4S$L'HV[NE1JQ^Y]F59WA4S0R#YK4.8E>7L58
ME1<H"QP$<BL_CHR1E:+#H6D?A+3(9VU*U-LFON\-BBNYG<X.PV';-_E"BZ^<
M&NEULGS0R]S!0.G8(B^L,4-KH0O<[O ",BW'A;DPT/8^(+%[O6]C2ZDWJ>U-
M>@GR1J'#)2( SJPP1SXTBTN:Q3/.$M\"$5+)5VW:6W/& 1EV3<;&0#&/A5XF
M]_?YG*L[Z#A\%'S1QSW*O%M5._\Z1MI707P[]&!LD!8Y4D7IN43W+)LV@(!8
MI>3I-&SQ/'G=\GO;-F64%69K*< <X!MU)_:J\R'/(9%/N;.QA#-KP]G8.\[/
M.\4F4TPTK]77@G:[A0\DWY]P(#KE\6W8Y818S#SH\/DK232,N6:'1$+3T57?
M9M. T#&L,( &!J8F:,J9T +_.CLZ.;N%-ALR%^=8)I*2[P,B=2Y4Z&HM<0('
M)12O6S]XY(/46TJ'G[[16-#(.S'I1+1^\/GN"'-6^NJMG!J#2;W7?"KTIY&W
MZ)<\MR7PS0? 6,^$[DMW6X+B,<P".MM7)P-#"4?-4>TKI,1X,&)0:'AS?M&_
M!_ <LC0?-AUAY)HI.R;7L?-TFC.6TI#N5$ (Z3'"!92)+)4]HA3[QP_2N9LB
M>%,T-C>V08VGO1'-E2835TH7M;WR$_AS-,9,>7??FYK1S3%OZ71QZ"L><^:J
M>^#XKJW1XD$L)Y]:KL2E]'[+$R,6\8H,\=QMA]S^TLK#>:?)O;]]DN<O$+=E
MC9 7VRN%.VK/8_?2[)].RK^]]N5>;,8UE8L%J%JC,(PTVIKZ]O2++7GSR/OD
M8H]7DM@//JA$'..VIF-/=0J.6>F,I@PW4V9/K:$S\H2FVXU-.+N](8WAR.ZP
MV:$<&6B205#*RF/FIZM[&-LWOR$]VITMN"0#B(L103.4-,J5T9\.;^6^UX!6
M3#X)K8<(WAEMN7QQIA0LOAB7E_W9]SD2A-M_PD_Q(386--)2N2'^>.V9SM<%
MI'[&?/='N&3]/>"*^>?[W&ZTH&U$5L%I4< [NH7@DB/* ;'#YD0U>URD*$&=
M79]E]Z(U;-'E2Y?BW'L4N(PO@S)1L.>BGKO4P'NQERU,$K!%M#R$-0$R]=TJ
M7ZYM5=PTQ"J6?7+8DR.Q3O3:%1ST8$(@/*BHT9Z'<#&")5\C-Q>N88L5:<XY
M4ZG8<@_($MAXQX!&7WX@$\Z#2OCA8&0Q:/\2+P#',10%\J+L1GOTQL_2H]\&
M.#T/]S8!NI&A)*8C?W6DE)4-P$ZL",(?I/\Y-LPY+PZ1\F]=R6L),YUY5@LZ
MA5(-L9=\D"R%"R/##BBNM\ON2DL_D\',/UF"X,!\L_)@.S);=)3>\_DK"?7.
MB0H[ ]5+2\FXG4M@Y @#"%.Y&5>WOKV8@"PQ7*Y:8-7+!#B#/X\,>$9S$(ZD
M15WP"X]9">I'<8PP60V"7@V2F & CHU2PKW[H6CJ3SF:AE]PQ27',8$AVAW?
ML;BF/N%74,S *="_M&".50B<RJ,9Q5O929*@VI:(<64(3O-%5'CR,O_V."X
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MJ1WS2'F?4HST:"O'+A0.QB+-)CP89EJESCV ?!0_:;%'LXE@/]X9G,C#X$C
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M"MQMI7W(N%-^TMH&:I?E04Y8:F*U$-"(+DH-.6Z'XIQ_.JN.<BS% !2N/3$
M&?A @$^.'I50C;#FI1'-_4"E6-QP69-)(>\5ZK"HRW%7G,X)C!F6'71N'?32
M&*O);&D4C.;:L="S'3X6#QZ%L-@S8$(OS<Y^;D4.7KZ5G8PQKQ<1Y6=/E3@Y
MQK> J&9T_+JU#-Y*B#)8"TS1-^EG722IU4":8U3SN?R_]UR2\S,UCDV;BF7
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ME0"<+\E3.XP+YR!JBL[/"?8'0XG(^IQH\_0V'A<W91PB7,->44XF=80O;#@
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M=_7K*M(X)8BH("ZOD226 $V!Y2LD0!*[/3LY30-CGZ@-]3DB>2W.AQU#14Z
M67)-()W^B.+)_TQ@.TV/]^N*L4!Y@J<\,I('AA],03">Z_)57U*(U#*3&N@%
M*5##W&?YW=ZN'0+XV7^N=!GIUF\X$-I0J]RZ5**(OJMK-6^Y=A<LGQ@@GM/
M=<*#=8$D!&U63)O)JDV?]44E![+3&/&NR?+KK<KTQ:->\L:..+33=9VQ4\WY
M@G$P<,"08_AZ>1NPPZ-&S[R!+0I(/K89X<M:O$85C8W?M"C145?XGO##V\;;
M;Y:#XL0G$KR:XF%>N5=WNNN'HQ.OO78V:X5@Y?M V5\$<:$SW4N+OF%J4@\/
M 7+]_D[!</F;\6IYH(\0/X'3D:)%@,C\-+]W6<9 L=QDY&-8V$R6O*F)B(PH
M[T")CAI?C$R^(UJ1&X@N26GI[/.]B^6F#MV%\P5&96Q#:8-)UNU?"I/>N.VU
M=&O:4/HY<]>/J7HQG(;' "$79/T+>T./"4IB#;&M0'\O5N.A7QZQ[9O"8*JI
MB/)WUDX(.ZY7U!"[F;-JUY*QZ?4FFR,DW7KC8%3+N7LWNG\B<LSXU)FWC])[
M-I%&XPKG+SYS<4V\4GY?W_7!EW6S"75$[<L#R?*:;T24DZ$M'ZT"ZO]BW_II
ME(!'Q/)WPIFTV=_.8=TPH"[GPN@;4_]M"8[V#Q4O Y6#G\3H)CI<%6FW-KCZ
M.3[E1D&P[R%@;WJTL^>.'5ILEJ?QJ;GW#.MRBJ-]TPT),XT&=YLU".D@?>M$
MU[)K.3Z]]:@ 9C6.OS-OM/U4>AOYZ>9SCM'I*R>>U98(6]V\JEDT]:_.GOO7
M*LY_C0U=_Y<JSG^=31 6 7)L>C$+S!9>?9VIW%"@.E 1O_V18Q$6;4CN[F@3
M$H1(Z=:)1=^#!1*,.&/3X#) ^]LEQ8J%9"5+".]##EEK!9I"I K_LI[4#KX>
MS H4IZ.X-PPW#N:UJ:U\/?[+)P&BQ\3R<^FW2;<07Q,XM-^R?0@2_SE=W>YA
ML(8>?;R5M)>(C,YF-:]$2S0+MHC&\*'E]IR^6#SP;G<8'I0*+UP9S6(R\PD0
M@Z=,1QWNO&U9)X(.^_4MIAC)V"9(-\C,AW6.W@<X1M(:B[X_AA>-FG>AFYVL
MM6@]!"33CB=$#?&YT!..W,_!E0>>$I[.J(8;B_]B4"JUK?^71,+S]-)S_TJ0
MHB5FMXL+CS;\8YWN/SR;1[P&N'9Y\"?]1D[$P>(/69@(9+E([8?TS+B!#.F<
M5@\K1A>%NA'(G4AD\K0EIPV5JGD4_(IVN!I[=OE6B.TZ+%Z)FMC)@HQ @;$@
M_S,S&95W:B6\THO4919>M\NRIM\,<1_,I"]\;23 O:SZ"1VR9/(F7\"WC%_"
MM"Q4ET*J-,I#Z,'24F2@KG_?&!SRSB_D>!A)R6H\SXXA8 ;PM.8*\38#&POQ
M%&SHH3?P.BG(@[RO%(.A/'7)0:>1NE\FX5"/["ZGD::H.Q*JI8'QV EGPB5I
M^4BV _T5*O :1%OM_<;:ENMREZ9CO(C"U%(V^ZJU\.-!?_CKH!<B:_MFV-66
M&WQ><#'[@7Y/^US@RLVT0!'Z&X[R3>7BIG&47RS4T]V7ZK^*MUO+&JNOYM9A
M*PP_CS(-OI#-PQY-3L'?7P@]!.B=722SJ^U'39)P1F&NOI_(8=.7(J AD3K9
M78ZE2Q\5NX+83N4O?ZRFH$!B:L5;&E_N>M)%O3_E7*^39RX1T1Z6!_%'D_9G
M?@^N.TZ$' L<F:JJ35JWF>8@FN_FU"=T];"(O2^X6T1'9K,+UG&*<L\'\/X8
M:^G=#;-#LU<;(TH&H'3.[Q*<M8)UU?@+1CXG37!,OC0E/;F.LF;.DMIZ[:1$
M7+(Q:5;26B#-3KS)CF"9>E<[/0/;CL3'OH?@*V&9'UTS[J&$X5[)...QG)RT
M]F$P;UPU<3J/<ZV" ],VG H+"$A8W9ELER&XI>&'E#H:A!L'V%JIBA%&V:(#
M7"G%05ZJWA[D-,J\9,9DYC8K#':K-/H4ZL(M2WFJ%R(GR,&((4=*]/7E'D&F
M5LW1<I(%DG*_9PLIG#IR&B3VGXML^RK)IC%(V:FT]&LYZ2;&F)OO17_T!X^Y
M,BN'QQ "&PHGMY>!!E<3AM2+4^\XBS2X)L+"N61!5KP;6ZKM=^IOI0L\W'\B
M]%S^H_!4#GW& I-8FM$</I1F]A9WRW'90W.C6U*!VY_E5/@<PCF6$":\KB0I
MG97><]=!/<FSC@U&[S#.</GH?\7-N/VKS0)WZ)U8P3IS3N6RO[?JK(/7A&(G
MN1Z5$LFK?ZJG/[@I38S>W'_:,)Q2==O^G(DQ?Y+1Y2K-$>RX-V]DJ0G[I&X<
MZ=IO4D',5?[\*JJ$=-CGAW*BVD#WDP&[+(@HZEX']U57=5WU^XD[)SPLS\H1
M?7U@7A;MXO$$WL<4FYWP>OPUJ11K:TPVCWMU?0][)(OI\GV$1%935?HR.=:8
M7<#K<YY;TI;Z3-(/M^N,?9/,[[O\]J:&-B#H:I]/5@I7,A]BKX>+$#5D=OI,
ME+N7T!.-^+2:UN0_61.,TB/T\.:%XZ[L]15=7Y%J@!0"5WDLPQ/-=07<\<S]
MS8\S[='7XEE\!,9_[:A*IP <;FZKV_UDR^#3A$]9@9]$"(RY]VO5:*WG*!&,
M/@NB&Y219-4-L0[+S-EF[(Z99VGJ79@0"S>!J\)6\YH-+^^L8[Q:,RWGANGQ
MF(Y:!XZG^6\4(H=O2L6HV#=QHDM@HEDF3U1+N3-X/4'=P6-73+[Q\&CW@UJV
M X_:7&O]R,$-G:HD[QM6EWP-W:_Z8JA\%L.-@(CE#DE+6_3[L9[IOC"9_;:H
M2J$Z1'0IU/L0D,+S# 1]HIIXLJ>$"*[#Z6X#V3"PJKL6NTYD@58B]YV *)_J
M-WBQ/P/\,-K=3K5_I/?:M@EMG=MQ8[^A\9GOZ=4XP4T@T@5QYLFI#-JC;^K2
MVN'GVQ-S T_Y)HC^R#&T[=N-'XJ9_QQ?^=9&9[W7!QD!W53SGI'G<N0HM? _
MZB:-Z*]'#GD3. W-HKUFOMNTX _0TZ&D5OE,5>$<[ALDC\O5TY,)G>!5\4>T
MG$P1G\9!=WD&5PJX3$5A5K3W,7/R=J0I ?/VLLMGFZ_['._69#QMG0G?E#1_
M'(_$:QE%,)-6-+]XOM*;TLBIECX$I(7>#IU5K>O& !80%PP=-FJHBUT*['RV
MTY4K">JG[W1_""W '5S_9/<N8Q)6VBF4B["OL*XR#?:@J4L5&5H@"YY=[\5L
MKR/.)6+8?4#H+W,%:4Y\KX\DU!W&&;T"U-Q?;8OA#:??JKEKH4;".QT?Y'D>
M(^01%*VLS?HL2+L'# Z'B3\&?V#]FHI KNJ>< KGC@K%=!GY1R1>)+F?/),?
MAP+@!'+!N]N[K'1'_;,\!:5 C3AF2*R:)2CRF!%HW.N/(QV@OJ'Q(L7I)HBK
MFV@0:,38N;Y#/(+%P@>W#!1"%@4K#L8RY/M%D3]/^7:RKP!8UIB[>OVH=]1K
M8B8ZQ^ <-@#Z^L-FNG-PP.6RI11PH:2#@"-Z<L-,-1HWYZL&JEZ+,AY &+ Z
M4J[M*5=F<]'%K;WU'%GO_=0) NUA$[BSJ[YL<6;PUA2A=*8U)%VKNT&@B$Y6
M9A=*9X/%>6::Y\ :,8+OE<&(:%,"*)#5VK.JI1*5>:B7?QUE%MCO?1_/'H94
MNRF950 >0&KDEES+=):5?P37?=U0BY0W=7IJ50X]P]AQ Y$OFK\]M>S&2]5-
MNAUXS30)AN-**UBB<<[WGKAX,1YTW!$ #7]LI%=ZGSC.A=2A6+W=%_B/ ;EE
MI?1(N2^LY3L*BIQ*>,OV;_S/!&@FUYE?Y!!PV7Z)%.G;9:8?-QI*+KMX@&HV
M_/7PI_#BN7]?_I^]I M1%R&";R[\LTZ*9^7M7S@$[-]:=__6.;*O,D -/'#1
M4GIP;<9$?T>2TMU4D@%#(MF['WVC-A1Q.$2.Z+H9Z$1F>3Q&L(R%(*;IBRNZ
M\,\V-&]?&9Y<SG:N,(L03C#WF?(R-^[W=\F/R]Q_T;CJ0<G4/FZ"9BM";_-\
M5V.D--[U,2'/-;[X])SXK:=R5I_F$SV7&L7&[J;Y1;NG3_2 '^9)35V0V8UQ
MP%(. ;7 (#;L7O@AX/?LU(!CK[?-H)2&E,.5*Y;W1&5]LSY1=FM PI3CIG69
M*OD@_K63>U )1XD*G=;(%_=;>D-K7&L:[H!Y\Q*);O"2_E?LJ>6(B=QYG7%4
M)(N$99)S9)L 7OT^S2:QUY-1P$LU#3RU%+UCD1MY.OM2QVP-NYO2SY%S[HGO
M-;@O9-E.IRS0!6*<7]G.*[2VU^MHG^OW#!O6$<K3OE"F6LIJ# J, OPGP4Y^
MQ%.=D)OX;B7]7D?=ILA.U59+C;)G".([%P_^Q(ZR?^S.7DF\UN*[()N<NKDJ
MK="]=+>V*3CS7I^LN) 1A@-/$3_9\X1UJW.G @X=,=P85C"/;#D$&/S BR@.
MY:-_[%4/7'#JB>E 2$UR=0H]U@L?%:F4 41$$]Q\O9NVBEZ*M96P+G#K#V<;
M!D&8?9T3)@HZ(R4/M/\AY2K%=I])M<L/H2>+/NQ3&[MB.^C#[XUQ,?Y%88>
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M)G3*OS\44P[E4Q5EY7=BE=_.%3H2$RS %[,LEZE5@.%P@_2*H=WL/LE6GAN
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MADQB^!9IQIQ=AH_/5_*JY@A*BJQ;%$AZ<$(L@XCB]\!8O7OM3D+@)NHC/=R
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M!-1/P ^+IX,%]C;FTS4T>#6T:<:F"ELS/H :=Y@GC748O;3U)M=^O5KY1 -
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MK/(6^FJ,M_-[?-\MM8PQ%RQC;VNV9#.<D6;HW%'*J*@]+D-'I$>]]A.<0Y$
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M;8@9]@@[0Y1N)<0S8NSE<6;W?*%9@-[>^=BS.JW/W ->R^\XRNO[\ J+P1Q
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M;$BOVN[P3J"RBF1(9>G$OTWWIRJ8QH\FY(:OQS)\B1FY&2\V3EL3RJ,Q-&'
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ML'9IR-JAI ;Y;ML12XL)H@Q*<RD#CP#Y4!$(.,(F[8Y[Z1I.I3@6L^'K_@<
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M2>$BLQNP!1S4QLYJ7&8RV?.UIQ!S8ZAQ(09GM&P%24H$W,M[NUL<\7B6A>"
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M(;0 =SC\;$Y&W_#NZ[Q94,>:MGW^>=XC[S>2[RR+JSU-55@O]+<3&KV;T2Q
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MH(=9XZDJ"!%1C=))V#VIB$'D#A/K&#:T'\Y8&W,6K*>VH>$ZV?LP!"EY33S
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M8.0W_D9T?[K+"<'.!@FP#X -@@Y#QK&\WO^"AV03I\6GZVV6Y$1XWKT)6WO
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M"PB"G8_>:) 58UZ_D,:4&H56'B5$KAP Y// /G13A[EU^Q1J7BE @Q9D.TP
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M-"VL5**[)R<FM1>$C!.1F'X'Z[AY81;F/'#)&H95QMQ(>=6IEL#N>I'_$0*
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M NHL<9M8R&(N+SP,5?3TYB<)+1#8;7)GT+WPC;LO#P#/^%]A'<H*ZIW$/)M
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M/O5I_V%*BY5:F6J%$04V)*X[+/=W\X[\]P.]NJZ\E$#5#HF2EV>9Q)E Y:_
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M76B<=2<P0$GXE7;UM,>++Y;WM9<RK@N[;' DB@!779+0E*8T+SO]T>X9 N,
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M*:)(NQ]X;=_0;&],FSVI;2)%:/A&=YO&IZW=M!D=A-?0&LHK*! /D:-ZV[S
M$AE;1@CE(N3([J_'BP< !\QAAYQ>%Z,[5[B15*MB@Y59@K_;6P:+Z#+N0Z-
M6)0@^?R[TMJ;HHF=3<J6<@(.>)!":7M],:4 -R$Q0'A9-WZMJMKNSAB,L ">
M^ SDD,E@0Z4;)0_3S+^?4IV&2KUD-)TU@VQFC1%&&T:/TOB9SL4$#)JFA*+J
MYD8W!&\IN87\>+R^EHQQ:/>H+(QW4QM9L.D#L;]/!AX S,-AK>:!#KR9G^^O
MK4S7M*HNK554E%ET' EXPH-FB*&$:%[/<HR\7OXR#=;4Q+3ZO<>TQ7=..GW@
M98DS%G*,!OOQ2/B(/0M_[!JZF'(ONHBX]H6R==:.7F-5WZ\#=>A'ETYC$OS>
M(5.3>$#"&FG&,3/7W=KT<]U+BW9BE+3/3M?:2*>^Y05;@GJI@:3-ZX/.M!T:
M4>5L6_K'VKJ2GQ;I-/R,I-J38+*@FHAZQDQ&W:R6=T%0<(&.1+MF$WM=>W\>
M6&?:P<<^%6F!'Y'G3MFX$SBNJ=5M<_$DKJZ.&&CW#;C1ITCV;0CE8E$ (LFY
MY$$^V7TBT[&@>OM>>,/,Y$6#]:; *I& R^9;1OED/ 9-S.+23L)7R,I2FT,.
M ,XJ+RV1E2<JFGIU[3&B.?F81F7NKMM$+ZO%^NBT*7"&PN22TH8IS)BYGG>6
M:TQ$NS_LI"!4&X57A9-3 "9/<S-"TADW;4U. ^L$6[/R)8TH/Y[YG>Y0.77.
MS??4EN8IK6CUS)%CO^-#-VY\6\LJ#V[4J+4/]BWTF0VQB%RPU]\LOLIME)TC
MQ+2_U2)*_JXCIQ^"_FQ6&0%+IQ)%?^:LC8@CORL; [11G^E7$C>0Z/2M!?/
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M4LP=A:D/Z^7]./I' 6NK^,OBT7]$:W_W^!\ ;MR]$"5Z:G?G<5'W?5PK@GP
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M41F&U5OE?9:)<!+>XA;T:?GX[58 3 P_DE'*["AWA#=)*9Y(LT%PQI"+H;R
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M0&7-2T0V2_:>-A.%HDG",CU9SFJ$9*J.[O;/BJJ"^>]Z'N=KD1QY$%!HH$U
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M[_]HZ2K=_/5ON]?]%;^#AIV< 15;E<4[3$AHV+/*'@[Q4I/5DSWGT<.L_ 4
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MS8=5URH#_E(_HE1),Z'J:<2X]$KQZL@)_T*5S*67]%^NO%'%;Z\#OE,<3BP
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M7,:@485;9D72JY#Q=D2Z-DW(^T;RFZR+XO<=_OK;F"MR1G3-UCTPY _ ,2%
M%36%ZKWR6:.0;+"H25J%WA56=5OFL5JCEJ<2:[6U>G8 CK^B=K-_Y^\XCAC_
M=&\78W78('A("B7.EH/>3%^ML(VR)^MUV%]3*/5@DZGCD4#&\N%G)E_=;!T(
MJLHA(N@ "P,Y=SWC1+IM[]7R,#&:R3]W-V!P@)#D[F5_T7QCDH'388YP9.>C
ML8(!MB \",48DG$9T5]\U?BZ!8G!,I$>75^.MQDVD/D(9=9R<J'% @;MBO6=
ML3^:5T'L;4=]GX_-"Q]TYR)X;QL9H%8+MTI*@DTV*/'$5"JJ14:]%6+\KH;I
MNOB-M)/U[,.U<=]OZ;L[U-O*'Z"15=12OG?8JC-I!\%#0NJF^WH+.-J6W#@I
M98'F,7C6%>)K>]7_!6  \E @"#')D>WX"!X?%8\>+4A=#>R"S,1.6BG)%C"=
MQ"$; )/4V*&(% 0RN&&L77*:D\&_$(IOF9+)5"AF]7^47KO>?C3C!CNDP^_#
M.!J.D@Z-KW(6U&DPU$[7IIA)W=W,G3BM+#1L?GJ<*;Q-];5F3JWC<$6-S'5B
MW@&Y@2!?*W9S]EC:OF15NI+]:E "J'4'-G:W,?I'7"0?R@O]EE>Q5DDJ+?NX
ME*&3FDOMBL:]B]/;JX5R(WM[>3:NU^U[*-[4#0P/F (&GH/WJ0.405Y @-"+
M!CW/W(A6GEB_QGWA=7H6L49VW+:M5(=F8Y @>B]-*$C#[F[C2.L6/:FCI'.-
MM5$$;'HG-FWI#W4[(ZYT5H>]+[209;5R[,)^,OZ9H<9,>"M(85+7W#; L2\R
M\P7579 S09/P[$PWLWYQ+'^OO:5^*CSI,3A@'!%>2#T9PAD 8IT]0]NS/^!D
MNZ0P%"!,CV]?53<$7#%/X_J^!@9XQK58^''*R5$^L!/8KS7/GC/*V?M]?L8A
M!B$VG/'!YP;@WSG-6=E>\2!/6Y?)L<C0%^<0Y;X#F3 +VM AS=:;1V:_4Y>M
MIS)*QOV9L-P38'VB#-.-F$M>L3&S 8PHS.XXCK?#/A5IY@(;]D5^B5V:#I\D
M!^*%1;7UE\/TA1!_!15=G[]7@.6\YQZ8K,L_J]=]6S.A$("V(Q.K& 2%L"=.
M>,"P@<6LZ)>XSBDDN[4DQM!UAZ3-GSJIP^#PGGAQ^(:PZ.<QF%^RK1H^B]!8
M7A?O]:@+R49JZV;$H;GJ#-GW9X;57)&JG(=-ESA[(X^!HYU.3XS6#,$7QR._
MMJ!R)+WA*/8Z1HU0($24=.);!EY2_R<Y-"W2F7@?]#'"/U2_W/!BW#%IH\K*
M_L=3VH5S($#=;186&#^(&DUTY6#BC/S'"B\_$]A"'7W/7!MCS%CK>\GQ'5K<
MR%.=Y>1,&ITJ#FMXNVZP,)+:_#81_[+!D#V,KY'PAR/B:DH1;,3'D. 3A[O+
M-O>X?]L%<%O/]N,H23DO+S]%=BQTS-_Y:K:+^J'3]B7S$ZR@S5B(P*L_R#E.
MK[%O?!G2CJF@>EDJ1J!IZB"7C!-*ATQSDU->VYY_<;)79Z]#>_!7DU%R0\?/
M_E<>T\BJJQ/UX2=E6B6L/\>> )(*E;H>,J\WA-3%H2/\VU#FWPR;[O@P)R?-
M79BO\S\7+\1],T&@6E$DU6ZW=X?!7$H6/=9ONQ"3W;*%O;@\O89@(<A#@7T
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M&DB"A<0FEIHO&,C&U#$[BC8\23OW&H/*V4+J+\Y(9F3=":6!"G<^_8!3Z-"
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M%O-C#YIAT8__^Y>/7\6=NF=@OBPV;"DL@6+^UZ+\\.-*L$V)^EF^HI-/V-]
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M*W=N)5OVT_?SI3&'<_.5WTZ-9VI=#^C=5O9Q ?4S#EOPVJ#N =EF:*3ST/Z
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M_G*[>OK1O%,IO_EAI_.'(TVBJ"<%:+3K] ,C^2_%F3W3S^;)C6.0.V,2RX2
M-+;5"K""@*!$ DHR@FB>)0J%=6O"\3ZR6I>,C![%'G J SD_EYF@\*=8A>LQ
M5B70ZXQ&#S\94_E= 3E_7>Y8^"GQ]M)&8&%H'.K-YDZMF])>9=98&:"VJ_<(
M!<$HRXP[I^W^6>0<<)I+P!&A2 @FF/3+IG(F/?:NN&;$%J@H6=G6FJN8*>-J
M/J_5 YM7\35+[SJ:'C [+@*C@.=IP\_A5H6HCE-VTQ^ X/&J9PE?*&+5%9#3
M,:O.(USF*KW3.I9_?&OVN=M0@!D6@A"1," 8S0#65-B<?0E0(K)<,:TRY57#
M=V+^)XI+O:W=9>-&/=1NU.]--"JKW:CRF4C:'H7:1K^$*2 V]?=AFCOA$6?Y
M<C?&#JYV^4AD96L5FG\%1YK#IN72IYT]N7]=GO<X4Q/ZPKHO&_T6PT]J\V$I
M5O?JXZHH9A@*S;)< $)R#'"&-: )0T#F"<P5RIE"=+99;=C";:G:&]UK(=G2
M<+8S3<ZFG_'?EQ^F*5,T54!*'0.<< 0XY F@*<TIRV/-H%=&27_Y^^>L#I'?
M;6GJ+97?PF$%JNA$/UA*IY=U;RM^5() -G9_[$DMX%&Q7MJGXP^%JGX_B[,\
MIJF$@#&MS3[=J! E<0)DG$D6BS1+$/,Q(8<D1K8CW^PKD3BL>3^TY'WO4O?C
MJ=BQ$O=CUK4/K&I'"%RXCOTII>MX<F!2Q]MY(8S9+XM -#T54IQ@Q20' B&S
MXZ10 IIG.<B@EA0BC6*_$M)=Q$9>U5KEWEK$7=HP^,/FII^AP/#3U/XX]$_U
MZ! P=*[',5*72?;H$/IDMD?7.SW5>[4VCO^RLA7B^9MQ^PLSJMT?7"]E^>NB
MJO7RLB]2KD3,2 Q!JC0"F,L4,&E<>"%@BB04.4%>ITV].1G;,%1\10UC48N5
MYLA\V_?1TTCT!M_1@DP!J:=Y.8IFS50)9YNMJ.YH-6IGJ\$HA;)1O?F8UH -
MA>O N@T></">PM I2V??K1;F_<+6KM@\;Y=KJE.,22H QZGMKT61L73&U8FY
M(KDD,,N85VT:5\(C&[86&Z7BM1GY;_](8I3_4U0QU'M#THVK]S8E&%J]-R_;
MXC2;Y[$[=#D)&WY_TTWV4KL>)S Z]D)N[_LGZAP>L.Z.7VTEG%]6<J[GHC1?
MU;'K?BA4'&LJ,YB!.$W,!LJ6ER&,VK!]E&:)RF26.&?V#.1E[.@#"W\=DR]:
MY]57D6IBEAXL&^4MFUPM%FQ=>-^TA9B2;JLT,=!];L#XZ0A\RUW49J^Y\KIR
MC1P+#K=[,M2$L/?+GIH ?J^TJT" =>1I#:4P66)7("C:F6"AANS9FZFB:4NS
M?EZOA%*R>&\DKAK)E7^9Y7$J;1LW(#"5MJ4S!DS(!"0*<Y9*$>=0S);JUN9*
M?//HV'26LI.FT4K3#NB[:QNK0K+F.\(1B%8VI,>SM=)Y*-T\U4#(]"NB6-..
M]&H=_="0CZP6_#EJ<1"P!9.SM*$Z,ITG.&V#)F< #OHUN;_9SSI\,>,8(V.3
MH%AQ9YQ?^X]U>I^,TICACW]:IR=3SC*S^R,@I20VGFAN[09D ,4,&Y,29TAY
M;7>',#.R4VIIEENZ\H<6]9Z-H ;A[F9DID+3S_P, -+;\(1 ()!)&L3*I,8J
M!&@OS5B0,7N&UIX^5<IHQAE/(*"2VVXHC '.L08"PASG5',&I5<4[*7.YXZ=
MQZF2@;]ZQIT./8*[Q*%;1><JNMZ8[QA_W)0A]IN5[5-K]U5C'+Y-=MSV6@[8
M_(_4@A^B[0U<=0E]^VA[,U51B>4FJRC_6$<M-ILH.6-*2I)3!5#.!<"YX(!Q
M" ''L22,IGDF<;._\5!U+R9Z;'7\C,"6TH!B8_[0>IB%\'!=//B[8;<5_QW8
MR/0"+:3Q\6-@>J/4"Z"CQJK?2%/7\['_L85ZMTRB6:J1X$1G0,>I CC)<L!A
MSD":,IIDQIN!R41U? Z9&]GSJ8G5^3FEY7M6;#U9E<5CT^%H$B\$\N3&LOPG
M:B8JN)$< <9+9[8<8^V/D;;2 6JXNCT=-/RO96W0B+A37VQ*RY'@N9G()),X
M-3O#7%" -:3&MDH.2*H5BY'FB#I?NYZA-;*IK*E':TO^JI6MZ'Z#=PZL\Q>B
M 2'P,V2-]%\JZ8_&KH8#POVJ,B @_:XB!P'C=<GH*&K')>*Y$2:[)'04I7T)
MZ/J*OPFS5XCJ]O9GM;YGR^?F:#Y+DR3)(5!Y@FT1) Q()A!(E.18*IU#[72V
M=8K R,:J)GD5U43=5?,H&N<-TU 9/>_@7HC7HU+L43G=[<Y0>?L9&^=I]3(L
M7;)T6).CKTUF0KJ8;MN-SN?Z;3ZMP[56=\;GFC^I*O&NBI=]&3N.6,8D1QC$
MFAHCDE(("*<22*ZA$BG*,?-*VG$E//9=7IL-QWS.84"Z;0G'@,?S<NX(,E>3
MA-;[RAYHC^9,=M+]ER\8+_=6WN_[.QT_KYE6"VWV8"]6($0()RP&$.KRJ!T"
MGIK]$D)8B1@E$B?"U>\X06-DZ["CVL/[. 7+>0<D@+!^NGY$SAYNR,GO@;,G
M$D#P?LZ(ST1[^2-G).IP24Z].9E7<H;UMF-R[M&>!^/SVV49#+G<7 NQ>ER6
MQSS6;,U5L5M0=4PRGJH<9#FR3:!3XYF03 -,),K,_@9BOT0;-[)C7^,_WM^S
M];,-56SQ$^T8BAJ./$^WW3!U/+<.CI3GB70W,M%OXQ37\Y(ZU &R&]%ICX:]
M@#@X]/5[^T*UIK>WNF[EIC'$F=8$2)WE "N9 4)S"@1&@J<ZQEK@F7F1KR8K
M..TE@(^JML7P#DRHLW:,=?N];+&Q*<:ODQ=VJG-&8$)( KBRY?R%4H!KF@.6
MYUDF(4J3Q*_@ZZN=Z#X=G';Q)Q<M+^XWI8Z+WJN=*,_%,V21\2/!+W^D.N.]
MIN2UE!KW8_YU71Z/,C'!"X[WXZ+'!;3Y2A4V3K)NM_&6/=MLC^O;VW49!5A_
M_+?5PFQQW["%>*Q*',P@PBI!& --8PJPV0@!F@@(,D4U)@A"3IVB?H8P,?:5
M=<-6M*D[N$C#6)FXQ!K6MG]Z*IF+Q(X[C_O<OI-P_EQG"FC]%H$=JDU?G+<-
MJENNMG^J^(K>3(JJQ_7Y!.CVO%<?"66_*_>!\'3=Q?<=>KI+^H'"[]W>#QUK
M8$F]5O-V5)^PJ@QJG.$,F)G) $8, 9++'$"=\%C&68QBKR.P#EHCF_F25(1Z
MELT[ HV;4Q](8#_CNXNON8HJNE=1+7_ 5JH>(H8NFW>$TF6JYIT6^631O(Y7
M^N:J&-M@UXXJ \:ZHJNE=3ZOO\^+&4KS%"O, 4&:& WF#+ ,4H!HG'')4T*%
MWW%"%[6Q=_]5I:,=S>@W2]4S*[8;+\>]>B@4_!3;&X >^2 .@@5+_>BB-7&6
MAX/8APD=+B_U4^H/2[%69M?X5E7_?EA>"[%^5+)516J&,HXUE S$.+8Y&4@"
MSA '.,YC27.)\BSUT6T7HB.K>$TP4KT:/CFAYJ;AH;'P4_2&>O1#0__/]@"L
M0>>C0W5N;]7WD3B0!7 B.:DA\ 'AI3WP>G?BE*Y/C];3N-%5MMGU$YLO; JS
MV5Z4K35F5"4<PCP'*$]C8T"P!"16$B0B(2ACB(K4*05A;$;'OATOJ4:L(5MN
MI:OV2_T37L>:LT#7"A/,1/@+A#/W!Q7O99!#-:/7>S-:"O *\L,<(;YTKM@Y
M-E_7T?] L(/ED+G2Z^L@-M69OID!RJT+S!C+A8 @0<K8<*T1X$@)ZQ@JIC"5
M'%(_=_ EB9&M[XY@9"GVVMT=P<75X1LBK:][YR5H#U?NE"S!'+<# A.[::<$
M/'3*3C[Y&MIH_KRV_:=RF,6)39_"B.0 <\@ D1 "2J$0*E%0^!VSCL#CR*J_
M[1H_N9?5,2TC.UAAP)[<M^KH2EDR_PK\JO/(7MJEZN#PC^%-G8=XW :1^Z3\
M3+E4\]F[Y6:^>?YZSQ:+GQZ+^5(9?6>9R%E,8Y!GML8)B7- <::!RF*&,B(R
MPIU2T4Z,/_;I>$DQ*DE&#4TW(WH*D&X#&$!,S^-O+PF=S<T9.8Z8BD*)O]RN
MGGXT;U96PORP,PZGQIM$L<\(TRCEN<=";$K>L(VZ7:WG_U4J>GUMBF*1("&,
M9HDX 9@2#KA"":":$4VRC"1^]1#/DYQLT]*W3*L#:GVV,$.QZ+NE&:/(JKMD
MHVQPCA*\X(:G"X#N#5#GF_ZKZ$<S<XO/=ZNEJDX[9I2J.,]A"DB22H 9,SN9
MS/R4()0AK1,6<^ZZA+X<?.P($4LN*NG5YX?NB^<!#N=7SB'2^:FFAV!>:^8I
M"7HMF >#3;9:GA*CO52>?,8_%O=%B&\9VGNC/[)B@Z"-^)KE.(L1HQF06&8
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M$8,,<8&=BE6Y$!O9FC=EF!:6?FG!F>4@$I8%=P-S%K+S)CHD$'ZF>%N*JL3
M&H62>%12OZIC]!P#E)S <+>J(4'I9ST'@N-E-%VE[3".9X>8S BZ"M,V=L[O
M]-NG?E1%H=2).X]?V.9Q;?[]9G?..P^ )!F%,&5 2TAMV5P*.(,IR%F6<BU4
MK#+HLW_MP</()O"KN%/R<5&&Y]<,V ,Q\]N+6[SHAB_FMQY%O8?@[K8''AE-
M/SM:,7/U$K:]R\_-*N(J^LSF\JH!^SGZK>1PG$:9 Q *M+WNP\&DV^X!$+W<
MC@\9RM]1:S3W1K>BN[XH>_RGY/O5^OVC(:@^%,4C,T"\4+ $YTRK- 8,46B<
MN#P%3,0*B$3'"',M=>)DV(8R,J%UJPO(-8R5]>,JUJ*&-W<O9Q#XY]W!J2#U
M,W%;-&]TU X$W6'Z_A!3'_L6%F9W1W,JN/LYH:/#[N6FAL"JPX4=-/QD[FT(
M$-JN;Y#Q>BPA?2OY7$OCFYM'V:(NBOBXN;/%",Q3RGR)S2XOQSRE,*<@3:
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M5+@'$V.K]Y8EZWI:5D#)2]4CPS?(K0_(CJ9@9.@\S40+M774\',4P6DR3(;
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M3EPNWA6 P_+QSF_V+&RXNK^?5Y=A9O_W9K6T=UIJ*>:JV*7[;V^T.<H)Y9
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MO]>V3%A]'S KC*V+"HI H8DT3CFEMC1 "K"2!<Z-#5S@TJ<^@#MIKPW,OWB
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M9:WS.V'6[7<SG7-C)-<WO9\>'BT-F]-LM.J=JF:IQAFB!0(94A! H16@65D
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M'$%[;VE;GQL#*R_23!6L(-2OU:\+T9&UQ\?56LWO;%ZGN+>;NDT&6U:+)O:
MR?]\JC;N19"]P'13&+$A\E,8-?5DCWS2AJS]9#GX2^UYU2$V[(]X"L-'Z$@*
MPXGDI K#!X27"L/KW4 'K8N-N]%6!7U<K'ZOKGG5'*[;^ 8%2P%D*0B L&"
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M*K0> D&L:U8?TM->N : <G#U&C+&Q?7COA@!V\(<I33^6"X$8(CCQCGC,I5
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M[<:Y)9K\UI#UK YY'""W17VQV'Y+V5]B[^4[*%&D17N<QJ1+=5#,EPMT^.'
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M7'\V/_W/_]%]8O[##8W_^3_^?U!+ P04    " "(.JA8IB[Z7V]Y   N? 4
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M;K81ZL#(."(.<L?%+!Q/9-&F*)/ !!E 96; 2U;SSYWGR&R)TN^%AAO+;8>
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M++>.-!\E: RVIPF$VHE]!!C:R(5,9U1)>P.>!3I5?4C@8^U6A=ZRPHM(J9^
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M-^QTPZ7I.Q.%*!/G'JR-M$%,L.!D]N #YA 22T&W=H >HF589[JQRA<]R']
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M" ZGVTR\GLY.R:^:1.69,DE"1$5L6"O!,8H=!/=*19N4\ZT;.#] RK"92(<
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M+*)(T+'</%5C>^I&Z:8>$J0]*7*\;NK;Z3S,T_;"U;'X4&@O6J\<N50V4PQ
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M+;]A?KM8OCTE)Q7?K5:G]6WBEB%'H:TM(H/4F@RY)Z\X<,; *AZ4T-&3PI^
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M]Z[OH6.T*<+/0<#=.;1["GP,Q_HM'NB?'7V?KB8YR,"UJS<NQ=%9@'06))5
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M%D_W?_=\ V$.R=7T">5E]0-9S;]G!4(14AC!G&>M<\OWH7?@3J"-,',G^>]
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MI#59LPA:QM(AQ1U*U&5RTDE*N'"]GG:&PN?Y;<W7\K8" )Z#4T5IS'R3782
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M!*,4C.=H-.J4!2\M55SUU+K1O;HG:U8TU>UT.L\; ,[3?9<>5_*A.@3BO37
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M+C.I7A:\D'#'$+D/"7<,87D#]]U^L"G^\F'*.%>&Q%@F-@AT8SUZFA'/6?1
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M'*]+1?:%AY<T<9Y]DA R+P,KA &?> :2D0\R6.)2[9AL=2(6JA@5D3F=LHR
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M6N]6X3 >4 :EF2ZE6A2-CV SLL2B$QT$?I?BGV/#!7X/B5EVY']B!9L=/:]
MC5Y^!K[X]&G;%?0^8A2>-S9:(4';A.=-J8WT3$E0V5GI(G'*MS;5=32Q"XTT
M-*^&YT%?*VI:QR!XR AZR1S3E$8&/)?4>5G&H]&8($EFN#0RAN#;M30?4;/0
M*,.2#,I3\+/P@5^%XCWCO@]T_SO^D_WPJX=$UAOZ]<*JYQS\-80!;0S_"E:7
MCFZN#$+P("CA8&0QS')@1J= (JU=*/U:AG\I(J,-.8+3Q):A@PX,1_XQ1&]D
MQFJC:@]C^,_PKZ&8G6[XUQ#Q-V A/9AV0!QSTI2T-(T7DW LHA.6+1B6N3*A
M5,C//D=D :._!D'@N3DB0^31$)9N1R$0W(:R'JSBQ5?@$CR)^$4Z0VB05%=O
MQMSL')%!DGQACL@ MLY<@'3!"+4OCK% E@21308=2R6RD:4(F7E )@GC$TF<
MQ1<,PMZ+M0&),9+<3,G6!@Z/"HDRUAG+/)%@ I4@.$<#P%(#R%,I;51<R[,7
M:]>9#K* X5FG7'IGEOV2T?[6K;;="\(]5_+C:O??;[>I/#$DQ,_U1[26+U'Y
MM:09#Y?,"8B(#''&:?".A.2))D8T\T[<EZB%IAF-1&DM)9D$,J]-AVY?PM^L
MOJYB6L<]0Z3S/ @+3CJ\0D7T:+4Y Y)Z([R0,>=F4F'[$K70/)\&=>ADR+Q6
M'?IC<X4?<X5V:<<2HS75T:$A*M'\%)%Q\%P&=(62BI0&1MDDD9)IR5IH#D[#
M>G0";%K1I#&AHN=8LD\QDDP$'K.!F/ X$5VR42G1Q%LYI2@5T6*2KJ634+/0
MU)J*>C,_2!8>3^Q^Z0<N%G:L=REOMMW/.[;M/J:P^;1>_<]MK&TW5;3QI#V=
M,Q99CWEM1"J%,%11KB P5:(^VJ)B!@:94)*IE?K>W/97%JF\&V:?ME]7(1TY
MVZZZC\0_O<_?!;KOQ]'M=/]\8Z1+624&C/( 0GL#3K$,R1#'A+;&A.I5[%,0
MLN@(YA L'X]@S@6+&8VPW?;Z\O?5=:'^W3H6?^S&776!%ZZ"B-25.77!E3?V
M$H)!OI:9%YZ;Z*COE96,*]S#-/[M.YZ/+MY*/',V0&QJ2J<U>/UC=?VYT^MB
MBWU>??E]\_/Z&IV7V^!.4D1DZL HF4"$*,$A24 9\9XH%;7A4P#O^6W- \E*
M '@.3A6E,7/0]%9;#V$\DRES*5)@GJ+"21O .9.!6J<EU=(:[U\P8'_\U(9@
M4%-PFRI<;. QX=T:C?KT&XJD\PI_.9S,G<I8)I4VB8.WP8+P^"=T/SDD+74P
M2ON8:D<YG]E.*^'+N>^XVI)K%X0'Q7216*X5<H41#<(E#X9G!RD6&Y92IL*9
M8-A"LD\UL?>#TP@9- "HCR@3W,#GBW5\D[ZFJ\V70M/AZ>$V:\5Y%HB*8)*B
M)6O%@HM($I?,2,TL1RHKPZK'MIH$UQ@0;*:52 ,@^VM:IRU:E^MX$?]<K5?%
MM2Z940^)BEX1%K4$[4HK1FH8ZJ13$)EDED;O\^.YQR?#K-?&YKU.IP-:?:DT
M +4Z-L?WR$(F4B09(QH:M#S_J  &[5Q OB8EN1=X=U0&96429@Z*-F<-SHF0
M!A3D:7HO60K&)^G $^;*,Z<')[*%Y"/WB?+$6?4*F2=W,N^U/BLX>@7T!TEJ
M--Z^IJW?3!M6/+R_?W#;ZV^_;QV2%[KWAO%!P9<^L5)(;]#&*P7DCJUY%Z90
M.3%-"9Z(@68\$:4"[Z4 GHCQRA+&0GT;_?D]U0NJ'5OI+]\>_*2[&M"-,Y$R
M X25,4T^&C J)&!:<503(BRMWG9VS$;G/>>JXNEXV&LJP<T<=_AI<U-R=+^4
MS=^5$V6?N%&$0,:-@E N@Y>>@Q7X7XD4&EHCJO74VJT$M283]Z8B[V?&SL?T
MY0:]>[S6+SYM4^?3/2;IX-OI&!A/.D)0Z.D+@Y19(A,:$)Q'U$UK=:_P_PN
MZKVA^0(4I\M\,[4 9@Y0O;EQZ_2KVWW^VYO_\^9O?[DX.._:9\HU#9!E&:3M
M" 57)KD0'PFUN0RY"#T"54]_^GQXF$B$FZK\;"TVWBF-XBFD; Q$9KI9!;&\
M@!/DC%<F1X5<FC?UX@QAJ7/<4J=SOS7XO! 3=M('I84';W29CAH%.(F,LIRD
M3))'-:QQ62T\M6(0 $Y(K1@BC9F!]I=-:<V4WZRV*>!O[7[Z[%;;/^\JIE'Y
M&(T4U<Y06]IGEZF[>/9&AY>_RBX&%RO@ZOE=- 2CFH+?3"*%!MXXCYSPG0J*
M9*FGT@/+E)5N>1:,RPRL0@XQ'KD0M1\ZG]E.*X_S4]^)M273+L@.BB@(E3:2
M5")Q:'BBJ0B&)(HVHU+4!<X=KUU@]^R&FGQN&B[V?G :(8.Y$PS_E<)-";[>
M'KQWCLWA!!8\*Y8XA<P4!Q&Z@3,N@K5.T"2(3O;1L^;3*8<OK-,D3,:(<S,1
M;]L]>!Z=U9UN49MLS-Q"R'AE"YDL4A;1Z,PJNBR4UZ%7PG.%J,"/NYNYZK"5
MN^]4N36&R(.R<A=E-MJ#QJV"T (/=$[+J9ZX)=0X1VL/M?YQ%TV>9B?+^QE8
MC6!^V^Z?U)3R(",8J=%A%D*"2YP#T21$:DD.ME=.V +=OUKR[>_E#6'VS+"Y
MRX?[+:2UVZXVG1II0[2CR8 MQ02",0*N9,-)%X+G)2#0S[=[ 2U/+CYS7_RS
MOFZ>SOVYX7/8]]_7NR\IK/(JQ8-J9>6-BC8!Y:YDEN$7IX4&[F24%-4@VAH/
MY$<W,-]34P6A;FISN!&8O-W@@>EV=_Z"\#RHJ"!G5GI$HC?B)5? HC2"*).T
MJ%%&^/3J,P*DCDB? ,D)_&W,^KUWXOYREP3(O-!4,P5*6E,<5[Q7I9>0F/16
M%_W*M5.27MK3S,,E6O&]QLEHYK>BW]R5VWZ[6,=_N$_(PKP*:?NWS?KZ\]6W
MDBVZ__%E\I;KZ BDW#4]DZB3DFHPU)"H%>4V/>J3]^2#4:_%VC&03Y?M9DI&
M3]_DY_"#\J7TL_C?_^O_ U!+ 0(4 Q0    ( (<ZJ%@I6CGX5@<  ,D@   9
M              "  0    !I;75X+3,S,3(T>&5X:&EB:70S,3$N:'1M4$L!
M A0#%     @ ASJH6/%"J:9*!P  OB   !D              ( !C0<  &EM
M=7@M,S,Q,C1X97AH:6)I=#,Q,BYH=&U02P$"% ,4    " "'.JA8_4$C"%@$
M   W$@  &0              @ $.#P  :6UU>"TS,S$R-'AE>&AI8FET,S(R
M+FAT;5!+ 0(4 Q0    ( (<ZJ%C\^]Z$7@0  $P2   ;              "
M 9T3  !I;75X+3-X,S%X,C1X97AH:6)I=#,R,2YH=&U02P$"% ,4    " "'
M.JA8\U7I@_D0 0!RIPL $               @ $T&   =G1L+3(P,C0P,S,Q
M+FAT;5!+ 0(4 Q0    ( (<ZJ%C:,S=T-Q   !>G   0              "
M 5LI 0!V=&PM,C R-# S,S$N>'-D4$L! A0#%     @ ASJH6 0L;'W%%
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M,C0P,S,Q7VQA8BYX;6Q02P$"% ,4    " "(.JA8IB[Z7V]Y   N? 4 %
M            @ %L2 0 =G1L+3(P,C0P,S,Q7W!R92YX;6Q02P4&      L
,"P#C @  #<($

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>vtl-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20240331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2024-05-02</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:January2024PIPETransactionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">vtl:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-08</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-03</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:EquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>vtl:financialInstitution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="numberofvote">
        <measure>vtl:numberOfVote</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-240">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-5" id="f-254">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-255">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-305">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-306">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-127" id="f-452">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">90079016</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">97312000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">46674000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">5303000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">5860000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">102615000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">52534000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">442000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">466000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">1098000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">1299000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">104155000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">54299000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">6767000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">5099000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">12419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">18664000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">960000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">966000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">20146000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">24729000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">433000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">639000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">433000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">639000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">20579000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">25368000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-58" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-60"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-61" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-62" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-63" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-64" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-65" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-66" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-69"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-70"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-71" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-72" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-73" unitRef="shares">90079016</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-74" unitRef="shares">90079016</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">45177730</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-76" unitRef="shares">45177730</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-77" unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-79" unitRef="usd">519757000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">436060000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">4287000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">3759000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">-440476000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">-410892000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">83576000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">28931000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">104155000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">54299000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-89" unitRef="usd">18736000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-90" unitRef="usd">22963000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-91" unitRef="usd">5145000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">4288000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">23881000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-94" unitRef="usd">27251000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">-23881000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">-27251000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-97" unitRef="usd">1187000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-98" unitRef="usd">800000</us-gaap:InvestmentIncomeInterest>
    <vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">4796000</vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts>
    <vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">0</vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-101" unitRef="usd">-2094000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">1179000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">-5703000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">1979000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-105" unitRef="usd">-29584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-111" unitRef="shares">97299955</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-112" unitRef="shares">97299955</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-113" unitRef="shares">43664783</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-114" unitRef="shares">43664783</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">-29584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-117" unitRef="usd">528000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">-29056000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">-24496000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-121" unitRef="shares">45177730</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-123" unitRef="usd">436060000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-124" unitRef="usd">3759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-125" unitRef="usd">-410892000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-126" unitRef="usd">28931000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-127" unitRef="usd">-29584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-29584000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-129" unitRef="usd">2750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">2750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">528000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">528000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-13" decimals="-3" id="f-133" unitRef="usd">4037000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-14"
      decimals="INF"
      id="f-134"
      unitRef="shares">44751286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-136" unitRef="usd">52360000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-137" unitRef="usd">52364000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c-11" decimals="-3" id="f-138" unitRef="usd">28396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">28396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-17" decimals="-3" id="f-140" unitRef="usd">6000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-18"
      decimals="INF"
      id="f-141"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-19" decimals="-3" id="f-142" unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-143" unitRef="usd">191000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-21"
      decimals="INF"
      id="f-144"
      unitRef="shares">90079016</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-145" unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-146" unitRef="usd">519757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-147" unitRef="usd">4287000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-148" unitRef="usd">-440476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-149" unitRef="usd">83576000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-150"
      unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-151" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-152" unitRef="usd">427925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-153" unitRef="usd">3035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-154" unitRef="usd">-317280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-155" unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-30" decimals="-3" id="f-156" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-157" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="-3" id="f-158" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-159" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-32" decimals="-3" id="f-160" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-161" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-33"
      decimals="INF"
      id="f-162"
      unitRef="shares">5096552</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-31" decimals="-3" id="f-163" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-5" decimals="-3" id="f-164" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-34"
      decimals="INF"
      id="f-165"
      unitRef="shares">44403838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-166" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-167" unitRef="usd">429955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-168" unitRef="usd">3811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-169" unitRef="usd">-342552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-170" unitRef="usd">91218000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">-29584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-172" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">26000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-3" id="f-174" unitRef="usd">32000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">-340000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-5" decimals="-3" id="f-176" unitRef="usd">-516000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">2750000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-178" unitRef="usd">1979000</us-gaap:ShareBasedCompensation>
    <vtl:ChangeInFairValueOfTrancheRights contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">4796000</vtl:ChangeInFairValueOfTrancheRights>
    <vtl:ChangeInFairValueOfTrancheRights contextRef="c-5" decimals="-3" id="f-180" unitRef="usd">0</vtl:ChangeInFairValueOfTrancheRights>
    <us-gaap:ManagementFeeExpense contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">1690000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">0</us-gaap:ManagementFeeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">-389000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-184" unitRef="usd">-123000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">1794000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">986000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-6145000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-5" decimals="-3" id="f-188" unitRef="usd">2072000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-25000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">51000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-23969000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-192" unitRef="usd">-19513000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c-5" decimals="-3" id="f-194" unitRef="usd">-5439000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-196" unitRef="usd">104000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-31000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-198" unitRef="usd">5335000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">191000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-5" decimals="-3" id="f-200" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-5" decimals="-3" id="f-202" unitRef="usd">51000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">74273000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">74464000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">51000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">174000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">143000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">50638000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-210" unitRef="usd">-13984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-211" unitRef="usd">46674000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-3" id="f-212" unitRef="usd">106745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-213" unitRef="usd">97312000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-38" decimals="-3" id="f-214" unitRef="usd">92761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">28396000</vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares>
    <vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">0</vtl:ConversionOfTrancheRightsLiabilityToEquityUponIncreaseInAuthorizedShares>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">544000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-219">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany. The Company had approximately 80 employees as of May 1, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#x201c;MS&#x201d;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&#x201c;UC&#x201d;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome and irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016.  The Company has an accumulated deficit of approximately $440.5 million as of March 31, 2024 and $410.9 million as of December 31, 2023.  Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through March 31, 2024, Immunic has raised net cash of approximately $430.9 million from private and public offerings of preferred stock, common stock, pre-funded warrants and tranche rights. As of March 31, 2024, the Company had cash and cash equivalents of approximately $97.3 million. With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the &lt;/span&gt;&lt;/div&gt;instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 22, 2024. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="c-39"
      decimals="-1"
      id="f-220"
      unitRef="employee">80</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentPrograms contextRef="c-3" decimals="INF" id="f-221" unitRef="lease">3</vtl:NumberOfDevelopmentPrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-222" unitRef="usd">-440500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-223" unitRef="usd">-410900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-40" decimals="-5" id="f-224" unitRef="usd">430900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-5" id="f-225" unitRef="usd">97300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-226">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the &lt;/span&gt;&lt;/div&gt;instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2023 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 22, 2024. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-227">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S. of approximately $73.2&#160;million, Germany of approximately $22.5&#160;million and Australia of approximately $1.6&#160;million as of March 31, 2024. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.2% during the period ended March 31, 2024. Cash and cash equivalents in Germany are earning interest at a rate of 3.5% to 3.75% during the period ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-240"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $26,000 and $32,000 for the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $36,000 and $1.8&#160;million of &lt;span style="-sec-ix-hidden:f-254"&gt;&lt;span style="-sec-ix-hidden:f-255"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2024 and 2023, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2019 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants and Tranche Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, financial instruments are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If financial instruments do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the financial instruments should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified financial instruments are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the financial instruments after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;instruments do not require liability classification under ASC 815-40, in order to conclude financial instruments should be classified as equity, the Company assesses whether the financial instruments are indexed to its common stock and whether the financial instruments are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified financial instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position. The weighted average shares outstanding calculation for basic and diluted earnings per share for the three months ended March 31, 2024 includes 11,193,564 pre-funded warrants.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-228">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-229">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock contextRef="c-1" id="f-230">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments- other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and deposits in banks located in the U.S. of approximately $73.2&#160;million, Germany of approximately $22.5&#160;million and Australia of approximately $1.6&#160;million as of March 31, 2024. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at JP Morgan and are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.2% during the period ended March 31, 2024. Cash and cash equivalents in Germany are earning interest at a rate of 3.5% to 3.75% during the period ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;</vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-41" decimals="-5" id="f-231" unitRef="usd">73200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-42" decimals="-5" id="f-232" unitRef="usd">22500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-43" decimals="-5" id="f-233" unitRef="usd">1600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtl:NumberOfFinancialInstitutionsUsedForCashDeposits
      contextRef="c-3"
      decimals="INF"
      id="f-234"
      unitRef="financialinstitution">2</vtl:NumberOfFinancialInstitutionsUsedForCashDeposits>
    <us-gaap:InvestmentInterestRate contextRef="c-44" decimals="3" id="f-235" unitRef="number">0.052</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-45" decimals="3" id="f-236" unitRef="number">0.035</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-46" decimals="4" id="f-237" unitRef="number">0.0375</us-gaap:InvestmentInterestRate>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-238">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-239">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-240"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-241">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">26000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-243" unitRef="usd">32000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-244">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-245" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-5" decimals="INF" id="f-246" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-247">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program, for clinical trials in MS and UC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-248">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c-1" id="f-249">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government  for reimbursement of research and development expenses up to one million Euros per year.  We recognized $36,000 and $1.8&#160;million of &lt;span style="-sec-ix-hidden:f-254"&gt;&lt;span style="-sec-ix-hidden:f-255"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent contextRef="c-49" decimals="3" id="f-250" unitRef="number">0.435</vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresPercent>
    <vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount contextRef="c-42" decimals="-6" id="f-251" unitRef="eur">1000000</vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">36000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-5" decimals="-5" id="f-253" unitRef="usd">1800000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-256">&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-257">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-258">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office and laboratory space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-47" id="f-259">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-48" id="f-260">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases contextRef="c-3" decimals="INF" id="f-261" unitRef="lease">3</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-262">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of March 31, 2024 and 2023, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2019 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-264">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants and Tranche Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued financial instruments either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, financial instruments are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If financial instruments do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the financial instruments should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified financial instruments are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the financial instruments after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If financial &lt;/span&gt;&lt;/div&gt;instruments do not require liability classification under ASC 815-40, in order to conclude financial instruments should be classified as equity, the Company assesses whether the financial instruments are indexed to its common stock and whether the financial instruments are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified financial instruments are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-265">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position. The weighted average shares outstanding calculation for basic and diluted earnings per share for the three months ended March 31, 2024 includes 11,193,564 pre-funded warrants.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-50"
      decimals="INF"
      id="f-266"
      unitRef="shares">11193564</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-267">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-51" decimals="0" id="f-268" unitRef="shares">10318323</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-52" decimals="0" id="f-269" unitRef="shares">5595841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-270">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-271">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expense consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.287%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-305"&gt;&lt;span style="-sec-ix-hidden:f-306"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-272">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expense consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.315%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.059%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-3" decimals="-3" id="f-273" unitRef="usd">2767000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-4" decimals="-3" id="f-274" unitRef="usd">2314000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-3" decimals="-3" id="f-275" unitRef="usd">770000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-4" decimals="-3" id="f-276" unitRef="usd">703000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount contextRef="c-3" decimals="-3" id="f-277" unitRef="usd">676000</vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount>
    <vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount contextRef="c-4" decimals="-3" id="f-278" unitRef="usd">670000</vtl:GovernmentAssistanceQualifiedResearchAndDevelopmentExpendituresMaximumAmount>
    <vtl:ResearchAndDevelopmentGrant contextRef="c-3" decimals="-3" id="f-279" unitRef="usd">0</vtl:ResearchAndDevelopmentGrant>
    <vtl:ResearchAndDevelopmentGrant contextRef="c-4" decimals="-3" id="f-280" unitRef="usd">1104000</vtl:ResearchAndDevelopmentGrant>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-281" unitRef="usd">1090000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-282" unitRef="usd">1069000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-283" unitRef="usd">5303000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-284" unitRef="usd">5860000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-285">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-286" unitRef="usd">6211000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-287" unitRef="usd">4726000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-288" unitRef="usd">115000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-289" unitRef="usd">160000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-3" decimals="-3" id="f-290" unitRef="usd">441000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-4" decimals="-3" id="f-291" unitRef="usd">213000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-292" unitRef="usd">6767000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-293" unitRef="usd">5099000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-3" decimals="-3" id="f-294" unitRef="usd">11497000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-4" decimals="-3" id="f-295" unitRef="usd">16863000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-3" decimals="-3" id="f-296" unitRef="usd">234000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-4" decimals="-3" id="f-297" unitRef="usd">216000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-3" decimals="-3" id="f-298" unitRef="usd">610000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-4" decimals="-3" id="f-299" unitRef="usd">1460000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-300" unitRef="usd">78000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-301" unitRef="usd">125000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-302" unitRef="usd">12419000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-303" unitRef="usd">18664000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-304">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.979%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.287%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-305"&gt;&lt;span style="-sec-ix-hidden:f-306"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-307" unitRef="usd">697000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-308" unitRef="usd">695000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-309" unitRef="usd">263000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-310" unitRef="usd">271000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-311" unitRef="usd">960000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-312" unitRef="usd">966000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-313">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#xe4;felfing, Germany office and November 30, 2028 for the research laboratory in Planegg, Germany.  These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $257,000 and $195,000 for the three months ended March 31, 2024 and 2023, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2024, the Company has non-cancelable contractual obligations under certain agreements related to its development programs vidofludimus calcium and IMU-856 totaling approximately $3.0&#160;million, all of which is expected to be paid in 2024 and 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-53" id="f-314">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-54" id="f-315">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod contextRef="c-55" id="f-316">P6M</vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod>
    <vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod contextRef="c-55" id="f-317">P3M</vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-53" id="f-318">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-56" decimals="-3" id="f-319" unitRef="usd">544000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-53" decimals="3" id="f-320" unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-57" decimals="3" id="f-321" unitRef="number">0.08</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">257000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-5" decimals="-3" id="f-323" unitRef="usd">195000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-324">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of March 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.833%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.015%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-325" unitRef="usd">551000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-326" unitRef="usd">433000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-327" unitRef="usd">78000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-328" unitRef="usd">82000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">79000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour contextRef="c-3" decimals="-3" id="f-330" unitRef="usd">0</vtl:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-331" unitRef="usd">1223000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-332" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-333" unitRef="usd">1130000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation contextRef="c-3" decimals="-5" id="f-334" unitRef="usd">3000000</us-gaap:ContractualObligation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-335">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.2% in a U.S. Government money market fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of March 31, 2024. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded tranche rights of $23.6&#160;million at January 8, 2024 as a result of the January 2024 Financing (see note 6).  The fair value measurement of the tranche rights associated with the January 2024 Financing was classified as Level 3 under the fair value hierarchy.  The fair value of the the tranche rights was determined using a Black Scholes Option Pricing Model. The inputs to this model included a risk-free rate range of 3.93%-4.36%, a stock price volatility range of 105-115%, an expected dividend rate of &#x2014;% and remaining term of 1.81-4.81 years.  This liability was revalued on March 4, 2024, upon approval to increase its authorized shares of common stock from 130&#160;million to 500&#160;million, which resulted in the reclassification of the tranche rights from a liability to equity.  This revaluation resulted in an increase in the tranche rights liability of $4.8&#160;million using a Black Scholes Option Pricing Model. The inputs to this model as of the date of the reclassification included a risk-free rate range of 4.16%-4.63%, a stock price volatility range of 90-105%, an expected dividend rate of &#x2014;% and remaining term of 1.66-4.66 years. The inputs used in the determination of fair value of the liability are level 3 inputs.  A rollforward of the fair value of the tranche rights is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of January 8, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value through March 4, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:51.239%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-58" decimals="-3" id="f-337" unitRef="usd">72961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-59" decimals="-3" id="f-338" unitRef="usd">72961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-60" decimals="-3" id="f-339" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-61" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-62" decimals="-3" id="f-341" unitRef="usd">72961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-63" decimals="-3" id="f-342" unitRef="usd">72961000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-343" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-344" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-345" unitRef="usd">34087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-346" unitRef="usd">34087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-348" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-349" unitRef="usd">34087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-350" unitRef="usd">34087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-351" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentInterestRate contextRef="c-41" decimals="3" id="f-353" unitRef="number">0.052</us-gaap:InvestmentInterestRate>
    <vtl:TrancheRightFairValueDisclosure contextRef="c-74" decimals="-5" id="f-354" unitRef="usd">23600000</vtl:TrancheRightFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-75" decimals="4" id="f-355" unitRef="number">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-76" decimals="4" id="f-356" unitRef="number">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-75"
      decimals="INF"
      id="f-357"
      unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-76"
      decimals="INF"
      id="f-358"
      unitRef="number">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-77" decimals="4" id="f-359" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-75" id="f-360">P1Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-76" id="f-361">P4Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-74" decimals="-6" id="f-362" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-78" decimals="-6" id="f-363" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement contextRef="c-78" decimals="-5" id="f-364" unitRef="usd">4800000</vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-79" decimals="4" id="f-365" unitRef="number">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-80" decimals="4" id="f-366" unitRef="number">0.0463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-79" decimals="2" id="f-367" unitRef="number">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-80" decimals="2" id="f-368" unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-81" decimals="4" id="f-369" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-79" id="f-370">P1Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-80" id="f-371">P4Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-372">A rollforward of the fair value of the tranche rights is as follows (in thousands):&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of January 8, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value through March 4, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to equity&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="0" id="f-373" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="0" id="f-374" unitRef="usd">23600</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="c-1" decimals="0" id="f-375" unitRef="usd">4796</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <vtl:ReclassificationToEquity contextRef="c-1" decimals="0" id="f-376" unitRef="usd">-28396</vtl:ReclassificationToEquity>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-3" decimals="0" id="f-377" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-378">Common Stock&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2023, we filed a shelf registration statement on Form S-3 (the "2023 Shelf Registration Statement").&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The 2023 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of May 8, 2024, the 2023 Shelf Registration statement has not been declared effective by the SEC, however, the Company can (i) continue to sell, subject to applicable SEC requirements, unsold securities remaining on the expired 2020 Shelf Registration Statement until the 2023 Shelf Registration Statement has been declared effective (or May 22, 2024, if sooner); and (ii) after the 2023 Shelf Registration Statement has been declared effective, offer and sell additional securities registered on the new Form S-3, as well as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;unsold securities from the expired 2020 Shelf Registration Statement that are permitted by SEC rules to be included in the 2023 Shelf Registration Statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2020, the Company filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement"). The 2020 Shelf Registration Statement permitted the offering, issuance and sale of up to $250.0 million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. The 2020 Shelf Registration Statement expired in November 2023 but, as explained above, unsold securities from this expired registration statement can continue to be sold under the 2023 Shelf Registration Statement. As of March 31, 2024, there is $75.0 million of unsold securities from this 2020 Shelf Registration Statement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners LLC) as agent ("December 2020 ATM"). The Company has used and intends to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2024, $7.3&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, the Company filed a Prospectus Supplement to the 2020 Shelf Registration Statement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with Leerink Partners LLC (formerly SVB Leerink LLC) as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through Leerink Partners LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by Leerink Partners LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of March 31, 2024, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay Leerink Partners LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide Leerink Partners LLC with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2024, we raised gross proceeds of $0.2&#160;million pursuant to the December 2020 ATM through the sale of 150,000 shares of common stock at a weighted average price of $1.31 per share. The net proceeds from the December 2020 ATM were $0.2&#160;million after deducting sales agent commissions of $6,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any ATM activity during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Private Placement of up to $240&#160;million ("The January 2024 Financing")&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2024, Immunic entered into a Securities Purchase Agreement with select accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a three-tranche private placement shares of the Company&#x2019;s common stock, $0.0001 par value per share or in lieu thereof, pre-funded warrants to purchase shares of Common Stock. The Pre-Funded Warrants are exercisable immediately for $0.0001 per share and until exercised in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The first tranche, which closed on January 8, 2024, resulted in the purchase by the Investors of an aggregate of $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.43 per share;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The second tranche is a conditional mandatory purchase by the Investors of an additional $80&#160;million of Common Stock (or pre-funded warrants) from the Company at a price of $1.716 per share, equal to 120% of the price paid in the first tranche and is subject to the satisfaction of three conditions:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;release by the Company of topline data from its Phase 2b clinical trial of vidofludimus calcium (IMU-838) in progressive multiple sclerosis, which data is currently expected in or around April 2025;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;the 10-day volume-weighted average price of the Common Stock is at least $8.00 per share during the 6 months following the data release; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25e6;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt"&gt;aggregate trading volume during the same 10-day period is at least $100&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The third tranche must occur no later than three years after the second tranche and is conditioned on the same volume-weighted average share price and minimum trading volumes as the second tranche. The third tranche provides for the issuance of $80&#160;million of shares of common stock (or pre-funded warrants) at the same price per share as the second tranche, but permits investors to fund their purchase obligations on a &#x201c;cashless&#x201d; or net settlement basis, which would reduce the cash proceeds to be raised by the Company in the Private Placement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any of the conditions in the second or third tranches can be waived by holders of a majority of the outstanding securities (including the lead investor).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Private Placement resulted in gross proceeds to the Company of approximately $80&#160;million in the first tranche, and an additional $80&#160;million if and when the second tranche occurs. If the second tranche is completed and conditions for the third tranche are satisfied or waived, the Company could receive up to an additional $80&#160;million in the third tranche. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the closing date of the transaction of January 8, 2024, the Company did not have enough authorized shares to be able to issue the potential shares for tranche 2 and tranche 3 (collectively referred to hereafter as "the tranche rights").  Therefore, the Company recorded the value associated to the tranche rights as a liability of $23.6&#160;million and allocated the remainder of the $80&#160;million received (or $56.4&#160;million) with the common stock and pre-funded warrants to equity.  On March 4, 2024, the stockholders voted to increase the Company's authorized common shares from 130&#160;million to 500&#160;million shares.  As a result of the ability to issue shares in satisfaction of the tranche rights, the instrument was reclassified to stockholders' equity.  The Company allocated the transaction cost across the instruments on a relative fair value basis at the grant date. As a result $4.0&#160;million was netted against the equity proceeds and $1.7&#160;million  was recorded in other expense in the Consolidated Statements of Operation for the three months ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company registered for resale by the investors in the January 2024 Financing up to 55,944,850 shares of common stock issued (or issuable upon exercise of pre-funded warrants) in the first tranche. The Company will not receive any proceeds from the sale of these shares of common stock. These shares are registered on a registration statement on Form S-3 (registration No. 333-277040), which was declared effective by the SEC on April 30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2024, the stockholders of the Company voted to increase the authorized shares of the Company from 130,000,000 shares of common stock to 500,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the Board of Directors, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through March 31, 2024, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pre-funded Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issued 11,193,564 pre-funded warrants in connection with the January 2024 Financing, which all remain outstanding as of March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, rights and preferences to be set by the Board of Directors. No preferred shares were issued or outstanding as of March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at March 31, 2024 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares reserved for tranche 2 rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,620,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Maximum shares reserved for tranche 3 rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,620,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,973,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-82" decimals="-5" id="f-379" unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays contextRef="c-83" decimals="INF" id="f-380" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-83" decimals="-5" id="f-381" unitRef="usd">7300000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-84" decimals="-5" id="f-382" unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays contextRef="c-85" decimals="INF" id="f-383" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNoticeNumberOfDays>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-85" decimals="-5" id="f-384" unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock contextRef="c-1" decimals="3" id="f-385" unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-86" decimals="-5" id="f-386" unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-86"
      decimals="INF"
      id="f-387"
      unitRef="shares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-83"
      decimals="2"
      id="f-388"
      unitRef="usdPerShare">1.31</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-86" decimals="-5" id="f-389" unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions contextRef="c-86" decimals="-3" id="f-390" unitRef="usd">6000</us-gaap:PaymentsForCommissions>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-87" decimals="-5" id="f-391" unitRef="usd">240000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-88"
      decimals="INF"
      id="f-392"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-89"
      decimals="INF"
      id="f-393"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-90" decimals="-6" id="f-394" unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-91"
      decimals="2"
      id="f-395"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-92" decimals="-3" id="f-396" unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-93"
      decimals="3"
      id="f-397"
      unitRef="usdPerShare">1.716</us-gaap:SaleOfStockPricePerShare>
    <vtl:SaleOfStockConsiderationReceivedPercentage contextRef="c-93" decimals="2" id="f-398" unitRef="number">1.20</vtl:SaleOfStockConsiderationReceivedPercentage>
    <vtl:ThresholdTradingDaysForWeightedAveragePriceCalculation contextRef="c-92" id="f-399">P10D</vtl:ThresholdTradingDaysForWeightedAveragePriceCalculation>
    <vtl:WeightedAveragePriceOfLast10Days
      contextRef="c-92"
      decimals="2"
      id="f-400"
      unitRef="usdPerShare">8.00</vtl:WeightedAveragePriceOfLast10Days>
    <vtl:ThresholdTradingDaysForAggregateTradingVolumeCalculation contextRef="c-92" id="f-401">P10D</vtl:ThresholdTradingDaysForAggregateTradingVolumeCalculation>
    <vtl:SaleOfStockAggregateTradingVolumeOfLast10Days contextRef="c-92" decimals="-6" id="f-402" unitRef="usd">100000000</vtl:SaleOfStockAggregateTradingVolumeOfLast10Days>
    <vtl:SaleOfStockEquityOfferingsPeriod contextRef="c-94" id="f-403">P3Y</vtl:SaleOfStockEquityOfferingsPeriod>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-94" decimals="-6" id="f-404" unitRef="usd">80000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-95" decimals="-6" id="f-405" unitRef="usd">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-96" decimals="-6" id="f-406" unitRef="usd">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-97" decimals="-6" id="f-407" unitRef="usd">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement contextRef="c-98" decimals="-5" id="f-408" unitRef="usd">23600000</vtl:FairValueReclassificationOfFutureTrancheRightLiabilityUponSettlement>
    <vtl:TrancheRightsAsALiabilityRemainderAmount contextRef="c-99" decimals="-6" id="f-409" unitRef="usd">80000000</vtl:TrancheRightsAsALiabilityRemainderAmount>
    <vtl:TrancheRightsAsALiabilityReceivedAmount contextRef="c-99" decimals="-5" id="f-410" unitRef="usd">56400000</vtl:TrancheRightsAsALiabilityReceivedAmount>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-100"
      decimals="-6"
      id="f-411"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-101"
      decimals="-6"
      id="f-412"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts contextRef="c-102" decimals="-5" id="f-413" unitRef="usd">4000000</vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts>
    <vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts contextRef="c-103" decimals="-5" id="f-414" unitRef="usd">1700000</vtl:FairValueChangeInFairValueOfTrancheRightsTransactionCosts>
    <vtl:CommonStockNumberOfSharesRegisteredForResale
      contextRef="c-91"
      decimals="INF"
      id="f-415"
      unitRef="shares">55944850</vtl:CommonStockNumberOfSharesRegisteredForResale>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-104"
      decimals="INF"
      id="f-416"
      unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-105"
      decimals="INF"
      id="f-417"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-78"
      decimals="INF"
      id="f-418"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vtl:NumberOfVotesPerEachShareOfCommonStock
      contextRef="c-3"
      decimals="INF"
      id="f-419"
      unitRef="numberofvote">1</vtl:NumberOfVotesPerEachShareOfCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-420"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-421"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-50"
      decimals="INF"
      id="f-422"
      unitRef="shares">11193564</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-423" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-424"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-425" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at March 31, 2024 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,193,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Shares reserved for tranche 2 rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,620,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Maximum shares reserved for tranche 3 rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,620,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,131,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,973,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-106"
      decimals="INF"
      id="f-427"
      unitRef="shares">1000011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-428"
      unitRef="shares">11193564</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-108"
      decimals="INF"
      id="f-429"
      unitRef="shares">10318323</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-109"
      decimals="INF"
      id="f-430"
      unitRef="shares">46620046</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-110"
      decimals="INF"
      id="f-431"
      unitRef="shares">46620046</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-111"
      decimals="INF"
      id="f-432"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-112"
      decimals="INF"
      id="f-433"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-113"
      decimals="INF"
      id="f-434"
      unitRef="shares">9131506</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-435" unitRef="shares">124973057</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-436">Stock-Based Compensation Plans &lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares initially reserved for delivery under the plan was 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This maximum number was increased by 1&#160;million shares through approval by stockholders of the Company at the Company's Special Meeting of stockholders held on March 4, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 199,989 shares life-to-date under the ESPP.   The Company recognized $0 and  $46,000 of expense related to the plan during the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan, as amended on June 28, 2023 (the &#x201c;2019 Plan&#x201d;), which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Stockholders meeting on June 28, 2023, stockholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  On March 4, 2024, the stockholders voted at the Company's Special Meeting to increase the allowable shares under the 2019 plan by 9,100,000.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:f-452"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Repricing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2024, the Company's stockholders voted to approve the repricing of outstanding stock options having an exercise price above $3.00 per share to $1.72 per share.  All other terms of the grant remained the same. There were 3,317,596 stock options that were repriced to $1.72 per share.  The repricing will result in an addition $1.2&#160;million of stock compensation being recognized by the Company over the remaining term of the repriced grants and $0.9&#160;million of this amount recognized in the quarter ended March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the quarters ended March 31, 2024 and 2023, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,196,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,175,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repricing Modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,224,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan (excluding the repriced stock options) during the three months ended March 31, 2024 and 2023 was $0.97 and $1.15, respectively. The weighted average grant date fair value of the repriced stock options was $1.22.  The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2024, there was $13.5&#160;million in total unrecognized compensation expense relating to the 2019 Plan, including $0.3&#160;million related to repriced stock options, to be recognized over a weighted average period of 3.17 years.  There was $0.6&#160;million and $0.3&#160;million of stock-based compensation expense during the three months ended March 31, 2024 related to the repricing included in general and administrative and research and development expense respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital Therapies, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 12, 2019, we assumed the equity incentive plans of Vital Therapies, Inc. (&#x201c;Vital&#x201d;) following an exchange transaction (the &#x201c;Transaction&#x201d;) with Immunic AG.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the Transaction, holders of ordinary shares of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the Transaction, we changed our name to Immunic, Inc.  Upon completion of the Transaction with Vital on April 12, 2019, Vital&#x2019;s 2012 Stock Option Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of March 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three months ended March 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-114"
      decimals="INF"
      id="f-437"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-114"
      decimals="INF"
      id="f-438"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-115"
      decimals="INF"
      id="f-439"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-116"
      decimals="INF"
      id="f-440"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-117"
      decimals="INF"
      id="f-441"
      unitRef="shares">199989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-118" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-119" decimals="-3" id="f-443" unitRef="usd">46000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-120"
      decimals="INF"
      id="f-444"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="c-121"
      decimals="INF"
      id="f-445"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-121"
      decimals="INF"
      id="f-446"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-122"
      decimals="INF"
      id="f-447"
      unitRef="shares">4408871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-123"
      decimals="INF"
      id="f-448"
      unitRef="shares">4440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-124"
      decimals="INF"
      id="f-449"
      unitRef="shares">9100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-125" id="f-450">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-126" id="f-451">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-128" id="f-453">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-80"
      decimals="2"
      id="f-454"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-79"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <vtl:ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares
      contextRef="c-81"
      decimals="INF"
      id="f-456"
      unitRef="shares">3317596</vtl:ShareBasedCompensationByShareBasedPaymentAwardOptionsRepricedNumberOfShares>
    <vtl:ShareBasedPaymentArrangementPlanModificationOptionExercisePrice
      contextRef="c-81"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">1.72</vtl:ShareBasedPaymentArrangementPlanModificationOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost contextRef="c-1" decimals="-5" id="f-458" unitRef="usd">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-5" id="f-459" unitRef="usd">900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the quarters ended March 31, 2024 and 2023, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,196,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,175,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repricing Modification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,318,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,224,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,815,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,595,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-129"
      decimals="INF"
      id="f-461"
      unitRef="shares">6196140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-129"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">7.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-130"
      decimals="INF"
      id="f-463"
      unitRef="shares">4175349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-130"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">1.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-130"
      decimals="INF"
      id="f-465"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-130"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod contextRef="c-1" decimals="INF" id="f-467" unitRef="shares">0</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRepricingModificationInPeriod>
    <vtl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice
      contextRef="c-1"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">9.55</vtl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRepricingModificationsPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-130"
      decimals="INF"
      id="f-469"
      unitRef="shares">53166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-130"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-131"
      decimals="INF"
      id="f-471"
      unitRef="shares">10318323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-131"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-130" id="f-473">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-131" decimals="0" id="f-474" unitRef="usd">462223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-131"
      decimals="INF"
      id="f-475"
      unitRef="shares">10318323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-131"
      decimals="2"
      id="f-476"
      unitRef="usdPerShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-130" id="f-477">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-131" decimals="0" id="f-478" unitRef="usd">462223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-131"
      decimals="INF"
      id="f-479"
      unitRef="shares">3224039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-131"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-130" id="f-481">P7Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-131" decimals="0" id="f-482" unitRef="usd">5500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-132"
      decimals="INF"
      id="f-483"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-132"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-133"
      decimals="INF"
      id="f-485"
      unitRef="shares">1815314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-133"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">1.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-133"
      decimals="INF"
      id="f-487"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-133"
      decimals="2"
      id="f-488"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-133"
      decimals="INF"
      id="f-489"
      unitRef="shares">11161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-133"
      decimals="2"
      id="f-490"
      unitRef="usdPerShare">13.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-134"
      decimals="INF"
      id="f-491"
      unitRef="shares">5595841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-133" id="f-493">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-134" decimals="0" id="f-494" unitRef="usd">161428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-134"
      decimals="INF"
      id="f-495"
      unitRef="shares">5595841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">8.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-133" id="f-497">P8Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-134" decimals="0" id="f-498" unitRef="usd">161428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-134"
      decimals="INF"
      id="f-499"
      unitRef="shares">1888367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-134"
      decimals="2"
      id="f-500"
      unitRef="usdPerShare">12.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-133" id="f-501">P7Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-134" decimals="0" id="f-502" unitRef="usd">1980</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-503" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-135"
      decimals="2"
      id="f-504"
      unitRef="usdPerShare">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-136"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions
      contextRef="c-1"
      decimals="2"
      id="f-506"
      unitRef="usdPerShare">1.22</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueForRepricedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-507">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.02&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-135" decimals="4" id="f-508" unitRef="number">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-136" decimals="4" id="f-509" unitRef="number">0.0397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-135"
      decimals="INF"
      id="f-510"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-136"
      decimals="INF"
      id="f-511"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-135" decimals="3" id="f-512" unitRef="number">1.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-136" decimals="3" id="f-513" unitRef="number">1.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-135" id="f-514">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-136" id="f-515">P6Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-516">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.529%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,163,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,979,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c-137" decimals="-3" id="f-517" unitRef="usd">1163000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-138" decimals="-3" id="f-518" unitRef="usd">903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-139" decimals="-3" id="f-519" unitRef="usd">1587000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-140" decimals="-3" id="f-520" unitRef="usd">1076000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-141" decimals="-3" id="f-521" unitRef="usd">2750000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-142" decimals="-3" id="f-522" unitRef="usd">1979000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-143" decimals="-5" id="f-523" unitRef="usd">13500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-135" decimals="-5" id="f-524" unitRef="usd">300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-135" id="f-525">P3Y2M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-5" id="f-526" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="-5" id="f-527" unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-146"
      decimals="INF"
      id="f-528"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-147"
      decimals="INF"
      id="f-529"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-148" decimals="INF" id="f-530" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-149" decimals="INF" id="f-531" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-532">Related Party Transactions&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month.  On October 17, 2023, Immunic, Inc.  and Dr. Duane Nash entered into Addendum Number 5  to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022, and December 28, 2022, to extend the term of Dr. Nash&#x2019;s employment as Executive Chairman of the Board of Directors of the Company to December 31, 2024.  In connection with the Addendum, the Company increased Dr. Nash&#x2019;s monthly base salary to $32,368 from $30,250 (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <vtl:SalaryAndWageOfficerMonthlyBaseSalary contextRef="c-150" decimals="0" id="f-533" unitRef="usd">30250</vtl:SalaryAndWageOfficerMonthlyBaseSalary>
    <vtl:SalaryAndWageOfficerMonthlyBaseSalary contextRef="c-151" decimals="0" id="f-534" unitRef="usd">32368</vtl:SalaryAndWageOfficerMonthlyBaseSalary>
    <vtl:SalaryAndWageOfficerMonthlyBaseSalary contextRef="c-150" decimals="0" id="f-535" unitRef="usd">30250</vtl:SalaryAndWageOfficerMonthlyBaseSalary>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
